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ABSTRACT 
 
Microparticles are small subcellular vesicles, which function in inter-cellular 
communication by transferring RNA, bioactive lipids, proteins and receptors to target 
cells. Neutrophil microparticles are abundant in rheumatoid arthritis synovial fluids. 
Current dogma dictates that cartilage is an impenetrable avascular matrix through 
which metabolites from the synovial fluid must diffuse; we present the first evidence 
that microparticles can access chondrocytes through the cartilage. Addition of 
neutrophil microparticles to chondrocytes in vitro and in vivo afforded protection from 
arthritogenesis, evidenced by reduced extracellular matrix degradation, increased 
expression of genes involved in cartilage matrix synthesis and reduced inflammatory 
mediator production. Adoptive transfer of fluorescently labelled neutrophils into mice 
with inflammatory arthritis migrated to the inflamed joints and released microparticles, 
which could be found abundantly within the cartilage. We propose a mechanism 
whereby microparticles deliver the pro-resolving protein Annexin A1, which engages 
the receptor FPR2/ALX on the chondrocyte, eliciting tissue protection. This protection 
could be blocked in part by TGF-β neutralising antibodies and by preventing 
microparticle phosphatidylserine interaction with chondrocytes by coating with Annexin 
V. Intriguingly, microparticle treatment directly inhibited the phosphorylation of Hsp27. 
Hsp27 exists as large oligomers within the resting cell, and upon phosphorylation are 
released as monomers which function to stabilise the mRNA of certain pro-
inflammatory genes such as IL-8, IL-6 and COX-2; which were effects seen during 
microparticle/chondrocyte coculture. Thus, microparticles may directly reprogram 
chondrocytes to prevent the expression of pro-inflammatory cytokines and mediators, 
but also they exert anti-inflammatory effects via the exposure of phosphatidylserine 
and induce the production of protective TGF-β by chondrocytes. As cartilage has 
limited capacity for self-repair, there is an unmet need for therapies that actively repair 
or protect cartilage, especially in Rheumatoid Arthritis. We envisage these 
microparticles could offer therapeutic possibilities in the protection of cartilage in situ in 
these difficult-to-treat patients. 
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“Nature makes nothing incomplete, and nothing in vain.” 
Aristotle 
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1.1 Inflammation 
1.1.1 Overview 
Inflammation is a dynamic tissue response mechanism, which has developed 
throughout evolution to defend the host against invasion by pathogens. All animals 
have innate mechanisms for dealing with pathogen invasion and injury, and even 
simple organisms such as protozoans are able to phagocytose infective agents 
(Withers, 1992). Interestingly, bacterial defence against bacteriophages and plasmids 
by clustered, regularly interspaced short palindromic repeats (CRISPRs) has recently 
been discovered. These sequences represent an adaptive, but also heritable record of 
past infections and encode small RNAs that target invasive nucleic acids, providing 
evidence that all kingdoms of life develop protection from other invading organisms 
(Mojica et al., 2000).  Higher organisms, especially those with developed vasculature 
are not only able to sense and react to pathogen presence, but also to detect host 
tissue injury and initiate repair programmes. 
 
Inflammation occurs primarily due to tissue infection or injury. Mammals and other 
vertebrates detect microbial presence directly by detecting conserved molecules 
produced by classes of microbes using receptors on innate immune cells: toll-like 
receptors and nucleotide-binding oligomerisation-domain protein-like receptors. The 
presence of microbes can also be detected indirectly. Pore forming toxins from gram-
positive bacteria self-assemble in the plasma membrane of the host cells causing an 
influx of intracellular K+ ions. This activates the NALP3 (NACHT-, leucine-rich repeat- 
and pyrin-domain-containing protein) inflammasome inducing the release of IL-1β, 
which elicits immune-cell recruiting responses. The host can also detect the non-
specific and indirect presence of microbes or injury by sensing products of cellular 
death. The desequestration of cellular components that are normally restricted to 
intracellular compartments, such as adenosine triphosphate (ATP), high-mobility group 
protein B1 (HMGB1) and S100 proteins A8 and A9, acts as an early warning of 
infectious invasion. Initial sensing responses are usually mediated by tissue resident 
macrophages and mast cells. Once an insult is sensed, inflammatory mediators are 
released to amplify the immune response, such as cytokines, chemokines, leukotrienes 
and eicosanoids, vasoactive amines and products of the complement cascade. The net 
result of the release of these mediators is an increase in vascular permeability leading 
to the delivery of plasma products, and the selective extravasation of neutrophils to the 
site of injury (Medzhitov, 2008). 
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1.1.2 Neutrophil Recruitment 
Neutrophils are the body’s main line of defence against invading pathogens such as 
bacteria, and make up 40-60% of all white blood cells in humans (Wright et al., 2010, 
Majno, 1996). These cells are critical to the defence of the host, and as such, two-
thirds of the activity of the bone marrow is dedicated to granulopoiesis (Borregaard, 
2010). Neutropenia can be catastrophic for the host, often leading to death from 
infections normally dealt with asymptomatically. Granulocytes are endowed with a non-
redundant anti-microbial armoury: they release reactive oxygen species, proteolytic 
enzymes and an array of bactericidal proteins (Witko-Sarsat et al., 2000) in a time and 
space-dependent manner. 
1.1.2.1 Neutrophil Capture  
The recruitment of leukocytes is a multistep process governed by chemokines, 
selectins and integrins on both the leukocyte and endothelial cells. These elements 
engage in a sequential, step-wise manner to activate intracellular signals and initiate 
adhesive bond formation to capture cells from the circulation to the site of injury (Dixit 
and Simon, 2012). Firstly, capture of the neutrophils from the circulation by the 
endothelium takes place by the exposure of E- and P-selectin on the apical surface of 
the endothelial membrane. Under resting conditions, P-selectin is stored in Weibl-
Palade bodies within the endothelium, but upon stimulation with histamine, cysteinyl-
leukotrienes and cytokines, these bodies fuse with the plasma membrane and P-
selectin, along with von Willebrand factor, is exposed. E selectin is synthesised de 
novo by the endothelium when stimulated. These selectins capture ligands on the 
neutrophil surface such as P-selectin glycoprotein ligand-1 (PSGL-1) or E-selectin 
ligand-1 (ESL-1) and CD44 (Phillipson and Kubes, 2011) via sialyl Lewis x motifs. 
These selectins have overlapping functions and ensure the maximal recruitment of 
neutrophils (Kolaczkowska and Kubes, 2013). 
1.1.2.2 Neutrophil Rolling  
Neutrophil rolling is achieved by catch-bond formation of these selectins and their 
ligands, and is crucial for slowing the leukocytes in order for their arrest. Rolling on 
selectins allows neutrophils to encounter immobilised intravascular chemokine 
gradients. Chemokines are small positively charged molecules which bind heparan 
sulphate on the apical side of the endothelium (Phillipson and Kubes, 2011), thus 
allowing the generation of a stable gradient unaffected by the flow of blood 
(Kolaczkowska and Kubes, 2013). Chemokines are sensed by G-protein coupled 
receptors (GPCRs) on the neutrophil surface and along with E selectin, induce integrin-
dependent arrest (Dixit and Simon, 2012) by inside-out signalling.  
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1.1.2.3 Neutrophil Arrest and Crawling 
Inside-out signalling is the conformational changes of integrins (that arises after GPCR 
ligation) from low-affinity and bent as on circulating neutrophils, to intermediate affinity 
and extended and finally to high-affinity extended and open. β2 integrins are 
responsible for discrete end-points within the recruitment cascade. For example, 
lymphocyte function-associated antigen-1 (LFA-1; αLβ2-integrin or CD11a/CD18) allows 
firm adhesion of the neutrophil to the endothelium whereas macrophage antigen-1 
(MAC-1; αMβ2-integrin, CD11b/CD18) is required for intravascular crawling once 
arrested (Phillipson and Kubes, 2011). 
 
In order to achieve arrest, chemokine receptors, such as CXCR2 on neutrophils 
interact with endothelial ligand CXCL1 causing further activation of inside-out signalling 
to induce the extension and opening to the high affinity conformation (Pick et al., 2013). 
Once extended and open, integrins bind ICAM-1 and -2 on the endothelium (Wright et 
al., 2010), after which the lamellipodium forms at the leading neutrophil edge to allow 
the cell to crawl to an optimal location to transmigrate. Crawling is achieved by the 
rapid polymerisation and depolymerisation of the actin cytoskeleton allowing the cell to 
move in a directed manner (Wang et al., 2006). 
1.1.2.4 Neutrophil Transmigration 
For neutrophils to reach sites of inflammation, they must first cross the endothelium in 
a process termed transendothelial migration or diapedesis. Neutrophils transmigrate 
preferentially between endothelial cells (known as paracellular transmigration), which is 
a dynamic process in which the endothelial cells play an active role by forming docking 
structures to allow the neutrophils to pass through (Voisin and Nourshargh, 2013). The 
best-characterised molecule involved in the transmigration process is PECAM-1, which 
can bind integrin αvβ3, but other molecules are highly involved, e.g. ESAM-1, ICAM-2 
and junctional adhesion molecules (JAMs) (Wang et al., 2006). Endothelial JAMs, 
which bind homotypically to molecules on the opposing endothelial cell surface under 
resting conditions, are able to bind neutrophil-expressed adhesion molecules to allow 
the cell to pass through (Muller, 2003). Occasionally, and under conditions of high 
ICAM-1, neutrophils may transmigrate through an endothelial cell, known as 
transcellular transmigration. Here, the endothelial cell extends its membrane up and 
around the neutrophil to allow the cell to pass through in a directed manner 
(Kolaczkowska and Kubes, 2013).  
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1.1.2.5 Neutrophil Migration Across the Basement Membrane 
The basement membrane is a dense network of extracellular matrix proteins, 
generated by both the endothelial cells, pericytes and smooth muscle cells, which must 
be crossed by neutrophils to reach the inflammatory site. It has become clear that 
neutrophils pass through the sub-endothelial basement membranes by seeking out 
areas of low collagen IV and laminin extracellular matrix protein by crawling in an 
amoeboid manner, which is followed by migration through the interstitial tissue to the 
site of inflammation (Wang et al., 2006, Pick et al., 2013). 
1.1.2.6 Neutrophil Antibacterial Activity 
At the site of insult or injury, the neutrophils release CXCL8 (IL-8), CXCL1 and 
leukotriene B4 to recruit further neutrophils, and the cells degranulate, releasing their 
proteolytic cargo from pre-formed intracellular stores. The contents of the granules 
include antimicrobial proteins such as lactoferrin, cathepsins and defensins, and 
degradative enzymes such as elastase and matrix metalloproteinase (MMP)-9. 
Neutrophils generate reactive oxygen species to damage invading bacteria. For 
hydrogen peroxide generation, nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH) is required, a complex multicomponent enzyme, which assembles at the cell 
membrane during priming. Hypochlorous acid can also be generated by neutrophils by 
the action of myeloperoxidase. Neutrophils phagocytose bacterial pathogens and kill 
them via the fusion of the endosome with lysosomes, which exposes them to lysozyme 
(Kolaczkowska and Kubes, 2013). It has been shown that activated tissue neutrophils 
have more phagocytic capacity than circulating neutrophils (Borregaard, 2010). Under 
extreme circumstances, it has been found that neutrophils extrude their DNA forming 
NETs (neutrophil extracellular traps), in which bacteria become trapped, allowing for 
easier phagocytosis. Bacteria also become exposed to anti-microbial histones within 
the NETs, as well as other small antimicrobial proteins, further facilitating bacterial 
killing and clearance (Kolaczkowska and Kubes, 2013). Recently, a new mode of 
antibacterial activity has been shown for neutrophils. Neutrophils release microparticles 
from their plasma membrane that have been shown to have antibacterial functions. 
These microparticles exhibit bacteriostatic activity by aggregating bacteria, and are as 
potent as their parent cells at inhibiting microbial infection (Timar et al., 2013).  
1.1.2.7 Inflammation Outcomes 
The outcome of the inflammatory reaction is dictated by the way in which the process 
starts. For example, the activation of neutrophils by prostaglandins during the normal 
pro-inflammatory stage is known to “reprogram” the cells to produce anti-inflammatory 
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lipoxins upon further stimulation, initiating the end phase of inflammation (Levy et al., 
2001). The successful elimination of bacteria or cause of injury results in the initiation 
of resolution and tissue repair programmes, but when the acute inflammatory response 
fails, inflammation persists and acquires new characteristics. Neutrophils that have 
migrated into the tissue are replaced by inflammatory macrophages and in the case of 
infection, with T cells. If this further response is insufficient, chronic inflammation 
ensues, characterised by the formation of granulomas and tertiary lymphoid organs. 
Chronic inflammation can also arise due to the generation of autoantibodies, which 
propagate inflammation by binding self-antigens in perpetuity. 
1.1.3 The Resolution of Inflammation 
In order to prevent the progression from acute to persistent inflammation, the 
inflammatory reaction must be actively resolved, inhibiting further tissue damage. 
Historically, it was believed that the resolution of inflammation was a passive process 
involving the dilution of chemokine gradients over time, thus circulating leukocytes 
would no longer sense gradients and be recruited to the site of injury. However, 
extensive work over the past few decades have revealed that the resolution of 
inflammation is a carefully managed active process, and deficiencies in any of its 
components leads to over-active, uncontrolled chronic inflammation. One example of 
this is chronic airway inflammation seen in patients with cystic fibrosis, allergic airway 
disease and asthma, who have been shown to produce reduced levels of anti-
inflammatory lipoxin A4 (Levy, 2005). 
 
The resolution of inflammation represents a return to tissue homeostasis, defined as 
the clearance of tissue migrated neutrophils, and a reduction in the number of 
monocytes and macrophages accompanied by a return of these cells to the pre-
inflamed phenotype. The resolution process occurs in four stages: firstly, leukocytes 
that have fulfilled their pro-inflammatory function undergo apoptosis, which is followed 
by the clearance of these cells by macrophages (Reville et al., 2006), which then 
reprogram to switch their mediator production from pro- to anti-inflammatory, and 
finally, these phagocytes leave the tissue via the lymphatics to fulfil the requirements of 
a return to homeostasis (Serhan and Savill, 2005).  
 
The resolution of inflammation is governed in part by tissue macrophages. These cells 
perform a variety of functions that down-regulate inflammatory signals and clear 
cytokines. Macrophages release proteases at the site of inflammation to cleave 
chemokines at their ELR motifs, which are required for chemokine-receptor binding. 
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This renders the chemokines inactive, and clears chemokine gradients preventing 
neutrophil recruitment. Macrophages also control the lifespan of neutrophils by 
releasing death receptor ligands such as Fas ligand and tumour necrosis factor (TNF) -
α. When released in low concentrations, FasL prolongs the lifespan of neutrophils, but 
at higher concentrations, it induces their apoptosis. Apoptotic neutrophils release 
bioactive resolving proteins, such as Annexin A1, which translocates to the plasma 
membrane, binds the formyl-peptide receptor 2/ALX (FPR2/ALX) and suppresses 
further neutrophil recruitment whilst inducing apoptosis in neighbouring cells (Ortega-
Gomez et al., 2013).  
 
Apoptotic neutrophils release “find me” signals, such as lysophosphatidylserine, which 
promotes the migration of macrophages towards them. The membrane of apoptotic 
neutrophils undergoes rearrangement so that phosphatidylserine is expressed on the 
outer envelope. Phosphatidylserine acts as an “eat me” signal and induces clearance 
of apoptotic neutrophils by macrophages by engaging the TIM4 receptor (Ortega-
Gomez et al., 2013). Annexin A1 can also act as a bridging molecule to enhance the 
binding of apoptotic cells to phagocytes (Serhan and Savill, 2005), and N-terminal 
derived peptides of Annexin A1 can also act as “eat me” signals (Ortega-Gomez et al., 
2013). 
 
Engulfment of apoptotic neutrophils induces a phenotypic switch in macrophages from 
a pro-inflammatory M1 to an anti-inflammatory M2 phenotype. Anti-inflammatory 
macrophages alter their metabolism of lipids from proinflammatory prostaglandins and 
leukotrienes to pro-resolving bioactive lipids such as lipoxins and resolvins, protectins 
and maresins (Ortega-Gomez et al., 2013). Lipoxins are able to suppress neutrophil 
chemotaxis, reduce vascular dilatation and permeability and promote the efferocytosis 
of apoptotic neutrophils by macrophages and promote their egress from the tissue via 
the lymphatics (Nathan and Ding, 2010). These anti-inflammatory lipid mediators 
suppress neutrophil and enhance monocyte recruitment, which aids in the further 
clearance of apoptotic cells (Ortega-Gomez et al., 2013). M2 macrophages also 
secrete anti-inflammatory cytokines such as IL-10, which inhibits proinflammatory 
cytokine production (such as TNF-α and IL-1β) by recruiting suppressor of cytokine 
secretion 3 (SOCS3); and transforming growth factor β (TGF-β), which has a broad 
range of anti-inflammatory functions. TGF-β can induce neutrophil apoptosis, inhibit T 
cell proliferation and induce monocyte differentiation to macrophages (Rossol et al., 
2011) and is a potent suppressor of proinflammatory (classical) monocyte activation 
(Nathan and Ding, 2010). 
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After phagocytosing apoptotic neutrophils, macrophages down-regulate their CD11b 
and become unresponsive to TLR4 signals, which hints at a “satiated” phenotype. 
These cells egress via the lymphatics (Schif-Zuck et al., 2011), returning the tissue to 
the pre-inflammatory state. 
 
 
1.2 Rheumatoid Arthritis 
1.2.1 Introduction 
Rheumatoid arthritis is a chronic systemic inflammatory disease of unknown aetiology 
that affects approximately one per cent of the population, causing symmetrical 
irreversible damage of the diarthrodial joints. Disease onset typically occurs between 
forty and fifty years of age and patients present with stiffness, swelling and joint pain 
often accompanied by weight loss, fever and fatigue. The disease is associated with a 
reduction in life expectancy by around 10 years. 
1.2.2 Rheumatoid Arthritis Aetiology 
Rheumatoid arthritis is unique among inflammatory diseases in that no aetiological 
agent has been identified, despite extensive efforts to determine joint-specific self-
antigens. However, rheumatoid arthritis is a systemic disease that manifests most 
visibly in joint destruction, implying that there may be systemic defects in the immune 
system, in combination with a pathological process occurring in the synovial joint, 
which results in persistent chronic inflammation. In terms of susceptibility, the majority 
of patients are female, and outnumber male patients 3:1 (Patel, 2010). Rheumatoid 
arthritis is a complex and multifactorial disease with a mild to moderate genetic 
association. Genetic and environmental factors, including lifestyle choices such as 
smoking, may have an impact on individual susceptibility. Genetic linkage studies have 
shown a strong association between destructive forms of rheumatoid arthritis and 
certain major histocompatibility complex (MHC) class II alleles (human leukocyte 
antigen (HLA) DR4). The association is with a sequence motif of amino acids 70-74 in 
the 3rd hyper variable region of the β1 domain of the HLA-DR4 molecule (Mallone and 
Nepom, 2004) and is mainly associated with the expression of the “shared epitope”. 
This region encodes genes for MHC class II molecules, which bind and present antigen 
to the T cell receptors of CD4+ T cell (Trouw et al., 2013). Other susceptibility genes 
include PTPN22 and STAT4 (Imboden, 2009), genes that are highly involved in T cell 
survival, T cell effector responses (Rieck et al., 2007) and immune regulation 
(Remmers et al., 2007).  
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1.2.3 Rheumatoid Arthritis Pathogenesis 
The disease process is characterized by an adaptive immune response mediated by B 
cells and T cells, which results in a cascade of inflammatory events leading to the 
recruitment of neutrophils, macrophages and further lymphocytes (Distler et al., 
2005b). The progressing disease culminates in tissue and joint damage as the 
leukocytes and reactive synovium invade the cartilage and bone and produce 
cytokines and degradative enzymes. The synovial tissue transforms into an aggressive 
hyperplastic tumour-like organ which projects into the joint space, coming into direct 
contact with the cartilage to degrade matrix components and bone, causing extensive 
disability (D'Aura Swanson et al., 2009). 
1.2.3.1 Autoantibodies 
The formation of autoantibodies characterises autoimmune diseases such as 
rheumatoid arthritis. Physiological mechanisms exist (such as deletion, receptor editing 
and induction of anergy of potentially autoreactive lymphocytes) to prevent the 
adaptive immune system from reacting to autoantigens whilst still allowing a response 
to foreign antigens. Autoreactive cells sometimes survive, which are required to be 
supressed by regulatory cells, but if these processes fail, self-tolerance can be broken, 
allowing self-reactive lymphocytes to mature. The autoantigen becomes the target of 
the immune response, leading to chronic autoimmune disease, as the autoantigen can 
never be successfully cleared from the body. 
1.2.3.2 Complement Cascade 
The complement cascade is an enzymatic network critical for the innate immune 
system to dispatch invading pathogens by the production of self-assembling lytic 
factors, which form pores in the membrane of bacteria. The cascade can be activated 
in three ways: via the classical, lectin or alternative pathways, of which the classical 
pathway is the most relevant to rheumatoid arthritis. Here, complement is activated by 
the presence of the IgM and IgG immune complexes, and transactivates downstream 
proteins to convertases, ultimately culminating in the generation of membrane attack 
complex (MAC) and the lysis of cells. Prior to the generation of MAC, several of the 
convertases have immune-cell stimulating capabilities. For example, C3 is the most 
highly abundant complement protein and is activated to C3a, which can directly 
stimulate mast cell degranulation. A second complement product, C5a, has important 
implications for rheumatoid arthritis as it is able to interact with neutrophil receptors and 
prime or directly activate these cells to induce intracellular calcium flux, chemotaxis 
and the generation of oxygen radicals (Ward, 2010). C5a is locally increased in the 
synovial fluid of rheumatoid arthritis patients, but not in their plasma (Jose et al., 1990). 
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1.2.3.3 Synovial Fibroblasts in Rheumatoid Arthritis 
The normal physiology of the joint includes a single-cell layer of synovium surrounding 
the joint capsule, and consists of macrophage-like synoviocytes and synovial 
fibroblasts (Filer et al., 2008). Its function is to produce the synovial fluid that lubricates 
and nourishes the joint tissues, including the cartilage. In the early phases of 
inflammatory arthritis, tissue oedema becomes prominent, angiogenesis occurs, and 
the synovial lining becomes hyperplastic. As the disease progresses, the synovium 
forms multiple folds and villi, and the subintima becomes chronically infiltrated by T 
cells, B cells, macrophages and dendritic cells. The synovial fibroblasts act as immune 
sentinel cells that bridge the innate and adaptive immune systems and the stromal 
compartment to orchestrate the complex immune response by releasing a broad array 
of inflammatory mediators.  
 
Subsets of synovial fibroblasts express CD40, which, upon engagement of the CD40 
ligand (CD40L) expressed on activated T cells, leads to the production of cytokines 
and the production of antibodies by CD40-expressing plasma cells. Adaptive immune 
cells migrate to the joint in response to fibroblast-secreted CXC- and CC-type 
chemokines, and neutrophils are recruited by interleukin IL-8, CXCL5 and CXCL1 
(GROα). Monocytes are also recruited via CCL2 (also known as MCP-1), CCL4 and 
CCL5. Synovial fibroblasts become invasive and directly damage tissue via the 
secretion of matrix-metalloproteinases (MMPs) and cathepsins that degrade cartilage 
matrix and bone (Neumann et al., 2010). This aggressive phenotype, characteristic of 
the persistently activated rheumatoid synovial fibroblast, is stable and can persist 
through passaging in vitro for several months (Filer, 2010).  
 
Multiple factors contribute to the phenotypic acquisition of fibroblasts, including 
exposure to growth factors such as fibroblast growth factor (FGF), transforming-growth 
factor β (TGF-β) and platelet-derived growth factor (PDGF). Direct contact with 
cartilage matrix via adhesion molecules such as cadherin-11 and integrins and 
exposure to fragments of degraded matrix such as vitronectin and fibronectin induce 
MMP synthesis. Contact with matrix which has been denuded by these enzymes 
further influences invasive behaviour and migration (Neumann et al., 2010).  
1.2.3.4 Lymphocytes in Rheumatoid Arthritis 
T cells are present in the synovial fluid of rheumatoid arthritis patients, and early 
arthritis (less than 3 months’ duration) is characterised by a transient increase of T-cell 
modulating cytokines indicating T cell (and stromal cell) activity (Raza et al., 2005). 
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Dendritic cells and macrophage-derived cytokines activate auto-reactive CD4+ T cells 
to provide help to B cells to differentiate into arthritogenic autoantibody-producing 
plasma cells. Activated T cells produce their own cytokines which act upon the cells 
present in the joint to increase inflammation (Murphy, 2008). In around 10% of cases T 
cells along with B cells develop into highly organised secondary and tertiary lymphoid 
structures, often with germinal centres (Weyand and Goronzy, 2003) further 
highlighting the chronicity of the inflammation in this disorder.  
1.2.3.5 Neutrophils in Rheumatoid Arthritis 
Although rheumatoid arthritis disease progression resembles non-resolving chronic 
inflammation, the role of the neutrophils in this disease suggests reinitiation of an acute 
inflammatory process. Neutrophils are the most numerous cells within the synovial fluid 
during flares, and the influx of neutrophils into the joint space can exceed 1 billion 
neutrophils per day, and a half-life estimated at approximately four hours (Nathan and 
Ding, 2010). These cells have been shown to have a pre-activated or “primed” 
phenotype suggesting that they have previously been exposed to activating stimuli 
(Nemeth and Mocsai, 2012) and produce a large variety of cytokines and proteinases 
which contribute to joint destruction (Cassatella, 1995, Cassatella et al., 1997, Quayle 
et al., 1994, Quayle et al., 1995, Quayle et al., 1997, Tecchio and Cassatella, 2014, 
White et al., 1996). In normal physiology, neutrophils undergo apoptosis when 
redundant and are cleared by macrophage engulfment, preventing inflammation. In 
rheumatoid arthritis, the synovial fluid contains a both pro- and anti-apoptotic factors, 
dysregulating the usually constitutive and controlled apoptosis of neutrophils (Cross et 
al., 2006). Neutrophils contain a variety of degradative enzymes in their 
armamentarium meant for combatting invading pathogens and these enzymes become 
aberrantly released during necrosis. One of these enzymes, peptidyl arginine 
deiminase type 4 (PAD4) converts side chains of L-arginine residues generating 
citrulline, and citrullinated proteins (Nathan and Ding, 2010). Autoantibodies in 
rheumatoid arthritis have been shown to react with citrullinated peptides, and further, 
type II collagen, the major collagenous constituent of cartilage, has been shown to be 
citrullinated in rheumatoid arthritis patients (Uysal et al., 2009).  Thus, dying neutrophils 
are thought to sustain self-antigen production by releasing PAD4 to citrullinate proteins, 
which once bound by autoantibodies, recruit neutrophils further to release destructive 
reactive oxygen species and proteases (Nathan and Ding, 2010).    
1.2.3.6 Chondrocytes in Rheumatoid Arthritis 
The ultimate end-point of joint erosion is the destruction of the bone and cartilage. 
Cartilage is composed solely of chondrocytes, which in a resting state turn over the 
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cartilage matrix very slowly. They do this by producing cartilage extracellular matrix 
proteins such as type II collagen (with a half-life of 120 years) and aggrecan (with a 
half-life of 120 days) and the enzymes required for their degradation (including MMPs 
and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs)).  
 
During the development of the skeleton, chondrogenesis occurs: chondrocytes arise 
from mesenchymal progenitor cells to synthesize the cartilage anlagen (template) for 
the developing limbs. Following chondroprogenitor cell differentiation, the chondrocytes 
undergo proliferation, followed by terminal differentiation, hypertrophy and then 
apoptosis, where the hypertrophic cartilage is replaced by calcified bone in a process 
termed endochondral ossification (Goldring, 2012). Transcription factors such as Sox9 
(Bi et al., 1999) and Runx2, and various signalling pathways, play stage-specific roles 
in chondrogenesis. The resulting articular cartilage in adults is composed of four 
regions from the superficial tangential zone, nearest the synovial space, through to the 
middle zone, deep zone and finally the calcified zone nearest the subchondral bone. 
The territorial (or pericellular) matrix adjacent to the cells contains little or no fibrillar 
collagen but does contain type VI collagen microfibrils. The interterritorial matrix is 
composed of a fibrillar collagen network, with type II collagen fibrils interwoven with 
type XI collagen, and type IX collagen integrated into the fibril surface allowing 
retention of proteoglycans and permitting association with other matrix components 
(van den Berg, 2008).  Compressive resistance is maintained by the retention of water 
molecules by the expression of aggrecan, a large aggregating proteoglycan. The 
expression of cartilage specific proteins, and the alignment of the collagen fibrils differs 
between each of the zones, and allows mechanical pressure to be distributed correctly 
(Goldring and Marcu, 2009).  
 
Aberrant production of cartilage degrading enzymes occurs in rheumatoid arthritis, due 
to the influx and stimulation of immune cells, and the activation of synovial fibroblasts; 
these enzymes tip the equilibrium of cartilage production and remodelling to outright 
degradation. The principal MMPs responsible for cartilage degradation are the 
collagenases (MMP-1, MMP-8 and MMP-13), the gelatinases (MMP-2 and MMP-9), 
stromelysin (MMP-3) and membrane type I MMP (MMP-14). ADAMTS-4 and -5 are 
regarded as the principle aggrecan-degrading enzymes (Stanton et al., 2011). 
 
Rheumatoid arthritis differs from osteoarthritis in terms of cartilage degradation in that 
in rheumatoid arthritis chondrocytes display intrinsic chondrolytic activity and contribute 
to their own cartilage degradation, not only at the cartilage-pannus junction but also 
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within deeper zones of the cartilage. In osteoarthritis, cartilage degradation usually 
manifests as a surface lesion with evidence of pericellular cartilage degradation only in 
late disease progression. Chondrocytes produce, and react to, inflammatory cytokines 
such as TNF-α (Saklatvala, 1986) and IL-1β, and respond by producing 
prostaglandins, nitric oxide and proteases. In addition, chondrocytes produce, and 
express the receptors for chemokines such as CXCL8, which may play a role in 
cartilage catabolism (Fernandes et al., 2002). IL-1β is known to suppress the 
expression of a number of genes associated with the differentiated chondrocyte 
phenotype, such as the type II collagen gene COL2A1, by activating transcription 
factors including nuclear factor-kappa-B (NF-κB), CCAAT enhancer-binding protein 
(C/EBP), activator protein (AP-1) and E26 transformation specific family members, 
which regulate inflammation and stress-induced signalling (Fan et al., 2007). 
 
Degraded articular cartilage has limited capacity for repair, and a multitude of 
techniques are currently being investigated to try to enhance chondrogenesis in 
patients suffering cartilage trauma or loss due to diseases such as osteo- or 
rheumatoid arthritis. So far, treatment of large cartilage lesions has involved tissue-
engineering strategies to try to enhance chondrogenesis using synthesised cartilage 
scaffolds, stem cells and autologous chondrocyte reimplantation, but their routine 
clinical efficacy is lacking. Ultimately, severe cartilage injury or degradation is 
overcome by total joint replacement, but the development of multidisciplinary 
approaches to achieve cartilage regeneration would improve quality of life for arthritis 
patients (Tuan et al., 2013).   
1.2.4 Rheumatoid Arthritis Therapy 
Although some of the molecular mechanisms behind the disease have been 
elucidated, especially by the use of mouse models, the underlying cause of the disease 
remains a mystery (Patel, 2010). Further, the presence of Rheumatoid Factor in some 
normal individuals, and in other diseases, and the absence of such antibody in some 
rheumatoid arthritis patients highlights a lack of basic understanding of the processes 
which lead to clinical disease (Majno, 1996). Further, citrullinated proteins that are 
putative auto-antigens are not synovium-specific (Vossenaar and van Venrooij, 2004). 
Nonetheless, new treatments for rheumatoid arthritis have recently represented a 
revolution in disease management. Modern rheumatoid arthritis therapy centres on the 
use of non-steroidal anti-inflammatory drugs, glucocorticoids and disease modifying 
anti rheumatic drugs (DMARDs). Glucocorticoids are effective at reducing joint swelling 
and stiffness as well as pain, but the risk of considerable side effects such as 
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osteoporosis is high. The bulk of treatment relies on the use of DMARDs, which slow 
the progression of joint destruction, reduce swelling associated with synovitis and 
preserve joint function. Methotrexate, leflunomide and sulfasalazine represent the 
mainstay of synthetic DMARD options, but with progressing disease, biological drugs 
are required. Biological treatments are usually humanized antibodies or recombinant 
human proteins that target the cytokine network present within the rheumatoid joint. 
The most widely used are the TNF inhibitors, such as etanercept, infliximab, 
adalimumab, or the IL-1 receptor antagonist anakinra, but other biologicals exist and 
target the IL-6 receptor (tocilizumab), deplete B-cells by targeting CD20 (rituximab) or 
inhibit T cell co-stimulation by binding CD80 (abatacept) (Herold, 2012). Despite this 
revolution in therapy for rheumatoid arthritis, a large proportion of patients (30-40% in 
terms of anti-TNF therapy) remain refractory to treatment (Hyrich et al., 2006, Patel, 
2010), and few markers are available to predict which patients will respond to 
treatment. An intriguing study by Wright et al. (2012) found that patients that went on to 
be responders to anti-TNF therapy had elevated synovial fluid levels of T-cell-derived 
cytokines, such as IL-2, and that Treg function, suppressed by high levels of TNF-α 
could be restored by TNF blockade. Patients without a T-cell driven inflammatory 
phenotype did not respond to anti-TNF therapy, as their persistent inflammation is 
likely dominated by different cellular microenvironments within their synovial joints that 
could instead make them candidates for anti-IL-6 therapy. Furthermore, this study 
highlighted the fact that circulating cytokines in RA patients did not necessarily 
correspond to the levels of cytokines present in the synovial fluid, and that the levels of 
local cytokine production provided a clearer indication of patient therapy stratification.  
Still, few rheumatoid arthritis patients achieve lasting remission after cessation of 
DMARD or biological treatments (Nathan and Ding, 2010). Thus, there is an unmet 
need of both understanding the fine detail of how the disease develops and 
progresses, as well as new treatments which can halt the over-active chronic 
inflammation, and push the disease to fully resolve. 
 
 
1.3 Microparticles 
1.3.1 Introduction 
Microvesicles are small plasma membrane coated bodies released from cells in a 
variety of circumstances. The umbrella term “microvesicle” refers to exosomes, 
microparticles, and small apoptotic bodies, and distinct rules for their classification 
have not been devised. Their size and functions often overlap, but there exist certain 
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markers that may be used to help in determining the population in question. For 
example, exosomes are thought to be formed right side out, from multivesicular bodies 
(MVB) within the cell. Exosomes are therefore usually preformed; they bud from the 
internal MVB membrane within the cell (Figure 1.3.1), and carry tetraspannins, which 
can be used to identify them. Their protein repertoire is also more restricted (Roos et 
al., 2010) and their size smaller (between 30-100nm). Microparticles are small, 
membrane-coated, microstructures between 100nm and 1µm in size and bud from the 
plasma membrane of the parent cell (Deregibus et al., 2007). They are released from 
many, if not all, eukaryotic cell types and have a diverse range of functions. Their 
increased levels have been associated with many disease states (Distler et al., 2005b, 
Distler et al., 2005a) including atherosclerosis and coronary disorders (Inal et al., 2012, 
New et al., 2013, Kapustin et al., 2011), type II diabetes mellitus (Omoto et al., 2002), 
inflammation and rheumatoid disease (Distler et al., 2005b) as well as cancer (Lima et 
al., 2009) when released from platelets, endothelial cells, lymphocytes, monocytes and 
other cell types. 
 
Microparticles were first discovered indirectly, by Chargaff and West (1946), who noted 
that ultracentrifuged plasma displayed delayed clotting times, and that re-adding the 
isolated pellet to plasma rescued coagulation. But it was not until 20 years later that it 
was found that the ultracentrifuged pellet contained spherical vesicle-like structures 
with a plasma membrane coating (Wolf, 1967), but these were regarded incorrectly as 
inert cellular debris. Preliminary studies in thrombosis provided strong evidence of the 
potency of microparticles to promote coagulation due to the phosphatidylserine 
expression on the outer microparticle membrane, which provides a negatively charged 
surface for coagulation factor binding. Microparticles have also been shown to display 
tissue factor under certain circumstances (Boilard et al., 2010, Beyer, 2010). The 
exposure of phosphatidylserine on the microparticles is one of the features that can be 
used to discriminate them from other membrane vesicles, such as exosomes 
(Ratajczak et al., 2006). Microparticles, although released during early apoptosis, differ 
from apoptotic bodies that occur during the final stages of cell death. Apoptotic bodies 
are usually much larger than microparticles (around 4µm) and contain histones and 
nuclear material.  
1.3.2 Microparticle Formation 
Microparticles are formed by vesiculation (Figure 1.3.2). Firstly, cytoskeletal 
rearrangement occurs consequent to a sustained influx of calcium (Hugel et al., 2005). 
The activation of calcium-dependent proteases calpain and gelsolin (Inal et al., 2012) 
cleave talin and α-actinin, freeing the plasma membrane from the cytoskeleton 
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(Miyoshi et al., 1996). The cytoskeleton itself is also transformed by these enzymes as 
they cleave the actin filaments facilitating microparticle shedding (Inal et al., 2012). The 
cytoskeleton is further modified by the phosphorylation of myosin light-chain kinase 
which enhances the contractility of myosin “resulting in the production of sliding forces” 
and the activation of Rho-associated kinase-1, which decouples actin-myosin filaments 
from the plasma membrane (Distler et al., 2006).  
 
Second, the directional segregation of the phospholipid bilayer is disrupted due to the 
activation of membrane-direction governing proteins (Morel et al., 2011), such as 
floppase and scramblase by calcium, and the inactivation of flippase (Hugel et al., 
2005). This causes the normal physiological state of the plasma membrane to be 
unsegregated: phosphatidylserine and phosphatidylethanolamine, anionic 
aminophospholipids (Inal et al., 2012), normally reside on the inner membrane leaflet, 
whereas phosphatidylcholine and sphingomyelin (the choline-phospholipids) reside on 
the external membrane leaflet (Morel et al., 2011). Transposing of the membrane to 
expose phosphatidylserine precedes the formation of microparticles and in THP-1 
monocytes this event occurs 2-10 seconds after stimulation of the P2X7 receptor with 
an ATP mimetic. Vesicle blebbing occurred 40-150 seconds after stimulation 
(MacKenzie et al., 2001).  
Microparticle  
formation 
Exosome  
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Apoptosis 
C 
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Figure 1.3.1 Types of extracellular vesicles and their formation. Several types of extracellular 
vesicles exist, and are formed by different mechanisms. (A) Microparticles are formed de novo 
via budding from the surface of activated cells, and express phosphatidylserine on their outer 
surface. (B) Exosomes are formed within multivesicular bodies and are released from the cell 
when this structure fuses with the plasma membrane, expelling the exosomes. (C) Apoptotic 
bodies are released from cells undergoing programmed cell death and contain nuclear material 
such as histones. 
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Finally, the plasma membrane of the cell and microparticle must undergo resealing 
prior to microparticle shedding to ensure retention of membrane integrity (MacKenzie 
et al., 2001). Investigations into how nucleated cells protect themselves from attack by 
pore-forming toxins have led to an increased understanding of the events surrounding 
this process. Injury of the plasma membrane by pore-forming toxin streptolysin O leads 
to an influx of extracellular calcium. This rise in calcium ions is sensed by intracellular 
Annexin A6, which induces recruitment of this protein to the damaged plasma 
membrane. Annexin A6 facilitates the formation of lesion-containing microparticles by 
binding the membrane and resealing the lesion outside of the cell, which is then shed. 
If the cell has to deal with larger, or multiple, injuries, a global rise in calcium induces 
homogeneous binding of Annexin A6 to the entire plasma membrane, regardless of 
proximity to injury. In this case, Annexin A6 can no longer repair the lesion, and 
Annexin A1, a less sensitive calcium-binding annexin, translocates to the injured area 
of the plasma membrane, which retains a higher calcium concentration, especially in 
an area of cellular protrusion. Here, Annexin A1 can efficiently seal off the lesion 
resulting in the release of microparticles containing both Annexin A1 and A6 as well as 
the lesion (Potez et al., 2011). Although these studies were carried out in transfected 
HEK293 cells injured with streptolysin O, the findings could be extrapolated to the 
release of microparticles due to stimulation of cells.  
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Figure 1.3.2 Microparticles are shed through an orchestrated process of cytoskeletal 
remodelling, membrane rearrangement and resealing. PS, phosphatidylserine; PE, 
phosphatidylethanolamine; PC, phosphotidylchloline; Sp, sphingomyelin; ROCK, Rho-associated 
kinase-1; MLCK, myosin light-chain kinase; GTP, guanosine triphosphate; P, phosphorylation. 
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The binding of ligand to GPCRs induces receptor-operated calcium entry, a moderate 
influx of calcium from stores in the endoplasmic reticulum. This process is followed by 
a global rise in calcium by store operated calcium entry, where calcium-sensing 
molecules translocate to membrane-associated calcium ion channels to induce an 
influx of calcium from the extracellular milieu (Hillson and Hallett, 2007). These rises in 
calcium are sufficient to achieve the activation of calcium-dependent enzymes that 
cleave cytoskeletal-anchoring proteins (Dixit and Simon, 2012) and could conceivably 
induce translocation of annexins to the plasma membrane to operate in microparticle-
associated membrane sealing. The transverse migration of phosphatidylserine to the 
outer membrane leaflet, coupled with the disassociation of the plasma membrane from 
the cytoskeleton, and sealing of the membranes equal the shedding of microparticles 
(Inal et al., 2012).  
 
1.3.3 Microparticle Function 
 The ubiquity of microparticles suggests a role in cell regulation, in addition to providing 
a surface upon which the coagulation cascade takes place (Inal et al., 2012). 
Microparticles possess characteristic signatures of the cells from which they originate 
(Beyer, 2010); in addition, the activation status of the parent cells influences the 
composition and function of the offspring microparticles (Mause, 2010, Timar et al., 
2013). For example, although both cell activation and early apoptosis give rise to 
microparticle production, their resultant microparticles differ both phenotypically and 
quantitatively: microvascular endothelial cell-derived microparticles preferentially 
express CD51 and ICAM-1 (CD54) when produced by activation, whereas PECAM-1 
and E-selectin were more highly expressed when produced via apoptosis (Jimenez et 
al., 2003). This is also true in terms of their differential functions. Timar et al. (2013) 
have shown that microparticles generated by neutrophils stimulated with opsonised 
Staphylococcus aureus particles inhibited the growth of S. aureus bacteria by forming 
microparticle-bacterial aggregates, but microparticles generated by stimulating 
neutrophils with other pro-inflammatory agents (e.g. fMLP) did not display antibacterial 
activity. Microparticles are enriched in certain phospholipids and bioactive lipids 
depending on stimulus applied to the parent cell (Distler et al., 2005a). The cytoplasmic 
component contained by the microparticle may also have pre-selected contents. 
MacKenzie et al. (2001) found that THP-1 monocytes formed microparticles when 
stimulated with various agents, but that the resulting microparticles contained IL-1β 
only when stimulated with a P2X7 receptor antagonist. Shedden et al. (2003) found that 
solid tumour cells that were chemotherapy-resistant expressed more genes associated 
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with vesicle shedding and the vesicles shed from these cells contained higher 
concentrations of doxorubicin compared to the cells from which they were generated. 
Similar results have been found in cisplatin resistant cells, where microparticles from 
resistant cells contained 2.6-fold more than those released from sensitive cells leading 
to increased expulsion (Safaei et al., 2005). These cells also expressed more genes 
associated with microvesicle shedding suggesting that preferential loading of 
microparticles, as expropriated here by chemotherapy-resistant cancer cells, has 
specific genetic machinery. 
 
Microparticles contain a wide variety of intracellular proteins, RNA and lipids and these 
components may undergo extensive remodelling to enable adaptive or specialised 
functions (Muralidharan-Chari et al., 2010). Electron and confocal microscopic analysis 
of microparticle formation has shown selective arrangement processes occurring in 
cells stimulated with C5b-9 complexes (Moskovich and Fishelson, 2007) so that the 
subsequent phenotype of the shed vesicles is not random. Raft domains and the lateral 
organisation of the plasma membrane segregate particular proteins and lipid species 
and confer this inclusive or exclusive sorting (Hugel et al., 2005). Lipid rafts are 
membrane micro domains enriched in certain proteins and cholesterols.  It has been 
shown that microparticles may be shed from lipid raft regions: Jy et al. (2002) showed 
that prior to microparticle release, PECAM-1 clustered on the cell surface in lipid rafts 
and the subsequent microparticles generated by these cells were enriched in PECAM-
1. Further, disruption of lipid-rich domains using either nystatin or methyl-β-cyclodextrin 
impairs the ability of endothelial cells to produce microparticles (Burger et al., 2011). 
Proteins known to co-localise with lipid rafts have also been found in microparticles, in 
particular CD39, flotillin-2, eNOS and caveolin-1 (Banz et al., 2008, Burger et al., 
2011). 
 
Microparticles are able to signal as discrete elements by possessing a large array of 
bioactive substances, adhesion molecules and membrane-anchored receptors on their 
surface. They contain cytokines, enzymes, signalling proteins and functioning mRNA 
and miRNA (Andaloussi et al., 2013), where the incorporation of the microparticle into 
the target cell is required before the content of the microparticle may exert its effects 
(Mause, 2010). The transfer of RNA by exosomes or extracellular vesicles has been 
characterised more extensively. Extracellular vesicles have been shown to deliver 
mRNA that can be translated into protein by the recipient cell – human mast cell-
derived exosomes delivered mRNA to mouse mast cells, which translated the human 
protein (Valadi et al., 2007). Artificially, reporter mRNA carried by extracellular vesicles 
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derived from glioma cells could be transferred and expressed in recipient cells (Skog et 
al., 2008). Further, extracellular vesicles from a variety of cell types have been shown 
to contain machinery associated with RNA processing and transport (Andaloussi et al., 
2013). Interestingly, Bolukbasi et al. (2012) may have identified a potential “post-code” 
located in the 3’ untranslated region of mRNAs that lead to their incorporation into 
extracellular vesicles, showing that even the enrichment of mRNA into microvesicles is 
pre-selected by the cell. Although these are examples of exosomal RNA transportation, 
given the lack of consensus on definitions and with a lack of a gold standard in 
isolation techniques, these mechanisms could conceivably be part of the microparticle 
functional repertoire.  
 
Microparticles not only act in the neighbourhood of their parent cells, but also at target 
sites much further away.  For example, cancers release microparticles rich in MMP-2 
and MMP-9, which when disseminated via the vasculature, are capable of degrading 
the basement membrane collagen and other ECM components allowing the tumour to 
metastasise (Graves et al., 2004). It is also likely that microparticles contribute to 
tumour metastasis by the induction and support of angiogenesis; in fact Baj-
Krzyworzeka et al. (2006), Baj-Krzyworzeka et al. (2007) demonstrated that upon 
fusion of tumour-derived microparticles with monocytes, the transfer of nucleic acid 
material occurs resulting in the induction of VEGF and hepatocyte growth factor, 
demonstrating transfer of functional transcribed messages. 
 
Microparticles do not only convey chemical signals to target cells, but can also endow 
them with new functions. Rozmyslowicz et al. (2003) and Majka et al. (2000) showed 
that CD4+/CXCR4-null cells were able to acquire CXCR4, the principle co-receptor for 
lymphotrophic HIV-1 strain infection, from platelet and megakaryocyte microparticles 
rich in the receptor; in this manner they became vulnerable to HIV-1 infection, 
demonstrating transfer and retention of functional receptors. Comparable results have 
been shown with another chemokine receptor, CCR5, which was transferred to null 
macrophages via peripheral blood monocyte-derived microparticles, rendering them 
susceptible to a macrophage-tropic strain of HIV (Mack et al., 2000). Similarly, platelet-
derived microparticles have been shown to transfer the CD41 antigen (αIIbβ3 integrin) to 
lung cancer cells, increasing their adhesiveness to the endothelium and the rate of 
metastasis (Janowska-Wieczorek et al., 2005). Further, endothelial progenitor cell-
derived microparticles function by reprogramming quiescent endothelial cells to endow 
them with angiogenic properties, a process reliant on α4 and β1 integrins and the 
transfer of RNA (Deregibus et al., 2007). Combes et al. (2005) demonstrated that the 
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ATP-binding cassette transporter A1 (ABCA-1), a receptor which regulates the 
distribution of phosphatidylserine to the outer membrane leaflet during microparticle 
shedding, played a key role in the development of cerebral malaria. They showed that 
ABCA-1-/- mice were resistant to cerebral malaria infection and produced a diminished 
level of plasma microparticles. Administration of microparticles isolated from ABCA-1+/+ 
mice however, transferred the receptor and rendered the animals susceptible to 
cerebral malaria. 
1.3.4 Microparticles as Biomarkers of Disease 
Circulating microparticles and the proteins they express have become an attractive 
putative biomarker for several diseases, and their increased levels noted in 
atherosclerotic lesions (Baron et al., 2011), heatstroke, cancer and immunological 
diseases such as lupus and rheumatoid arthritis (Nielsen et al., 2012). Low levels of 
circulating MPs in patients with septic shock were correlated with organ dysfunction 
and higher mortality rates. Furthermore, data from this laboratory show that the 
phenotype of surface molecules on circulating microparticles in sepsis patients is an 
indicator of survival (Dalli et al., 2014). 
 
Urinary microparticles, attractive as potential biomarkers of disease due to ease of 
sampling, have been used to identify diagnostic markers for both nephrotic syndrome 
(Rood et al., 2010) and prostate cancer (Rood et al., 2010, Nilsson et al., 2009). 
Microparticles as biomarkers of rheumatic diseases have become relatively well 
characterised in recent years. The levels of platelet microparticles, as identified by the 
expression of either CD41 or CD61 are increased in the plasma of patients with 
systemic lupus erythematosus (Lazarus et al., 2000, Joseph et al., 2001, Nagahama et 
al., 2001, Pereira et al., 2006), systemic sclerosis (Guiducci et al., 2008, Nomura et al., 
2008) and rheumatoid arthritis (Knijff-Dutmer et al., 2002). Leukocyte microparticles, 
derived from a broad spectrum of immune cells, have also been identified in these 
diseases, especially in diseases with more vascular manifestations. For instance 
Nagahama et al. (2003) reported higher macrophage-derived microparticles (CD14 
positive) in the plasma of anti-phospholipid syndrome patients; Guiducci et al. (2008) 
reported increased numbers of CD45-positive leukocyte-derived microparticles in 
systemic sclerosis; Daniel et al. (2006) showed higher levels of neutrophil-derived 
(CD66b positive) microparticles in systemic vasculitis patients. In agreement with this, 
Erdbruegger et al. (2008) found increased levels of CD45 and CD11b positive 
microparticles in acute vasculitis. Berckmans et al. (2005) characterised microparticles 
present within rheumatoid arthritis synovial fluid and found various leukocyte-derived 
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microparticles positive for CD4, CD8, CD14, CD20, CD66b and CD66e suggesting a 
complex contribution of not only these cells but also their resultant offspring 
microparticles to the disease pathogenesis. 
1.3.5 Scott Syndrome 
Although most reports centre on the inflammatory nature of microparticles, complete 
absence of these structures results in pathology. Platelets possess the highest flippase 
and scramblase rate of all cells and the microparticles derived from platelets provide a 
substrate surface that is 50-100 fold more pro-coagulant than platelets themselves. 
The importance of microparticles in haemostasis is demonstrated most clearly by the 
phenotype of patients with a rare bleeding disorder caused by a deficiency in 
microparticle shedding, known as Scott syndrome. These patients suffer episodes of 
moderate bleeding due to the inability to expose phosphatidylserine via microparticles, 
and the exact genetic identification of the trait has only recently been elucidated due to 
the rarity of human cases (Yang et al., 2012, Castoldi et al., 2011, Suzuki et al., 2010). 
Mutations in phospholipid scramblase TMEM16F (Anoctamin 6) are responsible for this 
phenotype. A similar disorder has been noted in German Shepherd dogs, where 
platelets display a similar lack of pro-coagulant activity (Morel et al., 2011), and could 
provide a good experimental model for investigations into microparticle shedding.  
 
Inhibiting extracellular vesicle production or release and inhibition of the uptake of 
extracellular vesicles by recipient cells has been suggested to model their functions in 
vivo. This approach, required to determine the true physiological role of microparticles, 
is technically challenging and may not be possible experimentally. For example, 
inhibiting ceramide formation (important in protein sorting and exosome biogenesis) or 
PCD6IP (required for exosome formation) to limit exosome generation; or the 
interference of RAB27a to inhibit exosome release have been shown to limit the effects 
of exosomes, but also inhibit other non-specific cellular processes (Andaloussi et al., 
2013). Treatment with the blood-pressure lowering drug dimethyl amiloride has been 
shown to attenuate endocytic vesicle recycling and inhibit exosome release, and in vivo 
has been shown to reduce mouse and human tumour cell growth by blocking the 
release of exosomes bearing Hsp72 which would otherwise exhibit 
immunosuppressive effects (Chalmin et al., 2010). Although off-target effects may have 
occurred during this study, it is interesting to note that therapeutic inhibition of 
microvesicle release is efficacious in certain circumstances. Prevention of microvesicle 
uptake by recipient cells would require blocking of phosphatidylserine receptor which is 
known to have far-reaching and catastrophic consequences (Andaloussi et al., 2013). 
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Phosphatidylserine receptor knockout mice are known to die at birth and histological 
analysis of the internal organs revealed profound inflammation and the presence of a 
large number of apoptotic bodies (Li et al., 2003). Thus, blocking of this receptor is 
likely to have severe consequences aside from blocking the uptake of microparticles. 
TMEM16F null mice also suffer a high rate of perinatal mortality, and thus, conditional 
knockouts must first be generated in order to elucidate their full role in physiology. 
1.3.6 Microparticles as Potential Therapeutic Vectors 
Encompassing all types of extracellular vesicles, reports exist of the therapeutic 
capabilities of certain vesicles when administered exogenously. For example, 
extracellular vesicles derived from mesenchymal stem cells have been used to 
stimulate cardiac tissue repair following myocardial infarction in mice (Andaloussi et al., 
2013) and extracellular vesicles derived from tumour antigen-pulsed dendritic cells 
have been exploited in cancer immunotherapy (Zitvogel et al., 1998). Extracellular 
vesicles have been shown to induce pro-angiogenic programs in endothelial cells and 
to stimulate proliferation by delivering mRNA associated with the PI3K and Akt 
pathway (Deregibus et al., 2007). 
 
Although the functions of microparticles may be exploited for therapy, these structures 
are also amenable to molecular manipulation and can even be used as non-viral 
vectors of nucleic acids. For example, it has been shown that extracellular vesicles 
derived from pre-transfected parent cells so that they carry suicide gene mRNA 
reduced schwannoma tumour burden in mice (Mizrak et al., 2013). Extracellular 
vesicles, when generated from autologous patient-derived cells as immunologically 
inert and biocompatible (Andaloussi et al., 2013). Furthermore, extracellular vesicles 
have access to physiological sites that remain privileged to the parent cells: for 
example, platelet microparticles can enter rheumatoid synovial fluid where intact 
platelets cannot (Boilard et al., 2010). Alvarez-Erviti et al. (2011) have demonstrated 
that extracellular vesicles are capable of crossing the blood-brain barrier: immature 
dendritic cells transfected with a plasmid encoding LAMP2 (an exosomal membrane 
protein) fused with a brain-specific peptide (rabies virus glycoprotein-derived peptide) 
which allowed brain-specific targeting of offspring exosomes. These targeted 
exosomes were then loaded via electroporation with siRNA that silenced GAPDH, a 
ubiquitous and highly expressed housekeeping gene, or BACE1, a strong candidate for 
anti-Alzheimer’s disease therapeutics. Strong inhibition of GAPDH was noted in the 
brains of mice receiving GAPDH modified exosomes by tail-vein injection, with only 
minimal silencing effects seen in the liver and spleen. However, in mice receiving 
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exosomes containing BACE1 silencing RNA, a brain specific knockdown of BACE1 
mRNA (60%) and BACE1 protein (62%) could be seen. This study demonstrates not 
only that exosomes are capable of crossing the blood-brain barrier, but also that these 
exosomes can easily be manipulated for targeting to specific organs. 
 
Norling et al. (2011) harnessed neutrophil microparticles and enriched them with 
bioactive lipid mediators to enhance their efficacy, creating “nanomedicines”. These 
structures were inherently anti-inflammatory, and increased the potency of aspirin-
triggered Resolvin D1 and a stable analogue of lipoxin A4 so that much lower 
concentrations were effective at reducing neutrophil recruitment in models of acute 
inflammation (the zymosan peritonitis model) and temporomandibular joint 
inflammation.  
1.3.7 Microparticles in Inflammation and Rheumatoid 
Arthritis 
Microparticles have been found to play pathogenic roles in rheumatoid arthritis. It has 
been shown that microparticles produced by platelets are increased in the plasma of 
rheumatoid arthritis patients, and levels correlate with disease scores and activity 
(Knijff-Dutmer et al., 2002). It has been demonstrated that these microparticles are 
formed during stimulation of the platelet glycoprotein receptor VI by collagen, and are 
present in the synovial fluid of rheumatoid arthritis patients where intact platelets are 
absent. These platelet microparticles were rich in IL-1 and elicited pro-inflammatory 
responses when interacting with synovial fibroblasts (Boilard et al., 2010). Additionally, 
patients with rheumatoid arthritis have a disproportionately high cardiovascular 
mortality risk compared to the normal population. A causal relationship between the 
increased levels of highly pro-coagulant platelet-derived microparticles and the risk of 
thrombosis has been suggested by experiments in vitro, and high levels of 
microparticles were found in atherosclerotic plaques (Knijff-Dutmer et al., 2002). 
Microparticles isolated from rheumatoid joints patients are capable of also coagulating 
the synovial fluid, and induces the formation of fibrin macro-aggregates, known as rice 
bodies (Berckmans et al., 2002).  
 
Microparticles from various cellular origins have been shown to be present in 
rheumatoid synovial fluid, with high levels of granulocyte-derived (CD66b positive) and 
monocyte-derived (CD14 positive) microparticles. CD4+ and CD8+ T cell, platelet and 
erythrocyte microparticles are also present, but in much lower numbers (Berckmans et 
al., 2002). As synovial fibroblasts are localised in the intimal lining layer, in direct 
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contact with the synovial fluid, it is possible for microparticles to interact with synovial 
fibroblasts directly, influencing the release of an array of pro-inflammatory mediators 
(Berckmans et al., 2005). Microparticles produced by primary T cells and monocytes 
strongly induce MMPs -1, -3, -9 and -13 when co-cultured with rheumatoid synovial 
fibroblasts. Importantly, the induction of these enzymes in response to monocyte and 
T-cell microparticles seems to be specific for fibroblasts as no significant effects were 
noted when MCF-7 and BT549 breast cancer cells were exposed to microparticles. 
Further, co-incubation of microparticles with rheumatoid synovial fibroblasts induced 
the production of IL-6, IL-8 and CCL2 and CCL8 (Distler et al., 2005a, Morel et al., 
2011) plus soluble ICAM-1 and RANTES (Berckmans et al., 2005). Immune cells occur 
abundantly in the rheumatoid synovium and the microparticles produced by these cells 
may induce and amplify pathways of activation and destruction without the need for 
direct cell-to-cell interaction.  
 
Microparticles may play an important role in the development of autoantibodies by 
displaying intracellular self-antigens on their surface that, if recognised by antigen 
presenting cells, could elicit a T-cell response that through interactions with B cells 
could trigger the production of autoantibodies. Further display of the same 
autoantigens for recognition by autoantibodies has been shown to induce immune-
complex formation on microparticles in patients with Systemic Lupus Erythematosus 
(SLE) (Nielsen et al., 2012). This correlates with a report by Ullal et al. (2011) who 
found that anti-double stranded (ds) DNA antibodies bound plasma microparticles in 
SLE patients, and that increased microparticle-immune complex aggregates correlated 
with high anti-dsDNA titres. The report by Nielsen et al. (2012) went further in 
identifying double-labelled microparticles (Annexin V positive) in the circulation, 
positive for IgG which then correlated to anti-histone and anti-Sm/RNP levels in SLE 
patient serum. These microparticles may activate complement resulting in further 
damage. Reduced clearance of these microparticles may be the key to autoantibody 
formation increasing the likelihood of recognition by antigen presenting cells. 
 
Microparticles have been shown to promote adhesion and rolling of leukocytes in vitro 
and to activate complement, suggesting a contributing role in inflammation (Distler et 
al., 2005b). Microparticles can contain cytokines and are able to disseminate into 
regions that are inaccessible to the parent cells. As mentioned previously, platelets 
activated through the GP VI by collagen release IL-1β-enriched microparticles, which 
were shown to be present within synovial joint fluid of rheumatoid arthritis patients, 
where intact platelets are rarely present (Boilard et al., 2010). Additionally, IL-1β 
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secretion occurs preferentially via microparticles. The synthesis of IL-1β by cells is 
unconventional in terms of protein export, in that it does not follow the classical 
endoplasmic-reticulum-to-Golgi pathway and does not have a secretory signal 
sequence and there is no evidence that is stored preformed intracellularly (MacKenzie 
et al., 2001). It has been shown that mature IL-1β secretion from macrophages relies 
on ABCA1, a pivotal gene in the regulation of cellular cholesterol homeostasis (Zhou et 
al., 2002) and key for microparticle release.  
 
Microparticles may directly release lipid mediators such as oxidised phospholipids, 
lysophosphatidic acid and arachidonic acid, especially where microparticles are 
exposed to high levels of secretory phospholipase A2 (sPLA2) as it does occur in the 
rheumatoid joint (Berckmans et al., 2005, Pruzanski et al., 1988). Secretory PLA2, 
derived mainly from activated platelets and neutrophils, catalyses the release of 
arachidonic acid from phospholipids, which is in turn enzymatically converted into 
prostaglandins by cyclooxygenase-2 (COX-2) (Knijff-Dutmer et al., 2002). High levels 
of prostaglandin E2 play key roles in the pathogenesis of rheumatoid arthritis and 
mediate not only pain sensitivity and inflammation but also stimulate angiogenesis. Its 
biosynthesis is strictly controlled by PLA2, cyclooxygenases and prostaglandin E 
synthases (Jungel et al., 2007). COX-2 in particular is unregulated in the rheumatoid 
synovium and correlates with the level of inflammation present. Platelet microparticles 
can carry arachidonic acid, stimulating the expression of COX-2 in endothelial cells, 
increasing the production of prostaglandins (Barry et al., 1998, Barry et al., 1997). T 
cell- and monocyte-derived microparticles are also capable of inducing Prostaglandin 
E2 synthesis when co-incubated with rheumatoid arthritis synovial fibroblasts, by up-
regulating the enzymes involved in the conversion of arachidonic acid to Prostaglandin 
E2, namely COX-2 and mPGES-1.  
 
Microparticles express phosphatidylserine, which is sensed as an “eat me” signal by 
phosphatidylserine receptors on macrophages, which are responsible for the clearance 
of apoptotic cells and cellular debris. As microparticles in the synovial fluid bind less 
annexin V than the microparticles found in plasma, the phagocytic removal of these 
particles may be impaired. The reduced binding may be due to the exposure of 
microparticles to sPLA2 which catalyses the phosphatidylserine into other compounds 
thus reducing annexin V binding (Knijff-Dutmer et al., 2002). 
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1.3.8 Neutrophil Microparticles 
Gasser and Schifferli (2004) proposed that neutrophil microparticles feature 
immunosuppressive and anti-inflammatory qualities, which further challenges the linear 
model of inflammation, suggesting pro-inflammatory and anti-inflammatory events are 
initiated and coincide in a parallel manner. Neutrophil microparticles were shown not to 
induce IL-8, TNF-α and IL-10 secretion when co-incubated with human monocyte 
derived macrophages (HMDMs) as predicted. Instead, an increase in the anti-
inflammatory cytokine TGF-β was observed. Furthermore, when co-incubated with 
HMDMs, neutrophil microparticles dose-dependently blocked the LPS-dependent 
production of TNF-α and reduced the release of IL-8 and IL-10 compared to HMDMs 
stimulated LPS alone. This effect was not dependent on the phagocytosis of the 
microparticles by the HMDMs, as demonstrated by inhibiting phagocytosis with the 
addition of cytochalasin D, rather binding of the microparticles to the cells or the 
microparticle membranes alone, was sufficient for the anti-inflammatory effects to be 
exerted. Neutralizing antibodies to TGF-β partially inhibited the anti-inflammatory 
effects of the microparticles by blockade of IL-8 production and reduction of IL-10 and 
TNF-α suggesting only a partial contribution of TGF-β in the anti-inflammatory activity 
of these microparticles. Potentially, the anti-inflammatory effects of microparticles 
observed here could be due to the engagement of the phosphatidylserine receptor on 
the HMDMs by phosphatidylserine-exposing microparticles, as this process, as 
mentioned earlier, is crucial for the production of TGF-β. 
 
Neutrophil microparticles have been shown to inhibit dendrite formation in dendritic 
cells (DCs) matured with LPS, with cellular morphology directly altered by exposure to 
these microparticles with or without LPS stimulation. Furthermore, microparticle 
treatment reduced the phagocytic capabilities of both immature and mature DCs, 
inhibited the up-regulation of key surface markers (CD40, CD80, CD83, CD86 and 
HLA-DP DQ DR) and the release of inflammatory cytokines (IL-8, IL-12, IL-10, TNF-α) 
by LPS-matured monocyte-derived DCs.  Dendritic cells treated with neutrophil 
microparticles at the time of LPS stimulation induced significantly less T cell 
proliferation compared to LPS-stimulation alone. Co-incubation of the cells with 
neutrophil microparticles also elicited a pro-resolving response, similar to that 
described by Gasser and Schifferli (2004), where the release of TGF-β1 was 
consistently induced, regardless of whether the cells were immature, LPS-matured, or 
even from non-autologous donors. The chemokine receptor CCR7 is inhibited by TGF-
β1, in agreement, down-regulation of this receptor was observed in these experiments. 
Both the anti-inflammatory and pro-resolving effects of these microparticles were 
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partially inhibited by annexin V binding showing that these effects were mediated at 
least partly by phosphatidylserine recognition (Eken et al., 2008). The content of the 
microparticles may be contributing more to this anti-inflammatory process however, as 
Hoffmann et al. (2005) were able to demonstrate that phosphatidylserine and binding 
of its receptor was sufficient to generate anti-inflammatory effects in the majority of 
adaptive immune cells, except dendritic cells. The phosphatidylserine receptor cloned 
by this group was also not expressed on dendritic cells and thus phosphatidylserine 
liposomes could not induce TGF-β production in these cells. The anti-inflammatory 
effects reported by Eken et al. (2008) and the subsequent partial blocking of these 
effects by annexin V binding to phosphatidylserine in dendritic cells should be 
interpreted with caution. The authors state that annexin V coated neutrophil 
microparticles alone induced TNF-α release when incubated with immature dendritic 
cells, indicating that annexin V may have induced or blocked other interactions not 
directly related to phosphatidylserine binding. 
 
Some of these effects may be explained by analysing the signalling cascades 
modulated by the microparticles. Eken et al. (2010) demonstrated that neutrophil 
microparticles significantly supressed the phosphorylation of NFκB p65 at Ser536, a 
position which is reported to enhance transcriptional activation of NFκB. NFκB is a key 
transcription factor involved in the control of major pro-inflammatory genes as well as 
proliferation, differentiation and cell survival. The neutrophil microparticles also 
prevented the translocation of NFκB to the nucleus and its subsequent transactivation. 
The inhibition of NFκB p65 phosphorylation was lost when blocking antibodies to 
MerTK were added demonstrating that MerTK is required for the biological activity of 
neutrophil microparticles in this setting. Upstream, it was shown that PI3K and Akt 
were involved in the inhibition afforded by neutrophil microparticles. Downstream, the 
mRNA of six genes associated with NFκB signalling were measured: TNF-α, IL-1β, IL-
6, IL-8, IL-10 and IL-12, all of which were significantly down regulated in HMDMs 
treated with neutrophil microparticles and zymosan compared to zymosan treatment 
alone, as were the supernatant levels of these cytokines. 
 
Microparticles are intercellular communicators able to deliver lipid-mediators to aid in 
the resolution of inflammation (Norling et al., 2011). Deuterium-labelled d5DHA was 
incorporated into neutrophil microparticles when administered during the onset of 
inflammation in a mouse model of zymosan peritonitis. These microparticles contained 
enzymatic metabolites of d5DHA: d5-17-HDHA and d5-14-HDHA, which are biosynthetic 
pathway markers of D-series resolvins and maresin. This implicates microparticles as 
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intercellular communicators that act by delivering pro-resolving lipid mediator 
precursors to inflammatory sites to be metabolised into resolvins and maresins. 
Resolvins and maresins are extremely potent anti-inflammatory poly-unsaturated fatty 
acids, generated during the resolution phase of inflammation (Serhan and Petasis, 
2011). Therefore, neutrophil microparticles may contribute to the balance of pro-
resolution versus pro-inflammation in rheumatoid arthritis by carrying bioactive lipid 
precursors. 
 
Secretory PLA2 is secreted constitutively by neutrophils, and by chondrocytes, the cells 
which produce cartilage, when stimulated with cytokines (Fourcade et al., 1995) and 
sPLA2 levels are elevated within synovial fluid (Berckmans et al., 2002) and during the 
resolution phase of inflammation (Norling et al., 2011). Secretory PLA2 readily 
hydrolyses phosphatidylserine and phosphatidylethanolamine into 
lysophosphatidylserine and lysophosphatidylethanolamine, but cannot penetrate inside 
cellular membranes and therefore has limited action on intact cells. As microparticles 
express both of these anionic lipids on their outer leaflet, it has been suggested that 
microparticles are the biological substrate for sPLA2 action. Further, when neutrophils 
were incubated with deuterium-labelled DHA, microparticles were generated containing 
both d5-DHA and d5-HDHA esterified into phosphatidylcholine which when co-
incubated with sPLA2 liberated esterified pro-resolving mediator precursors from the 
microparticle surface (Norling et al., 2011). It has been shown that another lipid present 
in the microparticle membrane, phosphatidic acid, has anti-inflammatory properties 
when hydrolysed by sPLA2 into lysophosphatidic acid (Fourcade et al., 1995). Similarly, 
orally administered 2-polyunsaturated lysophosphatidylethanolamine significantly 
inhibited leukocyte migration into the peritoneal cavity in a model of zymosan-induced 
peritonitis, reduced the production of the inflammatory cytokines TNF-α, IL-1β and IL-6, 
and of the chemokines MIP-1α, MCP-1 and MIP-2; and significantly up-regulated IL-10, 
a potent anti-inflammatory cytokine (Hung et al., 2011). Microparticles characterised in 
patients with arthritis did express high levels of lysophosphatidylethanolamine and 
lysophosphatidylserine (Fourcade et al., 1995) but subsequent investigation of the role 
of these microparticles has not been carried out. 
 
The anti-inflammatory effects of neutrophil microparticles are not broadly 
immunosuppressive, like simple anti-inflammatory cytokines such as IL-10, but instead 
play tightly restricted roles that depend on the inflammatory circumstances. Timar et al. 
(2013) have shown that in a context-dependent setting, neutrophils stimulated with 
opsonised Staphylococcus aureus bacteria produce microparticles with antibacterial 
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properties that were capable of aggregating bacteria to prevent their growth. 
Furthermore, opsonised S. aureus generated microparticles that were as effective as 
their parent neutrophils at inhibiting bacterial activity. In this way, the antibacterial 
activity of neutrophils is enhanced, without the broad suppression of the immune 
system. 
 
Our laboratory has extended the study of neutrophil microparticles. Dalli et al. (2013) 
have shown that neutrophils stimulated in suspension produce microparticles with a 
proteome distinct from those produced by neutrophils in contact with the endothelium. 
In both neutrophil microparticle subsets, myeloperoxidase, Annexin A1, cathepsins G 
and S100A8 (also known as myeloid-related protein 8; MRP8) are highly abundant. 
Suspension neutrophil microparticles generated in vitro express higher amounts of 
heat shock protein 71 compared to adherent neutrophil microparticles, which are 
enriched in α2-macroglobulin and ceruloplasmin, and this protein profile reflects the 
function of the microparticles. When co-incubated with human umbilical vein 
endothelial cells, each microparticle subset modulated the transcriptional phenotype of 
the cells: suspension neutrophil microparticles altered the gene expression pattern of 
1154 genes, most closely representing genes modulated during anti-inflammatory drug 
treatment; whereas adherent neutrophil microparticles influenced the transcription of 
501 genes, which most closely resembled those modulated during antibacterial or 
antifungal drug treatments. These microparticles were also seen to have chemotactic 
properties capable of migrating towards a chemokine gradient, which has exciting 
implications for these structures, which were once considered inert, empty cellular 
debris.  
 
So far, the functional effects of microparticles or the contribution of microparticles to the 
pathogenesis of rheumatoid arthritis has been studied only in relation to the pro-
inflammatory effects of these structures, particularly to fibroblast-like synoviocytes. 
Microparticles from arthritic joints have been shown in vitro to stimulate synovial 
fibroblasts to release chemokines (CCL2, CCL8, CCL5), cytokines (IL-6, IL-8) and 
adhesion molecules (ICAM-1) (Distler et al., 2005b) and to induce the production of 
cartilage-matrix degrading enzymes such as MMP-3, -9 and -13. All of these effects 
contribute to the inflammation and degradation characterising this disease (Beyer, 
2010). As of yet the role of neutrophil microparticles in rheumatoid arthritis remains 
unclear, and, overall, the effects of microparticles on the cartilage and the 
chondrocytes have not been explored.  
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Endogenously produced microvesicles of chondrocyte and osteocyte origin are 
involved in the calcification of bone in both development and adult bone remodelling 
(Balcerzak et al., 2003, Balcerzak et al., 2008), where the combination of 
phosphatidylserine exposure and Annexin A1 promote hydroxyapatite crystal formation 
by nucleation. Similar effects have been reported in extracellular vesicles associated 
with calcification during atherosclerosis, where vesicles were shown to associate with 
collagen fibrils (Kapustin et al., 2011, New et al., 2013). No reports exist of the 
functional relevance of microparticles in relation to mature, adult healthy or arthritic 
cartilage, but these extracellular matrix-associating properties indicates that 
microparticles may have a propensity for interaction. Neutrophil microparticles, due to 
their abundance in the inflamed joint make ideal candidates assessing any possible 
relationship.  This project aims to investigate the role of neutrophil microparticles in the 
rheumatoid joint, and if any, the contribution of the proteins expressed within the 
microparticles as determined by previous proteomic analysis. Particular attention will 
be paid to their effects on the chondrocytes within both healthy and rheumatoid joints. 
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1.4 Hypothesis and Aims 
 
Previous reports have demonstrated that neutrophil microparticles have potent anti-
inflammatory effects in vitro when co-cultured with innate immune cells and stromal 
cells, and that Annexin A1 may be a contributing player in these settings.  
 
This thesis challenges the hypothesis that neutrophil microparticles could have 
protective actions on non-immune cell types, such as the chondrocytes and the 
extracellular matrix, as microparticles have previously been shown to associate with 
collagen fibrils, and are abundantly present within the joint. 
 
Thus, the overall aim of the thesis is to dissect the role of neutrophil microparticles 
using experiments that represent the physiology of the human joint, in the setting of 
rheumatoid arthritis pathology. 
 
Objectives: 
In Vitro Assays 
• Generate neutrophil-derived microparticles in vitro and assess their 
characteristics, number and mode of formation with different stimuli 
• Elucidate the roles of the extracellular matrix in microparticle production 
• Determine the effects of neutrophil microparticles in co-culture with 
chondrocyte cell lines cultured in high-density micromasses 
• Explore the involvement in Annexin A1 in the chondroprotection seen, 
including the roles of the Annexin A1 receptor 
• Assess the contribution of other microparticle components on 
chondroprotection 
Ex Vivo Assays 
• Generate an ex vivo culture system for the study of cartilage-native 
chondrocytes 
• Investigate the relationship between microparticles and cartilage native 
chondrocytes using imaging techniques 
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In Vivo Assays 
• Assess the effect of systemic neutrophil microparticle administration 
during on-going inflammatory arthritis  
• Assess the effect of local neutrophil microparticle administration during 
on-going arthritis with both histological and live-imaging tools 
• Determine the requirement for the Annexin A1 receptor during 
microparticle-induced chondroprotection 
• Generate an in vivo protocol to elucidate the physiological process of 
neutrophil trafficking and microparticle generation in inflamed joints 
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CHAPTER 2: MATERIALS AND 
METHODS 
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2.1 Materials 
 
All antibody suppliers, clones and concentrations are listed in Table 2.1.1. All 
chemicals and reagents were purchased from Sigma-Aldrich, Poole, UK, unless 
otherwise stated, including 0.1µm, 0.5µm and 1µm latex calibration beads, cytoskeletal 
inhibitors, recombinant human lactoferrin, histology reagents, dyes and tissue 
cassettes. Power SYBRgreen mastermix was purchased from Applied Biosystems Inc., 
CA, USA. Isoflurane inhalable gas anaesthetic was purchased from Baxter, Norfolk, 
UK. Human Fc block, TGFβ1 cytokine bead array, transwell inserts and FITC-Annexin 
V apoptosis detection kit I were purchased from BD Bioscience, Abingdon, UK. 
Polystyrene ultracentrifuge tubes were purchased from Beckman Coulter, High 
Wycombe, UK. Laemmli buffer was purchased from Bio-Rad, Hemel Hempstead, UK, 
Genomic DNA from Bioline, London, UK and Alcian Blue 8GS dye from Carl Roth, 
Karlsruhe, Germany. Prostaglandin E2 EIA and resolvin D1 was purchased from 
Cayman, Ann Arbor, MI, USA; Neubauer Chamber from Celeromics, Valencia, Spain 
and Wax Pens from Dako, Glostrup, Denmark. Mouse Fc block, Cell 
Fix/Permeabilisation kit and IL-8 Ready-Set-Go! ELISA kit were purchased from 
eBioscience, Hatfield, UK. Histoclear and Hoefer Western Blotting equipment were 
purchased from Fisher Scientific, Loughborough, Leicestershire, UK. Hyperfilm and 
High-range rainbow molecular weight markers were from GE Healthcare, Little 
Chalfont, UK and ITS supplement, Foetal bovine serum (both heat inactivated and non-
heat inactivated) and trypsin/EDTA were purchased from Gibco, Invitrogen, Paisley, 
UK. Hamilton syringes were from Hamilton, Bonaduz, Switzerland. Bodipy FL N-(2-
aminoethyl)maleimide), DAPI, Dithiothreitol, First Strand Buffer, AlexaFluor 546-
conjugated Phalloidin, ProLong immunogold antifade reagent, PureLink FFPE Total 
RNA Isolation kit, RNAse OUT, Superscript III, SYBRgreen I dye and AlexaFluor 633-
conjugated Wheat Germ Agglutinin were all purchased from Invitrogen, Paisley, UK. 
Dextran (MW 450,000-650,000), DiOC6 dye, GelRed, HEPES, Oligo(dT), 1µm 
fluorescent beads, 500nm fluorescent beads, collagenase type II and cytochalasin D 
were all purchased from Life Technologies, Invitrogen, Paisley, UK. Primary adult 
human articular chondrocytes (AHAC), AHAC growth medium, AHAC differentiation 
medium and trypsin deactivation solution were purchased from Lonza. Mowiol and 
human recombinant ceruloplasmin were purchased from Merck Millipore, Darmstadt, 
Germany. 0.22µm and 0.70µm filters, Accutase, Luminata forte, Polyvinylidene 
difluoride membranes and ApopTag fluorescein in situ apoptosis detection kit were 
purchased from Millipore, Watford, UK. Polyacrylamide Protogel, Resolving Buffer and 
  
59 
Stacking Gel Buffer were from National Diagnostics, Charlotte, NC, USA. Bovine 
serum albumin, DMEM high glucose, penstrep and phenol red-free RPMI were 
purchased from PAA, Somerset, UK. IL-8 was purchased from Peprotech, EC, London, 
UK, BCA Assay from Pierce, Rockford, IL, USA and dNTP mix and Griess Reagent 
System were from Promega, Madison, WI, USA. RNeasy minikit and Gene primers 
(see Table 2.1.2) were purchased from Qiagen, Hilden, Germany. IL-1β was from R&D 
Systems, Abingdon, UK and OCT Tissue-Tek compound from Sakura Finetek, Europe. 
Diamond microtome blades were from C.L. Sturkey, Lebanon, PA, USA and all 
needles including 21 Gauge Butterfly needles were purchased from Terumo, Heverlee, 
Belgium. Glass microscope slides and ThermoPrime ReddyMix PCR Mastermix were 
from ThermoScientific, Leicestershire, UK. All cell culture flasks, plates and plastics 
were from Corning Amsterdam, NL. 
 
Software packages utilised during this project were IDEAS and INSPIRE software, 
Amnis Corporation, Seattle, WA, USA; FCAP Assay Software, BD Bioscience, 
Abingdon, UK; Zeiss Imaging Software, Carl Zeiss, Cambridge, UK; Living Imaging 3.0, 
Caliper, Hopkinton, MA; FlowJo Software, FlowJo, Stanford, CA, USA; Lucia Imaging 
Software, Lucia Laboratory Imaging, Prague, CZ; ND 1000 software, NanoDrop 
Technologies, Wilmington, DE; NTA software version 2.3, NanoSight Ltd., Amesbury, 
UK and ImageJ software, NIH, Bethesda, MD, USA. 
 
Analytical hardware included ImagestreamX mk. II, Amnis corporation, Seattle, WA, 
USA; ABI Prism 7900 real-time PCR system, Applied Biosystems Inc., CA, USA; BD 
LSRFortessa and BD FACSCalibur, BD Bioscience, Abingdon, UK; IVIS 200 
bioluminescence imaging system, Caliper, Hopkinton, MA, USA; Zeiss LSM 510 laser 
scanning confocal microscope, Carl Zeiss, Cambridge, UK; EVOS LED Fluorescence 
microscope, Invitrogen, Paisley, UK; Multiskan Bichromatic 348 Spectrophotometer, 
Labsystems, Finland; Leica tissue processor and Leica microtome, Leica 
Microsystems, Milton Keynes, UK; NanoDrop Spectrophotometer, NanoDrop 
Technologies, Wilmington, DE; NanoSight LM10 system, NanoSight Ltd, Amesbury, 
UK; Nikon DXM1200 digital camera, Nikon, Melville, NY, USA; Olympus BH-2 light 
microscope, Olympus, Tokyo, Japan; FluorChem E digital darkroom, Protein Simple, 
Santa Clara, CA, USA; TECAN M200 Spectrophotometer, Tecan, Mannedorf, 
Switzerland and Abgene Thermal Cycler, ThermoScientific, Leicestershire, UK. 
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Table 2.1.1 Antibody concentrations, suppliers and clones. 
Antigen Clone, host Company Fluoroc
hrome 
Ig type Final 
Concentration 
CD11b (human) ICRF44, mouse eBioscience APC IgG1κ 0.1µg/ml 
CD62L (human) DREG56, 
mouse 
eBioscience PECy5 IgG1κ 0.1µg/ml 
CD66b (human) G10F5, mouse Biolegend PE IgM 10µg/ml 
MRP8/S100A8 
(Human) 
CF-145, mouse Lifespan 
Biosciences 
FITC IgG2b 20µg/ml for flow 
cytometry, 50µg/ml 
Immunofluorescen
ce 
MRP14/S100A9 
(human) 
MRP 1H9, 
mouse 
Pierce FITC IgG1κ 10µg/ml 
MRP14 
(mouse) 
Goat polyclonal LSbio Purified IgG 15µg/ml 
α2-
Macroglobulin 
(human) 
257316, mouse R&D 
Systems 
Purified IgG1 5µg/ml 
Ceruloplasmin 
(human) 
8, mouse BD 
Transduction 
labs 
Purified IgG1 20µg/ml 
Heat-shock 
Protein 70 
(human) 
4E7, mouse AbD Serotec Purified IgG1 40µg/ml 
Annexin A1 
(Human) 
1b, mouse In house 
generated 
Purified IgG1 50µg/ml for flow 
cytometry and 
immunofluorescen
ce, 2µg/ml 
Westerns  
Secondary Ab 
(mouse) 
Goat Invitrogen Alexa 
594 
IgG1 20µg/ml 
Secondary Ab 
(Rabbit) 
Goat Life 
Technologies 
Alexa 
594 
IgG 20µg/ml 
Ly6G (mouse) 1A8 (rat) BD 
Biosciences 
FITC IgG2aκ 0.5µg/ml 
Annexin A1 
(human, cross 
reacts with 
mouse, rat) 
Polyclonal, 
rabbit 
Thermo 
Scientific 
Purified IgG 20µg/ml 
Immunofluorescen
ce 
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FPR2 (human) 304405, mouse R&D 
Systems 
Purified IgG2b 2.5µg/ml 
FPR1 (human) 350418, mouse R&D 
Systems 
Purified IgG2a 2.5µg/ml 
TGF-β (human 
isoforms 1, 2 & 
3) 
Ab66043, 
Rabbit 
polyclonal 
Abcam Purified IgG 20µg/ml for 
blocking 
experiments 
Isotype 17-4714 
(CD11b) 
Mouse  eBioscience APC IgG1κ 0.1µg/ml 
Isotype 
(CD62L) 
Mouse eBioscience PECy5 IgG1κ 0.1µg/ml 
Isotype 
(CD66b) 
Mouse Biolegend PE IgM 10µg/ml 
Isotype (MRP8) Mouse Lifespan FITC IgG2b 20µg/ml 
Isotype 
(MRP14) 
Mouse Pierce FITC IgG1κ 10µg/ml 
Isotype (Ly6G) R35-95 (Rat) BD 
Biosciences 
FITC IgG2aκ 0.5µg/ml 
 
Table 2.1.2 Primers used for mRNA expression analysis 
Gene code Catalogue Number Gene code Catalogue Number 
Hs_COL2A1 QT00049518 Hs_SP1 QT01870449 
Hs_ACAN QT00001365 Hs_JAG1 QT00031948 
Hs_GAPDH QT01192646 Hs_JAM3 QT00024997 
Hs_RPL32 QT01668198 Mm_Adamts5 QT00131376 
Hs_Sox9 QT00001498 Mm_Il1b QT01048355 
Hs_Anxa1 QT00078197 Mm_Mmp13 QT00111104 
Hs_FPR2 QT00204295 Mm_Acan QT00175364 
Hs_FPR1 QT00199745 Mm_Col2a1 QT01055523 
Hs_SGPP2 QT00041832 Mm_Sox9 QT00163765 
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2.2 Development, Validation and Optimisation of 
Techniques 
 
This PhD project presented several opportunities to develop and optimise various 
methods and techniques. Primarily, as the field of microparticle study is relatively new, 
the techniques used for microparticle detection and measurement are not 
standardised, and as yet no gold standard exists. With the tools available to me, I have 
endeavoured to ensure that the data collected, especially in terms of microparticle 
assays, were as robust as possible. Where limitations cannot be overcome, such as 
with the direct measurement of the size of the microparticles, I have tried to build up a 
portfolio of evidence using techniques including flow cytometry, ImagestreamX imaging 
cytometry, nanoparticle tracking analysis, confocal microscopy and live cell 
fluorescence microscopy to give confidence that the microparticles fall below the 
prescribed 1µm upper size limit. In the future it is likely that technologies will be 
combined so that the concentration, size and biochemical characteristics of 
microparticles can be measured simultaneously in high-throughput assays. Until then, 
the optimisations performed on these individual techniques are described herein.  
 
2.2.1 Microparticle Generation 
 
Microparticles were generated from human or mouse neutrophils. Human neutrophils, 
from healthy donors, were isolated from the peripheral blood using a 
Dextran/Histopaque density gradient (see section 2.3.1). Mouse neutrophils were 
recruited to the peritoneum using zymosan peritonitis before collection and stimulation. 
Cell populations were analysed by flow cytometry to determine purity and/or activation 
status (see section 2.3.2) 
 
2.2.1.1 Microparticle Generation for Co-Culture and Flow Cytometry 
Every effort was made to keep microparticle preparations sterile to ensure co-culture of 
cells with microparticles was free of contamination. Microparticles were generated from 
freshly isolated neutrophils. Cells (2 x 107/ml) were stimulated with TNF-α (50ng/ml, 
Sigma) or IL-8 (50ng/ml, Peprotech) or vehicle (PBS) for 20 minutes at 37°C. Cells 
were then pelleted by centrifugation at 4500 x g for 15 minutes at 4°C and collected for 
flow cytometric analysis (see section 2.3.2.1), and any residual platelets depleted by a 
second centrifugation at 10,000 x g at 4°C for 2 minutes. Microparticles were pelleted 
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from the supernatant by ultracentrifugation at 100 000 x g for 1 hour at 4°C. 
Microparticle pellets were resuspended in 200µl 0.22µm filtered sterile PBS and 10µl 
per sample was taken for flow cytometric analysis. The remaining microparticle 
suspension was kept at -80°C until further use. 
 
2.2.1.2 Fluorescent Microparticle Generation for Visualisation in Confocal 
Microscopy and Fluorescent Microscopy 
For generation of fluorescent microparticles (used in fluorescence and confocal 
microscopy) 2 x 107/ml neutrophils were stained with Bodipy-maleimide stain in DMSO 
(2.5µM) on ice for 10 min prior to stimulation. After staining, cells were washed with 
40ml PBS and centrifuged at 300 x g for 10 minutes, resuspended to 2 x 107 per ml in 
phenol-red free RPMI. Cells were stimulated with TNF-α (50ng/ml) or vehicle (PBS) for 
20 minutes in the dark at 37°C.  Following incubation, samples were centrifuged at 
4500 x g for 15 minutes at 4°C to pellet cells, then 10,000 x g for 2 minutes to pellet 
platelets, which were then discarded, and the microparticles pelleted from the 
supernatant by ultracentrifugation at 100 000 x g for 1 hour at 4°C ensuring that all 
sample handling occurred in the dark. Microparticle pellets were resuspended in 200µl 
0.22µm filtered sterile PBS and stored at -80°C until use. 
 
2.2.1.3 Generation of Microparticles from Neutrophils Treated with 
Cytoskeletal Function Modifying Drugs and Calcium Chelator 
To investigate the requirements for microparticle generation, freshly isolated 
neutrophils (1x106 in 100µl) were treated for 10 minutes with Cytochalasin D (2µM), 
Jasplakinolide (1µM), Blebbistatin (10µM), ML-7 (20µM) or 1,2-Bis(2-
aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis(acetoxymethylester) (BAPTA-
AM; 20µM) at 37°C. Neutrophils were then plated into 96-well plates and centrifuged 
briefly and gently at 200 x g for 30 seconds at room temperature, following by washing 
in PBS (supplemented with 1% bovine serum albumin). Cells were then stimulated with 
TNF-α (50ng/ml) or vehicle (PBS) for 20 minutes. Supernatants were collected, stained 
with Bodipy-maleimide (2.5µM) and immediately acquired with an ImageStreamX mk. II 
to quantify microparticle number and size.  
 
To ensure that these drugs did not interfere with neutrophil viability, Trypan blue dye 
was added to the cell suspension (1:2 dilution), 10µl applied to a Neubauer counting 
chamber, and 200 cells were assessed for Trypan blue exclusion, an indicator of cell 
viability. These cells appeared bright, whereas the dead cells that could not exclude 
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this dye were a deep blue colour. The percentage of live to dead cells was then 
recorded.  
 
2.2.1.4 Generation of Microparticles with Annexin V Coating 
In order to inhibit microparticle interaction with chondrocytes, microparticles were 
coated with Annexin V in the presence of calcium ions. Microparticle aliquots were 
removed from -80°C and thawed quickly to 37°C. Calcium binding buffer (2X, diluted 
with microparticles 1:2 to generate a 1X solution) was added, then FITC-conjugated 
Annexin V in excess (25µg in 100µl) was added to coat the microparticles for 20 
minutes at room temperature in the dark. An aliquot of coated microparticles was 
analysed by flow cytometry to determine their Annexin V expression (see section 
2.2.2.3). Microparticles were immediately used for co-culture experiments.   
 
2.2.1.5 Generation of Murine Neutrophil Microparticles 
Neutrophils were obtained by zymosan peritonitis (Figure 2.2.1). Male 8-week old wild 
type or Anxa1 -/- C57BL/6 mice were injected with 1mg Zymosan A diluted in PBS and 
sacrificed at 4 hours. Cells were collected in ice-cold PBS by peritoneal lavage: skin 
was resected and the peritoneum exposed. Using a 23-gauge needle, 4ml saline was 
injected into the peritoneum taking care not to touch any organs within the peritoneal 
cavity. The needle was removed and the hole pinched closed. Using gentle massage, 
the cells were loosened from within the peritoneum then collected using the same 
syringe. The cells were counted, then stained with Ly6G antibodies (a neutrophil 
marker) and analysed by flow cytometry (see section 2.3.2.1). Cells (2 x 107/ml) were 
stimulated with recombinant mouse TNF-α (50ng/ml) for 20 minutes at 37°C and 
isolated by centrifugation and ultracentrifugation in the same way as human 
microparticles. Microparticles were then pooled according to genotype and counted by 
flow cytometry (see section 2.2.2).  
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Figure 2.2.1 Schematic for mouse neutrophil microparticle generation. (A) Schematic of 
experimental procedure. (B) Neutrophils were analysed by flow cytometry and appeared as a 
homogenous population on the forward/side scatter. (C) Approximately 75% of the total events 
collected were Ly6G positive, indicating that they were of neutrophil origin.   
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2.2.2 Microparticle Detection and Measurement by Flow 
Cytometry 
 
Flow cytometry is the simultaneous detection of multiple parameters, such as the size, 
granularity (internal complexity), surface topography and biochemical makeup, of a 
population of cells in suspension. Cells guided in a hydrodynamically focussed stream 
pass one-by-one through a flow cell. Fixed alignment lasers transmit light through the 
flow cell, and as the cell passes through the beam, an optical signal is generated. This 
optical signal reaches a detector, which translates the signal to an electronic one. Two 
types of detector are used in this system, photomultiplier tubes (PMT), used to detect 
weaker signals such as those generated by fluorescent labels and the side scatter (a 
measure of internal cellular complexity), and photodiodes, used to detect stronger 
forward scatter signals (a rough measure of cellular size).  
 
To allow accurate detection of different fluorescent signals, the signals pass though 
filters and mirrors arrayed around the flow cell (Figure 2.2.2). Long pass dichroic filters, 
placed in front of the PMT detectors transmit wavelengths that are longer than a 
specified value, steering shorter wavelengths of light to the next PMT so that 
progressively shorter wavelengths are detected by the last PMT. Band-pass filters are 
used to only transmit a narrow bandwidth of light to the detector.  
 
The digital signals generated using this system can be used to probe multiple 
parameters of cellular phenotype, and data generated are usually displayed in 
histograms of one parameter, such as fluorescence intensity, or in 2-parameter scatter 
plots, such as forward/side scatter (showing size and complexity). 
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2.2.2.1 Principles and Limitations of Flow Cytometric Analysis of 
Microparticles 
 
The primary method used to detect and characterize microparticles in the published 
literature is flow cytometry. Microparticles in suspension are stained using antibodies 
raised against a specific antigen of interest and conjugated to a fluorochrome. The 
fluorescence intensity and the size of the particle are then measured using a flow 
cytometer. 
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Figure 2.2.2 The laser and detector configuration of a BD LSR Fortessa flow cell. As a single 
cell passes into the flow cell it is interrogated via laser. The resulting optical signal generated by 
fluorescently-labelled cells is then detected by photomultiplier tubes (PMT) placed behind long-
pass (LP) dichroic filters (inner rings) which redirect progressively shorter wavelengths to the 
next PMT, starting from PMT A. Band-pass (BP) filters (outer ring) transmit only a narrow 
spectrum of light allowing for a defined signal. The bandwidth of transmitted light is defined by 
specified numbers: Long-pass 500 filters only transmit wavelengths longer than 500nm and 
Band-pass filter 500/50 has a bandwidth of 50nm centred at 500nm wavelength. Finally, the 
narrowed optical signal is collected by the PMT and converted into an electronic signal. Figure 
adapted from BDLSR Fortessa product brochure accessed from the Biosciences website 
(2010).  
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During classical flow cytometric analysis, the suspension of cells is hydro-dynamically 
focused, which ensures single cells are measured individually. The size of cells is 
measured using a detector placed in line with the laser beam – the “forward scatter” – 
as particles larger than the wavelength of light produce a scatter predominantly in a 
forward direction (Figure 2.2.3). The granularity is a measure of the anatomy within the 
cell, as organelles are usually similar in size to the wavelength of light (>500nm), so 
they scatter light predominantly in a perpendicular direction. Thus, the size of the cell 
and its contents can be measured by analysis of both the forward- and side-scatter 
signals (Van der Pol, 2010, Nebe-von-Caron, 2009).  
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Figure 2.2.3 Light scattering of cells versus microparticles. (A) Cells passing through the laser 
beam scatter light in a forward direction, which can be used to approximate its size, and 
perpendicularly, which is collected by the sensitive side-scatter detector to produce a measure 
of granularity. This gives an indicator of the complexity of the cell’s interior. (B) Microparticles 
are often smaller than the wavelength of light used to illuminate the sample and do not scatter 
light significantly in a forward direction. Forward scatter detection can therefore not be used to 
size microparticles. However, microparticles do scatter light in a perpendicular direction, and 
teamed with fluorescent labelling, can aid in microparticle detection and phenotyping. 
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Using flow cytometric analysis to obtain size information about microparticles, however, 
is difficult. The lower detection limit of the BD LSRFortessa is 500nm and for the BD 
FACScalibur around 400nm (BDLSR Fortessa brochure (2010)). The smallest 
polystyrene beads that can be detected by commercial flow cytometers are between 
200nm and 300nm. However, as microparticles have a refractive index and scatter light 
approximately 10-fold less efficiently than polystyrene beads, the smallest single 
vesicles that can be detected using the forward scatter detector must be larger than 
500nm (van der Pol et al., 2012). As microparticles range in size from approximately 
100nm to 1µm, a significant proportion of the population is smaller than the lower 
detection limit of most cytometers (Van der Pol, 2010). The microparticles that fall 
below the detection limit of the forward scatter are then placed erroneously along the 
forward-scatter axis, thus discriminating between microparticles and noise using the 
forward scatter (as in most published literature) is not possible. Whilst fairly robust for 
the measurement of cells, the forward scatter detector also gives a variable signal 
between instruments, affecting reproducibility between institutes. It is the most 
alignment critical detector within the cytometer and can be affected by multiple 
variables, including mismatches in the refractive index between the sheath fluid and 
sample, beam geometry, polarisation, stop position and collection angle. The forward 
scatter position of microparticles of different sizes does not therefore follow their 
relative order in physical size. Furthermore, resolving two microparticles requires a 
difference in size between them of at least 280nm (Nebe-von-Caron, 2009). The 
paucity in accurate forward-scatter data collection can be demonstrated with the use of 
calibration beads (Figure 2.2.4). Although 1µm beads are placed with confidence in 
small discrete populations (Figure 2.2.4A), from forward/side-scatter plots of 500nm 
beads, “comet-tails” appear where the forward scatter is unable to size these beads 
accurately (Figure 2.2.4B). 
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In contrast, side-scatter or “right-angled light scatter” (RALS, Figure 2.2.3) shows good 
correlation to size. This is because all instruments aim for maximal light collection and 
are therefore designed to achieve similar numerical apertures. This makes the side-
scatter a more robust discriminator, especially between instruments (Nebe-von-Caron, 
2009). Side-scatter information teamed with fluorescence labelling allows further 
discrimination between cell fragments, noise and true microparticles (Figure 2.2.4). 
Setting the axis parameters to side-scatter versus fluorescence allows the more 
accurate placement of 0.5µm beads (Figure 2.2.4F compared to B) and eliminates 
background noise from overlapping with the microparticle populations.  
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Figure 2.2.4 Comparison of the 
sensitivity of the Forward/Side 
scatter classical cytometry plots 
with the improved sensitivity 
Side scatter/fluorescence 
analysis. (A) The forward scatter 
of the BD LSR Fortessa is 
sensitive enough to resolve 1µm 
beads accurately, but not (B) 
0.5µm beads. Thus, the presence 
of machine noise (C) overlaps 
with the (D) microparticle 
population using these plots. A 
more sensitive method is to use 
the fluorescence versus side-
scatter, where (E) 1µm and (F) 
0.5µm beads can both be 
resolved accurately, but due to 
brightness are viewed with the 
red laser. This removes (G) 
electronic instrument noise from 
the (H) positively stained 
microparticle population. 
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As microparticles expose antigens from their parent cell, fluorescence versus side-
scatter analysis provides information on the biochemical composition of microparticles 
(Van der Pol, 2010). To achieve side scatter versus fluorescence plots, Bodipy-
maleimide dye is employed to label the entire microparticle population. Bodipy-
maleimide attaches to biological membranes via cysteine residues and thiol groups in 
proteins and its fluorescent nature enables its use in flow cytometry (Enjeti et al., 
2008). The entire cytosolic compartment of cells and microparticles, and the membrane 
therefore become positively labelled. This dye does not allow exclusion of 
contaminating platelets, or cellular debris, apoptotic bodies or exosomes however, but 
allows the detection of biological particles from machine noise. Furthermore, 
membrane-labelling dyes such as PKH-26 are less suitable for microparticle analysis 
as the labelling reaction must be stopped by the addition of protein to the samples, 
usually serum or bovine serum albumin. This interferes with flow cytometric analysis of 
microparticle suspensions and generates high noise levels. These dyes are also 
incompatible with the polystyrene tubes used for ultracentrifugation, as these plastics 
irreversibly sequester the dye from the samples. 
 
Fluorescence-associated cytometry does have its limitations as a method for detecting 
microparticles, even when using the side-scatter method for analysis. Firstly, accurate 
staining relies heavily on the properties and quality of the antibodies being used. 
Antibodies bind not only to their specific epitope, but also bind FC receptors on the 
surface of cells and microparticles and adhere to sticky proteins such as albumin and 
fibrinogen, or bind non-specifically. To control for this background fluorescence isotype 
antibodies are used. The isotype antibody is an irrelevant antibody of the same Ig type, 
bound to the same fluorochrome and added at the same concentration as the test 
antibody. By analysing the background fluorescence of the isotype antibody, any 
fluorescence above this background is considered antibody-epitope binding. Positive 
and negative samples are compared to the isotype control. However, the addition of 
antibodies in excess to microparticle samples can cause immunoglobulin aggregation, 
which appear as positively fluorescent signals within the cytometer. These 
immunoglobulin complexes are insensitive to detergent treatment, whereas 
microparticle-antibody labelling is sensitive. Therefore it is possible to subtract the 
fluorescence remaining after microparticle lysis to generate a true microparticle-
epitope-bound fluorescence measurement. This issue is compounded by multi-labelling 
microparticles with multiple markers as these samples are not washed between 
staining incubations, and instead it is relied upon that positive-microparticles will 
appear above background fluorescence. 
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A second practical obstacle in the multi-labelling of microparticle samples is 
coincidence (Figure 2.2.5). The fluidics of flow cytometers is designed for passing 
single cells in a hydro-dynamically guided stream through the cuvette (Figure 2.2.5A). 
Isolated polymorphonuclear cells, as one example, occupy 630µm3 (Ladinsky and 
Westring, 1967), whereas microparticles are much smaller, and occupy around 2-3µm3 
(see Figure 3.1.3 in Results). This results in non-optimal fluidics flow allowing multiple 
microparticles to be interrogated at one time, especially in concentrated samples, 
where false double or triple, or more, false-positive single events may be recorded 
(Figure 2.2.5B). Performing dilutions of the sample so that microparticles travel more 
rarely through the cuvette may aid in the reduction in coincidence (Figure 2.2.5C), but 
this significantly lengthens sample collection time, from experience, from around 5 
minutes per sample, to over 20 minutes or more per sample. 
 
  
A B C 
Figure 2.2.5 Coincidence within flow cytometry. (A) The fluidics of flow cytometers are designed 
to pass single cells through the flow cuvette for laser interrogation. (B) Microparticles are 
several orders of magnitude smaller than cells, and in concentrated samples, several 
microparticles may pass through the cuvette at once, generating false-positive signals. (C) 
Diluting the microparticle sample to ensure events are more rare may reduce coincidence.  
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Flow cytometers themselves require regular maintenance.  Contamination from non-
sterile sheath fluid or any microorganisms proliferating anywhere in the peripheral 
fluidics compartments of the flow cytometer (for example in tubing or tank-caps) 
significantly affects sample collection and analysis if they enter the sample line. A 
significant, sudden increase in machine noise can be indicative of this. By sterile-
filtering and de-gassing the sheath fluid to remove small bubbles and impurities, and by 
deep-cleaning the cytometer before each use, noise can be minimised. 
 
Although there may be limitations associated with the detection and characterization of 
microparticles using flow cytometry, there are many advantages to using this method. 
Not least is the availability, ease of use and relative low cost.  By combining light-
scatter measurements with that of fluorescence-labelling, accurate information about 
the biochemical composition, and cell of origin may be obtained, even if more sensitive 
equipment is required to elucidate detailed size measurements of microparticles. At 
present, analyses of microparticles have not been standardized. However, as this field 
of research progresses, it is hoped that the proposed side-scatter analysis method for 
microparticles will be more widely adopted.    
 
2.2.2.2 Staining Microparticles for Characterisation by Flow Cytometry 
All microparticle staining was carried out with double-filtered (0.22µm) sterile PBS. An 
aliquot (10 µl) of the microparticle suspension was stained using purified antibodies 
against α2-macroglobulin, ceruloplasmin, Annexin A1 or heat shock protein 70 (see 
Table 2.1.1) for 30 minutes in the dark on ice before the addition of AlexaFluor 594-
conjugated secondary antibody. The secondary antibody was incubated for 30 minutes 
in the dark on ice, followed by the addition of CD66b PE-conjugated antibodies for 20 
minutes in the dark on ice. Immediately prior to running, Bio-maleimide dye (2.5µM) 
was added to label the entire microparticle population. 
 
The structure and components of the microparticles were also investigated using 
specific labelling: Annexin V binding was used to assess phosphatidylserine 
expression and phalloidin was used to investigate the presence of cytoskeletal 
remnants. For Annexin V binding, microparticle aliquots (10µl) were diluted in 10µl 2x 
calcium binding buffer. This allows the calcium-dependent binding of the Annexin V to 
any exposed phosphatidylserine on the microparticle. Fluorescently conjugated 
Annexin V (5µl) alongside CD66b was then added to the microparticles for 20 minutes 
in the dark at room temperature to allow Annexin V binding to occur. For phalloidin 
staining, the addition of CD66b for 20 minutes in the dark on ice was followed by the 
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addition of Alexa546-conjugated phalloidin (final 0.01U/ml) for 10 minutes in the dark at 
room temperature. Immediately prior to running, Bio-maleimide dye (2.5µM) was added 
to label the entire microparticle population. Microparticle suspensions were not washed 
during preparation for flow cytometry to prevent loss of microparticles during this 
process.    
 
As MRP8 and MRP14 antibodies had not been used previously, titration of the 
antibodies was performed on human neutrophils to determine the optimum 
concentration (Figure 2.2.6). Antibodies were tested at various dilutions with 
permeabilised neutrophils (see section 2.3.2.2 for permeabilisation protocol) for 30 
minutes at room temperature before acquisition using a BD LSRFortessa.  Final 
concentrations of 20µg/ml for MRP8 and 10µg/ml for MRP14 were selected as they 
had the highest signal-to-noise ratio. These concentrations were then used to stain 
microparticles, for 30 minutes at room temperature before the total population of 
microparticles was labelled with Bodipy-maleimide and CD66b.  
 
Triple staining was carried out on each set of microparticles (i.e. antigen of interest plus 
CD66b and Bodipy-maleimide). Enumeration of microparticles is possible if the 
fluorescent staining appears above background and if the flow rate is known. The 
number of microparticles appearing Bodipy-maleimide medium to high and side-scatter 
positive was multiplied by the volume of sample measured, calculated from the flow 
rate, which if run on low equates to 12µl per minute. 
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Figure 2.2.6 Antibody titration of MRP8 and MRP14. Increasing concentrations of antibody were 
tested to find optimum binding of (A) MRP8 and (B) MRP14 in permeabilised neutrophils. 
10µg/ml was selected for MRP8 and 20µg/ml for MRP14. 
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2.2.2.3 Acquisition of Microparticles by Flow Cytometry 
All microparticle sample acquisition was performed using a BD LSRFortessa with 
trigger set on side-scatter, with a voltage of 400V, gain of 1 and a threshold of 200 (as 
low as possible). 10,000 events that were double positive for both CD66b and Bodipy-
maleimide were collected in order to calculate percentage positive microparticles and 
their mean fluorescence intensity. As a low threshold was applied to forward or side-
scatter detectors, electronic, fluidic and optical noise contributed significantly to the 
events seen. 
 
Events were analysed using FlowJo software, reapplying gates where necessary. 
Scatter plots of microparticle fluorescence signals in one channel plotted against 
fluorescence signals of another (for example, CD66b versus Bodipy-maleimide) do not 
form characteristic populations as seen in flow cytometric analysis of cells, as the 
fluorescence of a microparticle is a function of its size. Therefore, a highly positive 
microparticle with a small size will still only fall in the low-end of the Bodipy-maleimide 
fluorescence. Careful positive and negative gating was applied so that false-positive 
and false-negative results were not generated (Figure 2.2.7).  
 
Figure 2.2.7 Determination of double-positive gates requires careful consideration. Unstained, 
phalloidin single-stained and Bodipy-maleimide single stains are used to set correct gates for 
double-stained microparticle samples. CMP, control microparticles, TMP, TNF-α microparticles 
and IMP, IL-8 microparticles. 
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2.2.3 ImageStreamx mk. II Analysis of Microparticles 
 
We have recently gained access to a high sensitivity imaging cytometer, the Amnis 
ImagestreamX mk. II (ISX). This cutting edge instrument uses charge-coupled devices 
instead of PMTs and captures up to 12 images of each event as it passes through the 
flow cell. The machine was designed to allow the co-localisation of subcellular particles 
within cells and is equipped with a X60 objective in order to do this, and is 
subsequently amenable to microparticle detection and analysis. Acquisition parameters 
can be determined by a huge variety of physical parameters rather than just size, 
complexity and fluorescence intensity. In terms of microparticle research, this analyser 
represents important advancements in sample detection and measurement. Firstly, 
each event recorded is paired with a bank of images generated for each single event. 
Dot plots and image galleries are therefore searchable and can be used to corroborate 
event identity by eye. Furthermore, multicolour staining can be used for accurate 
identification of various subpopulations. 
 
We have tried to define the lower limits of measurement parameters using 
commercially available sizing beads, 1µm, 0.5µm and 0.1µm in size (Figure 2.2.8). 
These could be placed confidently using their fluorescence intensity, but sizing 
according to area or diameter measurements were somewhat less useful, even when 
measured using the fluorescence channel. This is because, at such high magnification, 
a pixel still represents an area of 0.3µm2, which is a large proportion of a 0.5µm 
diameter bead or microparticle. The masking applied to the fluorescence channel also 
requires alteration from the default setting to ensure stringent measurements can be 
made.   
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Figure 2.2.8 Detection of various sized calibration beads using the ImageStreamX mk. II 
imaging cytometer. Latex fluorescent calibration beads, 1µm, 0.5µm and 0.1µm in size were 
analysed using an ImageStreamX imaging cytometer. (A) Beads could be detected and 
separated according to size using fluorescence intensity and area and diameter measurements 
plotted against side-scatter. (B) Beads were visible in the fluorescence channels, but not always 
on the brightfield channel. Ch, Channel. 
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2.2.3.1 Generation of Microparticles for Analysis with ImageStreamX 
For ImageStreamX analysis, it was not necessary to remove neutrophils from the 
supernatant to analyse the microparticle population. In this way it was possible to 
prepare isolated neutrophils and stimulate them immediately prior to microparticle 
acquisition to determine the rate at which microparticles are generated. To do this, 
freshly isolated neutrophils were resuspended at 1 x 106 cells per millilitre in phenol 
red-free RPMI and labelled with Bodipy-maleimide dye (2.5µM) 2 minutes prior to 
sample acquisition, then the sample loader lowered. TNF-α (50ng/ml) was added 
immediately prior to placing the eppendorf into the sample loader and loading. 
Acquisition of events was started immediately, and the events appearing in the 
microparticle population gate collected on low for 45 minutes (see section 2.2.3). 
 
To assess microparticle number using ISX analysis, pre-prepared microparticles were 
placed in a 1.5ml eppendorf after removal from -80°C and quick thawing to 37°C. 
Bodipy-maleimide (2.5µM) was added immediately prior to acquisition. Alternatively, 
freshly isolated, live neutrophils were stained with Bodipy-maleimide (2.5µM) then 
stimulated immediately prior to acquisition. 
 
The instrument and INSPIRE software were set up as follows: Channels 01 (bright 
field), 02 (green fluorescence), 03 (spill-over from green fluorescent channel allowing 
visualisation of over-saturated Bodipy-maleimide loaded cells), 06 (bright field 2) and 
channel 12 (scattering channel) were made active, plus any other fluorescence 
channels required. Magnification was 60X, providing a pixel size of 0.3µm2 and the 
lasers 488 and 745 activated for fluorescence and side-scatter, respectively; with or 
without 405 and 642 laser activation. The flow rate was set to low speed/high 
sensitivity and stream alignment was adjusted where necessary. To obtain a collection 
gate, a scatter plot of channel 02 fluorescence intensity was plotted against channel 12 
(side scatter) signal intensity. This allows discrimination of speed beads, which are 
used as an internal calibrator for the machine’s image capture system to determine the 
flow rate. These speed beads run continuously throughout both sample collection and 
while the machine is idle, but can be completely excluded from microparticle analysis 
as they form a discrete high-scatter intensity, low channel 02 fluorescence intensity 
population (Figure 2.2.9). Bodipy-maleimide labelled microparticles appear as a low-
scatter, low to mid fluorescence intensity, and any contaminating cells appear as high 
fluorescence intensity (Figure 2.2.9 right hand panels). Each gated population was 
interrogated via the image gallery to determine the upper and lower limits of 
microparticle size and shape. Microparticles characteristically appear as small, 
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spherical green-fluorescent points, and can be discriminated from cells, which are 
much larger, or cellular debris, which is not uniformly spherical. Furthermore, 
coincidence, or the appearance of more than one microparticle in an image, does not 
skew analysis as it does with flow cytometry and the gates containing coincident 
microparticles may be included or excluded in the analysis.   
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Figure 2.2.9 Acquisition of TNF-α-stimulated neutrophil samples allows differentiation 
between contaminating cells and microparticles. Acquisition of samples using a scatter plot of 
side-scatter (SSC; dark field) versus Channel 02 intensity allows for the accurate discrimination 
of microparticles from contaminating neutrophils, platelets, erythrocytes and speed beads when 
Bodipy-maleimide stain is used. Right hand panels show representative gallery images of 
events residing in each of the different colour-coded gates.  
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For real-time neutrophil microparticle generation experiments (see 2.2.3.1), the upper 
collection event gate was set to 1x106 to prevent premature termination of sample 
acquisition. For simple enumeration of pre-prepared microparticle samples, the 
acquisition cut-off was set to 10,000 to prevent sample wastage. To determine the 
concentration of the sample, IDEAS software was used. Raw image files with the entire 
number of events were opened. A scatter plot showing channel 02 fluorescence 
intensity plotted against scattering intensity of channel 12 was generated and a 
microparticle gate re-applied and inspected visually to exclude inappropriate events. 
The gate was adjusted where necessary. The objects/mL feature was added to the 
analysis area, and applied to the microparticle gate under the channel 02 fluorescence 
trigger, after the default area mask had been adjusted to around 75%. This was more 
sensitive at capturing microparticles than the bright field as significant haloing 
contributes to the sample fluorescence, augmenting the signal. Other parameters, such 
as diameter and perimeter were determined by addition to the features list, after 
adjusting the mask in channel 02 to fit tightly around the event. To analyse the number 
of microparticles generated over the 45-minute sample acquisition, all events falling in 
the microparticle gate were plotted on a scatter graph showing time versus objects/sec 
or time versus objects/ml. Each plot was manually adjusted so that the machine noise 
generated at the beginning of acquisition was set to zero, allowing determination of the 
rate of microparticle production over time, regardless of the number of microparticles 
that were already present within the sample.  
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2.2.4 In Vitro Cartilage Models 
 
2.2.4.1 Culture of C28/I2 Chondrocyte Cell Line.  
The C28/I2 cell line was originally generated by immortalisation of primary human 
juvenile rib cartilage chondrocytes with simian virus-40 transfection, selection on 
agarose and expansion in serum-containing medium. These cells express type II 
collagen, one of the most labile features of cultured (primary and immortalised) 
chondrocytes, and produce matrix that reacts with antibodies to type II collagen, large 
proteoglycan and sulphated glycosaminoglycans. They also exhibit decreased 
expression of type II collagen and increased expression of matrix metalloproteinases 
(MMPs) in response to IL-1β stimulation (Goldring et al., 1994), reminiscent of the true 
chondrocytic phenotype. 
 
Cells were cultured in Dulbecco’s modified Eagle medium (DMEM) containing high 
glucose (4.5g/litre; PAA) supplemented with 10% non heat-inactivated foetal calf serum 
and 1% penstrep (complete medium) during monolayer culture. C28/I2 cells were 
cultured to confluence before subculture. Flasks were rinsed with PBS to remove any 
serum, and cells were detached with 0.25% warm trypsin/EDTA (Gibco, Invitrogen). 
Once cells had rounded and detached, the trypsin was deactivated by the addition of 
an equal volume of complete medium. Cells were resuspended in 30ml complete 
medium and transferred to new flasks (10ml per T75 flask) to achieve a 1:3 subculture. 
Cells were used between passage 3 and 20 for micromass culture.  
 
2.2.4.2 Generation of C28/I2 Chondrocyte Micromass Cultures 
C28/I2 can be differentiated into matrix-producing chondrocytes when cultured in high 
density and serum free conditions (Figure 2.2.10) (Greco et al., 2011). Confluent 
C28/I2 in monolayer (Figure 2.2.10A) were trypsinised with 0.25% trypsin-EDTA for 3 
minutes at 37°C, collected in 10ml complete medium then centrifuged for 10 minutes at 
400 x g before being resuspended in 5ml complete medium for counting. If required, 
cells were centrifuged a second time (400 x g, 10 minutes at room temperature) and 
resuspended to a volume of 2.5 x 107 cells/ml in complete medium. Using a reverse 
displacement Gilson pipette, 20µl of the thoroughly mixed cell suspension was placed 
into individual wells of a 48-well plate, so that the surface tension allowed a rounded 
drop to be formed on the floor of the well (Figure 2.2.10B). The 48-well plates were 
pre-filled with sterile PBS around the periphery to prevent evaporation of the medium 
containing the cells (Figure 2.2.11). Plates were carefully transferred to an incubator 
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without disrupting the pellets and cells were left to adhere for 3 hours at 37°C in 5% 
CO2. After the 3-hour period, 2ml complete medium was added very slowly to each 
well, taking care not to dislodge the delicate cell pellet (Figure 2.2.10D). After 24 hours 
the medium was replaced with 1ml chondrocyte differentiation medium (serum free, 
phenol-red free RPMI containing 1% insulin/transferrin/selenium (ITS) supplement) and 
cells were treated 24 hours later.  
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Figure 2.2.10 C28/I2 Micromass generation. (A) Confluent cells in monolayer were harvested 
and (B, C) reseeded at high density (5 x 105 cells in 20µl). (D) At 3 hours cells retained their 
spherical morphology and medium was added. Following 24-hour serum starvation and ITS 
supplementation, micromasses were stimulated for 24 hours. (E) micromasses were fixed then 
(E) proteoglycan content was quantified by Alcian blue staining. 
  
84 
Micromasses were treated with recombinant human IL-1β or TNF-α with or without 
CMP, TMP or IMP or Annexin A1-null TMP or wild type mouse TMP at the 
concentrations indicated. For FPR antagonist experiments, WRW4 or CycH (10µM 
each) were added 10 minutes before stimulation. Recombinant ceruloplasmin and 
lactoferrin were added for 24 hours at various concentrations, diluted in PBS. Resolvin 
D1, stored in ethanol, then diluted in PBS was added for 24 hours at various 
concentrations. For TGFβ blocking experiments, TGFβ neutralising antibodies (see 
Table 2.1.1) were added (20µg/ml) at the same time as stimulation for 24 hours. 
Apoptosis experiments were performed as described in section 2.3.4. During 
neutrophil-transwell separation experiments, neutrophils were treated with or without 
cytoskeletal-altering drugs as described (see section 2.2.1.3) and treated with TNF-α 
for 10 minutes prior to addition to transwells with various pore-sizes placed above 
micromasses that had been stimulated with IL-1β (30ng/ml) for 1 hour. Transwells were 
removed 4 hours later, and micromasses fixed for Alcian blue staining at 24 hours. For 
RNA analyses, micromasses were stimulated for 6 hours, for westerns of 
unphosphorylated proteins, 24 hours, and for signalling westerns, for the times 
indicated. For Annexin V coated microparticles, see section 2.2.1.4. 
 
 
Cells formed a visible gel-like matrix under serum-free conditions by 72 hours (Figure 
2.2.10E), which could be stained with Alcian blue dye (Figure 2.2.10F). Micromasses 
were stimulated for a total of 24 hours for Alcian Blue dye measurement, or for 6 hours 
for PCR. All supernatants were collected and stored at -80°C for Prostaglandin E2, 
cytokine or proteoglycan analysis.  
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Figure 2.2.11 48-well plate plan for micromass culture. Grey outer circles represent wells filled 
with PBS prior to micromass seeding to prevent evaporation of the low volume of culture 
medium (20µl) during the 3-hour adhesion stage. C represents wells that act as control for 
every plate of micromasses seeded to prevent inter-plate variation. 
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2.2.4.3 Generation of Micromasses Using Adult Human Articular 
Chondrocytes 
To determine whether results observed with C28/I2 chondrocyte micromasses were 
reflective of human primary chondrocyte cultures, primary adult human articular 
chondrocytes were purchased from Lonza. Cells were cultured in the recommended 
commercially available medium and cultured in monolayer before high-density 
micromass culture (Figure 2.2.12).  
 
Cells were cultured to confluence in primary chondrocyte growth medium (growth 
medium; LonzaCC-3216; complete; containing 10% non heat-inactivated foetal bovine 
serum (FBS), 1% penstrep, insulin-like growth factor-1 (IGF-1) 0.2%, basic fibroblast 
growth factor (bFGF) 0.5%, transferrin 0.1%, insulin 0.2%) before subculture. Flasks 
were rinsed with PBS to remove any serum, and cells were detached with 0.25% warm 
trypsin/EDTA (Gibco, Invitrogen). The trypsin was deactivated once cells had rounded 
and detached by the addition of an equal volume of trypsin deactivation solution 
(Lonza). Cells were resuspended in 30ml complete medium (in total) and transferred to 
fresh flasks (10ml per flask) to achieve a 1:3 subculture. Cells were used between 
passage 2 and 8 for micromass culture.  
 
Confluent monolayers (between passage 2 and 8) were detached with 0.25% trypsin-
EDTA for 3 minutes at 37°C then centrifuged for 10 minutes at 400 x g before being 
resuspended in 5ml growth medium for counting. If required, cells were centrifuged a 
second time (400 x g, 10 minutes at room temperature) then resuspended to a volume 
of 2.5 x 107 cells/ml in primary chondrocyte growth medium. Micromasses were plated 
as in section 2.2.4.2. After the 3-hour period, peripheral cells were checked for 
adhesion (Figure 2.2.12F) and 2ml primary chondrocyte differentiation medium (with 
10% serum, containing IGF-1 0.2%, bFGF 0.5%, Transferrin 0.1%, Insulin 0.2% and 
TGF-β1 0.5%; LonzaCC-3225) was added very slowly to each well, taking care not to 
dislodge the delicate cell pellet. After 24 hours the medium was replaced with 1ml 
primary chondrocyte differentiation medium (serum free, containing IGF-1 0.2%, bFGF 
0.5%, transferrin 0.1%, insulin 0.2% and TGF-β1 0.5%) and cells were treated 24 
hours later. Under resting conditions cells generated matrix that could be stained with 
Alcian blue (Figure 2.2.12G) and retained their spherical morphology throughout the 
culture, indicative of their chondrocytic phenotype (Figure 2.2.12H). These chondrocyte 
micromasses produced a lower absolute concentration of sulphated proteoglycans, 
reflected by a reduced Alcian blue staining intensity. Thus, a lower range of Alcian blue 
standards and also DNA standards were required to normalise data. In addition, 
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instead of 3 replicates per plate to generate n=1 as with C28/I2 chondrocyte culture, it 
was necessary to increase the replicates to 4 to generate less variable data.   
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Figure 2.2.12 Generation of micromasses with adult human articular chondrocytes. (A) 
Chondrocytes were cultured to confluence and used between passage 1 and 5. (B) Cells 
appeared more complex and fibroblastic than C28/I2 chondrocytes. (C) Cells were seeded in 
high density (500,000 cells in 20µl), (D) formed homogenous suspensions and (E) were 
spherical in shape. (F) At three hours cells had adhered, and retained their spherical 
morphology in high-density areas. (G) By 72 hours, cells had generated matrix that stained with 
Alcian blue dye and (H) still retained their spherical morphology, indicating chondrocytic 
phenotype. 
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2.2.4.4 Alcian Blue Staining 
For semi-quantitative analysis of cartilage-specific sulphated glycosaminoglycans 
(sGAGs) a method using Alcian Blue stain, optimised by De Bari et al. (2001) was 
employed. Alcian blue stains highly sulphated GAGs within the cartilage specifically at 
pH 0.2, but does not bind DNA, as this requires higher pH levels. After supernatant 
collection, micromasses were fixed in 4% glutaraldehyde (v/v in dH2O) for 15 minutes 
at room temperature followed by acidification by rinsing with 500µl 0.1N hydrochloric 
acid. 400µl of Alcian Blue 8GS dye at pH 0.2 (1% Alcian Blue 8GS in 0.1N HCl) was 
added and micromasses incubated overnight at room temperature. Micromasses were 
rinsed once with 0.1N HCl and any remaining unbound dye was removed by repeated 
washing with PBS. Dye (and DNA) was extracted from the matrix using a 6M guanidine 
hydrochloride for 72 hours. The extracted dye was measured in a flat-bottomed 96-well 
plate at 620nm using a Multiskan Bichromatic 348 spectrophotometer (Labsystems, 
Finland) and the concentration was interpolated from known-concentration Alcian Blue 
standards (top standard 250µg/ml Alcian Blue in guanidine hydrochloride for C28/I2 
micromasses, Figure 2.2.13A; top standard for primary adult human articular 
chondrocytes was 62.5µg/ml Alcian blue, Figure 2.2.13B).  
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Figure 2.2.13 Alcian Blue standard curve. Alcian blue was dissolved in guanidine hydrochloride 
and serial dilutions were performed to generate standard curves. (A) A higher concentration 
range was used for determining Alcian blue dye content in C28/I2 micromasses. (B) A lower 
concentration range was used for determining Alcian blue dye content in primary adult human 
articular chondrocyte micromasses. Blue points show data interpolation from representative 
experiments. 
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2.2.4.5 Normalisation of C28/I2 Chondrocytes Micromasses 
Although micromass culture of C28/I2 cells allows the reproducible assaying of 
chondrocyte matrix accumulation, significant variability was encountered between 
plates, or when serum-free or serum-supplemented medium was used. To avoid inter-
plate variation, each 48-well plate (Figure 2.2.11) contained 3 wells reserved strictly for 
the determination of control matrix accumulation. By transforming data to percentage 
change from these control wells ensured that variation introduced by uncontrollable 
outside factors, such as humidity, temperature, surface tension of the droplet, 
electrostatic charge of the plate or passage number did not interfere with overall matrix 
content observations, especially in experiments performed over a number of weeks. 
Furthermore, by normalising to cell number rather than protein content, made the data 
more reproducibly robust. Early attempts at normalisation of chondrocyte micromasses 
to protein content by bicinchoninic acid (BCA) assay (Pierce) were unsuccessful, for 
three reasons. Firstly, the extracted dye interfered significantly with the colourimetric 
analysis by spectrophotometer (Figure 2.2.14), leading to inaccurate results. Second, 
the dye extractions were not sufficiently high in protein for the assay to determine 
sensitively the protein extracted and third, the 6M guanidine solution in which the dye is 
extracted is not recommended for BCA assay and reduced sensitivity further.  
 
 
 
A 
C 
C 
Alcian Blue stained micromasses 
Extracted dye + Standards 
BCA Assay + Standards 
B
Figure 2.2.14 BCA Assay of dye/protein 
extractions from C28/I2 chondrocyte 
micromasses is affected by the inherent dye 
content. (A) Micromasses cultured for 72 
hours were fixed and stained with Alcian blue 
dye. (B) Dye was extracted with 6M guanidine 
hydrochloride and measured 
spectrophotometrically. (C) Normalisation by 
BCA assay was not accurate due to the 
presence of the dye. 
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2.2.4.6 Normalisation of Micromass Alcian Blue Dye Content to Cell 
Number Using SYBRgreen Dye 
The quantification of DNA was used to more accurately interpolate the approximate cell 
number from the guanidine dye extractions. Detection of double stranded DNA by the 
addition of SYBRgreen I dye (Invitrogen) is not affected by the presence of the Alcian 
blue and can be measured from a very small amount of dye extract. To normalise the 
results to cell number, 5µl of the extracted dye solution was removed and added to 1µl 
100X SYBRgreen dye and 94µl Tris-EDTA. Fluorescence was measured using a 
TECAN M200 spectrophotometer (Tecan, Mannedorf, Switzerland) in a flat-bottomed 
black plate at 485/535nm and again, concentration was interpolated from a known 
standard curve plotted by measuring the fluorescence of genomic DNA standards. 
C28/I2 micromasses contained a larger amount of DNA and required a standard curve 
with a higher uppermost standard of 800µg (Figure 2.2.15, left panel). Standards were 
assayed in duplicate. Primary adult human articular chondrocyte micromasses 
contained a smaller amount of DNA, therefore lower standards in triplicate were 
assayed to generate a standard curve (Figure 2.2.15, right panel). Results were used 
to generate absolute sGAG concentrations, and are expressed as percentage change 
from control. 
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Figure 2.2.15 DNA quantification standard curve. Standard curves were generated using 
known concentrations of genomic DNA and quantified by SYBRgreen fluorescent dye. (A) C28/I2 
C28/I2 micromass DNA was of a higher concentration and required a standard curve with a 
larger range with higher concentrations, performed in duplicate. (B) Primary adult human 
articular cartilage DNA was of a lower concentration and required a smaller range of low 
concentrations, which were performed in triplicate. Blue points show data interpolation from 
representative experiments. 
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2.2.5 Ex Vivo Cartilage Models 
2.2.5.1 Generation of Rat Primary Chondrocyte Micromasses 
Due to the expense and low passage capacity of human primary adult human articular 
chondrocytes, an alternative source for primary chondrocyte culture was explored. Rat 
femoral heads were collected (2 per donor), washed extensively with PBS and then 
minced before being placed in 50ml falcon tubes in 6ml DMEM high glucose 
supplemented with Collagenase type 2 (0.01%) for 18 hours in a water bath set at 
37°C and equipped with a rocker. The resulting cell suspension was passed through a 
70µm filter to remove cartilage pieces, and the cells were cultured in T25 culture flasks 
in DMEM high glucose supplemented with 10% FBS. Given the limited number of 
chondrocytes obtained, cells were not counted before plating, but instead allowed to 
expand for 3 days with half the medium changed each day. Cells had the characteristic 
cobblestone morphology of C28/I2 human chondrocyte cells in monolayer culture 
(Figure 2.2.16A). Micromasses were generated as described in section 2.2.4.2 (Figure 
2.2.16).  
 
Unfortunately, isolated rat chondrocytes did not generate sufficient matrix and did not 
stain intensely enough with Alcian blue to allow reproducible quantification (Figure 
2.2.16H).  
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Figure 2.2.16 Generation of micromasses with isolated primary chondrocytes from rat femoral 
heads. (A) Isolated chondrocytes had cobblestone morphology similar to the C28/I2 cell line 
chondrocytes in monolayer. Cells were cultured to confluence and used between passage 1 and 
5. (B) Cells were seeded in high density (5 x 105 cells in 20µl), (C, D) formed homogenous 
suspensions and were spherical in shape. (E, F) At three hours cells had adhered and in high-
density areas, retained the spherical morphology. (G) By 72 hours, cells had generated a small 
amount of matrix (H) that stained poorly with Alcian blue dye.  
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2.2.5.2 Culture of Rat Femoral Head Explants as a Model of Cartilage-
Native Chondrocytes 
As the culture of isolated rat femoral head chondrocytes was not feasible, the explants 
were instead used as a model of cartilage-native chondrocyte matrix preservation. The 
femoral heads were ideal for this type of culture as they did not require extensive clean 
up to remove cells from other tissue types, unlike knee cartilage explants (Figure 
2.2.17A and B). Furthermore, they could be obtained whole from the head of the femur 
ball without damaging the cartilage (Figure 2.2.17C), which prevented autocatalysis of 
the cartilage matrix by exposed chondrocytes.  
 
Rat cartilage explants were used for experiments to investigate the entry of 
microparticles into cartilage. Eight-week old male Wistar rats were obtained post-
mortem after intravital surgery, with only control or sham-operated rats used for explant 
collection. Tissue collection was carried out in a sterile flow cabinet under sterile 
conditions so that the tissue could be cultured. A paraspinal incision was made 
posteriorly to expose the dorsal hip joints with attaching ligaments and muscle 
dissected. The femurs were then dislocated and the femoral head caps detached 
carefully using forceps and the ligament teres removed. Femoral heads were then 
washed in 50ml PBS followed by agitation for one minute and replacement of PBS up 
to ten times. Femoral heads were incubated in 5% CO2 for 24 hours at 37°C in 5ml 
serum-free DMEM-high glucose containing penicillin (200U) and streptomycin 
(200mg/ml) plus 1% ITS supplement before stimulation with 50ng/ml human 
recombinant IL-1β or vehicle (PBS) each day for 3 days. 
 
In order to develop a method to quantify the sulphated glycosaminoglycan matrix 
content, the femoral heads were stained whole in the same manner as micromasses: 
fixed in glutaraldehyde (4%), acidified with 0.1N HCl and then stained overnight with 
Alcian blue. Although the femoral heads stained intensely with Alcian blue dye (Figure 
2.2.17D and E), the extraction was not 100% complete, nor homogenous for the whole 
explant. Therefore, the femoral heads were fixed in paraformaldehyde (4%) for 18 
hours before being embedded in OCT embedding medium for cryosectioning. This 
method was chosen over paraffin embedding as the tissue was perfectly preserved by 
freezing (Figure 2.2.17G) and allowed a faster throughput. Furthermore, the staining 
intensity with Safranin O was superior with frozen sections compared to paraffin 
embedded sections (Figure 2.2.17H and Figure 2.2.18).  
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Figure 2.2.17 Rat femoral head explants as a model of cartilage-native chondrocyte matrix 
preservation. (A) Cartilage explants were excised from sham-operated rats post-mortem, 
including the knee cartilage, (B) but required extensive clean-up to remove contaminating cell 
types. (C) Femoral heads could be easily resected and kept intact and were free of other cell 
types when the ligament teres was removed, thus were chosen for experiments. (D and E) For 
quantification of sulphated glycosaminoglycans, Alcian blue was used to stain femoral heads 
intensely, (F) but could not be extracted fully. (G) Cryoembedding preserved the ultrastructure of 
the cartilage matrix and (H) Safranin O was used to quantify the sulphated proteoglycan 
content. 
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2.2.5.3 Quantification of Safranin O Percentage Area Positive 
Percentage area Safranin O area positive could be measured using ImageJ imaging 
software, allowing quantification of cartilage integrity throughout culture (Figure 2.2.19). 
Six images from each section, and 3 sections per femoral head were obtained using an 
Olympus BH-2 light microscope with Nikon DXM1200 digital camera attached. Colour 
images were split into their individual red/green/blue channels and the blue channel 
was used for quantification as it best represented the positive Safranin O areas. A 
positivity threshold was applied by eye using positive and negative controls from the 
experiment and checked against the original colour image. The threshold was applied 
and the area traced with the freehand tool. The threshold was the same for each batch 
of femoral heads sectioned. Measurements were collected and data displayed as 
percentage area positive for Safranin O staining. 
Paraffin embedded OCT cryo-embedded 
Untreated rat femoral heads 
Figure 2.2.18 Superior sulphated proteoglycan staining in unstimulated rat femoral heads 
using Safranin O with OCT embedded explants. Rat femoral heads were collected and cultured 
for 3 days in supplemented DMEM high-glucose before fixation in 4% paraformaldehyde for 18 
hours then either OCT embedded and frozen using dry ice before sectioning on a cryotome, or 
processed and paraffin embedded. Sections were then dewaxed before rehydration and 
staining with Safranin O. Sections at X4 magnification were captured using a standard light 
microscope (Olympus BH-2) with digital camera attachment (Nikon DXM1200).  
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Figure 2.2.19 Sulphated proteoglycan content was quantified using ImageJ imaging software. 
Rat femoral heads were collected and cultured for 3 days in supplemented DMEM high-glucose 
before fixation in 4% paraformaldehyde for 18 hours then OCT embedded and frozen using dry 
ice before sectioning on a cryotome. Sections were stained with Safranin O. Sections at X4 and 
(A) X20 magnification were captured using an Olympus BH-2 standard light microscope with 
Nikon DXM1200 digital camera attachment. (B) Images were split into their individual 
red/green/blue channels and the blue channel was used for quantification. (C) A positivity 
threshold was applied by eye using positive and negative controls from the experiment and 
checked against the original colour image. (D) The threshold was applied and the area traced 
with the freehand tool. (E) The threshold was the same for each batch of femoral heads 
sectioned. (F) Measurements were collected and data displayed as percentage area positive for 
Safranin O staining. 
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2.2.5.4 Immunofluorescence Using Rat Femoral Heads 
 
Cryopreservation of the cartilage explants was ideally suited for immunofluorescence 
analysis, and ensured that staining could be carried out without the need for antigen 
retrieval. Very low background staining could be achieved with anti-human antibodies, 
used during microparticle localisation experiments (Figure 2.2.20). Furthermore, as the 
processing of samples for OCT embedding is minimal, fluorescently labelled 
microparticles (with Bodipy-maleimide) retained their fluorescence and could be 
detected by both fluorescence and confocal microscopy after culture, sectioning and 
staining. 
 
A 
C D 
MRP8 (200µg/ml) X20 DAPI (1µg/ml) X20 
MRP8 (50µg/ml) DAPI (10µg/ml) X20 
B 
Figure 2.2.20 Rat femoral head explants did not stain positively for human MRP8. Rat femoral 
heads were collected and cultured for 3 days in supplemented DMEM high-glucose before being 
fixed in 4% paraformaldehyde for 18 hours then OCT embedded and frozen using dry ice before 
sectioning on a cryotome. Sections were stained with anti-human MRP8 antibodies (A 
200µg/ml and C 50µg/ml) and DAPI (B 1µg/ml and D 10µg/ml) to visualise the nuclei. 
Sections at X4 and (A) X20 magnification were captured using a standard fluorescence 
microscope with digital camera attachment.  
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To determine entry of TMP into femoral head explants, explants were cultured phenol 
red-free RPMI supplemented with 1% ITS in a 24 well suspension plate for 24 hours to 
equilibrate. Explants were stimulated for 3 days with IL-1β (50ng/ml) or vehicle (PBS) 
then transferred to a 96 well suspension plate. As a control for microparticle entry, 
femoral head explants were treated with 100,000 synthetic fluorescent microcapsules 
loaded with a similar content of Annexin A1 or 100,000 Bodipy-maleimide loaded TMP. 
Femoral heads were washed thoroughly in PBS 18 hours later to remove any residual 
microparticles, fixed in PFA (4%) overnight then collected into OCT embedding 
medium and snap frozen. Femoral heads were cryosectioned at 10µm, placed on 
charged glass microscope slides to dry then stained for confocal microscopy (see 
section 2.3.14). 
 
2.2.5.5 Culture of Mouse Femoral Head Explants as a Model of Cartilage-
Native Chondrocytes  
In later experiments, mouse femoral head cartilage was utilised as they could be 
genetically manipulated. Collection of mouse femoral head cartilage was carried out in 
the same way as for the rat femoral head isolation, but was technically challenging due 
to the small size of the tissue. 
 
Mouse femoral head cartilage was collected from C57BL/6 wild type, Fpr1 or Fpr2 
knockout animals (day -2) aseptically less than 40 minutes post mortem and thoroughly 
washed in sterile PBS before incubating for 48 hours in serum-free DMEM high 
glucose (4.5g/l) plus 1% ITS supplement to equilibrate. After this period (day 0), 
suspension culture plates were used, and medium replaced, to prevent microparticle 
adhesion to the plastics. Recombinant mouse IL-1β (10ng/ml) was added along with 
100,000 microparticles per whole cartilage. Treatment was repeated on day 3 and 6 
then collected and stained with Safranin O in the same way as rat femoral head 
explants.  
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2.2.6 In Vivo Delivery of Microparticles via Intra-Articular 
Injection 
 
Intra-articular delivery of microparticles in vivo into arthritic mice was required. This 
technique allowed for the paired analysis of microparticle treatment in arthritic mice, 
reducing inter-donor variability. Damage to the cartilage during this method was 
avoided by repeated practice of the intra-articular injections post mortem in naïve 
C57BL/6 mice. First, the skin was resected so that the patella could be clearly 
visualised (Figure 2.2.21A). Intra-articular injection of Evan’s blue dye was 
administered approximately half way up the patella. This would ensure the dose was 
delivered exactly within the joint space (Figure 2.2.21B). Care had to be taken not to 
guide the needle too far into the knee, to prevent contact with the medial and radial 
menisci or anterior cruciate ligament (Figure 2.2.21C). Contact with these structures 
causing damage to any of the matrix is liable to cause arthritis in itself. (Figure 2.2.21D) 
Delivery of 6µl of Evan’s blue filled the entire cavity and could be seen behind the 
patella. (Figure 2.2.21E) Resection of intact injected knees showed that the doses had 
been delivered and damage to the menisci or ligaments could not be seen. For in vivo 
intra-articular injections in live mice, mice were anaesthetised with isoflurane mixed 
with oxygen and placed on a nose cone. The fur of the knees was then trimmed with 
clippers so that the patella could be visualised through the skin. A maximum of 6µl was 
injected into each knee. 
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Figure 2.2.21 Accurate intra-
articular injections require 
delivery of compounds directly 
to the joint space. In order to 
administer anti-inflammatory 
compounds via intra-articular 
injection, the injections 
themselves should induce no 
inflammation. (A) Skin was 
resected post-mortem so that 
the patella could be clearly 
visualised. (B) The patella was 
removed to expose the joint 
space. (C) Dissection 
microscopy revealed the 
medial and radial menisci and 
anterior cruciate ligament, 
structures that needed to be 
avoided when performing intra-
articular injections. (D) Intra-
articular injection of Evan’s 
blue dye was administered 
approximately half way up the 
patella in intact knees. This 
ensured the dose was 
delivered exactly within the 
joint space. Delivery of 6µl of 
Evan’s blue filled the entire 
cavity and could be seen 
behind the patella. (E) 
Resection of the intact, 
injected knee showed that the 
dose had been delivered and 
damage to the menisci or 
ligaments could not be seen. 
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2.3 Methods 
2.3.1 Neutrophil Isolation from Peripheral Blood 
Neutrophils were isolated from the peripheral blood of healthy volunteers, after 
providing informed consent, using the dextran sedimentation method. Blood (60ml) 
was drawn with a tourniquet applied using a 21-gauge butterfly needle into a 60ml 
syringe. Once drawn, blood was handled quickly but gently at room temperature to 
prevent activation of the neutrophils. The blood was immediately transferred into two 
50ml falcon tubes containing 3ml 3.2% sodium citrate for anticoagulation. The falcon 
tubes were then gently inverted to mix, and then centrifuged at 130 x g for 20 minutes 
at room temperature to sediment the cells (Figure 2.3.1A). The platelet rich plasma 
was removed then 10ml PBS was carefully layered over the cell suspension, without 
mixing the two together. This prevents the activation of the cells by turbulence. Dextran 
(from Leuconostoc, molecular weight 450,000 to 650,000; 6% w/v, 8 ml) was gently 
added to the PBS. The tubes were inverted gently to mix the cell suspension with the 
PBS and dextran (Figure 2.3.1B).  
 
Dextran causes red cells to form aggregates, which sink to the bottom of the tube, 
leaving a layer of PBS/dextran enriched in blood leukocytes that is largely depleted of 
red blood cells. This process takes around 20 minutes, after which the leukocyte rich 
layer was carefully removed without generating bubbles and layered over 10ml 
Histopaque 1077 in a fresh 50ml falcon tube (Figure 2.3.1C), with a maximum of 25ml 
of leukocyte suspension per 10ml Histopaque. Tubes were then centrifuged for 30 
minutes at room temperature at 450 x g. Histopaque 1077 is of a specified density 
which allows cells to travel through only if they are of a sufficiently small density. Thus, 
red blood cells and granulocytes become pelleted at the bottom of the tube below the 
Histopaque (Figure 2.3.1D), whereas the peripheral blood mononuclear cells remain 
above this layer, allowing separation of the two populations of leukocytes. The 
mononuclear cells were then collected with every effort made to remove as many cells 
as possible to prevent contamination of the granulocyte population.  
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Figure 2.3.1 Neutrophil Isolation from Whole Blood via Dextran Sedimentation. (A) Platelet-rich 
plasma is removed from blood samples following the first centrifugation of 800 x g for 20 
minutes, leaving the buffy coat and red cells. (B) Dextran is used to aggregate the red cells and 
enrich the leukocyte layer. (C) Histopaque 1077 is used to separate the populations of 
leukocytes, (D) which can then be collected separately. PRP, platelet-rich plasma; RBC, red 
blood cells; PBMC, peripheral blood mononuclear cells; PMN, polymorphonuclear cells. 
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The remaining plasma and Histopaque were removed, and the red blood cells were 
lysed through hypotonic shock with 9ml ice-cold ultrapure distilled water. Isotonicity 
was quickly restored (after less than 20 seconds) by drawing up the cell/water 
suspension and adding it to a new falcon tube containing 1ml 10x Hanks solution. New 
tubes were used for isotonicity restoration to prevent any mononuclear cells adherent 
to the plastic of the tube from being washed into the granulocyte suspension. PBS 
(40ml) was gently added to the cell suspension for washing, and the cells were 
centrifuged to pellet the cells at 300 x g for 10 minutes at room temperature. Once the 
cells were pelleted, the PBS was carefully aspirated to ensure as much as the red 
blood cell lysis fluid was removed as possible. The resulting neutrophil pellets were 
pale cream in colour, indicating full lysis of the red blood cell population. The 
granulocyte population was then gently but thoroughly resuspended in 3ml phenol red-
free, incomplete RPMI for counting. To count, 10µl of the cell suspension was added to 
490µl Turk’s stain (98ml distilled H2O, 2ml acetic acid and 2g crystal violet) in a 1.5ml 
eppendorf, then vortexed briefly to obtain a homogenous cell suspension with no 
aggregates. Cells in Turk’s dye were applied to a Neubauer counting chamber with 
coverslip applied. The cells were visualised with an Olympus BH-2 standard light 
microscope with x40 objective, and cells in the 4 larger outer squares were counted 
(Figure 2.3.2). The average was taken and multiplied by the dilution factor to provide 
the number of neutrophils per ml x 104, and this value was multiplied by the number of 
millilitres the cells were resuspended in, to give the total number of cells isolated. The 
cell concentration was adjusted to 2 x 107/ml for stimulation. 
x dilution factor x 104 = cells/ml  
x total volume = total cells 
number of cells 
4 
Figure 2.3.2 Counting Neutrophils using a 
Neubauer chamber and the formula for 
calculation. Neutrophils were diluted 1:50 
with Turk’s solution for counting and 10µl 
applied to the Neubauer chamber. Cells were 
visualised using a light microscope on X40 
objective. All cells in the out four corner 
squares (highlighted red) were counted and 
divided by 4 to obtain the average. This 
number, multiplied by the dilution factor 
provides the number of cells per millilitre x 
104. Neutrophils were counted if they had 
characteristic multi-lobed nuclei (red arrows). 
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2.3.2 Flow Cytometric Analysis of Cells 
 
Flow cytometry is a well-characterised and useful tool for the analysis of populations of 
cells in suspension. By labelling cells with fluorochrome-conjugated antibody labels, 
the phenotype of cell populations can be determined.  
 
2.3.2.1 Determination of Granulocyte Purity and Activation Status  
Freshly isolated human neutrophils were analysed by flow cytometry to determine their 
purity, and their expression of activation markers, CD11b and CD62L. Cells (5x105) 
were added to a round-bottomed 96 well plate and pelleted by a brief spin (30 seconds 
at 400 x g, room temperature) before re-suspending in 50µl Fc block (16mg/ml) for 30 
minutes on ice to prevent nonspecific binding of antibodies. Monoclonal, fluorochrome-
conjugated antibodies to CD62L and CD11b were added (for concentrations, clones 
and catalogue numbers, see Table 2.1.1), or the relevant isotype at the same 
concentration, for 1 hour on ice in the dark. Cells were washed 3 times briefly with 
200µl/well PBS (supplemented with 1% bovine serum albumin) and centrifuged for 30 
seconds at 400 x g. Cells were resuspended in 200µl supplemented PBS and 
transferred to flow cytometry tubes for immediate acquisition. Cells were analysed 
using a BD FACSCalibur flow cytometer and the PMN population identified from the 
FSC/SSC dot plots (similar to Figure 2.2.1B). Single stains were used to determine the 
correct amount of compensation required, where a signal emitted from one 
fluorochrome appears inappropriately in two channels.  
 
Mouse neutrophils collected from the peritoneal lavages of mice receiving 1mg 
zymosan from Saccharomyces spp. were stained with Annexin A1 polyclonal 
antibodies for one hour on ice in the dark, after being blocked for one hour with Fc 
block (16mg/ml). The cells were washed three times with PBS (supplemented with 1% 
BSA) followed by centrifugation briefly at 400 x g for 30 seconds, then the secondary 
anti-rabbit Alexa594 added for half an hour in the dark on ice. Ly6G antibodies were 
added following a second washing step, again for one hour on ice in the dark. The cells 
were washed three times before being resuspended in 200µl supplemented PBS and 
then analysed using a BD FACSCalibur.  
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2.3.2.2 Flow Cytometric Analysis of C28/I2 Chondrocyte Cell Line 
C28/I2 cells cultured in micromass (see section 2.2.4.2) were dissociated into a single 
cell suspension using Accutase cell dissociation solution for 10 minutes at 37°C 
followed by pipetting up and down 10 times to remove any aggregates (Figure 2.3.3A). 
Cells were then fixed and permeabilised using a fix/perm buffer commercially available, 
according to manufacturer instructions (eBioscience, Figure 2.3.3B). Cells were fixed in 
the fix buffer (which contains blocking buffer) for 10 minutes at room temperature in the 
dark then permeabilised by the addition of 200µl permeabilisation buffer without 
removing the fixative. After 20 minutes, cells were pelleted by brief centrifugation at 
400 x g for 30 seconds. Antibodies against FPR2/ALX, FPR1 and appropriate isotype 
controls were diluted to the correct concentrations (see Table 2.1.1) in permeabilisation 
buffer and incubated in the dark at room temperature for 30 minutes. Goat-anti-mouse 
Alexa594 secondary antibodies were diluted to 20µg/ml using permeabilisation buffer 
and added after several washes in permeabilisation buffer with brief centrifugations (30 
seconds at 500 x g). Finally, after washing again, cells were resuspended in 
permeabilisation buffer and analysed using a BD FACSCalibur. 10,000 events were 
recorded, with fluorescence excited with the 488 laser and emission signals collected. 
 
SS
C 
FSC 
Dissociated cells 
FSC 
SS
C 
Permeabilised cells 
A B 
Figure 2.3.3 C28/I2 micromasses can be dissociated and permeabilised for flow cytometry. (A) 
Cells were dissociated by incubation in Accutase for 10 minutes at 37°C followed by pipetting to 
disperse clumps. (B) Cells following fixation and permeabilisation.  
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2.3.3 Nanoparticle Tracking Analysis 
 
Nanoparticle tracking analysis was used to determine the absolute size of 
microparticles below 1µm in diameter. This method allows the absolute quantification 
of particle size by recording the Brownian motion of laser-illuminated particles by video 
microscopy. The relationship between the Brownian motion of microparticles in 
suspension and their size requires the diffusion coefficient and the sphere equivalent 
hydrodynamic radius to be calculated, which is performed by the NTA software, using 
the Stokes-Einstein equation. This gives the rate of diffusion of spherical particles 
through liquid with a low Reynolds number (i.e. with little or no turbulence). To 
illuminate the microparticles, a precisely focussed laser beam is introduced via a glass 
prism into the sample. As the laser beam is refracted at a low angle via the prism, a 
fine beam of laser light is generated at the interface between sample and prism. A 
camera is mounted perpendicularly to the sample chamber in order to collect the 
highest amount of light scattered by the illuminated particles. Frame-to-frame analysis 
of the particles’ motion tracks allow their absolute size to be determined as smaller 
particles move more rapidly and travel a greater distance, whereas larger particles 
move slowly and do not travel very far. Pre-prepared, TNF-α generated microparticles 
were pooled from 6 donors to create a test volume of 1ml with sufficiently high 
microparticle numbers for analysis (around 107/ml). Microparticle diameters were 
analysed with NanoSight LM10 system with a 405nm laser (NanoSight Ltd., Amesbury, 
UK) at 22°C. Samples were introduced via manual syringing, and videos recorded for 
90 sec using NTA software (version 2.3): blur setting, auto; detection threshold, 10; 
minimum expected particle size, auto; minimum track length, auto; viscosity, 0.95 cP. 
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2.3.4 Measurement of Apoptosis in Chondrocytes 
 
2.3.4.1 DIOC6 Staining 
Early events in apoptosis, those occurring before cell shrinkage, blebbing and nuclear 
fragmentation, include the loss of the potential across the mitochondrial membrane 
(Zamzami et al., 1995). This can be measured using the cationic fluorochrome DiOC6 
(3,3'-dihexyloxacarbocyanine iodide), which permeates the cell membrane and 
accumulates within mitochondria due to the large negative membrane potential. 
Apoptotic cells lose this potential and the fluorescent signal subsequently decreases. It 
is therefore possible to distinguish DiOC6-high resting cells from DiOC6-low apoptotic 
cells using flow cytometry. To determine early apoptosis, cells were dispersed 
thoroughly in their wells before being incubated with DiOC6 dye (40nM dissolved in 
100% ethanol) for 30 minutes at 37°C in the dark. Cells were washed three times in 
PBS supplemented with 1% bovine serum albumin followed by brief centrifugation for 
30 seconds at 400 x g. Cells were resuspended in 200µl supplemented PBS for 
sample acquisition using a BD FACSCalibur flow cytometer (see section 2.3.2.2). 
10,000 events were acquired and fluorescence detected using the 488nm laser. 
Results are expressed as a percentage of cells DiOC6 low. 
 
 
Micromasses were treated with valproic acid (5mM, 10mM or 20mM) as a positive 
inducer of chondrocyte apoptosis for 24 hours and this was determined by DiOC6 
staining to induce the same level of apoptosis as IL-1β (50 or 100ng/ml) (Figure 2.3.4). 
Thus, IL-1β (50ng/ml) was added to micromasses with or without 100,000 CMP, TMP 
or IMP for 18 hours. The cells were then dissociated with Accutase for 10 minutes at 
37°C and dispersed by gentle pipetting. 
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Figure 2.3.4 IL-1β is as effective at inducing apoptosis as Valproic Acid positive control. C28/I2 
chondrocytes in micromass culture were stimulated for 18 hours with IL-1β (50 or 100ng/ml)  
or Valproic acid and apoptosis was measured using DIOC6 staining. Data are expressed as 
mean ± SEM of 3 separate micromasses ***P<0.001 with One-way ANOVA and Bonferroni 
post-test. Top panels are representative plots from the experiment. 
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2.3.4.2  TUNEL Staining 
To determine more advanced apoptosis, a TUNEL staining kit was used (Millipore 
ApopTag Plus Fluorescein In Situ Kit). TUNEL staining was used to detect fragmented 
DNA of terminally apoptotic cells. The assay is based on the incorporation of 
fluorescently conjugated FITC-dUTPs by the enzyme terminal deoxynucleotidyl 
transferase (TdT) at the 3’-OH ends of the DNA fragments.  
 
 
Cells were added to charged glass microscope slides and checked using a light 
microscope to ensure they were at sufficiently low density for quantification. The slides 
were then dried and fixed in 1% paraformaldehyde (in PBS, pH 7.4) for 10 minutes. 
The slides were then washed twice in PBS and post-fixed and permeabilised in 
ethanol/acetic acid (100ml 100% ethanol containing 50ml acetic acid) for 5 minutes at -
20°C. After washing twice in PBS again, 25µl equilibration buffer was added, followed 
by TdT enzyme (77µl reaction buffer and 33µl TdT). Slides were then incubated for 1 
hour at 37°C in a humidified chamber, then dipped 3 times in Stop buffer (1ml Stop 
buffer in 34ml distilled water) before being incubated in Stop buffer for 10 minutes. 
Following another wash step, pre-warmed 25µl anti-digoxigenin conjugate was added 
to the slides before incubation in the dark for 30 minutes in a humidified chamber at 
room temperature. Slides were then washed several times more before being mounted 
in Mowiol containing DAPI to visualize the nucleus. Slides were visualized using an 
Olympus BH-2 light microscope equipped with fluorescent lamps, and images captured 
with a Nikon DXM1200 digital camera. Any green positive cells, as determined by 
applying a threshold using ImageJ were checked for obvious nuclear changes such as 
condensation, indicating apoptosis (Figure 2.3.5). Data are expressed as a percentage 
of 200 cells evaluated.  
DAPI TUNEL Merge 
Figure 2.3.5 Apoptotic cells have condensed nuclei and stain positively with TUNEL stain. 
C28/I2 cells stimulated with IL-1β (50ng/ml) for 18 hours then were stained using a 
commercially available TUNEL kit and analysed by fluorescence microscopy for nuclear changes 
coinciding with TUNEL positivity. 
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2.3.5 1,9-Dimethylmethylene Blue Dye Binding Assay 
 
The quantity of free sulphated glycosaminoglycans (sGAG) released into the culture 
medium of C28/I2 micromasses was measured by 1,9-dimethylmethylene blue dye-
binding assay. For the culture supernatants to be sufficiently concentrated, 
micromasses were stimulated for the final 24 hours in a reaction volume of 300µl. 
Supernatants (100µl) were collected and digested in an equal volume of digestion 
buffer containing 0.5mg/ml Papain, 20mM disodium orthophosphate, 1mM EDTA and 
2mM Dithiothreitol (DTT). The samples were digested for 18 hours at 65°C before 20µl 
was applied to the wells of a 96-well round-bottom plate in triplicate (used to aid 
mixing). Chondroitin-4-sulphate diluted in digestion buffer and serially diluted acted as 
standards at known concentrations (1mg/ml to 30µg/ml). Using a multichannel pipette, 
190µl 1,9-dimethylmethylene blue dye (0.016%, 40.5mM glycine, 40.5mM NaCl, 197µl 
37% HCl) was added and the plate left to equilibrate for 30 seconds. Optical density at 
530nm was immediately determined using a TECAN M200 spectrophotometer. 
Absolute sGAG concentrations were determined from the standard curve generated by 
plotting known standard concentrations against absorbance (Figure 2.3.6). 
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Figure 2.3.6 Standard curve for DMMB dye-binding assay. Supernatants from C28/I2 
micromasses stimulated for 24 hours with or without IL-1β (30ng/ml) and 100,000 
microparticles were digested overnight with papain then assayed with 1,9 dimethylmethylene 
blue to quantify released glycosaminoglycans. Blue points show data interpolation from a 
representative experiment.  
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2.3.6 SDS-PAGE  
 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) allows 
analysis of proteins present within a supernatant sample or cell lysate by using gel 
electrophoresis to separate molecules according to size and charge then transferring 
them onto a polyvinylidene difluoride membrane, where proteins can be detected with 
specific monoclonal antibodies. The anionic detergent SDS denatures proteins by 
disrupting hydrogen bonds and gives the protein a negative charge by covering the 
polypeptide backbone of the protein in its hydrophobic tail. Consequently, the proteins 
migrate in the gel according to size, with the smallest proteins moving furthest through 
the gel. The structure of the protein is completely unfolded by the addition of DTT, 
which acts as a reducing agent that cleaves the disulphide bonds of the protein.  
 
C28/I2, primary adult human articular chondrocyte or microparticle (100,000) samples 
were collected in boiling hot Laemmli buffer (50mM Tris-HCl (pH 6.8), 2% SDS, 10% 
glycerol, Sigma), before being diluted 5 parts sample to 1 part 6x SDS loading-buffer 
[600mM DTT, 0.6% bromophenol blue, 300mM Tris-HCl (pH 6.8), 12% SDS and 60% 
glycerol] and boiled for 5 minutes. Samples were loaded onto pre-prepared 4% 
stacking and a 10% or 12% resolving polyacrylamide gel (w/v; see Table 2.3.1 for 
volumes and ingredients). All reagents were combined except the APS and TEMED, 
which act as polymerisation catalysts, so were added immediately before casting the 
gels. The Hoefer casting kit and electrophoresis system were used: sandwiches of 4 
gel casting cassettes were assembled by adding two T-separators to a short-plate and 
applying a 1.5mm front-plate (x4) and sealing the cast with clamps ensuring all rubber 
seals were in place. Resolving gel was poured into the cast, then overlaid with 
isopropanol to prevent a curved meniscus forming. Gels were left to polymerise for 20 
minutes at room temperature, after which the isopropanol was poured off and the 
stacking gel applied. To prevent bubbles forming, the gel was poured before the 10-
well combs were carefully set into each cassette. After polymerisation, the gel 
cassettes were placed into the electrode assembly tanks for electrophoresis. Cassettes 
(2 per tank) were clamped to the tank, which was filled with 200ml running buffer 
(25mM Tris-base, 200mM glycine and 0.1% SDS). The cavity behind the gel cassettes 
was then filled with running buffer from the tank using a Pasteur pipette. Combs were 
removed and 30µl of sample was added to each well, along with 7µl high-range 
rainbow molecular weight marker (GE Healthcare, Amersham) into one well, to 
visualise separation and sample protein size. The electrophoresis tank was run at 
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30mA per gel for 30 minutes to pass through the stacking gel, and then increased to 
50mA per gel until the rainbow markers were separated.  
 
Once the dye front had reached the bottom of the gel, the stacking gel from each plate 
was discarded, and the resolving gel placed in transfer buffer (25mM Tris-base, 
192mM glycine and 20% methanol) for transfer assembly. Blotting paper (2 sheets) 
was placed on a sponge, the gel was placed on the blotting paper, and a methanol-
activated polyvinylidene difluoride membrane was placed on top. Another layer of 
blotting paper was added before the sandwich was completed by the addition of the 
final sponge. Gel/membrane sandwiches were transferred in sample cages to Bio-Rad 
transfer tanks and were transferred overnight at 50V (constant current). 
 
Table 2.3.1 Composition of 10% and 12% SDS-PAGE Resolving and 4% Stacking Gels 
Composition 
10% 
Resolving Gel 
 
12% 
Resolving Gel 
 
4% 
Stacking Gel 
 
30% (w/v) Acrylamide: 0.8% Bis 
acrylamide stock solution (37.5:1) 
(Protogel) (ml) 
13.32 16 3.9 
Resolving Buffer: 1.5M Tris-HCl, pH 8.8, 
0.4% SDS (Protogel) (ml) 
10.4 10.4  
Stacking Gel Buffer: 0.5M Tris-HCl, pH 
6.8, 0.4% SDS (Protogel) (ml) 
  7.5 
dH2O (ml) 15.84 13.16 18.3 
10% (w/v) Ammonium persulfate: APS 
(Sigma) (µl) 
400 400 150 
TEMED (Sigma) (µl) 40 40 40 
 
For the detection of proteins, membranes were blocked for 60 minutes in 5% milk in 
Tris-buffered saline (TBS) (150mM sodium chloride, 2mM Tris-base pH 7.4) containing 
0.1% Tween 20 (Sigma) (TBST) at room temperature on a rocker. Antibodies were 
diluted to the correct concentration (Table 2.3.2) in either 3% non-fat dried milk in 
TBST for native proteins or 5% BSA for phosphorylated antigens and incubated as 
indicated in Table 2.3.2.  Membranes were washed five times for 5 minutes each in 
TBST before the secondary antibody was added for 1 hour at room temperature.  
Membranes were washed a further 5 times before proteins were detected using a 
Luminata Forte HRP substrate and visualised on hyperfilm (GE Healthcare, Little 
Chalfont, UK) after a 2-minute exposure.  
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Table 2.3.2 Antibodies used for Western Blotting of proteins. 
Protein of 
interest 
Antibody Source Dilution Incubation time 
Annexin A1 Polyclonal rabbit 
anti-human 
Thermo 
Scientific 
1:250 
(stock 
0.7mg/ml) 
4°C overnight 
Sox9  Polyclonal rabbit 
anti-human  
Abcam 140µg/ml 1 hour, room temperature 
Total p38 Rabbit Cell Signalling 1:5000 1 hour, room temperature 
Total Akt Clone C67E7 Cell Signalling 1:10,000 1 hour, room temperature 
Total Hsp27 Mouse anti-human, 
Clone 631 
Cell Signalling 1:2000 1 hour, room temperature 
Total JNK Rabbit Cell Signalling  1:5000 1 hour, room temperature 
Total ERK1/2 Rabbit Cell Signalling  1:5000 1 hour, room temperature 
Total MK2 Rabbit Cell Signalling 1:2000 1 hour, room temperature 
β Actin Mouse anti-human, 
Clone AC-15 
Sigma 1:15,000 1 hour, room temperature 
Phospho p38 Rabbit Cell Signalling  1:1000 Overnight, 4°C, rocking 
Phospho Akt – 
Serine 473 
Mouse anti-human, 
clone 587FH  
Cell Signalling  1:2000 Overnight, 4°C, rocking 
Phospho 
Hsp27 (S78) 
Rabbit anti-human Cell Signalling 1:2000 Overnight, 4°C, rocking 
Phospho MK2 
(T222) 
Rabbit anti-human, 
Clone 9A7 
Cell Signalling 1:2000 Overnight, 4°C, rocking 
Phospho JNK Rabbit Cell Signalling 1:5000 Overnight, 4°C, rocking 
Phospho 
ERK1/2 
Rabbit Cell Signalling 1:5000 Overnight, 4°C, rocking 
Goat HRP Anti-mouse IgG Dako 1:2000 30 minutes, room 
temperature 
Rabbit HRP Anti-goat IgG Dako 1:2000 30 minutes, room 
temperature 
Rat HRP Anti-rabbit IgG Dako 1:2000 30 minutes, room 
temperature 
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For signaling experiments, C28/I2 cells grown in monolayer were used to detect the 
phosphorylation of several molecules involved in signaling pathways. Monolayers were 
used in preference to micromass constructs to prevent time-critical diffusion through 
multiple cell layers affecting the temporal modulation of the pathways. Confluent C28/I2 
were serum starved for 24 hours in phenol red-free RPMI supplemented with 1% ITS. 
Cells were then stimulated with IL-1β (30ng/ml), microparticles, or recombinant 
Annexin A1 (10nM; generated in-house) for 1, 5, 10, 30, 60, 120 or 240 minutes. Some 
samples were pretreated with microparticles for 18 hours. Supernatants were removed 
by aspiration and cells lysed with boiling hot laemmli buffer containing phosphatase 
inhibitor b (Sigma). Wells were scraped to ensure cells were thoroughly lysed. Samples 
were collected and boiled for 5 minutes. Following electrophoresis, transfer and 
incubation with antibodies, proteins were visualised using Luminata Forte HRP 
substrate and imaged on x-ray film or with a FluorChem E Digital Dark Room 
(ProteinSimple). For normalisation, the expression of each phosphorylated antigen was 
normalised to its total antigen. To do this, membranes were stripped using 6M glycine 
at pH 2, washed thoroughly in TBST then blocked in 5% non-fat milk for 1 hour at room 
temperature. Membranes were then reprobed for total antigen for one hour at room 
temperature, and then washed thoroughly in TBST 3 times. Secondary antibodies 
conjugated to HRP were added for a further 2 hours at room temperature before a final 
thorough washing in TBST and visualisation with Luminata Forte HRP substrate. 
Images were captured using either Hyperfilm (GE Healthcare) x-ray film or FluorChem 
E Digital Darkroom (Protein Simple). Densitometry of phospho proteins was 
determined using ImageJ imaging software and expressed as relative intensity of total 
target antigen.  
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2.3.7 Real-Time Polymerase Chain Reaction 
 
Real-Time PCR allows sensitive quantification of mRNA within cells by using 
SYBRgreen dye to visualise amplicon generation from a complimentary-DNA template. 
SYBRgreen dye binds to newly synthesised double-stranded DNA and emits 
fluorescent light in direct proportion to the number of amplicons generated in the 
reaction. A threshold of fluorescence detected above background was set in the 
exponential phase of amplification, and the cycle number at which the samples 
reached this level was referred to as the cycle threshold value (Ct), thus reflecting the 
relative abundance of the specific mRNA transcripts. To quantify the relative 
expression of each gene, Ct values were normalized with an endogenous 
housekeeping (reference) gene. Housekeeping gene was determined for C28/I2 
micromasses by testing three conventional housekeeping genes to detect any 
modulation across stimuli. The housekeeping gene with the least modulation was 
selected (Figure 2.3.7), which was RPL32.  
 
The comparative Ct method (Pfaffl, 2001) was used to measure gene transcription in 
samples. These results were expressed as relative units based on the calculation of 2-
ΔΔCt, which gives the relative amount of gene normalised to the endogenous control. 
The control samples were averaged, used as the calibrator and given a value of 1. 
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Figure 2.3.7 Housekeeping gene expression in C28/I2 micromasses with IL-1β stimulation. 
RPL32 was modulated the least by IL-1β stimulation and was therefore chosen as the 
housekeeping calibrator gene for subsequent mRNA expression studies. Ct, cycle threshold; ACTB 
beta-actin; GAPDH, glyceraldehyde phosphate dehydrogenase; RPL32, ribosomal protein L32; IL-
1β, interleukin 1β.  
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2.3.7.1 RNA Extraction 
Total RNA was extracted using a commercially available kit (Qiagen RNeasy Mini Kit) 
following manufacturer’s guidelines. Briefly, micromass samples were lysed in 350µl 
RLT buffer [containing 1:100 β-mercaptoethanol] and frozen at -80°C to increase RNA 
yield. Samples were defrosted on ice before being homogenised by syringing 5 times 
through a 27.5 gauge needle. 350µl of 70% molecular biology grade ethanol was 
added and samples were mixed well by pipetting before transferring the entire volume 
to the RNeasy kit columns. Samples were centrifuged at 10,000 x g for 15 seconds and 
flow-through discarded. 700µl RW1 wash buffer was added to columns and 
centrifugation for a second time at 10,000 x g for 15 seconds followed. Flow through 
was discarded before the addition of 500µl RPE and a further centrifugation step. A 
second wash with 500µl RPE followed, and samples were centrifuged a further time at 
10,000 x g, this time for 2 minutes. The collection tube was discarded and replaced 
with a new collection tube followed by a centrifugation at 12,000 x g for 1 minute to dry 
the membrane. Columns were placed into new collection eppendorfs and 30µl RNase-
free water was added directly to the membrane for RNA elution. Total RNA 
concentrations and purity was measured using a NanoDrop spectrophotometer and ND 
1000 software (NanoDrop Technologies, Wilmington, DE) at 260 and 280nm.  
 
2.3.7.2 cDNA Synthesis 
Complementary DNA (cDNA) was obtained via reverse transcription of 0.5µg of the 
total RNA samples, using Superscript III reverse transcriptase system (Invitrogen, 
Carlsbad, CA, USA). Firstly, mastermix 1 was created containing 1µl Oligo(dT)15  
primer, 1µl dNTP mix and 4µl water per sample. Mastermix 1 (6µl) was added to 0.5µg 
RNA sample (total 7µl volume) and incubated for 5 minutes at 65°C to denature RNA 
secondary structure followed by incubation on ice at 4°C to allow primer annealing. 
Mastermix 2 was made by adding 4µl First Strand buffer, 1µl DTT, 1µl RNase OUT and 
1µl Superscript III (enough for each sample plus one) and 7µl was added to the 
samples. Samples were then placed in the Abgene thermal cycler and incubated for 1 
hour at 55°C for cDNA extension then heated at 70°C for 15 minutes to deactivate the 
enzyme and stop the reaction. Negative controls were samples run without Reverse 
Transcriptase enzyme to exclude the possibility of human (or mouse) genomic DNA 
contamination. 
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2.3.7.3 RT-PCR 
A mastermix was created for Real-Time PCR (RT-PCR): 2µl water, 5µl of 1X 
SYBRgreen mastermix and 1µl gene-specific primer - enough for each sample and 
corresponding gene. Primers were commercially available and used to probe for target 
mRNA. 2µl cDNA was added to the appropriate mastermixes.  RT-PCR was performed 
using the ABI Prism 7900 real-time PCR system (Applied Biosystems Inc., CA, USA), 
using the following amplification profile: 2 minutes at 50°C, 15 minutes at 95° followed 
by 40 cycles of 94°C for 15 seconds, 55°C for 30 seconds and 72°C for 30 seconds. A 
dissociation step of 95°C for 15 seconds, 60°C for 15 seconds and 95°C for 15 
seconds was added after the PCR reaction to confirm the absence of non-specific PCR 
products. mRNA data were normalised relative to RPL32 mRNA and then used to 
calculate expression levels. Results are expressed as 2-ΔΔCT, which gives the relative 
amount of target gene normalised to the endogenous constitutive control (RPL32 RNA) 
and to the untreated samples (on the same 24 well plate) with the control samples set 
as 1. Negative controls were PCR without cDNA template. 
 
2.3.7.4 Standard PCR 
Conventional end-point PCR was performed by adding 1µl of non-diluted cDNA, 1µl 
GAPDH or ANXA1 primer to 10µl ThermoPrime ReddyMix PCR Mastermix (Thermo 
Scientific). PCR tubes were placed in an Abgene thermal cycler and the following 
program employed: 95°C for 5 minutes, then (95°C for 30 seconds, 55°C for 20 
seconds, 72°C for 20 seconds) for 35 cycles; 72°C for 10 minutes. The resulting 
samples were then loaded on a 3% agarose gel containing 20µl GelRed for 
visualisation of bands using a FluorChem E Digital Dark Room (Protein Simple).  
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2.3.8 Prostaglandin E2 Enzyme Immuno-Assay 
 
Prostaglandin E2 (PGE2) enzyme immuno-assay (EIA) was carried out on micromass 
supernatants from cells stimulated for 24 hours with IL-1β and treated with 100,000 
microparticles, Annexin A1 or ceruloplasmin. The Prostaglandin E2 EIA is a competitive 
assay based on the competition between Prostaglandin E2 and a PGE2 tracer 
(Prostaglandin E2-acetylcholinesterase) for a limited amount of the Prostaglandin E2 
monoclonal antibody. The colour change occurs when the substrate to the 
acetylcholinesterase is added to the wells so that it is proportional to the amount of 
PGE2 tracer bound to the well and therefore inversely proportional to the amount of 
Prostaglandin E2 present in the sample. The plate is set up to provide absorbance 
values needed in order to calculate the concentrations of Prostaglandin E2. Blank, non-
specific binding, total activity and total binding wells are required, along with known 
Prostaglandin E2 standard samples for interpolation of the results (Figure 2.3.8). The 
plate wells were filled following Table 2.3.3.  
 
 
Table 2.3.3 For PGE2 EIA, wells require different reagents to obtain absorbance values for 
Total Activity, Non-specific binding, total binding and blank wells. 
Well EIA buffer Sample or standard Tracer Antibody 
Blank     
Total 
Activity 
  5µl at development 
stage 
 
Non-
specific 
Binding 
100µl  50µl  
Maximum 
Binding 
(B0) 
50µl  50µl 50µl 
Sample or 
standard 
 50µl of diluted sample 
or standard 
50µl 50µl 
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The plate was then covered and incubated for 18 hours at 4°C before the wells were 
washed thoroughly 5 times with wash buffer before 200µl of Elman’s development 
reagent was added to all wells. The plate was covered and incubated for approximately 
60 minutes on a shaker at room temperature until the absorbance of the total binding 
well reaches >0.3 AU when measured spectrophotometrically. The plate was then 
measured at 420nm using a Multiskan Bichromatic 348 spectrophotometer 
(Labsystems). To interpolate the concentrations of the EIA, first the non-specific 
binding well absorbances were averaged, as were the absorbances of the Maximum 
Binding wells (B0). The non-specific binding was subtracted from the entire plate, as a 
blank reading would be during an ELISA. The standards and sample values (denoted 
B) were then calculated as B/B0. The %B/B0 can then be used to generate a logistic 
four-parameter fit, and the sample concentrations were interpolated. 
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Figure 2.3.8 Prostaglandin E2 Standard Curve. The Binding of the Standards (B) is transformed 
by dividing by the Corrected Maximum Binding (B0), generated by subtracting the averaged 
absorbance of the non-specific binding wells from the average absorbance of the Maximum 
Binding wells. By multiplying by 100, the %B/B0 can then be used to generate a logistic four-
parameter fit from which the samples can be interpolated after subtraction of non-specific 
binding. Supernatants collected from C28/I2 micromasses stimulated with or without IL-1β (3 
or 30ng/ml) and 100,000 microparticles for 24 hours were assayed for Prostaglandin E2 
concentration.  Blue points show data interpolation from a representative experiment. 
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2.3.9  Cytokine ELISA 
 
IL-8 and IL-6 content in micromass supernatants were assayed using ready-set-go! 
ELISA kits (eBioscience). Corning Costar 9018 96-well plates were coated with 100µl 
capture antibody prepared in coating buffer, covered with parafilm and incubated 
overnight at 4°C. Wells were washed 3 times using 250µl wash buffer (PBS containing 
0.05% Tween-20; 1 minute incubation between each wash) before blotting dry on 
paper towels. Wells were blocked with 200µl 1X assay diluent (diluted in deionized 
water) for 1 hour at room temperature. Standards were generated by diluting 
recombinant IL-8 or IL-6 to achieve a top standard or 250pg/ml for IL-8 and 200pg/ml 
for IL-6 and serially diluted down to 3.125pg/ml. After washing, 100µl of each standard 
was added to two columns of the 96-well plate, including two blank wells, which 
included only phenol-red and serum-free RPMI, the same medium the micromasses 
were stimulated in. The plate was then sealed and incubated at room temperature for 2 
hours. The plate was washed three times as before, then 1X detection antibody was 
diluted in assay diluent and 100µl added to each well. The plate was incubated for 1 
hour at room temperature before another 3 washes, with 2-minute incubations to 
ensure any excess detection antibody was removed. 100µl of substrate solution was 
added to each well and the plate incubated at room temperature for 15 minutes before 
50µl stop solution (2N H2SO4) was added. The plate was then read at 450nm with 
570nm wavelength subtraction using a Multiskan Bichromatic 348 spectrophotometer 
(Labsystems, Finland). Sample concentrations were then interpolated from the 
standard curve (Figure 2.3.9).   
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Figure 2.3.9 Standard Curve for IL-8 or IL-6 ELISA. C28/I2 micromasses were stimulated with or 
without IL-1β (3ng/ml and 30ng/ml) and 100,000 microparticles for 24 hours. Supernatants 
were collected and assayed for IL-6 and IL-8 concentration. Blue points show data interpolation 
from a representative experiment.  
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2.3.10  Cytokine Bead Array for TGF-β  
 
Transforming growth factor beta 1 (TGF-β) concentrations were measured in the 
supernatants of micromasses using a BD Cytometric Bead Array. Supernatants from 
micromasses cultured in 300µl serum free differentiation medium were assayed for 
TGF-β content following acidification to remove the latency-associated protein. To do 
this, samples (300µl) were acidified to pH 3.0 with 60µl 1N HCl, mixed thoroughly and 
incubated at room temperature for 10 minutes. Samples were neutralised to pH 7.2 
with 60µl of 1.2N NaOH/0.5M HEPES. Once the latency-associated protein was 
removed, the immunoreactive TGF-β could then be assayed. 
  
The cytokine bead array system uses particles with discrete fluorescence intensities to 
test low concentration analytes such as cytokines. The TGF-β is captured by antibody-
coated beads of a known size and fluorescence, and is detected by PE-conjugated 
detection antibodies, allowing determination of the concentration of the sandwich 
complexes by flow cytometry. It is the PE intensity from which the concentration can be 
inferred.  
  
Firstly, standards are generated for inferring the unknown sample concentrations, 
which are reconstituted and serially diluted to give a range of 10ng/ml to 39pg/ml plus a 
0ng/ml blank sample. The capture beads are then diluted 1:50 in capture bead diluent, 
vortexed for 15 minutes then 50µl added to each undiluted sample (50µl 
acidified/neutralised sample). Samples were incubated for 1 hour at room temperature. 
The PE detection reagent was then diluted 1:50 in detection reagent diluent, mixed 
well, then 50µl was added to each sample. Tubes were incubated for 2 hours in the 
dark at room temperature. 1ml of wash buffer was added to each sample and 
eppendorfs centrifuged for 5 minutes at 200 x g, supernatant discarded and pellets 
resuspended in 300µl wash buffer for sample collection using a BD LSRFortessa flow 
cytometer. During sample acquisition, standards were acquired with blank first, then 
increasing concentrations from lowest to highest. Samples were acquired on high and 
analysed using FCAP Array software downloaded from the BD website. Sample 
concentration was interpolated from the standard curve after fitting with a 5 parameter 
logistic (which resulted in the best curve fit, with a higher R2 (>0.98) value than 4 
parameter logistic). Sample concentrations were then multiplied by a 1.4 dilution factor 
to account for the acidification/neutralisation step.  
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2.3.11  Griess Assay 
 
Conditioned supernatants (phenol-red free RPMI supplemented with ITS 1%) from the 
culture of rat femoral heads were snap frozen and stored at -80°C before Griess assay. 
Nitric oxide levels in biological fluids can be inferred from the concentration of one of 
the stable breakdown products, nitrite (NO2-), measured by the Griess assay.  The 
Griess reagent system (cat. G2930, Promega) uses sulphanilamide and N-1-
napthylethylenediamine dihydrochloride (NED; added sequentially to increase 
sensitivity) which react with NO2- producing an Azo compound under acidic conditions.  
To measure the nitrite concentration in femoral head cultures, 50µl was added in 
triplicate to a 96-well plate. A nitrite standard reference curve was generated in the first 
three columns of the 96 well plate: 1ml of a 100µM nitrite solution was made by diluting 
0.1M nitrite standard 1:1000 in supplemented RPMI (the same buffer used for femoral 
head culture). 100µl of the top concentration standard was added to three wells and a 
serial dilution performed by taking 50µl from the first well and added to 50µl 
supplemented RPMI and so on, to generate 7 standards of decreasing concentration, 
from 100µM, 50µM, 25µM, 12.5µM, 6.25µM, 3.125µM and 1.56µM. Supplemented 
RPMI only was added to the final well to create a blank reading. Using a multichannel 
pipette, 50µl room temperature sulphanilamide solution (1% in 5% phosphoric acid) 
was added to every well and incubated for 10 minutes at room temperature in the dark. 
Then, 50µl of NED (0.1% in water) was added to every well. The plate was incubated 
at room temperature in the dark until the standard curve had developed a magenta 
colour, which took around 5 minutes. The plate was then analysed using a 
spectrophotometer at 530nm. The standard curve was generated by plotting the 
average absorbance of each standard against the nitrite concentration (Figure 2.3.10).   
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Figure 2.3.10 Standard Curve used in Griess Assay. Supernatants collected from the culture of 
rat femoral heads stimulated with or without IL-1β (10ng/ml) and 100,000 microparticles every 
two days for 7 days, then assayed for nitrite concentration.  Blue points show data interpolation 
from representative experiments. 
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2.3.12 In Vivo Experiments 
 
All experiments were approved and performed under the guidelines of the Ethical 
Committee for the Use of Animals, Barts and The London School of Medicine and 
Home Office regulations (Scientific Procedures Act, 1986). C57BL/6 mice were 
purchased from Charles River. Fpr1, Fpr2/3 and Anxa1 null mice were generated in-
house on the C57BL/6 background. In all experiments age and sex-matched controls 
were used. Mice were fed standard laboratory chow and water ad libitum and were 
maintained on a 12 hour light-dark cycle under specific pathogen-free conditions. All 
experiments strictly followed UK Home Office regulations (Guidance on the Operation 
of Animals, Scientific Procedures Act, 1986). 
 
2.3.12.1  K/BxN Serum Arthritis 
K/BxN serum transfer arthritis was used to recapitulate the neutrophil-rich flare-phase 
of human RA. This model is adaptive immune cell-independent; instead the deposition 
of glucose-6-phosphate isomerase antibodies from the arthritogenic serum onto the 
surface of the cartilage initiates an innate immune response mainly mediated by 
leukotriene B4 recruiting neutrophils and mast cells (Chou et al., 2010). K/BxN serum 
transfer arthritis is an acute, aggressive polyarthritis with high disease penetrance, 
which resolves over 28 days. Eight-week old male C57BL/6 mice were injected 
intraperitoneally with 100µl arthritogenic serum (generated in-house and diluted in 
100µl PBS) on day 0 and day 2. Arthritic parameters were recorded everyday including 
clinical score, where any digits, wrists, ankles or pads on each limb were swollen, for a 
total score out of a possible twelve (Figure 2.3.11); weight loss (cachexia) and water 
displacement plethysmometry performed to determine paw volume. In addition, mice 
injected intra-articularly had their knee widths measured using digital calipers daily. 
 
In the first set of arthritis experiments, K/BxN mice received 100,000 TMP 
intravenously, or 100µl saline as a vehicle control, at the peak of disease on day 5, with 
joints collected on day 8 for histological analysis. 
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In further experiments where microparticles were delivered locally, mice were injected 
on day 3, intra-articularly into the knees with 6µl buffer using a 31.5-gauge needle 
attached to a 10µl gas-tight Hamilton syringe for increased accuracy. The buffer 
contained either vehicle (sterile saline), TMP (10,000 or 30,000) with or without WRW4 
(10µM) or WRW4 alone. Both wild type and Fpr2/3 mice were used. Some mice had 
their arthritis evaluated by in vivo bioluminescence imaging (see section 2.3.12.2). 
Joints were collected on day 5 for histological analysis.  
 
 
  
0 – No signs of arthritis 
1 – A single swollen digit, wrist, ankle or pad 
2 – a combination of two swollen areas.  
Multiple digits count as a score of 1. 
3 – Swollen wrist or ankle AND pad AND any digit 
Figure 2.3.11 Arthritis scoring 
procedure. Arthritis scoring was carried 
out as follows: each limb was inspected 
for signs of swelling and given a score 
based on the part of the paw which was 
swollen. Any swollen digit (one, or more 
than one) was given a score of one, as 
was a swollen pad, wrist or ankle. Any of 
these in combination could be observed 
to give a total score out of three. This 
scoring system was used for both K/BxN 
K/BxN arthritis and collagen-induced 
arthritis, and was used to monitor the 
progression of the disease throughout 
the experiment. 
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2.3.12.2 Adoptive Transfer of Bodipy-maleimide Labelled Mouse 
Neutrophils into K/BxN Mice 
Wild type C57BL/6 donor mice were injected with zymosan (1mg/mouse, i.p.) to induce 
neutrophilic peritonitis (Figure 2.3.12). Exudated neutrophils were collected 4 hours 
later by peritoneal lavage with PBS and the cells were labelled with Bodipy-maleimide 
dye (2.5µM) and analysed by flow cytometry. Labelled neutrophils (1 x 106 per mouse) 
were adoptively transferred to wild type mice on day 3 of K/BxN serum-induced arthritis 
via tail vein injection. Wrists were collected 24 hours later into OCT medium and 
sectioned using diamond blades on a cryotome. Sections were processed for confocal 
microscopy. Sections were stained with rat anti-mouse MRP14/S100A9 antibodies and 
DAPI to visualise the nuclei (see section 2.3.14). 
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Figure 2.3.12. Generation of Bodipy-maleimide labelled neutrophils for adoptive transfer into 
K/BxN mice. (A) Schematic of experimental procedure. (B) All cells stained with Bodipy-
maleimide when analysed by flow cytometry.  
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2.3.12.3 IVIS Bioluminescence Imaging  
On day 5, anaesthetised (isoflurane mixed with oxygen) mice undergoing K/BxN 
arthritis were imaged using an IVIS bioluminescence imager to detect inflammation 
(Gross et al., 2009). The mice were injected with 50mg/kg luminol sodium salt (Sigma) 
in PBS 10 minutes prior to imaging with the IVIS 200 system (Caliper, Hopkinton, MA). 
Extracellular myeloperoxidase, a product of neutrophil primary granule release and 
therefore indicative of acute or neutrophillic inflammation, cleaves luminol into a 
luminescent compound allowing detection by bioluminescent imaging. For photon 
quantification, a region of interest was manually selected and kept constant throughout 
(f/stop 1, no optical filter). Photons emitted from live mice were acquired as photons 
per s/cm2 per steradian, using Living Imaging 3.0 (Caliper). By creating regions of 
interest (ROIs), the photon emission per second can be determined and background 
luminescence subtracted by placing an ROI on a non-inflamed part of the body, in this 
case the abdomen or chest of each mouse (Figure 2.3.13).  
 
 
K/BxN Naïve 
Figure 2.3.13 Interrogation of Regions of Interest (ROI) during IVIS Bioluminescence Imaging. 
Mice were injected with 50mg/kg Luminol salt for 10 minutes before imaging. Regions of 
interest were generated using Living Imaging 3.0 and photons per second analysed after 
subtracting the background signal from the abdomen or chest of each mouse. 
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2.3.13  Histological Staining and Analysis 
Joints were collected on day 8 or day 5 for K/BxN experiments. The entire hind limbs 
with skin removed were fixed for 48 hours in neutral buffered formalin (40X the volume 
of the limb, around 50ml each; 10% neutral buffered formalin containing 0.4% sodium 
phosphate, monobasic and 0.65% sodium phosphate dibasic) before decalcification in 
10% formic acid for 24 to 48 hours. To determine full decalcification, a fine needle was 
used to test the softness of the bones. Once decalcification was complete, tissues 
were dissected into knee tissues and paw tissues and placed in labeled tissue 
cassettes for embedding separately. Cassettes were placed in running tap water for 
one hour, then left in tap water overnight to help remove the formic acid. Samples were 
then placed in 70% ethanol and processed for wax infusion in a Leica Tissue 
Processor. Finally, knee samples were embedded in molten paraffin wax using small 
molds. Knees were embedded coronally, so that the knee joint faced the front of the 
block with the femur and tibia perpendicular to each other. Embedded sample blocks 
were left to harden on a cold plate (-4°C) before being removed from their molds. 
Blocks were then kept at -20°C degrees to harden for cutting. Sections (10µm) were 
cut using a Leica microtome, and placed on lukewarm water to remove wrinkles. 
Sections were transferred to charged glass microscope slides and left to dry. 
  
Before staining, dried slides were placed in a 65°C oven to soften the wax, which was 
removed by two 5-minute incubations of histoclear (xylene replacement). Sections 
were rehydrated by moving from 100% ethanol for 5 minutes to 95% ethanol for 5 
minutes followed by distilled water for 2 minutes before proceeding to staining. 
  
2.3.13.1 Toluidine Blue Staining 
Toluidine blue is superior to Safranin O in delineating differences in metachromasy 
between pericellular and interterritorial regions of articular cartilage. The reproducibility 
of staining between serial sections relies on section thickness: sections thinner than 
8µm show modest to significant variability in metachromatic staining, whereas those 
cut at 8-10µm achieve superior reproducibility and staining intensity (Getzy, 1982). 
  
Slides were placed in 1% toluidine blue dye for 10 minutes before being washed with 
tap water for 5 minutes (or until the water was clear). Slides were air dried before 
mounting in DPX slide mountant (Sigma) and left to harden for 24 hours.  
 
  
127 
2.3.13.2  Toluidine Blue Percentage Area Positive Quantification 
The quantification of percentage area toluidine blue positive was carried out in a similar 
manner to that of Safranin O quantification (2.2.5.3). Slides were viewed using an 
Olympus BH-2 standard light microscope and Nikon DXM1200 digital camera. 
Acquired images were opened in ImageJ and split into individual RGB channels. The 
hue of the toluidine blue dye is dependent on the pH, thus, the channel which best 
represented the positive and negative staining was not necessarily the same for each 
experiment, and had to be selected at the time of analysis. The selected channel then 
had a threshold masked over the top and the area of the cartilage traced. The 
threshold mask was then measured over the selected area. 
 
2.3.13.3 Safranin O Staining 
Rat femoral head cartilage explants were collected and fixed overnight in 
paraformaldehyde (4%) before embedding in OCT and sectioned at 10µm. Slides were 
counterstained in fast green (0.1% dye in distilled water) or haematoxylin for 5 minutes 
then dipped 10 times in 0.1% acetic acid. Slides were incubated for 20 minutes in 
Safranin O (0.1% in acetate acid buffer; 0.1M acetic acid-sodium acetate buffer at pH 
5.0; 0.8% sodium acetate in 0.1M acetic acid) before washing in gently running tap 
water for 5 minutes. Slides were then air dried, mounted with DPX and left to harden 
for 24 hours. Sections were imaged using a standard light microscope (Olympus BH-2) 
and Nikon DXM1200 digital camera. Percentage area Safranin O positive staining was 
calculated using a threshold applied using ImageJ imaging software (see section 
2.2.5.3). 
 
2.3.13.4 Haematoxylin and Eosin Staining 
Dewaxed and rehydrated slides were incubated in haematoxylin for 2 minutes then 
rinsed in tap water for 5 minutes to remove excess stain but also to blue the nuclei by 
introducing a more alkali pH. Slides were then stained for 30 seconds to 1 minute in 
eosin before another wash in tap water. Slides were then dehydrated with 5 minutes 
each in graded ethanol (70%, 90% and 100% ethanol, five minutes each) followed by 
clearing twice in Histoclear for 5 minutes. Slides were left to dry completely before 
mounting in DPX mounting medium and left to harden for 24 hours. Images were 
captured using an Olympus BH-2 microscope (Tokyo, Japan) with fluorescent filters 
and Nikon DXM1200 digital camera (Melville, NY). 
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2.3.14  Fluorescence and Confocal Microscopy 
 
2.3.14.1 Sample Preparation 
Freshly isolated neutrophils (1x105) were seeded onto positively charged glass 
microscope slides and checked to ensure even distribution of the cells using a light 
microscope. Cells were left to dry at room temperature. Once dried, slides were either 
mounted immediately using ProLong immunogold antifade reagent containing DAPI for 
visualisation of the nucleus, or permeabilised in ice-cold acetone for ten minutes. Once 
dry, a wax ring was applied using a Dako wax pen and slides placed in a humidified 
chamber for staining.  Cells were blocked for 1 hour at room temperature using 10% 
fetal bovine serum in Tris-buffered saline (FBS/TBS). MRP8 antibody or isotype 
antibodies at the same concentration diluted in 10% FBS/TBS (50µl) were added 
directly on top of the blocking solution and incubated for 1 hour in the dark at room 
temperature. Slides were then rinsed three times in 1% FBS/TBS followed by a brief 
dip in double-distilled ultrapure water to dissolve any remaining salts. Slides were then 
dried in the dark and mounted in ProLong immunogold antifade reagent containing 
DAPI to stain the nuclei. 
  
Pre-labelled microparticles were applied to charged glass microscope slides and 
allowed to dry. Slides were dipped briefly into double distilled ultra-pure water to 
dissolve any salts in the buffer before being allowed to dry again. Microparticles were 
mounted with ProLong immunogold antifade reagent.  
 
Rat femoral heads were cryosectioned to 10µm, applied to charged glass microscope 
slides and allowed to dry. To determine whether any background staining from MRP8 
antibodies occurred, MRP8 antibodies were tested at two concentrations. Sections 
were permeabilised in ice-cold acetone for 10 minutes and once dry, a wax ring was 
applied using a Dako wax pen and slides placed in a humidified chamber for staining. 
Sections were blocked for 1 hour at room temperature using 10% fetal bovine serum in 
Tris-buffered saline. MRP8 antibody or isotype antibodies at the same concentration 
diluted in 10% FBS/TBS (50µl) was added directly on top of the blocking solution and 
incubated for 1 hour in the dark at room temperature. Slides were then rinsed three 
times in 1% FBS/TBS. DAPI nuclear stain was tested at two concentrations, diluted in 
TBS and incubated for 10 minutes in the dark followed by a brief dip in double-distilled 
ultrapure water to dissolve any remaining salts. Sections were left to dry then mounted 
with ProLong immunogold antifade reagent.  
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Alternatively, rat femoral head explants treated with human microparticles were stained 
to determine the localization of human antigen. After ringing with a Dako wax pen, 
sections were blocked using 10% fetal bovine serum in Tris buffered saline (FBS/TBS) 
for one hour in a humidified chamber. Sections were either stained with Annexin A1 
purified monoclonal antibody for one hour in the dark at room temperature followed by 
washing 3 times in 1% FBS/TBS before the secondary antibodies were added, or 
stained with anti-human MRP8 conjugated antibody. Slides were then washed 3 times 
in 1% FBS/TBS. The matrix was visualised by staining with wheat germ agglutinin 
conjugated to AlexaFluor633 (1:500 diluted in 1% FBS/TBS) for 10 minutes in the dark 
at room temperature followed by a further 3 washes in FBS/TBS. Slides were dipped 
briefly into double distilled water to dissolve any salts and sections left to dry. Slides 
were mounted using ProLong immunogold antifade reagent containing 4,6-diamidino-
2-phenylindole (DAPI). 
  
2.3.14.2 Fluorescence Microscopy 
Slides were analysed by fluorescence microscopy using an Olympus BH-2 microscope 
connected to a Nikon DXM1200 digital camera. Image capture was carried out using 
Lucia imaging software. DAPI staining was visualised on the UV channel (excitation 
wavelength 360-370 nm), Alexa488 FL1 channel (excitation wavelength 460-490 nm) 
and Alexa555 FL2 channel (excitation wavelength 530-560 nm).  
 
2.3.14.3 Fluorescence Time-Lapse Imaging 
For fluorescence microscopy time-lapse imaging, freshly isolated neutrophils 
resuspended at 1 x 106 cells/ml in phenol red-free RPMI were added to a 12-well 
suspension culture plate following labelling with Bodipy-maleimide dye (2.5µM). Cells 
were visualised with an EVOS fluorescence microscope (Invitrogen) with a X60 long 
working-range objective. TNF-α (50ng/ml) was added once the cells had settled and a 
budding neutrophil visualised. Following 5-minute stimulation, time-lapse images were 
captured once every minute using a GFP LED cube. Images were cropped using 
Microsoft Office PowerPoint but no further adjustments made. 
  
2.3.14.4 Confocal Microscopy 
Confocal microscopy was carried out using a Zeiss LSM 510 laser scanning confocal 
microscope with supplied Zeiss imaging software. The following excitation/emission 
conditions were used in separate channels with either the X40 or X63 oil immersion 
objective: DAPI 364/475–525 nm, Bodipy-maleimide or 488/505–530 nm, and 
AlexaFluor546 at 543/560 – 600 nm. 
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2.3.14.5 Analysis of Images for Microparticle Penetration 
Images acquired with the Zeiss LSM scanning confocal microscope were analysed for 
the distance travelled by microparticles co-cultured in Rat femoral heads using ImageJ 
imaging software. Micrographs were checked for microparticle positivity by eye: distinct 
double-stained puncta, positive for MRP8 and Bodipy-maleimide fluorescence, or 
Annexin A1 and Bodipy-maleimide fluorescence; or diffusely double-positive 
chondrocytes which had taken up and dismantled microparticles were measured. 
Using the ImageJ measurement tool, the distance from the centre of the microparticle 
or cell to the articular surface was measured. The metadata from the file ensured 
correct pixel/absolute size calibration, and this was double-checked by measuring the 
scale bar in each image. All microparticle positivity was measured in each micrograph 
(in total 140 microparticles from control femoral heads and 166 microparticles in IL-1β 
treated femoral heads) and 6 micrographs from each treatment were measured 
(maximum 2 micrographs from each cartilage donor). Each of the measurements was 
then manually binned in GraphPad Prism software to generate histograms. The data 
was then displayed as Box and Whisker plots with Tukey’s whiskers to demonstrate 
outliers. 
 
2.3.15  Preparation of Samples for Electron Microscopy 
 
C28/I2 and primary adult human articular chondrocyte micromasses were collected 24 
hours after stimulation with IL-1β (30ng/ml) and were fixed in 4% paraformaldehyde, 
0.5% glutaraldehyde and 0.1M sodium cacodylate buffer (pH 7.4) for 24 hours at 4°C. 
The micromasses were then transferred to 10% fixative solution (diluted in sodium 
cacodylate buffer) at 4°C and transported to São José do Rio Preto, 
Immunomorphology laboratory department. Samples were kindly processed by Dr 
Cristiane Damas Gil. 
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2.3.16  RNA Extraction From Formalin-Fixed, Paraffin 
Embedded Sections. 
  
In order to determine mRNA expression profiles from K/BxN mice injected intra 
articularly with microparticles on day 3 of 5, total mRNA was extracted from formalin-
fixed, paraffin embedded sections using a commercially available kit (PureLink FFPE 
Total RNA Isolation Kit, Invitrogen). Sections (8 x 10µm) at the region of interest (cut 
far in to the joint enough to create sections where the menisci form triangles) were 
collected into sterile, RNase free eppendorfs before 300µl Melting Buffer was added. 
Eppendorfs were centrifuged for 20 seconds at 10,000 x g then incubated for 10 
minutes at 72°C using a heating block, to melt the paraffin. Proteinase K (20µl, for 
genomic DNA removeal) was then added to each sample, and the tubes incubated at 
60°C for 1 hour before gentle mixing. The samples were then incubated for a further 30 
minutes, so that the lysis was complete. The samples were immediately transferred to 
a microfuge and centrifuged for 1 minute at 10,000 x g so that the paraffin separated 
from the sample lysate. The lysate was then collected by piercing the paraffin 
meniscus with a pipette tip and aspirating the lysate. This was placed in a fresh sterile 
eppendorf and 400µl Binding Buffer and 800µl 100% molecular biology grade ethanol 
added. The solution was mixed well, then 700µl transferred to a Spin Cartridge 
mounted on a Collection Tube. The sample was centrifuged at 800 x g for 1 minute, 
flow-through discarded, and the remaining sample added to the Spin Cartridge to 
ensure all RNA was collected. The tube was spun again at 800 x g for 1 minute. The 
flow-through was discarded and the Spin Cartridge placed into a clean Wash Tube. 
Wash solution was made by adding 80ml 100% molecular biology grade ethanol to 
20ml Wash Buffer and mixing well. 500µl Wash solution was added to each Spin 
Cartridge and samples centrifuged at 10,000 x g for 1 minute. This wash step was 
repeated 3 times, with flow-through discarded each time. The Spin Cartridge was spun 
once more at 10,000 x g without adding wash solution to remove any excess ethanol 
and dry the membrane. For elution of the RNA, Spin Cartridges were mounted onto a 
clean Recovery Tube then 50µl of RNase-free water, heated to 65°C, was added to the 
center of the cartridge membrane. After 1 minute, the samples were centrifuged for 1 
minute at 10,000 x g. The elution step was repeated once more to increase RNA yield. 
Samples were then analysed for concentration and purity using a NanoDrop 
spectrophotometer. Total RNA was reversed transcribed as described (section 2.3.7) 
and used for RT-PCR analysis as described (section 2.3.7), using mouse primers (see 
Table 2.1.2). 
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2.3.17 Statistical Analysis 
Statistical analysis was assessed using GraphPad Prism 4 (San Diego) software, 
SPSS software or GraphPad Prism software. Data are expressed as mean ± standard 
error of the mean (SEM) of n experiments for parametric data, and median, 
interquartile range (IQR) and range for non-parametric data. All data were tested for 
normal distribution and statistical differences were analysed using the tests outline in 
Table 2.3.4. A P value of <0.05 was considered significant to reject the null hypothesis 
and differences were considered significant. All tests performed used a two-tailed 
significance value unless specifically stated. One-tailed significance cut-offs were 
chosen a priori. 
  
Table 2.3.4 Statistical tests used during this project and when they were applied. 
Statistical Test Data used Parametric/non 
parametric 
Paired t-test Two groups within the same animal, 
e.g. paired knee analysis of 
proteoglycan content 
Parametric 
Mann-Whitney t-test Two groups with non-Gaussian 
distribution, such as the distance of 
microparticle penetration measured in 
IL-1β-treated or resting cartilage  
Non-Parametric 
Kruskall-Wallis test with 
Dunn’s multiple 
comparison post-test 
Nonparametric data generated with 2-
ΔΔCT values, three or more groups 
tested 
Non-parametric 
One-way ANOVA with 
Bonferroni post-test 
Three or more groups tested, with 
normal, homogenous data such as 
proteoglycan release into the medium 
of micromass cultures measured by 
DMMB assay 
Parametric 
Two-way ANOVA with 
Bonferroni post-test 
Three or more groups tested with two 
variables. Used for testing differences 
both within and between groups and 
determining differences in mRNA 
expression from RT-PCR on Logged 
data. 
Parametric 
Matched Two-way Three or more groups tested with two Parametric 
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ANOVA with Bonferroni 
post-test 
variables. Used for testing differences 
within groups over a period of days, 
such as with mouse body weight 
during arthritis, or for data paired for 
individual mice, for example intra 
articular injections of TMP in one 
knee, and vehicle in the contralateral 
knee. 
Mixed Model ANOVA with 
Bonferroni post-test 
Used for matched (in vivo) data of 
more than two groups, with more than 
one variable (e.g. genotype) where the 
group sizes are not necessarily equal. 
Parametric 
  
  
Non-parametric data which required Two-way ANOVA analysis were normalized by 
logging the data before performing Two-way ANOVA statistical analysis. Data is 
displayed in the graphs as unnormalised. 
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CHAPTER 3: CHARACTERISATION 
OF HEALTHY NEUTROPHIL-DERIVED 
MICROPARTICLES   
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3.1 Characterisation of Neutrophil Microparticles 
 
Microparticles derived from various cell-types have been shown to be abundant in the 
rheumatoid synovium (Berckmans et al., 2005, Berckmans et al., 2002, Boilard et al., 
2010, Cloutier et al., 2013), and yet microparticle phenotype (and function) reflects the 
phenotype of the parent cell (Timar et al. 2013). For example, Dalli et al. (2013) 
showed that neutrophils stimulated in suspension produce proteomically distinct 
microparticles from those adhered to endothelial cells. Additionally, Timar et al. (2013) 
demonstrated that differential stimulation of neutrophils leads to different numbers of 
microparticles being generated. Neutrophils exposed to opsonised Staphylococcus 
aureus bacteria generated the highest number of microparticles, followed by phorbol 
esters and TNF-α. In contrast, resting neutrophils generated more microparticles than 
those stimulated with stromal-derived factor (SDF-1 also known as CXCL12), 
lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP). Therefore 
it was important to characterise the function of microparticles not only derived from a 
single cell type (in this case the neutrophil) but also to demonstrate that a neutrophil 
microparticle derived from a resting cell may be phenotypically dissimilar to one shed 
by a stimulated cell.  
 
Furthermore, as microparticles are known to be abundant within the rheumatoid 
synovium, I wanted to generate neutrophil microparticles in vitro to use as a surrogate 
model. In order to induce microparticle shedding in a manner relevant to rheumatoid 
arthritis, I selected TNF-α and IL-8 to stimulate the neutrophils. In addition to these 
cytokines present within the rheumatoid joint are a multitude of other cytokines, 
chemokines and proinflammatory mediators, but these are the most potent cytokine 
stimulators of neutrophil degranulation, and induce neutrophil activation in a manner 
representative of this autoimmune disease, rather than say, bacterial infection or cell 
injury (such as LPS or formylated peptides). Of note, IL-1β is known to have important 
functions in rheumatoid pathogenesis, however its actions are more indirect in terms of 
neutrophil activation, instead inducing stromal cells to produce activation and survival 
signals (Prince et al., 2004).  
 
Thus, TNF-α, an important cytokine involved in the pathogenesis of rheumatoid arthritis 
was chosen as the stimulus for microparticle generation in preliminary studies, and 
compared to those generated by IL-8 (CXCL8) stimulation, a potent neutrophil 
chemoattractant, which had not previously been tested.  
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3.1.1 Characterisation of Neutrophil Microparticles by Size 
and Number 
 
The sizing and enumeration of microparticles from biological fluids or culture 
supernatants is not simple, and no gold standard exists for the accurate measurement 
of microparticle parameters. Traditionally, flow cytometry has been used as the 
mainstay of microparticle analysis, however this technique has major drawbacks in 
terms of detecting microparticle size, and differentiating the true microparticle signal 
from noise. Thus a variety of methods must be used to corroborate data, including the 
use of cutting edge imaging technologies, such as the ImageStreamx, and re-
appropriating analysers used for quality control in industrial chemical applications, such 
as with Nanoparticle Tracking Analysis. 
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To confirm the purity of isolated neutrophils from healthy volunteers, they were first 
characterised by flow cytometry (Figure 3.1.1). From forward scatter/side scatter plots 
the isolated cell population was 98% polymorphonuclear cells, with 2% contaminating 
lymphocytes, with no visible contaminating monocytes when nuclei were fluorescently 
stained (Figure 3.1.1A and B). To determine whether the cells were activated by TNF-α 
(50ng/ml) and IL-8 (50ng/ml), the cells were stained for the activation markers CD11b 
and CD62L (Figure 3.1.1C and D). TNF-α induced CD11b up-regulation and near-
complete shedding of CD62L, which is a typical profile for activated neutrophils. IL-8, a 
potent chemotactic stimulus, did not induce full CD62L shedding nor CD11b up-
regulation to the same extent, which was expected. Therefore the cells had not 
released their secretory granules to the same extent when exposed to this stimulus.  
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Figure 3.1.1 Characterisation of neutrophils used to generate microparticles. Neutrophils (2 x 
107/ml) were isolated from healthy donors, stimulated with TNF-α (50ng/ml), IL-8 (50ng/ml) or 
Ctrl (vehicle; PBS) for 20 minutes at 37°C and analysed by flow cytometry for activation 
markers. (A) Purity of isolated neutrophil (polymorphonuclear cells; PMN) population as shown 
by representative FSC/SSC plot. (B) Fluorescent micrograph of freshly isolated neutrophils 
stained with DAPI to demonstrate characteristic nuclei. Scale bar denotes 25µm. (C) Expression 
of neutrophil activation markers CD11b and (D) CD62L. Data are shown as mean ± SEM of 
mean fluorescence intensity (MFI; arbitrary units) of 3 different blood donors. **P<0.01 using 
One-way ANOVA with Bonferroni post-test. Right-hand panels show representative histograms. 
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Microparticle production however was significantly up-regulated by both TNF-α and IL-
8 as measured by flow cytometry (Figure 3.1.2A). TNF-α stimulation of 1 x 107 
neutrophils (total; at 2 x 107/ml) induced more than double the number of microparticles 
(referred to as TMP) shed in 20 minutes at 37°C compared to control (referred to as 
CMP; 9.1 ± 1.3 vs. 3.9 ± 0.3 x107/ml, P<0.01 with One-way ANOVA), and IL-8 induced 
double the amount of microparticle shedding (IMP; 8 ± 1.1 vs. 3.9 ± 0.3 x107/ml, 
P<0.05). The offspring microparticles appeared below 1µm calibration beads (shown in 
purple) on the forward/side scatter plots set to log scale, when gated from their 
fluorescence versus side-scatter signal following loading with Bodipy-maleimide dye 
(Figure 3.1.2B).   
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Figure 3.1.2 Stimulation of neutrophils increases microparticle generation. Neutrophils (1 x 
107) were stimulated with TNF-α (50ng/ml), IL-8 (50ng/ml) or vehicle (PBS) for 20 minutes at 
37°C to induce microparticle release. (A) Microparticle numbers were quantified by flow 
cytometry after loading with Bodipy-maleimide dye (2.5µM) and by measuring the number of 
events double positive for neutrophil marker expression (CD66b) and Bodipy-maleimide versus 
flow rate. Data are shown as mean ± SEM of 5 different blood donors. *P<0.05 and **P<0.01 
using One-way ANOVA with Bonferroni post-test. (B) Representative FSC/SSC plot showing 
microparticles (grey) with 1µm (purple) and 0.5µm (blue) comparison beads. 
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Flow cytometry is a largely inaccurate method for sizing and enumeration of 
microparticles, so a new technology, in the form of ImageStreamx analysis was 
employed to further analyse neutrophil microparticles.  This analyser is part high-
sensitivity flow cytometer, part high-resolution microscope, which uses a syringe pump 
to drive the sample and can therefore calculate the absolute concentration from the 
volume consumed during analysis, allowing for accurate derivation of the sample 
concentration without the need for calibration beads. Also, unlike a flow cytometer, the 
smallest object that can be detected is a function of its brightness, so fluorescently 
labelled samples as small as 50nm can be assessed (see section 2.3.3).  
 
Using this method it was found that the number of TMP produced from 5 x 106 TNF-α-
stimulated neutrophils (total; at 2 x 107/ml) is over double that of resting cells (3.6 ± 0.9 
vs. 1.2 ± 0.3 x107 microparticles/ml, P<0.05 with paired t test), although around two 
times lower than that calculated by flow cytometry (Figure 3.1.3). It is also possible to 
get some idea of the size of the microparticles using this technology. It was found that 
microparticles appeared to be more than 1µm in diameter, have a perimeter between 4 
and 5µm and a volume of around 2µm3 (calculated from the diameter), regardless of 
stimulus. This data is calculated from the bright field images generated during sample 
collection, which, as can be seen in Figure 3.1.3E, does not always correlate with the 
fluorescence image generated by the higher-sensitivity fluorescence detector. Analysis 
from the fluorescence channel is possible, however significant haloing occurs around 
each microparticle due to the brightness of the Bodipy-maleimide dye they are loaded 
with. Therefore, any size measurements performed using this technique are likely to be 
an over-estimation of the true microparticle size and volume. Thus, further analysis of 
microparticle size is required using nanoparticle tracking analysis technology.
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Figure 3.1.3 Stimulation of neutrophils increases microparticle production but does not alter 
the size of the offspring microparticles. Microparticles generated from resting neutrophils (5 x 
106, total; at 2 x 107/ml; CMP) and following stimulation with TNF-α (50ng/ml; TMP) were 
analysed using ImageStreamX after loading with Bodipy-maleimide dye (2.5µM). (A) Accurate 
quantification of microparticle numbers performed using IDEAS software. Analysis of 
microparticle (B) diameter and (C) perimeter from bright field channel images. (D) Spherical 
volume of microparticles calculated from diameter values. (E) Representative images of the two 
microparticle subsets from ImageStreamX Analysis gallery. Data are shown as mean ± SEM of 6 
blood donors. *P<0.05 using paired t test. 
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Nanoparticle tracking analysis allows the absolute quantification of particle size. This 
technique uses the Brownian motion of laser-illuminated particles recorded by a 
microscope with attached video camera to determine the size of a heterogeneous 
particle population, such as the case with microparticles. Frame-to-frame analysis of 
the particles’ motion tracks allow their absolute size to be determined as smaller 
particles move more rapidly and travel a greater distance, whereas larger particles 
move slowly and do not travel very far (see section 2.3.3).  
 
Neutrophil microparticles generated from 6 separate donors and pooled to ensure 
sufficient sample volume (1ml of approximately 1 x 107 objects/ml are required) were 
analysed using this technology (Figure 3.1.4). Representative histogram and relative 
intensity plots show that microparticle sizes are largely homogenous, with CMP 
observed to be larger than TMP (Table 3.1.1). The main caveat to this technique is that 
particles above 1µm in size are completely excluded from analysis as their movement 
is below the limit of observable Brownian motion; thus tracks cannot be generated, and 
size and concentration cannot be calculated. Thus, the true distribution of CMP and 
TMP sizes cannot be generated without such skewing towards smaller particles.  
 
Stimulation of neutrophils with TNF-α led to double the number of microparticles shed 
compared to resting cells.  The pooled samples were generated from 40 million 
neutrophils per donor and were interpolated to find the number of microparticles 
generated per million neutrophils. Resting neutrophils (106) basally produced 
approximately 2.5 x 106 microparticles over 20 minutes at 37°C following isolation from 
the circulation. Upon stimulation with TNF-α neutrophils (106) produced approximately 
4.2 x 106 microparticles (Figure 3.1.4). It is not possible to produce enough 
microparticles from a single donor for individual analyses.  
 
Small particle skewing in NTA and large particle bias in flow cytometry and 
ImageStreamx analysis makes sizing the entire populations of biologically diverse 
microparticles extremely difficult. 
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Figure 3.1.4 Nanoparticle Tracking Analysis of microparticles. Microparticles generated from 6 
pooled donors’ (4 x 107 per donor; isolated and resuspended to 200µl/donor) resting 
neutrophils (CMP) and following stimulation with TNF-α (50ng/ml; TMP) were analysed using 
nanoparticle tracking analysis. (A) A single frame from a nanoparticle tracking analysis video. 
White arrows denote microparticles. (B) Representative histogram of microparticle size 
distribution (CMP). Dotted line represents 90% of microparticles appear below 412nm. The 
majority of microparticles are 143nm followed by 297nm. (C) The population distribution of 
microparticles in terms of size and scattering intensity. (D) Percentile of microparticle 
population appearing below each size.  
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Table 3.1.1 Data generated from Nanoparticle Tracking Analysis. Microparticles generated 
from 6 pooled donors’ (4 x 107 per donor; isolated and resuspended to 200µl/donor) resting 
neutrophils (CMP) and following stimulation with TNF-α (50ng/ml; TMP) were analysed using 
Nanoparticle tracking analysis. D10, D50 and D90 percentile sizes are given for each 
population along with pooled counts. 
 
 
Parameter CMP  TMP  
Mean (nm) 231 195 
Mode (nm) 143 118 
D10 (nm) 106 81 
D50 (nm) 195 161 
D90 (nm) 412 351 
Absolute sample counts (108) 4.93 8.39 
Interpolated count per million 
neutrophils (approximate value, 106) 
2.465 4.195 
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Finally, it was important to determine for future imaging studies whether microparticles 
loaded with Bodipy-maleimide dye could be visualised using fluorescence microscopy. 
Although X60 or X40 magnification is sufficient for microparticle analysis, the resolution 
of conventional light microscopes is not great enough to visualise unstained 
microparticles unless they are around 1µm apart from each other, and have a 
difference in size that is a function of their surface area. However, it is possible, using a 
bright dye such as Bodipy-maleimide, to take advantage of the significant haloing that 
occurs in these small particles. In this way, single particles may be distinguished by 
eye and the heterogeneity of the size of the microparticle population may be observed. 
TMP and IMP appeared to have a greater spread of microparticle sizes from very small 
to very large, compared to CMP, which had fewer large particles (Figure 3.1.5). 
Although fluorescent micrographs of isolated microparticles are not information-rich, 
the fact that microparticles could be visualised at X60 magnification ensured that 
imaging studies with pre-loaded microparticles was feasible.  
CMP 
TMP 
IMP 
Figure 3.1.5 A proportion of fluorescently 
labelled microparticles are visible by 
standard fluorescence microscopy. 
Microparticles generated from resting 
neutrophils (CMP) and following stimulation 
with TNF-α (50ng/ml; TMP) and IL-8 
(50ng/ml; IMP) were loaded with Bodipy-
maleimide dye (2.5µM) before being applied 
to positively charged glass microscope 
slides. Visualisation using oil immersion 
objectives and integrated fluorescence/light 
microscope with FL1 channel (excitation 
wavelength 460-490 nm) connected to a 
digital camera. Representative photographs 
of microparticles generated from 4 donors. 
Scale bar denotes 50µm. CMP, control 
microparticles, TMP, TNF-α generated 
microparticles, IMP, IL-8 generated 
microparticles.   
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Together, these results demonstrate that stimulation of neutrophils leads to increased 
microparticle shedding, and the offspring microparticles are around 150nm in size. 
Importantly, it is possible to detect microparticles by flow cytometry, ImageStream 
analysis, Nanoparticle Tracking Analysis and fluorescence microscopy. I wanted to 
determine the temporal kinetics of microparticle release along with investigating what 
regulated this increase in microparticle shedding. Furthermore, I wanted to investigate 
whether these offspring microparticles had an altered phenotype.  
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3.1.2 Kinetics and Regulation of Microparticle Formation 
 
It was next important to determine the temporal regulation of the process of 
microparticle shedding. To determine the kinetics of microparticle production, time-
lapse video fluorescent microscopy of neutrophils loaded with Bodipy-maleimide dye 
(2.5µM) immediately following isolation (Figure 3.1.6) was carried out. Cells stimulated 
with TNF-α at 5 minutes prior to image capture could be seen shedding microparticles 
from approximately 10 minutes post-TNFα stimulation. This method of microparticle 
kinetics analysis proved to be extremely intensive and time-consuming, thus only a 
small number of samples were analysed, and only one representative cell shown.  
t9 t8 t7 t5 t6 
t0 t1 t2 t3 t4 
Figure 3.1.6 Time-lapse video recording of a TNF-α stimulated neutrophil releasing several 
microparticles over a period of 10 minutes. Freshly isolated neutrophils were loaded with 
Bodipy-maleimide dye (2.5µM) and visualised using an integrated fluorescence/light 
microscope with FL1 channel (excitation wavelength 460-490nm) connected to a digital 
camera. TNF-α (50ng/ml) was added 5 minutes prior to imaging (t-5), and one image acquired 
each minute from time 0 (t0) at X60 magnification with oil immersion objective. Scale bar 
denotes 5µm, t denotes time in minutes. Grey arrowheads depict fully formed microparticles 
prior to dislocation from the cell. 
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To generate meaningful data, the ImageStreamx was instead used to enumerate 
microparticle generation over time. Uniquely among analytical instruments used for 
microparticle testing, this analyser allows parallel analysis of both parent neutrophils 
and offspring microparticles in the same sample collection, thus making it a powerful 
tool for assessing the kinetics of microparticle formation. ImageStreamx analysis of 
neutrophils immediately visualised following isolation showed that the rate of neutrophil 
microparticle production was much higher when the cells were stimulated with TNF-α 
(50ng/ml) than that of resting cells over a 45-minute period (Figure 3.1.7). Although a 
plateau of neutrophil microparticle production with TNF-α was not reached after 45 
minutes, analysis of a longer time point was limited by the size of the data files 
produced, and therefore would require a different sampling technique over time.  
Figure 3.1.7 Microparticle production kinetics. Freshly isolated neutrophils were loaded with 
Bodipy-maleimide dye (2.5µM) and stimulated with TNF-α (50ng/ml) immediately prior to 
ImageStreamX analysis. Samples were acquired constantly for 45 minutes collecting only 
microparticle events. Objects per second were determined using IDEAS software by adding the 
feature to the features list and applying it to the microparticle gate. (A) Representative plot of 
paired neutrophils stimulated with TNF-α (50ng/ml) or vehicle (PBS) from n=4 separate 
neutrophil donors. (B) Representative ImageStreamX gallery images of neutrophils budding at 
the times indicated.  
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Microparticle shedding is known to involve the rearrangement of the cytoskeleton, and 
as microparticles are known to contain cytoskeletal proteins (Dalli et al., 2013), I 
wanted to determine whether the presence of filamental actin could be detected within 
neutrophil microparticles. Interestingly, all subsets of microparticles displayed positivity 
for phalloidin staining, as shown by flow cytometry. This could have implications for 
microparticle generation and motility, which requires cytoskeletal components including 
a cortical actin network (Figure 3.1.8).  
 
CMP TMP IMP
0
20
40
60
80
Ph
al
lo
id
in
+  M
ic
ro
pa
rti
cl
es
 (%
)
Phalloidin 
C
ou
nt
s 
! CMP 
! TMP 
! IMP 
 control       
Figure 3.1.8 Neutrophil microparticles contain filamental actin. Microparticles generated from 
resting neutrophils (CMP) or following stimulation with TNF-α (50ng/ml; TMP) or IL-8 (50ng/ml; 
IMP) were analysed by flow cytometry for phalloidin positivity indicating the presence of 
filamental actin. Right-hand panel shows representative histogram. Data are expressed as 
percentage of Bodipy-maleimide/CD66b double-positive population and shown as mean ± SEM 
of 3 blood donors, not significant with One-way ANOVA and Bonferroni post-test. 
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As the presence of filamental actin had been detected, I next wanted to determine the 
involvement of cytoskeletal rearrangement during microparticle generation. Firstly, 
Trypan blue dye exclusion was used to determine if the cytoskeletal inhibitors or 
calcium chelator tested had detrimental effects on the viability of isolated neutrophils 
(Figure 3.1.9).  
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Figure 3.1.9 Drugs affecting microparticle production do not impair neutrophil viability. 
Neutrophils were treated with Jasplakinolide (1µM), Blebbistatin (10µM), Cytochalasin D (2µM), 
ML-7 (20µM) or BAPTA-AM (20µM) for 10 minutes then TNF-α (50ng/ml) for 20 minutes. 
Viability was assessed by Trypan blue dye exclusion. Data are shown as mean ± SEM of 4 
donors, not significant with Two-way ANOVA and Bonferroni post-test. 
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As neutrophil viability was not significantly affected, the offspring microparticles were 
loaded with Bodipy-maleimide dye and quantified using ImageStreamx analysis. 
Jasplakinolide, which inhibits actin depolymerisation and cytochalasin D, which inhibits 
actin polymerisation, both had significant effects on the number of microparticles 
produced by neutrophils without altering the size or shape of the microparticles 
generated (Figure 3.1.10). Jasplakinolide significantly inhibited microparticle production 
induced by TNF-α stimulation (0.9 ± 0.3 vs. 1.9 ± 0.5 x107 microparticles/ml, P<0.05 
with Two-way ANOVA and Bonferroni post-test) whereas cytochalasin D increased 
microparticle production in unstimulated (2.6 ± 0.2 vs. 0.8 ± 0.3 x107 microparticles/ml, 
P<0.01 with Two-way ANOVA and Bonferroni post-test) as well as TNF-α stimulated 
neutrophils (3.0 ± 0.1 vs. 1.9 ± 0.5 x107 microparticles/ml, P<0.05 with Two-way 
ANOVA and Bonferroni post-test), and induced the highest amount of microparticle 
shedding of all the drugs tested. These data implicate the actin cytoskeleton in the 
regulation of microparticle production, as enhanced actin polymerisation inhibits 
microparticle shedding and disruption of the cortical actin network enhances the 
number of microparticles generated. 
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In contrast, the number of microparticles produced during treatment with drugs that 
inhibit myosin activity did not reach statistical significance, even when repeated with 
seven blood donors (Figure 3.1.11). The size of the microparticles was also not altered. 
This suggests that formation of focal adhesions between the actin and myosin 
cytoskeleton, processes inhibited by Blebbistatin and ML-7, are not necessary in these 
settings for microparticle formation.  
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Figure 3.1.10 Microparticle formation involves regulation of the actin cytoskeleton. Neutrophils 
were treated with Jasplakinolide (1µM) or Cytochalasin D (2µM) for 10 minutes then TNF-α 
(50ng/ml) for 20 minutes and supernatant microparticles analysed using ImageStreamX after 
loading with Bodipy-maleimide dye (2.5µM). (A) Microparticles were accurately enumerated by 
ImageStream IDEAS software. Analysis of microparticle (B) diameter and (C) perimeter from 
bright field channel images. (D) Spherical volume of microparticles calculated from diameter 
values. Data are shown as mean ± SEM of 3-6 blood donors. *P<0.05, **P<0.01 and 
***P<0.001 using Two-way ANOVA with Bonferroni post-test. 
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Intracellular fluxes of calcium are known to be heavily involved in the events 
surrounding microparticle formation and shedding from initial receptor ligation up to the 
rearrangement of cytoskeletal components and phospholipid reorganisation. Calcium 
fluxes also recruit annexins to the plasma membrane to achieve membrane cleavage 
and microparticle release (Potez et al., 2011). Intracellular calcium chelation using 
BAPTA-AM significantly inhibited microparticle production compared to stimulation with 
TNF-α (0.3 ± 0.2 vs. 1.9 ± 0.5 x107 microparticles/ml, P<0.05 with Two-way ANOVA 
and Bonferroni post-test) as expected (Figure 3.1.12).  
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Figure 3.1.11 Microparticle formation is not myosin/actin focal adhesion dependent. 
Neutrophils were treated with Blebbistatin (10µM) or ML-7 (20µM) for 10 minutes then TNF-α 
(50ng/ml) for 20 minutes and supernatant microparticles analysed using ImageStreamX after 
loading with Bodipy-maleimide dye (2.5µM). (A) Microparticles were accurately enumerated by 
ImageStream IDEAS software. Analysis of microparticle (B) diameter and (C) perimeter from 
bright field channel images. (D) Spherical volume of microparticles calculated from diameter 
values. Data are shown as mean ± SEM of 7 blood donors, not significant with Two-way ANOVA 
and Bonferroni post-test.  
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Thus, microparticle shedding is a rapidly occurring event that requires intracellular 
calcium and the coordinated rearrangement of the actin cytoskeleton. The requirement 
of polymerisable and de-polymerisable actin was especially evident upon TNF-α 
stimulation, compared to resting cells, suggesting that differential processes may be 
inducing microparticle production. Therefore, it seemed likely that the content of these 
microparticles may also differ if the machinery involved in their production was different 
depending on the activation state of the parent cell.  
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Figure 3.1.12 TNF-α-induced Microparticle formation requires intracellular calcium. 
Neutrophils were treated with BAPTA-AM (20µM) for 10 minutes then TNF-α (50ng/ml) for 20 
minutes and supernatant microparticles analysed using ImageStreamX after loading with 
Bodipy-maleimide dye (2.5µM). (A) Microparticles were accurately enumerated by ImageStream 
IDEAS software. Analysis of microparticle (B) diameter and (C) perimeter from bright field 
channel images. (D) Spherical volume of microparticles calculated from diameter values. Data 
are shown as mean ± SEM of 3 blood donors. *P<0.05 using Two-way ANOVA with Bonferroni 
post-test. 
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3.1.3 Neutrophil Microparticles Contain Functional Proteins 
 
I next wanted to explore the potential cargo of these microparticles and whether their 
proteome was influence by the stimulus inducing their release, as previously reported 
(Dalli et al., 2013), (Timar et al., 2013). To characterise the expression of several 
markers associated with neutrophil microparticle formation, flow cytometric analysis 
was employed. Approximately 75% of microparticles expressed the neutrophil-surface 
marker CD66b, regardless of stimulus (Figure 3.1.13A). The majority could also bind 
Annexin V, a marker for phosphatidylserine exposure, an event thought to be key to 
microparticle formation and release (Figure 3.1.13B).  
 
CMP TMP IMP
0
20
40
60
80
100
C
D
66
b+
 M
ic
ro
pa
rti
cl
es
 (%
)
CMP TMP IMP
0
20
40
60
80
100
A
nn
ex
in
 V
+  M
ic
ro
pa
rti
cl
es
 (%
)
CD66b 
C
ou
nt
s 
! CMP 
! TMP 
! IMP 
 Isotype       
Annexin V 
C
ou
nt
s 
! CMP 
! TMP 
! IMP 
 Control       
A B 
Figure 3.1.13 Neutrophil microparticles express CD66b and Phosphatidylserine. Microparticles 
generated from resting neutrophils (CMP) or following stimulation with TNF-α (50ng/ml; TMP) or 
IL-8 (50ng/ml; IMP) were analysed by flow cytometry for (A) CD66b neutrophil marker 
expression and (B) Annexin V binding to indicate phosphatidylserine exposure. Bottom panels 
show representative histograms. Data are expressed as percentage of Bodipy-maleimide 
positive population and shown as mean ± SEM of 3 blood donors, not significant with One-way 
ANOVA and Bonferroni post-test. 
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I then wanted to determine if any of the other cytoplasmic constituents present in the 
neutrophil were also present within microparticles. Myeloid-related protein 8 (MRP8, 
also known as S100A8) constitutes more than 40% of the total cytoplasmic neutrophil 
protein content, and isolated human neutrophils stain intensely for this protein (Figure 
3.1.14).  
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Figure 3.1.14 Neutrophils express myeloid-related protein 8. Freshly isolated neutrophils were 
stained with FITC-conjugated monoclonal myeloid-related protein 8 (MRP8) antibody or isotype 
at the same concentration and visualised using an integrated fluorescence/light microscope 
with FL1 channel (excitation wavelength 460-490nm) and DAPI channel (excitation wavelength 
360-370nm) connected to a digital camera. Images were captured at X20 magnification. Scale 
bar denotes 25µm. Representative images, and right-hand panels show digital magnification for 
detail inspection. 
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It was therefore not surprising that more than 80% of each microparticle subset was 
positive for this protein (Figure 3.1.15A). MRP8 is also a protein specific to neutrophils, 
and could be used as a marker for microparticles of neutrophil origin. Physiologically, 
MRP8 is usually found with its binding and stabilising partner, MRP14 (also known as 
S100A9), though a lower percentage of microparticles expressed this protein on their 
surface (Figure 3.1.15B).  
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Figure 3.1.15 Neutrophil 
microparticles express 
Myeloid Related Protein 8 
and 14. Microparticles 
generated from resting 
neutrophils (CMP) or following 
stimulation with TNF-α 
(50ng/ml; TMP) or IL-8 
(50ng/ml; IMP) were 
analysed by flow cytometry for 
(A) MRP8 and (B) MRP14 
positivity. Right-hand panels 
show representative 
histograms. Data are 
expressed as percentage of 
Bodipy-maleimide/CD66b 
double-positive population 
and shown as mean ± SEM of 
3 blood donors, not 
significant with One-way 
ANOVA and Bonferroni post-
test. 
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Previous data from our laboratory showed that microparticles express over 300 
proteins when analysed by tandem LC/MS/MS (Dalli et al., 2013). It was therefore 
important to determine whether the expression of some of these proteins with potential 
immune-regulating functions was modulated by the differential stimuli applied to 
generate microparticles from neutrophils. Using flow cytometric analysis it was found 
that the number of microparticles expressing α2-Macroglobulin was significantly 
increased upon TNF-α stimulation compared to control (31.1 ± 3.9 vs. 13.7 ± 2.7%, 
P<0.01 with One-way ANOVA and Bonferroni post-test), while the per-microparticle 
surface expression remained similar across stimuli (Figure 3.1.16). Similarly, the 
percentage of microparticles positive for ceruloplasmin staining was significantly 
increased in TMP compared to CMP subsets (33.6 ± 3.2 vs. 23.5 ± 0.2%, P<0.05 with 
One-way ANOVA and Bonferroni post-test, Figure 3.1.16C) whilst the per-microparticle 
surface expression remained unchanged across stimuli (Figure 3.1.16D). In contrast, 
heat shock protein 70 expression was not modulated by stimulation in terms of 
percentage positive, or on a per-microparticle basis (Figure 3.1.16E,F). Both α2-
Macroglobulin and ceruloplasmin have anti-inflammatory functions and could predict 
immune-modulatory properties for neutrophil microparticles.  
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Neutrophil microparticles contain a potent anti-inflammatory and pro-resolving protein, 
Annexin A1 (Dalli et al., 2008), which has important functions in the resolution phase of 
inflammation (Perretti and D'Acquisto, 2009). Neutrophils are an abundant source of 
this protein, and aside from its inherent anti-inflammatory functions, Annexin A1 is 
involved in the resealing of the plasma membrane following injury (Potez et al., 2011), 
and could therefore have important implications in the release of microparticles. Upon 
stimulation with TNF-α, neutrophils released a larger percentage of microparticles 
positive for Annexin A1 compared to resting cells (21.7 ± 1.5 vs. 10.0 ± 0.7%, P<0.01 
with One-way ANOVA and Bonferroni post-test; Figure 3.1.17). An even greater 
percentage of IMP was positive for Annexin A1 compared to CMP (24.8 ± 2.5 vs. 10.0 
± 0.7%, P<0.001 with One-way ANOVA and Bonferroni post-test). Furthermore, the 
surface expression of Annexin A1 per microparticle was increased in both TMP and 
IMP subsets compared to CMP (142 ± 9.9 and 165 ± 22.4 vs. 88.0 ± 7.3 arbitrary units 
of mean fluorescence intensity, both P<0.05 with One-way ANOVA and Bonferroni 
post-test). 
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Figure 3.1.16 Neutrophil microparticles express proteins with immunological functions. 
Microparticles generated from resting neutrophils (CMP) or following stimulation with TNF-α 
(50ng/ml; TMP) or IL-8 (50ng/ml; IMP) were analysed by flow cytometry for (A) Alpha2 
macroglobulin positivity and (B) surface expression, (C) ceruloplasmin positivity and (D) surface 
expression and (E) heat shock protein 70 positivity and (F) surface expression. Data are 
expressed as percentage of Bodipy-maleimide/CD66b double-positive population or mean 
fluorescence intensity (MFI, arbitrary units) of this population and shown as mean ± SEM of 4 
blood donors. *P<0.05 and **P<0.01 using One-way ANOVA with Bonferroni post-test. 
  
160 
 
 
As it is not possible to determine the internal content of microparticles by flow 
cytometry (as permeabilisation of these small structures is not feasible), the Annexin 
A1 total protein expression was determined by Western blotting. The total Annexin A1 
content in TMP is much higher than CMP and IMP, suggesting that internal Annexin A1 
protein contributes significantly to the total Annexin A1 content (Figure 3.1.18). To 
determine the approximate amount of Annexin A1, CMP and TMP at various 
microparticle counts were loaded alongside known amounts of recombinant human 
Annexin A1. From this blot it is possible to tell that 5ng of Annexin A1 provides a similar 
signal intensity to that of 30,000 TMP and 100,000 CMP, suggesting that TMP are 
loaded with approximately three times the amount of Annexin A1 compared to CMP, 
which may have important consequences for microparticle function. 
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Figure 3.1.17 Neutrophil microparticles express anti-inflammatory protein Annexin A1. 
Microparticles generated from resting neutrophils (CMP) or following stimulation with TNF-α 
(50ng/ml; TMP) or IL-8 (50ng/ml; IMP) were analysed by flow cytometry for (A) Annexin A1 
positivity and (B) surface expression. Bottom panel shows a representative histogram. Data are 
expressed as percentage of CD66b/ Bodipy-maleimide double-positive population or mean 
fluorescence intensity (MFI, arbitrary units) of this population and shown as mean ± SEM of 4 
blood donors. *P<0.05, **P<0.01 and ***P<0.001 using One-way ANOVA with Bonferroni 
post-test. 
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Together, these results demonstrate that neutrophil microparticles contain a variety of 
putative anti-inflammatory proteins, the concentration of which was sometimes 
dependent on the stimulus that led to microparticle release. In particular, Annexin A1 
was shown to be highly abundant in microparticles, especially if they were derived from 
TNF-α stimulated neutrophils.  Some of the proteins levels were not changed upon 
stimulation, such as MRP8 and MRP14, and could represent a further neutrophil 
microparticle marker. 
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Figure 3.1.18 Neutrophil microparticles contain anti-inflammatory protein Annexin A1. 
Microparticles generated from resting neutrophils (CMP) or following stimulation with TNF-α 
(50ng/ml; TMP) or IL-8 (50ng/ml; IMP) were analysed by Western blotting for Annexin A1 
protein expression. (A) Densitometry of N=5 individual donor blots. Bands are normalised to 
100,000 microparticles; data are shown as mean ± SEM. *P<0.05 and ***P<0.001 using One-
way ANOVA and Bonferroni post-test (B) Representative blot showing comparison of different 
dilutions of CMP and TMP with known amounts of recombinant Annexin A1.  
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CHAPTER 4: EXAMINING THE ROLE 
OF NEUTROPHIL MICROPARTICLES 
IN IN VITRO MODELS OF CARTILAGE 
TURNOVER  
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4.1 Neutrophil Microparticles Protect 
Chondrocytes In Vitro 
 
The role of neutrophil microparticles in rheumatoid arthritis has not been studied. 
Previous reports have demonstrated an unexpected role for platelet microparticles, 
which deliver IL-1β to arthritic joints, contributing to the pathogenesis of the disease 
(Boilard et al., 2010). As the effect of microparticles on the aberrant synovial fibroblasts 
is an active area of research, I decided instead to turn my attention to the effect of 
neutrophil microparticles on chondrocyte and cartilage biology, an area which has 
never been studied before. Furthermore, if neutrophil microparticles had pathogenic 
effects on cartilage, this would broaden the repertoire of neutrophil microparticle 
functions, which have been previously reported to be anti-inflammatory (Dalli et al., 
2008, Gasser and Schifferli, 2004, Eken et al., 2008, Eken et al., 2010).   
 
4.1.1 Characterisation of the Effect of Microparticles on 
Extracellular Matrix Accumulation In Vitro  
 
To investigate the potential effects of neutrophil microparticles in the context of 
rheumatoid arthritis, it was important to characterise an in vitro model of cartilage 
matrix synthesis. By culturing the chondrocyte cell line C28/I2 at high density, the cells 
retain their spherical morphology and generate matrix rich in sulphated proteoglycans, 
reflecting physiological matrix generation. This matrix can be specifically stained with 
Alcian blue dye at pH 0.2, which after extraction can be quantified 
spectrophotometrically. This system allows for medium-throughput cartilage matrix 
assaying for the investigation of various catabolic (degradative) and anabolic 
(accumulative) stimuli. Importantly, this assay does not allow the determination of 
increased matrix synthesis or increased matrix degradation by enzymes, but can 
provide a good global measure of the net extracellular matrix content, hence matrix 
accumulation. 
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It was necessary to identify a stimulus that reduced chondrocyte extracellular matrix 
accumulation in the micromass culture system, to determine whether microparticles 
had any contribution to the cartilage integrity loss characteristic of rheumatoid arthritis. 
The cytokines that contribute most significantly to cartilage integrity loss in human 
rheumatoid arthritis are primarily IL-1β and TNF-α, which are increased in the synovial 
fluid of patients (Wright et al., 2012).  
 
IL-1β at increasing concentrations reduced matrix accumulation as shown by Alcian 
blue staining, with low concentrations, such as 3ng/ml inducing significant reduction 
compared to control (-23.8 ± 3.3 vs. 0.0 ± 4.6% P<0.01 with One-way ANOVA and 
Bonferroni post-test; Figure 4.1.1A). The sensitivity of this assay to small 
concentrations of IL-1β allows subtle changes in matrix accumulation to be monitored 
and provides a range of working concentrations for a variety of assays, up to 30ng/ml (-
68.5 ± 2.3 vs. 0.0 ± 4.6% P<0.001 with One-way ANOVA and Bonferroni post test). In 
contrast, TNF-α stimulation did not induce a significant reduction in matrix 
accumulation until concentrations reached 30ng/ml (-26.2 ± 6.4 vs. 0.0 ± 4.2% P<0.01 
with One-way ANOVA and Bonferroni post-test), providing a less sensitive assay for 
changes in matrix accumulation (Figure 4.1.1B).  
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Figure 4.1.1 IL-1β and TNF-α reduce C28/I2 chondrocyte micromass extracellular matrix 
accumulation. Chondrocyte micromasses were treated with increasing concentrations of (A) IL-
1β and (B) TNF-α for 24 hours before extracellular matrix accumulation was quantified with 
Alcian blue staining. Below are representative photographs of micromasses before dye 
extraction. Data are shown as mean ± SEM of 6 separate micromass preparations. **P<0.01 
and ***P<0.001 using One-way ANOVA and Bonferroni post-test. ECM, extracellular matrix. 
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As TNF-α induced more subtle degradative effects in the C28/I2 chondrocytes, this 
cytokine was dispensed with as a model cytokine in these assays. Although 
microparticles generated using TNF-α were being profiled for functionality in terms of 
the best activator of neutrophils, it made more sense to also select a stimulus of 
chondrocytes best suited to chondrocyte “activation”, providing more reproducible 
read-outs.
  
166 
Treatment of chondrocyte micromasses with IL-1β also significantly reduced the mRNA 
expression of ACAN at concentrations of 30ng/ml (0.4 IQR 0.2-0.6 vs. 1 IQR 0.9-1.1; 
P<0.01 with Kruskal-Wallis test and Dunn’s multiple comparison post-test) and 50ng/ml 
(0.3 IQR 0.2-0.5 vs. 1 IQR 0.9-1.1; P<0.05 with Kruskal-Wallis test and Dunn’s multiple 
comparison post-test; Figure 4.1.2A). COL2A1 expression was also down regulated by 
treatment with IL-1β (30ng/ml) compared to control (0.4 IQR 0.3-1 vs. 1 IQR 0.8-1.2; 
P<0.01 with Kruskal-Wallis test and Dunn’s multiple comparison post-test; Figure 
4.1.2B). These two genes are key to matrix production. At a 6-hour time point however, 
TNF-α did not significantly suppress ACAN expression (0.4 IQR 0.3-1 vs. 1 IQR 0.9-
1.1) or COL2A1 expression (1.1 IQR 1.1-1.4 vs. 1 IQR 0.8-1.2) compared to untreated 
micromasses (Figure 4.1.2C and D). The expression profile of COL2A1 induced by 
TNF-α stimulation was significantly different to that induced by IL-1β (3ng/ml) treatment 
(0.7 IQR 0.4-0.9 vs. 1.1 IQR 1.1-1.4; P<0.05 with Kruskal-Wallis test and Dunn’s 
multiple comparison post-test) or IL-1β (30ng/ml) treatment (0.4 IQR 0.3-0.6 vs. 1.1 
IQR 1.1-1.4; P<0.01 with Kruskal-Wallis test and Dunn’s multiple comparison post-
test). 
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Figure 4.1.2 IL-1β, but not TNF-α treatment of chondrocyte micromasses induces down-
regulation of key matrix production genes. Chondrocyte micromasses were treated with 
increasing concentrations of IL-1β (3ng/ml-50ng/ml) or TNF-α (10ng/ml) for 6 hours before 
mRNA extraction and RT-PCR. (A) Relative expression of ACAN and (B) COL2A1 following IL-1β 
treatment. (C) Relative expression of ACAN and (D) COL2A1 following IL-1β and TNF-α 
treatment. Data shown are 2-ΔΔCT with untreated as calibrator and RPL32 as housekeeping 
gene. Data expressed as median, interquartile range and range 5 and 3 separate micromass 
preparations. *P<0.05, **P<0.01 and ***P<0.001 using Kruskal-Wallis test and Dunn’s 
multiple comparison post-test.  
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Thus, microparticles were co-cultured with micromasses stimulated with IL-1β and 
TNF-α, to determine whether any effects in extracellular matrix accumulation could be 
observed. Interestingly, co-culture of chondrocyte micromasses with each subset of 
microparticles increased matrix accumulation during concomitant IL-1β stimulation 
(Figure 4.1.3A). No significant changes in matrix accumulation were observed during 
microparticle treatment alone (CMP -1.7 ± 0.4, TMP -2.2 ± 0.4 and IMP -1.7 ± 0.4 vs. 
0.0 ± 3.5%). However, in chondrocyte micromasses stimulated with IL-1β (3ng/ml), 
CMP, TMP and most significantly IMP increased extracellular matrix accumulation 
above that even of untreated control micromasses (CMP 78.5 ± 30.4, TMP 128.1 ± 
29.8 and IMP 228.0 ± 44.6 vs. control 0.0 ± 3.5% P<0.001 with Two-way ANOVA and 
Bonferroni post-test). IMP treatment achieved the greatest matrix accumulation of each 
of the microparticle subsets, significantly higher than TMP or CMP at 3ng/ml IL-1β (228 
± 44.6 vs. TMP 128.1 ± 29.8 or CMP 78.5 ± 30.4% P<0.001 with Two-way ANOVA and 
Bonferroni post-test). Strikingly, microparticle treatment with concomitant IL-1β 
(30ng/ml) stimulation also induced significant matrix accumulation (CMP 57.3 ± 1.4, 
TMP 64.9 ± 1.5 and IMP 24.1 ± 6.0 vs. -67.3 ± 2.4% P<0.001 with Two-way ANOVA 
and Bonferroni post-test), which was clearly visible in Alcian blue stained micromasses 
before dye extraction. This significant increase in matrix accumulation was also 
observed when TMP were co-cultured with TNF-α (30ng/ml) stimulated chondrocyte 
micromasses (72.9 ± 23.0 vs. -16.5 ± 3.1% P<0.01 with Two-way ANOVA and 
Bonferroni post-test; Figure 4.1.3B). Again, no increase in matrix accumulation was 
observed without the concomitant stimulation with TNFα (3.5 ± 27.5 vs. 0 ± 4.2%).  
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Figure 4.1.3 Microparticles reverse the effect of IL-1β and TNF-α to increase extracellular 
matrix accumulation. Chondrocyte micromasses were treated with (A) IL-1β or (B) TNF-α and 
100,000 CMP, TMP or IMP for 24 hours before extracellular matrix accumulation was quantified 
by Alcian blue staining. Right are representative photographs of micromasses before dye 
extraction. Data are shown as mean ± SEM of 6 separate microparticle donors. **P<0.01 and 
***P<0.001 using Two-way ANOVA and Bonferroni post-test. CMP, control microparticles; TMP, 
TNF-α generated microparticles; IMP, IL-8 generated microparticles; ECM, extracellular matrix. 
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The accumulation of matrix induced by microparticle co-culture was dose-dependent 
(Figure 4.1.4). With IL-1β (3ng/ml) as a stimulus, a concentration of 100,000 TMP 
significantly increased matrix accumulation above IL-1β alone (128 ± 29.8 vs. -21.8 ± 
3.9% P<0.001 with Two-way ANOVA and Bonferroni post-test). This concentration was 
more effective than lower concentrations of TMP (128 ± 29.8 vs. 10,000 TMP 13.4 ± 
13.4 and 50,000 TMP 2.1 ± 20% P<0.001 with Two-way ANOVA and Bonferroni post-
test). In contrast, all concentrations of TMP induced significant matrix accumulation 
compared to IL-1β (30ng/ml) alone (10,000 TMP 12.8 ± 12.1, 50,000 TMP 10.6 ± 20.1 
and 100,000 TMP 64.9 ± 1.5 vs. -66.8 ± 2.8% P<0.001 with Two-way ANOVA and 
Bonferroni post-test). 100,000 TMP induced significantly greater matrix accumulation 
compared to the two lower concentrations of TMP using 30ng/ml IL-1β (100,000 TMP 
64.9 ± 1.5 vs. 10,000 TMP 12.8 ± 12.1 and 50,000 TMP 10.6 ± 20.1 P<0.05 with Two-
way ANOVA and Bonferroni post-test). A similar effect was observed with CMP plus IL-
1β stimulation, but a lower concentration of 50,000 CMP induced significant matrix 
accumulation compared to IL-1β (3ng/ml) alone (30.7 ± 7.3 vs. -23.83 ± 3.3% P<0.05 
with Two-way ANOVA and Bonferroni post-test) as well as 100,000 CMP (78.5 ± 30.4 
vs. -23.83 ± 3.3% P<0.001 with Two-way ANOVA and Bonferroni post-test). Similarly, 
all microparticle concentrations produced significant matrix accumulation compared to 
IL-1β (30ng/ml) (10,000 CMP 24.5 ± 14.9, 50,000 CMP 45.9 ± 14.7 and 100,000 CMP 
57.3 ± 1.4 vs. -67.3 ± 2.4% P<0.001 with Two-way ANOVA and Bonferroni post-test), 
with 100,000 CMP at 30ng/ml IL-1β yielding the most significant difference (57.3 ± 1.4 
vs. 24.5 ± 14.9% P<0.05 with Two-way ANOVA and Bonferroni post-test).  
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Figure 4.1.4 Microparticles increase extracellular matrix accumulation in a concentration 
dependent manner. Chondrocyte micromasses were treated with increasing concentrations of 
IL-1β and 10,000, 50,000 or 100,000 (A) TMP or (B) CMP for 24 hours before extracellular 
matrix accumulation was quantified by Alcian blue staining. Right are representative 
photographs of micromasses before dye extraction. Data are shown as mean ± SEM of 6 
separate microparticle donors. *P<0.05, **P<0.01 and ***P<0.001 using Two-way ANOVA 
and Bonferroni post-test. CMP, control microparticles; TMP, TNF-α generated microparticles; 
ECM, extracellular matrix.  
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To determine whether this observed increase in extracellular matrix accumulation 
induced by microparticles was unique to the of C28/I2 chondrocyte cell line, primary 
adult human articular chondrocytes were cultured in micromasses and stimulated with 
IL-1β (3 and 30ng/ml) with concomitant microparticle treatment (Figure 4.1.5). 
Microparticle treatment (100,000 TMP) alone had no effect (-1.4 ± 2.0 vs. 0.0 ± 10%), 
but significantly increased matrix accumulation compared to IL-1β at 3ng/ml (23.9 ± 8.1 
vs. -15.1 ± 9.2% P<0.05 with Two-way ANOVA and Bonferroni post-test) and 30ng/ml 
concentrations (33.0 ± 10.1 vs. -25.7 ± 5.0% P<0.001 with Two-way ANOVA and 
Bonferroni post-test). 
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To investigate whether the increase in matrix accumulation observed during 
microparticle treatment was due to changes in the enzymatic degradation induced by 
IL-1β, a 1,9 dimethylmethylene blue dye-binding assay was performed on chondrocyte 
micromass supernatants. This assay allows quantification of free (and therefore 
enzymatically cleaved) proteoglycans released from chondrocyte micromasses during 
culture with IL-1β (Figure 4.1.6). IL-1β (3ng/ml) stimulation induced significant matrix 
degradation compared to control micromasses (6.9 ± 0.5 vs. 4.3 ± 0.5µg/ml P<0.05 
with One-way ANOVA and Bonferroni post-test). Concomitant IL-1β (3ng/ml) and 
microparticle treatment was not significantly changed from control (CMP 4.9 ± 1.1 and 
TMP 5.0 ± 0.5 vs. 4.3 ± 0.5µg/ml, not significant with One-way ANOVA and Bonferroni 
post-test). In contrast, IL-1β (30ng/ml) induced considerable matrix degradation (19.9 ± 
3.7 vs. 5.3 ± 0.2µg/ml P<0.001 with One-way ANOVA and Bonferroni post-test), which 
was inhibited significantly by microparticle treatment (CMP 7.0 ± 0.5 and TMP 4.4 ± 0.8 
vs. 19.9 ± 3.7µg/ml P<0.001 with One-way ANOVA and Bonferroni post-test).  
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Figure 4.1.5 Microparticles increase extracellular matrix accumulation in primary adult human 
articular chondrocyte micromasses. Primary human chondrocyte micromasses were treated 
with increasing 3ng/ml or 30ng/ml IL-1β and 100,000 TMP for 24 hours before extracellular 
matrix accumulation was quantified by Alcian blue staining. Right are representative 
photographs of micromasses before dye extraction. Data are shown as mean ± SEM of 4 
separate microparticle donors. *P<0.05 and ***P<0.001 using Two-way ANOVA and Bonferroni 
post-test. TMP, TNF-α generated microparticles; ECM, extracellular matrix. 
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These results indicate that the reduced matrix accumulation observed in chondrocyte 
micromasses stimulated with IL-1β (30ng/ml) is a consequence of enzymatic 
degradation, and that microparticles may inhibit this process. It was also therefore 
imperative to determine whether microparticles could induce matrix accumulation via 
its biosynthesis.  
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Figure 4.1.6 Microparticles prevent extracellular matrix degradation induced by IL-1β 
treatment. Chondrocyte micromasses were treated with (A) IL-1β (3ng/ml) or (B) (30ng/ml) and 
100,000 CMP or TMP for 24 hours before released sulphated proteoglycans were quantified in 
supernatants by 1,9 dimethylmethylene blue dye binding assay. Data are shown as mean ± 
SEM of 3 or 5 separate microparticle donors. *P<0.05 and ***P<0.001 using One-way ANOVA 
and Bonferroni post-test. CMP, control microparticles; TMP, TNF-α generated microparticles. 
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4.1.2 Neutrophil Microparticles Modulate Chondrocyte 
Gene Expression to Increase Extracellular Matrix and 
Prevent Chondrocyte Apoptosis.   
 
To determine whether microparticle treatment was inhibiting extracellular matrix 
production, the gene expression of matrix-metalloproteinases MMP13 and ADAMTS5, 
two enzymes induced by IL-1β stimulation and responsible for cartilage degradation in 
rheumatoid arthritis, was measured in C28/I2 chondrocyte micromasses stimulated 
with IL-1β and treated with 100,000 microparticles for 6 hours (Figure 4.1.7). The 
relative expression of MMP13 was significantly increased upon stimulation with IL-1β 
(30ng/ml) compared to control (10 IQR 8.3-15.3 vs. 1 IQR 1-1.1; P<0.001 with Kruskal-
Wallis test and Dunn’s multiple comparison post-test; Figure 4.1.7A). This was also the 
case for concomitant IL-1β (30ng/ml) treatment and CMP (6.3 IQR 4-11.2 vs. 10 IQR 
8.3-15.3; P<0.001 with Kruskal-Wallis test and Dunn’s multiple comparison post-test), 
and less significantly with TMP (5.3 IQR 3.6-6 vs. 10 IQR 8.3-15.3; P<0.001 with 
Kruskal-Wallis test and Dunn’s multiple comparison post-test). Whereas IL-1β did not 
significantly induce expression of ADAMTS5 mRNA at this time point (0.6 IQR 0.4-2.9 
vs. 1 IQR 0.8-1) and gene expression was not significantly altered upon microparticle 
treatment (CMP 1.4 IQR 1-2.7 and TMP 1 IQR 0.7-2.5 vs. 0.6 IQR 0.4-2.9; Figure 
4.1.7B). It is plausible that microparticles may be involved in events that occur post-
transcriptionally, such as the competitive inhibition of matrix degrading enzymes rather 
than modulating the transcription of the genes themselves at 6 hours. 
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The expression of genes associated with matrix accumulation, aggrecan and type II 
collagen, was next investigated in chondrocyte micromasses stimulated with IL-1β and 
treated with microparticles (Figure 4.1.8). The expression of ACAN mRNA upon IL-1β 
(3ng/ml) stimulation and TMP treatment was significantly different compared to IL-1β 
alone (1.2 IQR 0.8-1.5 vs. 0.7 IQR 0.2-0.9; P<0.05 with Kruskal-Wallis test and Dunn’s 
multiple comparison post-test), but IL-1β treatment was not significantly different from 
control (Figure 4.1.8A; 0.7 IQR 0.2-0.9 vs. 1 IQR 0.9-1.1). In contrast, IL-1β (30ng/ml) 
significantly reduced relative expression of ACAN mRNA compared to control (0.4 IQR 
0.2-0.6 vs. 1 IQR 0.9-1.1; P<0.01 with Kruskal-Wallis test and Dunn’s multiple 
comparison post-test; Figure 4.1.8B), but microparticle treatment was not significantly 
different to control or IL-1β (30ng/ml) (CMP 0.5 IQR 0.4-0.8 and TMP 0.5 IQR 0.3-1 vs. 
control 1 IQR 0.9-1.1 or IL-1β 0.4 IQR 0.2-0.6).   
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Figure 4.1.7 Microparticles do not significantly affect mRNA levels of matrix 
metalloproteinases associated with extracellular matrix degradation. Chondrocyte 
micromasses were treated with IL-1β (30ng/ml) and 100,000 CMP or TMP for 6 hours before 
mRNA extraction and RT-PCR. (A) Relative expression of MMP13 and (B) ADAMTS5. Data shown 
are 2-ΔΔCT with untreated as calibrator and RPL32 as housekeeping gene. Data expressed as 
median, interquartile range and range of 5 and 3 separate microparticle donors. **P<0.01 and 
***P<0.001 using Kruskal-Wallis test and Dunn’s multiple comparison post-test. CMP, control 
microparticles; TMP, TNF-α generated microparticles. 
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Treatment of micromasses with CMP or TMP significantly reversed the down-
regulation of COL2A1 mRNA induced by IL-1β (3ng/ml) (1.4 IQR 1-2 and 1.1 IQR 0.9-
1.5 vs. 0.7 IQR 0.4-0.9; P<0.01 with Kruskal-Wallis test and Dunn’s multiple 
comparison post-test; Figure 4.1.8C). At 30ng/ml IL-1β, COL2A1 expression was 
significantly down-regulated compared to control (0.4 IQR 0.3-0.6 vs. 1 IQR 0.8-1.1; 
P<0.05 with Kruskal-Wallis test and Dunn’s multiple comparison post-test) which was 
inhibited by CMP treatment (1.1 IQR 1-1.3 vs. 0.4 IQR 0.3-0.6; P<0.01 with Kruskal-
Wallis test and Dunn’s multiple comparison post-test) and TMP treatment (1.1 IQR 1-
1.5 vs. 0.4 IQR 0.3-0.6; P<0.05 with Kruskal-Wallis test and Dunn’s multiple 
comparison post-test; Figure 4.1.8D). Taken together, these data suggest 
microparticles have gene-modulating functions in stimulated chondrocyte micromasses 
as measured at the 6-hour time point.  
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Figure 4.1.8 Microparticles reverse the down-regulation of mRNA expression associated with 
extracellular matrix generation induced by IL-1β. Chondrocyte micromasses were treated with 
IL-1β (3ng/ml or 30ng/ml) and 100,000 CMP or TMP for 6 hours before mRNA extraction and 
RT-PCR. (A, B) Relative expression of ACAN and (C, D) COL2A1. Data shown are 2-ΔΔCT with 
untreated as calibrator and RPL32 as housekeeping gene. Data expressed as median, 
interquartile range and range of 5 and 3 separate microparticle donors. *P<0.05 and 
**P<0.01 using Kruskal-Wallis test and Dunn’s multiple comparison post-test. CMP, control 
microparticles; TMP, TNF-α generated microparticles. 
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The transcription of COL2A1 and ACAN mRNA is governed by the chondrocyte-
specific transcription factor SOX9; therefore the effect of microparticles on the relative 
expression of SOX9 was investigated (Figure 4.1.9). There was no significant alteration 
of SOX9 expression in chondrocyte micromasses stimulated with IL-1β (3ng/ml) for 6 
hours, however, at 30ng/ml IL-1β, SOX9 expression was significantly down-regulated 
compared to control (0.3 IQR 0.3-0.4 vs. 1 IQR 0.9-1.1; P<0.05 with Kruskal-Wallis test 
and Dunn’s multiple comparison post-test). Furthermore, concomitant treatment with 
TMP reversed this down-regulation (1 IQR 0.6-1.3 vs. 0.3 IQR 0.3-0.4; P<0.05 with 
Kruskal-Wallis test and Dunn’s multiple comparison post-test).  
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Figure 4.1.9 Microparticles induce SOX9 transcription factor mRNA expression associated with 
extracellular matrix generation. Chondrocyte micromasses were treated with (A) IL-1β (3ng/ml) 
(B) or (30ng/ml) and 100,000 CMP or TMP for 6 hours before mRNA extraction and RT-PCR. 
Data shown are 2-ΔΔCT with untreated as calibrator and RPL32 as housekeeping gene. Data 
expressed as median, interquartile range and range of 5 separate microparticle donors. 
*P<0.05 and **P<0.01 using Kruskal-Wallis test and Dunn’s multiple comparison post-test. 
CMP, control microparticles; TMP, TNF-α generated microparticles. 
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This increased relative expression of SOX9 transcription factor mRNA was mirrored by 
an increase in SOX9 protein at 24 hours post microparticle treatment as seen by 
Western blotting (Figure 4.1.10). The concomitant treatment of chondrocyte 
micromasses with IL-1β (30ng/ml) and microparticles led to a reversal of the down-
regulation induced by IL-1β alone (CMP 149 ± 53.6 and TMP 116.2 ± 30 vs. 62.2 ± 
14.5). Furthermore, microparticle treatment led to the appearance of further bands of a 
larger molecular weight (up to 100kDa) than IL-1β alone or control. The identity of 
these extra bands is unknown, but could represent IgG present within the microparticle 
fraction, although on reducing gels these usually appear at 25kDa and 50kDa. 
Alternatively, these extra bands could represent various splice variants and could 
account for some of the increased matrix accumulation seen in micromasses treated 
with both IL-1β and microparticles. Further identification of these bands would be 
interesting, even just to exclude endogenous IgG in the microparticle fraction.  
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Figure 4.1.10 Microparticles induce Sox9 
transcription factor protein expression. 
Chondrocyte micromasses treated with IL-
1β (30ng/ml) and 100,000 CMP or TMP 
for 24 hours were analysed by Western 
blotting for Sox9 protein expression. 
Expected band size 56kDa. Bands 
appearing at other molecular weights are 
unidentified. Data are shown as mean ± 
SEM of 4 separate microparticle donors 
and blots and expressed as percentage-
change from 100% control after 
normalisation to β Actin. CMP, control 
microparticles; TMP, TNF-α generated 
microparticles. Not significant with One-
way ANOVA and Bonferroni post-test. 
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SOX9 is an important regulator in chondrocytes, controlling not only matrix-associated 
gene transcription, but also protects these cells from apoptosis. Thus, apoptosis in 
chondrocyte micromasses stimulated with high levels of IL-1β (50ng/ml) was measured 
after 18 hours using an indicator of early apoptosis, DiOC6 dye (Figure 4.1.11). 
Approximately 40% of chondrocytes stimulated with IL-1β (50ng/ml) in micromass 
cultured entered early apoptosis by 18 hours and appeared as DiOC6-fluorescence low 
compared to non-apoptotic cells. This was significantly higher than baseline (45.4 ± 0.5 
vs. 26.3 ± 2.4% P<0.001 with One-way ANOVA and Bonferroni post-test). In order to 
analyse the cells using a flow cytometer, they must first be dissociated by gentle 
pipetting to create a single-cell suspension, which may account for the high baseline 
apoptosis. Regardless, concomitant CMP treatment significantly reduced the number 
of apoptotic chondrocytes compared to IL-1β treatment alone (35.3 ± 0.6 vs. 45.4 ± 
0.5% P<0.01 with One-way ANOVA and Bonferroni post-test), as did TMP treatment 
(37.4 ± 1.7 vs. 45.4 ± 0.5% P<0.05 with One-way ANOVA and Bonferroni post-test). 
However, both microparticle treatments in combination with IL-1β still induced 
significantly greater levels of apoptosis compared to untreated chondrocytes (CMP 
35.3 ± 0.6 and TMP 37.4 ± 1.7 vs. 26.3 ± 2.4% P<0.01 with One-way ANOVA and 
Bonferroni post-test).  
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Figure 4.1.11 Microparticles generated by resting neutrophils (CMP) inhibit chondrocyte 
apoptosis induced by high doses of IL-1β. Chondrocyte micromasses were treated with IL-1β 
(50ng/ml) and 100,000 CMP or TMP for 18 hours before apoptosis was quantified by DiOC6 
staining and flow cytometry. Right are representative dot plots of chondrocytes disassociated 
from micromasses. Data are shown as mean ± SEM of 4 separate microparticle donors. 
*P<0.05, **P<0.01 and ***P<0.001 using One-way ANOVA and Bonferroni post-test. CMP, 
control microparticles; TMP, TNF-α generated microparticles.  
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Late apoptosis was next quantified using TUNEL staining (Figure 4.1.12). Again, IL-1β 
induced significant levels of apoptosis compared to control (27.5 ± 2.2 vs. 15.9 ± 2.4% 
P<0.05 with One-way ANOVA and Bonferroni post-test) at 18 hours. In this case, only 
CMP treatment could significantly suppress IL-1β-induced apoptosis in C28/I2 
micromasses (15.8 ± 1.5 vs. 27.5 ± 2.2% P<0.05 with One-way ANOVA and Bonferroni 
post-test) to a degree similar to that of untreated micromasses (15.8 ± 1.5 vs. 15.9 ± 
2.4%). In the TMP treatment group, large variation was encountered as only a small 
number of samples were tested (n=3 individual microparticle donors). IMP treatment 
did not significantly reduce IL-1β-induced chondrocyte apoptosis.  
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Figure 4.1.12 Microparticles generated by resting neutrophils (CMP) inhibit chondrocyte 
apoptosis induced by high doses of IL-1β. Chondrocyte micromasses were treated with IL-1β 
(50ng/ml) and 100,000 CMP, TMP or IMP for 18 hours before apoptosis was quantified by 
TUNEL staining using ImageJ imaging software. Right are representative fluorescent 
micrographs of chondrocytes disassociated from micromasses then stained. Data are shown as 
mean ± SEM of 4 separate microparticle donors. *P<0.05 using One-way ANOVA and Bonferroni 
post-test. CMP, control microparticles; TMP, TNF-α microparticles; IMP, IL-8 generated 
microparticles. 
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Therefore, microparticle treatment is able to reverse some of the catabolic effects 
induced by IL-1β stimulation, including the transcription of MMP13, the suppression of 
ACAN and COL2A1 gene transcription, and the induction of apoptosis. Microparticle 
treatment also alters the expression of Sox9 protein, leading to the appearance of 
bands with different weights.  
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4.1.3 Neutrophil Microparticles Modulate the Expression of 
Pro-Inflammatory Cytokines 
 
Cartilage metabolism can be governed in 3 ways: by the regulation of anabolic and 
catabolic gene expression, by enzymatic remodelling and finally by the induction of 
degradative pathways by proinflammatory cytokines. Rheumatoid arthritis is not only 
characterised by a loss of cartilage matrix, but also by a dysregulated inflammatory 
response that does not resolve in a timely manner. The infiltration of immune cells into 
the joint usually occurs in response to chemoattractant signals, of which IL-8 is 
important in chondrocyte physiology. Therefore, the production of IL-8 by chondrocyte 
micromasses was investigated by ELISA (Figure 4.1.13). Microparticle treatment alone 
did not induce IL-8 production above baseline at 24 hours (CMP 1.6 ± 0.5 and TMP 
0.41 ± 0 vs. 0.6 ± 0.0ng/ml), however IL-1β (30ng/ml) induced a 20-fold increase in IL-8 
production (9.6 ± 0.9 vs. 0.6 ± 0ng/ml) which CMP and TMP both inhibited significantly 
(CMP 6.6 ± 0.4 and TMP 6.8 ± 0.3 vs. 9.6 ± 0.9ng/ml P<0.001 with Two-way ANOVA 
and Bonferroni post-test) at the same time point. 
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Figure 4.1.13 Microparticles inhibit 
chondrocyte IL-8 production induced by 
IL-1β. Chondrocyte micromasses were 
treated with IL-1β (30ng/ml) and 
100,000 CMP or TMP for 24 hours 
before IL-8 production was quantified 
by ELISA. Data are shown as mean ± 
SEM of 6 separate microparticle 
donors. ***P<0.001 using Two-way 
ANOVA and Bonferroni post-test. CMP, 
control microparticles; TMP, TNF-α 
generated microparticles. 
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Joint pain is also a significant burden in rheumatoid arthritis, and high levels of 
prostaglandin E2, associated with pain, and is detected in patient synovial fluid during 
flares of the disease. However, lower concentrations of prostaglandin E2 are thought to 
have protective effects on cartilage matrix and native chondrocytes, but these data 
remain controversial. However, high concentrations are known to directly suppress 
matrix production and influence the expression of cartilage-degrading enzymes. Thus, 
prostaglandin E2 levels were measured in chondrocyte micromass cultures (Figure 
4.1.14). Surprisingly, CMP treatment alone induced significant prostaglandin E2 
production in unstimulated micromasses compared to untreated micromasses (176.9 ± 
70.9 vs. 64.0 ± 6.0pg/ml P<0.05 with Two-way ANOVA and Bonferroni post-test). This 
level was significantly higher than that produced by TMP-treated unstimulated 
micromasses (176.9 ± 70.9 vs. 26.4 ± 6.3pg/ml P<0.01 with Two-way ANOVA and 
Bonferroni post-test) or IMP-treated unstimulated micromasses (176.9 ± 70.9 vs. 44.2 ± 
3.2pg/ml P<0.05 with Two-way ANOVA and Bonferroni post-test). It is possible that this 
result is a reflection of donor variation, but equally, CMP-induced PGE2 production 
could represent a caveat preventing in vivo microparticle testing. In contrast, CMP 
treatment as well as TMP treatment significantly reduced the levels of IL-1β-induced 
prostaglandin E2 in stimulated micromasses (CMP 197.2 ± 15.4 and TMP 165.6 ± 8.6 
vs. 746.5 ± 51.8pg/ml P<0.001 with Two-way ANOVA and Bonferroni post-test) 
representing a 4.5-fold decrease in prostaglandin E2 production. IMP reduced the 
amount of prostaglandin E2 produced upon IL-1β stimulation (592.0 ± 58.5 vs. 746 ± 
51.8pg/ml P<0.05 with Two-way ANOVA and Bonferroni post-test), but this was 
significantly different from CMP or TMP treatments (592.0 ± 58.5 vs. CMP 197.2 ± 15.4 
and TMP 165.6 ± 8.6pg/ml P<0.001 with Two-way ANOVA and Bonferroni post-test).  
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Figure 4.1.14 Microparticles inhibit 
chondrocyte Prostaglandin E2 
production induced by IL-1β. 
Chondrocyte micromasses were treated 
with IL-1β (30ng/ml) and 100,000 CMP, 
TMP or IMP for 24 hours before PGE2 
production was quantified by EIA. Data 
are shown as mean ± SEM of 6 
separate microparticle donors. 
*P<0.05, **P<0.01 and ***P<0.001 
using Two-way ANOVA and Bonferroni 
post-test. CMP, control microparticles; 
TMP, TNF-α generated microparticles; 
IMP, IL-8 generated microparticles; 
PGE2, prostaglandin E2. 
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Although the role of IL-6 as a pro-inflammatory cytokine in acute inflammatory events is 
well defined, IL-6 is known to have homeostatic effects on chondrocytes, and even 
high levels of expression are not known to induce significant cartilage integrity loss. 
However, IL-6 does affect the tissues surrounding cartilage within the joint. For 
example, synovial fibroblasts are sensitive to IL-6 and produce a host of inflammatory 
cytokines in response to IL-6 stimulation, which recruits immune cells in arthritis. 
Chondrocyte micromass IL-6 production was measured following stimulation with IL-1β 
and treatment with microparticles (Figure 4.1.15). Microparticle treatment alone in 
unstimulated micromasses did not induce any IL-6 production above control (CMP 0.0 
± 0 and TMP 0.1 ± 0 vs. 0.1 ± 0ng/ml). Treatment with CMP significantly altered the 
production of IL-6 by IL-1β-stimulated micromasses (1.4 ± 0.1 vs. 2.4 ± 0.01ng/ml 
P<0.001 with Two-way ANOVA and Bonferroni post-test), as did TMP treatment (1.3 
vs. 0.1 vs. 2.4 ± 0.01ng/ml P<0.001 with Two-way ANOVA and Bonferroni post-test) 
when compared to IL-1β alone. 
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Figure 4.1.15 Microparticles reduce 
chondrocyte IL-6 production induced by 
IL-1β. Chondrocyte micromasses were 
treated with IL-1β (30ng/ml) and 
100,000 CMP or TMP for 24 hours 
before IL-6 production was quantified by 
ELISA. Data are shown as mean ± SEM 
of 6 separate microparticle donors. 
***P<0.001 with Two-way ANOVA and 
Bonferroni post-test. CMP, control 
microparticles; TMP, TNF-α generated 
microparticles. 
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Interestingly, microparticles seem to influence the production of inflammatory 
mediators by chondrocytes stimulated with IL-1β. Taken with the previous data, this 
suggests that microparticles are acting in a variety of ways to protect the chondrocytes 
in vitro. Firstly, by inducing matrix accumulation, in part by preventing its enzymatic 
degradation, and also by the regulation of gene transcription involved with both matrix 
production and matrix degradation by matrix metalloproteinases. In addition, the 
microparticles also reduce the release of IL-8, Prostaglandin E2 and IL-6.
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4.1.4 Neutrophil Microparticles, Not Neutrophils, are 
Responsible for Microparticle-Induced 
Chondroprotection 
 
The pathogenic roles of neutrophils in rheumatoid arthritis are known, and the aberrant 
recruitment of these cells to the synovial joints during flares contributes to tissue 
damage. However, for neutrophil-derived microparticles to be functionally protective in 
vivo and in physiological settings, the spatial regulation of the protective process must 
allow for chondrocyte protection to occur. Therefore an experiment was devised to 
recapitulate the cartilage barrier separating neutrophils from chondrocytes to explore 
the spatial separation that inhibits direct contact between these cells physiologically in 
the joint, using transwells of varying pore sizes.   
 
Surprisingly, TNF-α stimulated neutrophils only significantly reduced matrix 
accumulation within chondrocyte micromasses when the pore size of the transwell was 
large enough to allow neutrophils to transmigrate (8000nm pore size -32.5 ± 14.2 vs. 
400nm pore size 5.6 ±11.2 and 200nm pore size -0.1 ± 17.7% P<0.01 with Two-way 
ANOVA and Bonferroni post-test; Figure 4.1.16). Strikingly, neutrophils separated by 
transwells with a pore size of 200nm or 400nm significantly increased matrix 
accumulation in micromasses stimulated with IL-1β (30ng/ml) compared to IL-1β 
treatment alone (400nm 60 ± 18.5 and 200nm 42.3 ± 8 vs. -43.8 ± 8% P<0.001 with 
Two-way ANOVA and Bonferroni post-test). In contrast, neutrophils separated by 
transwells with an 8µm pore size, large enough to allow neutrophils to pass through, 
significantly reduced matrix accumulation compared to IL-1β alone (-911.3 ± 529 vs. -
43.8 ± 8% P<0.001 with Two-way ANOVA and Bonferroni post-test). This suggests that 
the matrix accumulation was reduced by direct neutrophil-chondrocyte contact. With 
this large pore size, some micromasses lifted from the bottom of the wells, indicating 
necrotic cell death, with destruction of the micromass structure. In samples that weren’t 
completely degraded by direct neutrophil contact in combination with IL-1β, the matrix 
staining intensity was visibly drastically reduced. Thus, the spatial separation of 
neutrophils from chondrocytes is key to allowing neutrophil microparticles to perform 
their protective functions.  
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It was therefore pertinent to determine whether modulating microparticle release by 
neutrophils would still confer protection to IL-1β-stimulated micromasses. Thus, 
neutrophils were placed on 400nm transwells and treated with cytoskeletal-affecting 
drugs to modulate microparticle formation (Figure 4.1.17). Treatment of neutrophils 
with jasplakinolide, which inhibits actin depolymerisation and stiffens the cytoskeleton 
inhibiting microparticle release, and cytochalasin D, which prevents actin 
polymerisation leading to increased cytoskeletal fluidity and increased microparticle 
shedding, did not protect from IL-1β-induced matrix loss (-134 ± 27.3 and -123.9 ± 31.1 
vs. -70.5 ± 32.6%) compared with untreated neutrophils (60 ± 18.5 vs. -70.5 ± 32.6% 
P<0.001 with Two-way ANOVA and Bonferroni post-test).  
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Figure 4.1.16 Neutrophils induce extracellular matrix accumulation in C28/I2 chondrocytes 
only when separated from direct cell-to-cell contact by transwells. Chondrocyte micromasses 
were treated with IL-1β (30ng/ml) before application of transwells with various sized pores 
containing 1x106 freshly isolated, TNF-α-stimulated (50ng/ml; 10 minutes followed by washing) 
human neutrophils for 4 hours. (A) Schematic of experimental procedure. (B) Extracellular 
matrix accumulation was quantified by Alcian blue staining at 24 hours. (C) Representative 
photographs of micromasses before dye extraction. Data are shown as mean ± SEM of 6 
separate neutrophil donors. *P<0.05, **P<0.01 and ***P<0.001 using Two-way ANOVA and 
Bonferroni post-test. ECM, extracellular matrix. 
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Figure 4.1.17 Neutrophil microparticle protection is lost upon disruption of the actin and 
myosin cytoskeleton, or chelation of intracellular neutrophil calcium. Chondrocyte 
micromasses were treated with IL-1β (30ng/ml) before application of transwells (400nm pore 
size) containing 1x106 freshly isolated human neutrophils treated with (A) Jasplakinolide (1µM; 
increases cell rigidity), Cytochalasin D (2µM; increases cell cytoskeleton fluidity), (B) Blebbistatin 
(10µM, inhibits focal adhesion formation), ML-7 (20µM; inhibits cell contractility) or (C) BAPTA-
AM (20µM; chelates intracellular calcium) for 10 minutes then TNF-α (50ng/ml) for 20 minutes. 
Transwells were removed after 4 hours. Extracellular matrix accumulation was quantified by 
Alcian blue staining at 24 hours. Below are representative photographs of micromasses before 
dye extraction. Data are shown as mean ± SEM of 6 separate neutrophil donors. **P<0.01 and 
***P<0.001 using Two-way ANOVA and Bonferroni post-test. ECM, extracellular matrix; PMN, 
polymorphonuclear cells. 
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Thus, manipulating microparticle formation attenuates protection. Furthermore, these 
data suggest that the neutrophil actin cytoskeleton is required for the formation of 
microparticles with chondroprotective effects, as protein loading is likely dependent on 
a functioning cytoskeleton. Similarly, treatment of neutrophils with Blebbistatin, which 
binds and inhibits myosin II in an actin detached state, and therefore inhibits the 
formation of actomyosin, making the cell less rigid (Kovacs et al., 2004); or ML-7 a 
selective myosin light-chain inhibitor which prevents contraction of the cell necessary 
for blebbing (Shin et al., 2010) also prevented chondroprotection (-130.8 ± 13.1 and -
78.4 ± 48.8 vs. 60 ± 18.5% P<0.001 with Two-way ANOVA and Bonferroni post-test). 
This suggests that the loss of cellular contractility prevents the formation of functional 
chondroprotective microparticles. Furthermore, treatment of neutrophils with BAPTA-
AM, which chelates intracellular calcium, limiting microparticle formation, completely 
blocked chondroprotection (-139.8 ± 20.1 vs. 60 ± 18.5% P<0.001 with Two-way 
ANOVA and Bonferroni post-test). This indicates that limiting microparticle formation 
without affecting the cytoskeleton of the neutrophil also prevents chondroprotection in 
this co-culture model.   
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Next, we assessed the contribution of phosphatidylserine to the protective effects of 
microparticles (Figure 4.1.18). The expression of phosphatidylserine has been linked 
with the resolution of inflammation, by inducing the release of TGFβ1 in macrophages 
that have ingested apoptotic cells (Huynh et al., 2002). Incubation of microparticles 
with an excess of Annexin V led to approximately 80% positivity (Figure 4.1.18A). In 
micromass co-culture, Annexin V alone, used as a control, together with annexin V 
coated microparticles did not alter matrix accumulation in unstimulated micromasses 
as expected (13 ± 6.6 and 21.2 ± 5.3 vs. 4.3 ± 2.8%; Figure 4.1.18B). Annexin V 
treatment also did not affect the suppression of matrix accumulation induced by IL-1β 
(30ng/ml; -28.1 ± 2.3 vs. -18.2 ± 3.4%). However, treatment of IL-1β stimulated 
micromasses with Annexin V coated microparticles did induce significant matrix 
accumulation compared to IL-1β alone (23 ± 6.3 vs. -18.2 ± 3.4% P<0.001 with Two-
way ANOVA and Bonferroni post-test). Interestingly, Annexin V coated microparticle 
treatment induced significantly less matrix accumulation compared to uncoated 
microparticles (23 ± 6.3 vs. 50 ± 7.9% P<0.01 with Two-way ANOVA and Bonferroni 
post-test) in IL-1β stimulated micromasses, suggesting a partial inhibition of 
microparticle function by Annexin V shielding of exposed phosphatidylserine.  
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extracellular matrix 
accumulation. (A) TMP were 
coated in Annexin V (1mg in 
100µl) for 20 minutes at room 
temperature in the presence of 
calcium binding buffer then 
analysed by flow cytometry. (B) 
Chondrocyte micromasses were 
treated with IL-1β (30ng/ml) 
and 100,000 annexin V-coated 
TMP for 24 hours before 
extracellular matrix 
accumulation was quantified by 
Alcian blue staining. Data are 
shown as mean ± SEM of 4 
separate microparticle donors. 
**P<0.01 and ***P<0.001 
using Two-way ANOVA and 
Bonferroni post-test. TMP, TNF-
α generated microparticles; 
ECM, extracellular matrix; Anx 
V, Annexin V. 
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4.2  Microparticle Mediators Responsible for 
Chondroprotection 
 
The surprising finding that neutrophil microparticles protected chondrocytes in in vitro 
arthritic conditions merited further investigation to determine the molecules and 
mechanism responsible for these effects. From several hundred proteins found in 
neutrophil microparticles by mass spectrometry, candidates with known inflammation-
modulating functions were screened for functional microparticle effects. 
 
4.2.1 Is Annexin A1 Responsible for the Chondroprotection 
Observed with Microparticle Treatment? 
Characterisation of the Function of Annexin A1 in 
Chondrocyte Biology 
 
The first protein screened for chondroprotection was Annexin A1, which displays potent 
anti-inflammatory effects and drives the resolution of inflammation (D'Acquisto et al., 
2008). Firstly, the effect of Annexin A1 on chondrocyte micromass matrix accumulation 
was tested (Figure 4.2.1). Annexin A1, in low nanomolar concentrations significantly 
increased matrix accumulation in unstimulated micromasses compared to control (1nM 
113.8 ± 23.9 and 10nM 72.5 ± 18.1 vs. 0 ± 3.5% P<0.001 with Two-way ANOVA and 
Bonferroni post-test). This effect was lost at a higher concentration (30nM; 25.4 ± 17 
vs. control 0 ± 3.5%), and 1nM Annexin A1 (113.8 ± 23.9 vs. 25.4 ± 17% P<0.001 with 
Two-way ANOVA and Bonferroni post-test). Annexin A1 reversed the loss in matrix 
accumulation induced by IL-1β (3ng/ml) at concentrations of 10nM (57.3 ± 14.8 vs. -
23.8 ± 3.3% P<0.001 with Two-way ANOVA and Bonferroni post-test) and most 
notably 30nM (130.4 ± 26.8 vs. -23.8 ± 3.3% P<0.001 with Two-way ANOVA and 
Bonferroni post-test). The optimal concentration of Annexin A1 to reverse the effects of 
a high concentration of IL-1β (30ng/ml) was 10nM, although all three concentrations of 
Annexin A1 gave protection (1nM 6.8 ± 10.1, 10nM 75 ± 38.7 and 30nM 23.8 ± 24 vs. -
67.3 ± 2.4% P<0.001 with Two-way ANOVA and Bonferroni post-test).  
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To decipher the mechanism of ECM protection afforded by Annexin A1 treatment, the 
modulation of cartilage matrix-producing genes was first investigated (Figure 4.2.2). 
Surprisingly, Annexin A1 treatment across all concentrations significantly down-
regulated ACAN mRNA expression in resting chondrocyte micromasses (-0.4 ± 0.1 for 
each concentration vs. 0 ± 0.05 Figure 4.2.2A).  No other significant effects were seen 
in either the expression of ACAN mRNA or COL2A1 mRNA, whether the micromasses 
had been stimulated with IL-1β or not (Figure 4.2.2A and B).  
 
0 3 30
-200
-100
0
100
200
300
Control
1nM AnxA1
10nM AnxA1
30nM AnxA1
***
***
***
*** ***
***
***
***
IL-1! (ng/ml)
EC
M
 (%
 C
ha
ng
e 
fro
m
 C
on
tro
l)
IL-1! (3ng/ml) 
1 10 30 
Annexin A1 (nM) 
Figure 4.2.1 Annexin A1 increases 
chondrocyte extracellular matrix 
accumulation in vitro. Chondrocyte 
micromasses were treated with IL-1β (3 
or 30ng/ml) and increasing 
concentrations of Annexin A1 for 24 
hours before extracellular matrix 
accumulation was quantified by Alcian 
blue staining. Bottom is a 
representative photograph of 
micromasses before dye extraction. 
Data are shown as mean ± SEM of 6 
separate micromass preparations. 
***P<0.001 using Two-way ANOVA and 
Bonferroni post-test. ECM, extracellular 
matrix; AnxA1, Annexin A1. 
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Microparticles inhibited the production of IL-8 and Prostaglandin E2 in IL-1β stimulated 
micromasses, so the effect of Annexin A1 treatment on production of these pro-
inflammatory mediators was investigated. Annexin A1 treatment did not induce the 
production of IL-8 in unstimulated micromasses (1nM 0.4 ± 0, 10nM 0.9 ± 0.1, 30nM 1 
± 0.1 vs. 0.6 ± 0) nor suppress the production of IL-8 from IL-1β stimulated 
chondrocytes (Figure 4.2.3; 1nM 9.1 ± 0.4, 10nM 8.1 ± 0.6, 30nM 10.3 ± 1.6 vs. 9.6 ± 
0.9).  
Figure 4.2.2 Annexin A1 does not 
significantly reverse IL-1β-induced down 
regulation of cartilage matrix-producing 
genes. Chondrocyte micromasses were 
treated with IL-1β (3ng/ml or 30ng/ml) 
and increasing concentrations of Annexin 
A1 for 6 hours before mRNA extraction and 
RT-PCR. (A) Relative expression of ACAN 
and (B) COL2A1. Data shown are 2-ΔΔCT 
with untreated as calibrator and RPL32 as 
housekeeping gene. Data expressed as 
median, interquartile range and range of at 
least 3 separate micromass preparations. 
*P<0.05 using Two-way ANOVA with 
Bonferroni post-test performed on the 
logged data. AnxA1, Annexin A1. 
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Annexin A1 treatment did not induce prostaglandin E2 synthesis in unstimulated 
micromasses (Figure 4.2.4; 1nM 52.4 ± 3.1, 10nM 85.5 ± 21.4, 30nM 77 ± 3.2 vs. 64 ± 
6) or but did significantly reduce prostaglandin E2 generation at a concentration of 
10nM compared to IL-1β (30ng/ml) alone (10nM 466.1 ± 106 vs. 746.5 ± 51.8 P<0.001 
with Two-way ANOVA and Bonferroni post-test). With treatment of 30nM Annexin A1, 
this protection was lost (667.9 ± 12.2 vs. 466.1 ± 106 P<0.05 with Two-way ANOVA 
and Bonferroni post-test). Together, these results suggest that although Annexin A1 
significantly increases matrix accumulation in chondrocyte micromasses, and can 
reverse the down-regulation of matrix accumulation induced by IL-1β stimulation, 
Annexin A1 is not solely responsible for the anti-inflammatory properties observed in 
microparticle co-culture with chondrocytes. 
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Figure 4.2.3 Annexin A1 does not block 
chondrocyte IL-8 production induced by 
IL-1β. Chondrocyte micromasses were 
treated with IL-1β (30ng/ml) and 
increasing concentrations of Annexin A1 
for 24 hours before IL-8 production was 
quantified by ELISA. Data are shown as 
mean ± SEM of 3 separate micromass 
preparations, ***P<0.001 with Two-
way ANOVA and Bonferroni post-test. 
AnxA1, Annexin A1. 
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To determine whether microparticle Annexin A1 was responsible for the increases in 
ECM accumulation seen during IL-1β stimulation of chondrocyte micromasses, an 
experiment was designed to test whether microparticles generated from Anxa1 
knockout mice could increase matrix accumulation compared to those from wild type 
mice. Murine Annexin A1 is 78% homologous to human Annexin A1 and displays anti-
inflammatory effects in vitro with human cells. To obtain sufficient neutrophils, a 
peritonitis model was utilised, as the number of circulating neutrophils in mice is low. 
Furthermore, neutrophil isolation and purification techniques performed on mouse 
blood often have a very low yield. The increased purity in these samples would be 
advantageous, however to isolate enough neutrophils to obtain microparticles would 
involve a large number of mice being pooled. Instead, neutrophils were collected from 
the peritoneum of mice treated with 1mg/ml zymosan A to induce high levels of 
neutrophil recruitment at 4 hours. As expected, Annexin A1 null mice had an increased 
level of neutrophil recruitment to the peritoneum (WT 3.6 ± 0.4 vs. 5.95 ± 0.4 x 106 
cells/mouse P<0.01 with unpaired, two-tailed t-test), as had been previously published 
(Chatterjee et al., 2005) and were more than 75% positive for the neutrophil marker 
LY6G when characterised by flow cytometry (Figure 4.2.5B and C). As expected, 
mouse neutrophils obtained from Annexin A1 null mice did not stain for Annexin A1 
whilst wild type neutrophils were positive (Figure 4.2.5D). Following stimulation with 
recombinant mouse TNF-α (50ng/ml; 2x106 cells/ml), both genotypes of neutrophil 
shed similar numbers of microparticles, as counted by flow cytometry (2.5 ± 0.8 vs. 1.6 
± 0.7; Figure 4.2.5E).  
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Figure 4.2.4 Annexin A1 does not 
efficiently inhibit chondrocyte PGE2 
production induced by IL-1β. 
Chondrocyte micromasses were treated 
with IL-1β (30ng/ml) and increasing 
concentrations of Annexin A1 for 24 
hours before Prostaglandin E2 
production was quantified by EIA. Data 
are shown as mean ± SEM of 3 
separate micromass preparations. 
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using Two-way ANOVA and Bonferroni 
post-test. AnxA1, Annexin A1; PGE2, 
prostaglandin E2. 
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Figure 4.2.5 Characterisation of neutrophil microparticles generated from wild type or Annexin 
A1 null mice. (A) Wild type or Anxa1-/- C57BL/6 mice received an intraperitoneal injection of 
1mg/mouse zymosan A to induce neutrophil recruitment. Cells were collected 4 hours post 
injection,  (B) counted and characterised by staining with (C) LY6G and (D) Annexin A1 
polyclonal antibodies and analysed by flow cytometry **P<0.01 with unpaired t-test. (E) Cells 
were stimulated with recombinant TNF-α (50ng/ml) and offspring microparticles counted by 
flow cytometry following loading with BODIPY dye (2.5µM). Not significant with unpaired t-test. 
AnxA1, Annexin A1; WT, wild type; KO, Annexin A1 knockout; i.p., intraperitoneal.  
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Microparticles generated from either wild type or Annexin A1 knockout mouse 
neutrophils did not affect matrix accumulation in unstimulated micromasses (WT 3.7 ± 
2.5, Anxa1-/- 2.4 ± 1.2 vs. 0 ± 1.3%; Figure 4.2.6). Wild type microparticles significantly 
increased matrix accumulation in IL-1β-stimulated micromasses compared to IL-1β 
treatment (63.5 ± 4.2 vs. -19.2 ± 5.7% P<0.001 with Two-way ANOVA and Bonferroni 
post-test). Interestingly, Annexin A1 knockout microparticles prevented IL-1β-induced 
ECM reduction stimulated micromasses compared to IL-1β treatment alone (-2 ± 6.1 
vs. -19.2 ± 5.7% P<0.05 with Two-way ANOVA and Bonferroni post-test). However, 
Annexin A1 null microparticles did not cause an increase in ECM above basal levels as 
observed with wild type microparticles (-2 ± 6.1 vs. 63.5 ± 4.2% P<0.001 with Two-way 
ANOVA and Bonferroni post-test).  
 
These data suggest that although Annexin A1 treatment resembles some aspects of 
microparticle chondroprotection, it is clear that Annexin A1 is only partially responsible 
for chondroprotection in vitro. Other endogenous microparticle constituents may 
contribute to the suppression of cytokine release and control of gene transcription. 
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Figure 4.2.6 Annexin A1 null microparticles are anti-catabolic, but do not induce increased 
extracellular matrix accumulation to the same extent as wild type microparticles. Chondrocyte 
micromasses were treated with IL-1β (30ng/ml) and 100,000 wild type or Anxa1-/- TMP for 24 
hours before extracellular matrix accumulation was quantified by Alcian blue staining. Right are 
representative photographs of micromasses before dye extraction. Data are shown as mean ± 
SEM of 4 pooled microparticle preparations from each genotype and 5 separate micromass 
preparations. *P<0.05, **P<0.01 and ***P<0.001 using Two-way ANOVA and Bonferroni post-
test. TMP, TNF-α-treatment generated neutrophil microparticles; AnxA1, Annexin A1; ECM, 
extracellular matrix; WT, wild type; KO, Annexin A1 knockout. 
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4.2.2 The Annexin A1 Receptor FPR2/ALX is Required for 
Microparticle-Induced Chondrocyte Matrix 
Accumulation 
 
To investigate whether Annexin A1-induced matrix accumulation was receptor 
dependent, it was first important to assess expression levels of the receptors on 
chondrocytes. The expression of FPR2/ALX, and its orthologue, FPR1, was 
determined using flow cytometry, as the expression of either G-protein coupled 
receptor has not previously been reported in chondrocytes. Chondrocytes expressed 
FPR2/ALX as well as FPR1 (Figure 4.2.7).  
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Figure 4.2.7 C28/I2 
chondrocytes express the 
Annexin A1 receptor, FPR2/ALX, 
and its orthologue FPR1. 
Chondrocytes were treated with 
increasing concentrations of IL-
1β for 24 hours before 
dissociation and analysis by flow 
cytometry for (A) FPR2/ALX and 
(B) FPR1 mean fluorescence 
intensity (MFI, arbitrary units). 
Right hand panels show 
representative histograms. Data 
are shown as mean ± SEM of 3 
separate micromass 
preparations. *P<0.05 using 
One-way ANOVA and Bonferroni 
post-test.  
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Upon 24-hour stimulation with IL-1β (30ng/ml), FPR2 expression remained unchanged 
(3ng/ml 7.1 ± 0.6, 10ng/ml 7.1 ± 1.5, 30ng/ml 9.0 ± 1.7 vs. 6.6 ± 1.1) whereas FPR1 
expression was significantly increased (4.7 ± 0.3 vs. 2.5 ± 0.2 P<0.05 with One-way 
ANOVA and Bonferroni post-test). Modulation of FPR2 (Figure 4.2.8A; 1 IQR 0.8-1.4 
vs. 1.3 IQR 1.2-1.4) or FPR1 (Figure 4.2.8B; 1 IQR 0.9-1.7 vs. 0.5 IQR 0.5-1.6) gene 
expression by IL-1β (30ng/ml) at 6 hours was not seen, possibly because of the 
particular time-point chosen or because the transcriptional control of these receptors 
involves rapid degradation and transcriptional repression (Karoor et al., 1996, Mandal 
et al., 2005), thus it would be interesting to explore the kinetics of receptor regulation in 
these cells further.  
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To elucidate whether microparticle-Annexin A1 contributes to matrix accumulation by a 
receptor dependent mechanism, rather than direct binding to phospholipids on the 
chondrocyte cell membrane, pharmacological inhibitors WRW4 and cyclosporin H that 
antagonise FPR2/ALX and FPR1 were used (Figure 4.2.9). WRW4 treatment did not 
affect matrix accumulation in unstimulated micromasses (18.9 ± 13.5 vs. 0 ± 12%), or 
TMP-treated unstimulated micromasses (13.4 ± 19.4 vs. -1.9 ± 3.4%) and had no effect 
on IL-1β (30ng/ml) treatment alone (-65.7 ± 9.8 vs. -65.8 ± 3.4%). However, FPR2/ALX 
antagonism abrogated the microparticle-induced increase in matrix accumulation 
following IL-1β-stimulation (-51.5 ± 10.6 vs. 57.3 ± 1.4% P<0.01 with Two-way ANOVA 
and Bonferroni post-test), suggesting that FPR2/ALX is important for microparticle 
protection. Cyclosporin H treatment did not affect ECM in unstimulated micromasses 
yet reverted the effects of IL-1β (-11.4 ± 22.4 vs. -65.8 ± 3.4%), so the contribution of 
FPR1 to microparticle-induced matrix accumulation could not be determined. 
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Figure 4.2.8 C28/I2 chondrocyte FPR2 and FPR1 mRNA levels are not significantly modulated 
by IL-1β treatment. Chondrocyte micromasses were treated with IL-1β (30ng/ml) for 6 hours 
before mRNA extraction and RT-PCR. (A) Relative expression of FPR2 and (B) FPR1. Data shown 
are 2-ΔΔCT with untreated as calibrator and RPL32 as housekeeping gene. Data expressed as 
median, interquartile range and range of 6 separate micromass preparations, not significant by 
Mann-Whitney t-test.  
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It was therefore important to assess whether Annexin A1-induced matrix accumulation 
in unstimulated micromasses was receptor-dependent (Figure 4.2.10). The FPR2/ALX 
antagonist WRW4 was able to partially reverse the ECM accumulation observed with 
Annexin A1 treatment, although this did not reach statistical significance (34.3 ± 21.9 
vs. 91 ± 35.7%). Interestingly, in the case of Annexin A1 free protein (and not 
microparticle-associated), matrix accumulation was significantly inhibited upon FPR1 
antagonism with cyclosporin H (2.0 ± 13.1 vs. 91 ± 35.7% P<0.01 with Two-way 
ANOVA and Bonferroni post-test.  
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Figure 4.2.9 Antagonism of FPR2/ALX significantly inhibits microparticle induced extracellular 
matrix accumulation. Chondrocyte micromasses were treated with (A) an FPR2/ALX antagonist, 
WRW4 (10µM) or (B) Cyclosporin H (CycH; 2.5µM), an FPR1 antagonist for 10 minutes followed 
by IL-1β (30ng/ml) and 100,000 TMP for 24 hours before extracellular matrix accumulation was 
quantified by Alcian blue staining. Data are shown as mean ± SEM of 4 microparticle donors. 
**P<0.01 and ***P<0.001 using Two-way ANOVA and Bonferroni post-test. TMP, TNF-α-
treatment generated microparticles; ECM, extracellular matrix.  
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Taken together, these results suggest that Annexin A1 in suspension acts upon 
chondrocytes to increase extracellular matrix accumulation via both FPR2/ALX and 
FPR1 and microparticle-associated Annexin A1 (plus other molecules) increase matrix 
accumulation via FPR2/ALX, but the contribution of FPR1 remains to be determined. 
Figure 4.2.10 Annexin A1 induces extracellular matrix accumulation via FPR1 in unstimulated 
micromasses. Chondrocyte micromasses were treated with (A) WRW4 (10µM) or (B) Cyclosporin 
H (CycH; 2.5µM) for 10 minutes followed by Annexin A1 (10nM) for 24 hours before 
extracellular matrix accumulation was quantified by Alcian blue staining. Data are shown as 
mean ± SEM of 5 separate micromass preparations. **P<0.01 using Two-way ANOVA and 
Bonferroni post-test. AnxA1, Annexin A1; ECM, extracellular matrix.   
0 10
0
50
100
150
Control
CycH
****
AnxA1 (nM)
EC
M
 (%
 C
ha
ng
e 
fro
m
 C
on
tro
l)
0 10
0
50
100
150
Control
WRW4
**
AnxA1 (nM)
EC
M
 (%
 C
ha
ng
e 
fro
m
 C
on
tro
l)
A B 
  
203 
4.2.3 Endogenous Annexin A1 Expression by C28/I2 
Chondrocytes 
 
The expression of Annexin A1 and its physiological relevance in chondrocyte biology 
has not been reported. Therefore, the expression of Annexin A1 mRNA and protein 
were monitored in C28/I2 and primary adult human articular chondrocytes, and its 
cellular localisation was assessed by electron microscopy together with its receptor 
FPR2/ALX and orthologue, FPR1. C28/I2 chondrocytes express Annexin A1 gene 
products as confirmed by standard PCR and Western Blotting (Figure 4.2.11).  
GAPDH 
ANXA1 
+v
e 
-v
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37kDa 
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B 
Figure 4.2.11 C28/I2 chondrocytes express ANXA1 mRNA and Annexin A1 protein 
endogenously. (A) Chondrocytes micromasses were collected for mRNA extraction and standard 
PCR and gel electrophoresis. Gene expression was compared to neutrophil mRNA (positive 
control) and GAPDH as loading control. Negative control was molecular biology-grade water. 
Representative photograph of 3 separate micromass preparations. (B) Chondrocyte 
micromasses were treated with IL-1β (30ng/ml) for 24 hours before Western blotting for 
Annexin A1 protein. Representative blot shown, β-actin used as loading control. +ve, positive 
control; -ve, negative control; AnxA1, Annexin A1. 
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The subcellular location of Annexin A1 in C28/I2 and primary chondrocytes cultured in 
micromass was next interrogated by immunogold staining and transmission electron 
microscopy following IL-1β (30ng/ml) treatment for 24 hours. Annexin A1 expression 
was detected relatively uniformly, though sparsely, in both the nucleus and cytoplasm, 
and was also associated with electron-dense vesicles and mitochondria of C28/I2 cells 
(Figure 4.2.12). The distribution of Annexin A1 did not seem to be concentrated to the 
plasma membrane or nuclear envelope in either control or IL-1β stimulated cells in 
these micrographs.  
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Figure 4.2.12 C28/I2 chondrocytes express Annexin A1 endogenously. C28/I2 chondrocytes 
cultured in micromass were treated with IL-1β (30ng/ml; right-hand panels) or vehicle (PBS, 
control; left-hand panels) for 24 hours before fixing for immunogold staining. Annexin A1 was 
labelled with antibodies conjugated to 20nm gold beads (arrows). Black boxes indicate panels 
magnified below. Dotted line indicates plasma membrane, dashed line indicates nuclear 
envelope. PM, plasma membrane; C, cytoplasm; N, nucleus. Scale bars as indicated. With 
special thanks to Professor Sonia Oliani and Dr Cristiane Damas Gil for electron microscopy and 
immunogold labelling. 
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FPR2/ALX expression was detectable in C28/I2 chondrocytes and co-localised with 
Annexin A1 in resting and IL-1β-stimulated cells (Figure 4.2.13 and Figure 4.2.15). In 
control cells, Annexin A1 and FPR2/ALX appeared more rarely in the nucleus as a pair 
than in the cytoplasm (Figure 4.2.13, left-hand panels). Conversely, upon IL-1β 
(30ng/ml) stimulation, Annexin A1 and FPR2/ALX clustered next to the nuclear 
envelope (Figure 4.2.13, right-hand middle panel; arrows and arrowheads), whereas 
FPR2/ALX is cytoplasmic (Figure 4.2.13, right-hand panels; arrowheads). 
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Figure 4.2.13. C28/I2 chondrocytes express Annexin A1 and FPR2/ALX. C28/I2 chondrocytes 
cultured in micromass were treated with IL-1β (30ng/ml; right-hand panels) or vehicle (PBS, 
control; left-hand panels) for 24 hours before fixing for immunogold staining. Annexin A1 was 
labelled with antibodies conjugated to 20nm gold beads (arrows); FPR2/ALX was labelled with 
antibodies conjugated to 10nm gold beads (arrow heads). Black boxes indicate panels 
magnified below. Dotted line indicates plasma membrane, dashed line indicates nuclear 
envelope. PM, plasma membrane; C, cytoplasm; N, nucleus. Scale bars as indicated. With 
special thanks to Professor Sonia Oliani and Dr Cristiane Damas Gil for electron microscopy and 
immunogold labelling. 
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In contrast to FPR2/ALX, FPR1 staining did not co-localise with Annexin A1 expression 
in either resting (left-hand panels) or IL-1β-stimulated cells (right-hand panels; Figure 
4.2.14). FPR1 expression was diffuse and sparse throughout the cytoplasm and 
nucleus. Bottom right-hand panel shows an example of Annexin A1 expression 
associated with an electron-dense vesicle. These electron micrographs collectively 
indicate that Annexin A1 interacts with FPR2/ALX in the cytoplasm under resting 
conditions, which then translocates to the nucleus upon IL-1β stimulation. Endogenous 
Annexin A1 does not appear to co-localise with FPR1 under resting conditions or upon 
stimulation. 
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Figure 4.2.14 C28/I2 chondrocytes express Annexin A1 and FPR1 endogenously, but they do 
not co-localise. C28/I2 chondrocytes cultured in micromass were treated with IL-1β (30ng/ml; 
right-hand panels) or vehicle (PBS, control; left-hand panels) for 24 hours before fixing for 
immunogold staining. Annexin A1 was labelled with antibodies conjugated to 20nm gold beads 
(arrows); FPR1 was labelled with antibodies conjugated to 10nm gold beads (arrow heads). 
Black boxes indicate panels magnified below. Dotted line indicates plasma membrane, dashed 
line indicates nuclear envelope. PM, plasma membrane; C, cytoplasm; N, nucleus; M, 
mitochondrion. Scale bars as indicated. With special thanks to Professor Sonia Oliani and Dr 
Cristiane Damas Gil for electron microscopy and immunogold labelling. 
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Annexin A1 and FPR2/ALX were also detected in primary adult human articular 
chondrocytes cultured in micromasses (Figure 4.2.15). Annexin A1 and FPR2/ALX 
appear in close proximity within the cell, localised mainly within the cytoplasm.  
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Figure 4.2.15 FPR2/ALX and Annexin 
A1 are found in close proximity within 
primary adult human articular 
chondrocytes. Primary human 
chondrocytes were fixed for immunogold 
staining. Annexin A1 was labelled with 
20nm gold beads (arrows); FPR2/ALX 
was labelled with 10nm gold beads 
(arrow heads).  Grey boxes represent 
areas magnified to the right, dotted line 
represents nuclear envelope. N, nucleus; 
C, cytoplasm; PM, plasma membrane.  
With special thanks to Professor Sonia 
Oliani and Dr Cristiane Damas Gil who 
performed transmission electron 
microscopy and immunogold labelling. 
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These data demonstrate the presence of Annexin A1, and its receptor, FPR2/ALX in 
human primary and C28/I2 chondrocytes, along with the orthologue receptor FPR1. 
Importantly, Annexin A1 and FPR2/ALX co-localisation indicate that this pair interacts 
under resting condition and with IL-1β-stimulation. 
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4.2.4 Is Ceruloplasmin Responsible for the 
Chondroprotection Observed with Microparticle 
Treatment? Characterisation of the Effect of 
Exogenous Ceruloplasmin in Chondrocyte Biology 
 
Experiments performed using recombinant Annexin A1 indicated that Annexin A1 does 
not solely account for the chondroprotective functions of microparticles. Furthermore, 
Annexin A1 null microparticles still exert anti-catabolic effects on chondrocyte 
micromass matrix accumulation, reversing the effects of IL-1β at a concentration of 
30ng/ml. Thus, a second protein identified during previous proteomic analysis, namely 
ceruloplasmin, a plasma copper-transporting enzyme with putative anti-inflammatory 
functions was investigated.  
 
Exogenous addition of ceruloplasmin to micromass cultures exerted similar effects to 
those observed with Annexin A1 (Figure 4.2.16). Unlike microparticles, ceruloplasmin 
treatment alone significantly increased matrix accumulation in unstimulated 
micromasses at concentrations of 1nM (49.7 ± 9 vs. 0 ± 3.5% P<0.001 with Two-way 
ANOVA and Bonferroni post-test) and 30nM (61.0 ± 14.6 vs. 0 ± 3.5% P<0.001 with 
Two-way ANOVA and Bonferroni post-test). In micromasses stimulated with IL-1β 
(3ng/ml), ceruloplasmin treatment induced matrix accumulation with a similar 
concentration response as that seen with Annexin A1, where lower concentrations of 
ceruloplasmin induce significantly higher matrix accumulation compared to higher 
concentrations. In this case, only 1nM (74.9 ± 16.5 vs. -23.8 ± 3.3% P<0.001 with Two-
way ANOVA and Bonferroni post-test) and 10nM (21.2 ± 9.6 vs. -23.8 ± 3.3% P<0.001 
with Two-way ANOVA and Bonferroni post-test) ceruloplasmin concentrations induced 
higher matrix accumulation than IL-1β 3ng/ml alone. Again, similarly to Annexin A1, 
ceruloplasmin treatment at all concentrations in micromasses stimulated with IL-1β 
(30ng/ml) significantly increased matrix accumulation compared to IL-1β (30ng/ml) 
treatment alone (1nM -1.9 ± 13, 10nM -11.9 ± 10.7, 30nM 34 ± 14 vs. -67.3 ± 2.4% 
P<0.001 with Two-way ANOVA and Bonferroni post-test).  
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Ceruloplasmin treatment of IL-1β stimulated chondrocyte micromasses did not reverse 
the down-regulation of ACAN (1nM 0.8 IQR 0.5-0.9 or 10nM 0.5 IQR 0.5-0.7 vs. 0.4 
IQR 0.3-0.5) or COL2A1 (1nM 0.8 IQR 0.6-0.9 or 10nM 0.6 IQR 0.5-0.6 vs. 0.4 IQR 
0.3-0.5) mRNA induced by IL-1β stimulation (Figure 4.2.17). However, significant IL-1β-
induced MMP13 mRNA up-regulation (10 IQR 8.7-13.6 vs. 1 IQR 1-1.1; P<0.05 with 
Kruskal-Wallis test and Dunn’s multiple comparison post-test) was counter-regulated 
by ceruloplasmin treatment (1nM 0.7 IQR 0.4-1 vs. 10 IQR 8.7-13.6 P<0.05 and 10nM 
0.7 IQR 0.5-0.8 vs. 10 IQR 8.7-13.6; P<0.01 with Kruskal-Wallis test and Dunn’s 
multiple comparison post-test). ADAMTS5 gene expression was not significantly 
altered by IL-1β treatment (0.8 IQR 0.5-2.8 vs. 1 IQR 0.8-1) or ceruloplasmin treatment 
(1nM 0.9 IQR 0.7-1 or 10nM 0.7 IQR 0.5-0.9 vs. 0.8 IQR 0.5-2.8). 
Figure 4.2.16 Ceruloplasmin 
increases chondrocyte extracellular 
matrix accumulation in vitro. 
Chondrocyte micromasses were 
treated with IL-1β (3 or 30ng/ml) 
and increasing concentrations of 
ceruloplasmin (CP) for 24 hours 
before extracellular matrix 
accumulation was quantified by 
Alcian blue staining. Bottom are 
representative photographs of 
micromasses before dye extraction. 
Data are shown as mean ± SEM of 6 
separate micromass preparations. 
*P<0.05 and ***P<0.001 using 
Two-way ANOVA and Bonferroni post-
test. ECM, extracellular matrix. 
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Ceruloplasmin did not significantly induce IL-8 production in resting chondrocyte 
micromasses (1nM 1.8 ± 0, 10nM 1.8 ± 0 and 30nM 1.7 ± 0 vs. 0.6 ± 0ng/ml), nor alter 
the production levels of IL-8 in chondrocyte micromasses stimulated with IL-1β 
(30ng/ml) (1nM 8.8 ± 0, 10nM 9.7 ± 0.8 and 30nM 9.6 ± 1.2 vs. 9.6 ± 0.1ng/ml; Figure 
4.2.18). 
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Figure 4.2.17 Ceruloplasmin counter-regulates MMP13 induction by IL-1β but  does not 
reverse the down regulation of cartilage matrix-producing gene mRNA. Chondrocyte 
micromasses were treated with IL-1β (30ng/ml) and increasing concentrations of ceruloplasmin 
(CP) for 6 hours before mRNA extraction and RT-PCR. (A) Relative expression of ACAN, (B) 
COL2A1, (C) MMP13 and (D) ADAMTS5. Data shown are 2-ΔΔCT with untreated as calibrator and 
RPL32 as housekeeping gene. Data expressed as median, interquartile range and range of 4 
separate micromass preparations. *P<0.05 and **P<0.01 using Kruskal-Wallis test and 
Dunn’s multiple comparison post-test. 
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In contrast, although ceruloplasmin did not alter prostaglandin E2 production in resting 
chondrocyte micromasses (1nM 171.6 ± 19.3, 10nM 123.9 ± 14.9 and 30nM 138.4 ± 
7.5 vs. 122.5 ± 24.2ng/ml), prostaglandin E2 levels were significantly increased at 1nM 
ceruloplasmin treatment in IL-1β stimulated micromasses compared with IL-1β 
(30ng/ml) (1027 ± 182.1 vs. 746.5 ± 51.8ng/ml P<0.05 with Two-way ANOVA and 
Bonferroni post-test; Figure 4.2.19).  Comparatively, Ceruloplasmin (30nM) treatment 
partially reduced (25%) IL-1β-induced prostaglandin E2 levels (552.7 ± 81.1 vs. 746.5 ± 
51.8ng/ml P<0.05 with Two-way ANOVA and Bonferroni post-test). These effects were 
modest compared to the 75% reduction seen with microparticle treatment (Figure 
4.1.14).
0 30
0
5
10
15
Control
1nM CP 
10nM CP 
IL-1! (ng/ml)
30nM CP 
IL
-8
 (n
g/
m
l)
***
Figure 4.2.18 Ceruloplasmin does not 
inhibit chondrocyte IL-8 production 
induced by IL-1β. Chondrocyte 
micromasses were treated with IL-1β 
(30ng/ml) and increasing 
concentrations of ceruloplasmin (CP) for 
24 hours before IL-8 production was 
quantified by ELISA. Data are shown as 
mean ± SEM of 3 separate micromass 
preparations, ***P<0.001 with Two-
way ANOVA and Bonferroni post-test. 
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Finally, the effect of lactoferrin was also explored in extracellular matrix accumulation in 
chondrocytes. Previous reports have suggested both an anti-inflammatory role in 
arthritis (Guillen et al., 2000) and a pro-proliferative role for lactoferrin in primary 
human chondrocytes, whose receptor is LRP-1 (Brandl et al., 2010). In C28/I2 
micromasses however, lactoferrin did not modulate extracellular matrix accumulation in 
resting (-1.6 ± 2 vs. -13.1%) or IL-1β-stimulated micromasses (-23 ± 6 vs. -37.5 ± 
8.4%) nor increase the DNA content of resting (271.9 ± 20.2 vs. 224.4 ± 
18.5µg/micromass) or stimulated micromasses (222.3 ± 22.3 vs. 206.7 ± 
30µg/micromass), a crude measure of cell number (Figure 4.2.20).    
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Figure 4.2.19 Ceruloplasmin enhances 
IL-1β-induced chondrocyte 
Prostaglandin E2 biosynthesis at lower 
concentrations, but suppresses it at 
higher concentrations. Chondrocyte 
micromasses were treated with IL-1β 
(30ng/ml) and increasing 
concentrations of ceruloplasmin (CP) for 
24 hours before supernatant 
Prostaglandin E2 (PGE2) generation was 
quantified by EIA. Data are shown as 
mean ± SEM of 3 separate micromass 
preparations. *P<0.05 and 
***P<0.001 using Two-way ANOVA and 
Bonferroni post-test.  
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Figure 4.2.20 Lactoferrin does not modulate extracellular matrix accumulation in vitro, or 
induce cellular proliferation. Chondrocyte micromasses were treated with IL-1β (30ng/ml) and 
Lactoferrin (10µg/ml) for 24 hours before (A) extracellular matrix accumulation was quantified 
by Alcian blue staining and (B) DNA was quantified using SYBRGreen I dye. Data are shown as 
mean ± SEM of 4 separate micromass preparations. **P<0.01 using Two-way ANOVA and 
Bonferroni post-test. ECM, extracellular matrix. 
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Taken together, these results suggest that ceruloplasmin may contribute to the matrix 
accumulation seen during microparticle co-culture, but that ceruloplasmin has little, if 
any, capacity to reduce pro-inflammatory mediators produced by chondrocytes during 
IL-1β stimulation. Interestingly, ceruloplasmin did dramatically inhibit the transcription 
of MMP13 by the chondrocytes stimulated with IL-1β, but without the use of 
ceruloplasmin null mice to corroborate this data, the full role of this protein will remain 
unclear. Lactoferrin, a putative anti-oxidant with pro-proliferative properties did not alter 
chondrocytes matrix accumulation or proliferation, suggesting little contribution of this 
protein to chondroprotection in vitro. 
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4.2.5 Pro-Resolving Lipid Mediators  
 
Microparticles are known to be vectors for not only functional protein cargo, but also 
are also highly involved in bioactive lipid transfer as their main constituents are the 
plasma membrane and its derivatives. Pro-resolving lipid mediators, for example 
Resolvin D1, are also highly involved in the resolution of inflammation and could 
therefore have important bearings on the anti-inflammatory properties. Neutrophil-
derived microparticles contain the precursors of pro-resolving lipid mediators (Norling 
et al., 2011), which, when delivered to cells, can be utilised to generate protective lipid 
mediators such as Resolvin D1 (Dalli and Serhan, 2012). Therefore the actions of 
Resolvin D1 were assessed in C28/I2 chondrocyte micromasses (Figure 4.2.21).  
0 30
-100
-50
0
50
100
Control
0.1nM RvD1
1nM RvD1
10nM RvD1
100nM RvD1
**
**
***
**
IL-1! (ng/ml)
EC
M
 (%
 C
ha
ng
e 
fro
m
 C
on
tro
l)
IL-1!  
(30ng/ml) 
IL-1! + RvD1 
(100nM) 
Figure 4.2.21 Pro-resolving lipid mediator Resolvin D1 increases extracellular matrix 
accumulation in vitro. Chondrocyte micromasses were treated with IL-1β (30ng/ml) and 
increasing concentrations of Resolvin D1 (RvD1) for 24 hours before extracellular matrix 
accumulation was quantified by Alcian blue staining. Bottom are representative photographs of 
micromasses before dye extraction. Data are shown as mean ± SEM of 6 separate micromass 
preparations. **P<0.01 and ***P<0.001 using Two-way ANOVA and Bonferroni post-test. ECM, 
extracellular matrix. 
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Resolvin D1 did not modulate matrix accumulation in resting chondrocyte micromasses 
compared to control (0.1nM 31 ± 19.8, 1nM 7.2 ± 17.6, 10nM 13.1 ± 13, 100nM 26.3 ± 
12.8 vs. 0 ± 8.3%). However, in micromasses stimulated with IL-1β (30ng/ml), Resolvin 
D1 at concentrations of 1nM (3.1 ± 7.5 vs. -43.6 ± 7% P<0.01 with Two-way ANOVA 
and Bonferroni post-test), 10nM (11.1 ± 6.5 vs. -43.6 ± 7% P<0.01 with Two-way 
ANOVA and Bonferroni post-test) and 100nM (14.8 ± 5.3 vs. -43.6 ± 7% P<0.001 with 
Two-way ANOVA and Bonferroni post-test) was able to counter-regulate IL-1β-induced 
reduction in matrix accumulation.  
 
As FPR2/ALX is a high-affinity receptor for Resolvin D1 (Krishnamoorthy et al., 2010), 
the receptor dependence was tested using the FPR2/ALX-specific antagonist, WRW4. 
As before, treatment with WRW4 had no adverse effect on matrix accumulation in 
unstimulated micromasses yet pre-treatment prior to Resolvin D1 addition to IL-1β-
stimulated micromasses blocked the matrix-accumulating effects observed with 
Resolvin D1 (-19.1 ± 2.2 vs. 35.8 ± 9% P<0.001 with Two-way ANOVA and Bonferroni 
post-test; Figure 4.2.22). As Annexin A1 knockout microparticles still exhibited anti-
catabolic effects in IL-1β-stimulated micromasses, whereas FPR2/ALX 
pharmacological inhibition completely blocked microparticle-induced matrix 
accumulation, the current data suggests that Resolvin D1 bioactive lipid mediator, as 
well as Annexin A1 pro-resolving protein might both contribute to the accumulation of 
matrix induced by microparticle treatment.   
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Figure 4.2.22 Antagonism of FPR2/ALX reverses Resolvin D1 induced extracellular matrix 
accumulation. Chondrocyte micromasses were treated with 10µM WRW4 (10µM) for 10 
minutes followed by IL-1β (30ng/ml) and Resolvin D1 (RvD1; 10nM) for 24 hours before 
extracellular matrix accumulation was quantified by Alcian blue staining. Data are shown as 
mean ± SEM of 4 micromass preparations. **P<0.01 and ***P<0.001 using Two-way ANOVA 
and Bonferroni post-test. ECM, extracellular matrix.   
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4.3 Chondroprotective Circuits Initiated by 
Microparticles  
 
As some of the effects noted during microparticle co-culture seemed to be Annexin A1-
mediated, it was next determined whether these effects were due to receptor ligation of 
FPR2/ALX on the surface of the chondrocyte. The downstream signalling pathways 
that follow FPR2/ALX ligation in immune cells is beginning to emerge (Cooray et al., 
2013, Bena et al., 2012b, Renshaw et al., 2010, Pupjalis et al., 2011), yet have never 
been explored in chondrocytes. Furthermore, the signalling induced by microparticle 
treatment, which results in extracellular matrix accumulation with IL-1β (or TNF-α) 
stimulated micromasses, is also unknown. 
 
4.3.1 Modulation of Signalling Molecule Phosphorylation by 
Microparticle and Annexin A1 Treatment  
 
As the signalling events surrounding microparticle treatment in chondrocytes has not 
been reported, a range of inflammatory signalling pathways were profiled for their 
phosphorylation status following IL-1β stimulation, microparticle treatment and, as a 
comparison, Annexin A1 treatment. Monolayer, rather than micromasses were used as 
the timing of the phosphorylation profiles of signalling molecules are key to elucidating 
their mechanism, and diffusion through multiple layers of cells combined with 
generated matrix could not be controlled for temporally.  
 
Firstly, p38 phosphorylation was investigated in C28/I2 chondrocytes seeded in 
monolayer and stimulated with IL-1β with or without microparticles (Figure 4.3.1). The 
activation of p38 regulates pro-inflammatory cytokine production and downstream 
targets of this signalling molecule, among many, are enzymes such as MMP13 and 
COX-2. Relevantly, MMP13 and the COX-2 product Prostaglandin E2 were both 
reduced upon microparticle treatment. The phosphorylation of p38 was not altered 
above baseline by microparticle treatment alone in resting chondrocytes (0.07 ± 0 vs. 
0.05 ± 0) or by Annexin A1 treatment (-0.24 ± 0.3 vs. 0.05 ± 0; used as a negative 
control as it did not induce reductions in prostaglandin E2 production) at 1 hour. IL-1β 
stimulation induced p38 phosphorylation at one hour as expected (0.55 ± 0.1 vs. 0.05 ± 
0 (Lin et al., 2008)).  
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Concomitant treatment with microparticles slightly increased the phosphorylation of 
p38 above IL-1β alone (0.92 ± 0.4 vs. 0.55 ± 0.1), whereas Annexin A1 caused a slight 
reduction (0.37 ± 0.1 vs. 0.55 ± 0.1). As microparticle treatment did not have a striking 
effect at one hour, a time course of p38 phosphorylation was carried out to determine 
whether microparticles temporally modulated p38 phosphorylation or alternatively 
modulated the duration of the IL-1β signal.  
 
Under basal resting conditions, no phosphorylation of p38 was observed in C28/I2 
chondrocyte monolayers and this was not modulated upon co-administration of 
100,000 TMP across any of the time points tested (Figure 4.3.2). In contrast, IL-1β 
induced phosphorylation of p38 by 30 minutes, which peaked at 1 hour and reduced 
down to baseline at 4 hours. The bands obtained from microparticle-treated IL-1β 
stimulated chondrocytes showed a less intense signal than IL-1β alone at 30 minutes, 
but at 1 hour both the microparticle and IL-1β signal were roughly similar. By 2 hours, 
microparticle treatment induced greater phosphorylation than IL-1β alone, but returned 
to baseline by 4 hours. This delay in phosphorylation of p38 is interesting, but its 
relevance requires further investigation.  
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Figure 4.3.1 Microparticles do not modulate chondrocyte p38 phosphorylation induced by IL-
1β at one hour. C28/I2 chondrocytes in monolayer were treated with IL-1β (30ng/ml) and 
100,000 TMP or Annexin A1 (10nM) for 1 hour before blotting for phospho-p38 and total p38 
protein. Positive control is human neutrophils stimulated for 10 minutes with TNF-α. Data are 
shown as mean ± SEM of 4 separate microparticle donors and blots and expressed as relative 
intensity after normalisation to total p38. **P<0.01 with Two-way ANOVA and Bonferroni post-
test. TMP, TNF-α-treatment generated microparticles. 
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Figure 4.3.2 Microparticles do not significantly modulate p38 phosphorylation in IL-1β-
stimulated micromasses. C28/I2 chondrocytes in monolayer were treated with IL-1β (30ng/ml) 
and 100,000 TMP or Annexin A1 (10nM) before blotting for phospho-p38 protein. Data are 
shown are examples of 4 separate microparticle donors and blots. Negative expression at 4 
hours shows positive control (10 minute, TNF-α-stimulated neutrophils) for validation. 
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Downstream of p38 phosphorylation is MAPKAPK2, which modulates the translation of 
pro-inflammatory mRNA via stabilisation. Phosphorylation of MAPKAPK2 is maximal at 
30 minutes following IL-1β stimulation (Jones et al., 2009), thus this time point was 
selected.  Phosphorylation of MAPKAPK2 was not observed under basal conditions, 
but was significantly up-regulated by IL-1β as expected (1 ± 0.4 vs. -0.1 ± 0.1, P<0.001 
with Two-way ANOVA and Bonferroni post-test). At 30 minutes, phosphorylation of 
MAPKAPK2 was not altered by treatment with microparticles in either unstimulated (0.1 
± 0 vs. -0.1 ± 0.1) or IL-1β-stimulated chondrocytes (0.8 ± 0.3 vs. 1 ± 0.4; Figure 4.3.3).  
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Figure 4.3.3 Microparticles do not 
modulate chondrocyte MAPKAPK2 
phosphorylation induced by IL-1β. 
C28/I2 chondrocytes in monolayer were 
treated with IL-1β (30ng/ml) and 
100,000 TMP for 30 minutes before 
blotting for phospho-MAPKAPK2 (MK2) 
protein. Data are shown as mean ± SEM 
of 4 separate microparticle donors and 
blots and expressed as relative intensity 
after normalisation to total MK2. 
**P<0.01 with Two-way ANOVA and 
Bonferroni post-test. TMP, TNF-α 
generated microparticles. 
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As prostaglandin E2, IL-6 and IL-8 synthesis was affected by microparticle addition, a 
further downstream target of p38 and MAPKAPK2, phosphorylation of heat-shock 
protein (Hsp) 27 was investigated (Figure 4.3.4). Surprisingly, phosphorylation of 
Hsp27 was completely inhibited at 10 minutes by microparticle co-administration with 
IL-1β (0.08 ± 0 vs. 0.4 ± 0.1 P<0.001 with Two-way ANOVA and Bonferroni post-test). 
Unphosphorylated Hsp27 exists as large oligomeric structures, and upon 
phosphorylation is released to form dimers. These dimers stabilise the mRNA of target 
genes such as COX2, TNFA1, IL6 and IL8 (Lasa et al., 2000).  Thus, microparticles 
may act directly at this step in the p38 MAPK pathway to prevent Hsp27 
phosphorylation directly and prevent its release from its oligomeric homopolymer, 
allowing the degradation of the unstable mRNAs encoding IL-8, IL-6 and COX-2. This 
would account for the reduction of these cytokines and prostaglandin E2 in the 
supernatants of chondrocyte micromasses stimulated with IL-1β and treated with 
microparticles. 
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Figure 4.3.4 Microparticles reduce 
chondrocyte Hsp27 phosphorylation 
induced by IL-1β. C28/I2 chondrocytes in 
monolayer were treated with IL-1β 
(30ng/ml) and 100,000 TMP for 10 
minutes before blotting for phospho-
Hsp27 protein. Data are shown as mean 
± SEM of 4 separate microparticle 
donors and blots and expressed as 
relative intensity after normalisation to 
total Hsp27, ***P<0.001 with Two-way 
ANOVA and Bonferroni post-test. TMP, 
TNF-α generated microparticles. 
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Other signalling pathways are also initiated downstream of IL-1β in chondrocytes (Lin 
et al., 2008). Indeed, phosphorylation of c-Jun N-terminal kinase (JNK) regulates 
cytokine production and matrix metalloproteinase expression in chondrocytes (Beier 
and Loeser, 2010). Intriguingly, IL-1β-induced MMP13 expression requires 
phosphorylation of both p38 and JNK; whereas inhibition of MMP13 requires blockade 
of only one of these signalling pathways. Microparticle treatment inhibited JNK 
phosphorylation in both resting (0.1 ± 0 vs. 0.2 ± 0.1) and IL-1β (30ng/ml) stimulated 
C28/I2 chondrocytes (0.3 ± 0.1 vs. 0.2 ± 0.1; Figure 4.3.5). This could account for the 
microparticle-induced down-regulation of proteoglycan cleavage and release into the 
medium seen by DMMB dye-binding assay. 
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Figure 4.3.5 Microparticles reduce 
chondrocyte JNK phosphorylation 
induced by IL-1β. C28/I2 chondrocytes in 
monolayer were treated with IL-1β 
(30ng/ml) and 100,000 TMP for 10 
minutes before blotting for phospho-JNK 
protein. Data are shown as mean ± SEM 
of 4 separate microparticle donors and 
blots and expressed as relative intensity 
after normalisation to total JNK, not 
significant with Two-way ANOVA and 
Bonferroni post-test. TMP, TNF-α 
generated microparticles. 
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Akt phosphorylation in cartilage is associated with the regulation of mRNA translation 
and protein synthesis via the activation of mammalian Target of Rapamycin (mTOR) 
and factors such as p70S6K, and 4E-BP-1 (eIF-4E-binding protein) (Yin et al., 2009). 
10-minute microparticle treatment alone in resting primary adult human articular 
chondrocytes induced significant Akt phosphorylation compared to resting 
chondrocytes alone (0.7 ± 0.2 vs. 0.2 ± 0, P<0.05 with Two-way ANOVA and 
Bonferroni post-test) and microparticle pre-treatment (18 hours; 0.7 ± 0.2 vs. 0.2 ± 0.1, 
P<0.05 with Two-way ANOVA and Bonferroni post-test; Figure 4.3.6). This was lost 
upon stimulation with IL-1β for 10 minutes (TMP 0.3 ± 0.1 vs. IL-1β 0.4 ± 0.2). After 40 
minutes, the phosphorylation of Akt had decreased and was no longer significant in 
resting chondrocytes (0.5 ± 0.2 vs. 0.4 ± 0.1) but had increased in IL-1β stimulated 
chondrocytes, although the level of phosphorylation did not vary between IL-1β-
stimulated groups (IL-1β 0.7 ± 0.1, TMP pre-treatment 0.8 ± 0.1 and IL-1β plus TMP 
0.6 ± 0.2). 
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Figure 4.3.6 Microparticles modulate primary adult human articular chondrocyte Akt 
phosphorylation temporally. Primary adult human articular chondrocytes in monolayer were 
either pre-treated with 100,000 TMP for 16 hours or treated with IL-1β (30ng/ml) and 100,000 
TMP for (A) 10 minutes or (B) 40 minutes, before blotting for phospho-Akt protein. Data are 
shown as mean ± SEM of 4 separate microparticle donors and blots and expressed as relative 
intensity after normalisation to total Akt, *P<0.05 with Two-way ANOVA and Bonferroni post-
test. TMP, TNF-α-treatment generated microparticles. With thanks to Dr Sadani Cooray for 
performing this western. 
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Phosphorylated ERK1/2 on the other hand induces the phosphorylation and activation 
of other kinases and several other factors promoting cell proliferation and/or gene 
transcription in cartilage (Yin et al., 2009). ERK1/2 phosphorylation was not 
significantly altered upon IL-1β stimulation at 10 minutes (1.2 ± 0.3 vs. 1 ± 0.3) or 40 
minutes (1.3 ± 0.2 vs. 1.1 ± 0.4) or concurrent microparticle treatment at 10 minutes 
(1.1 ± 0.1 vs. 1.2 ± 0.3) or 40 minutes (1.1 ± 0.1 vs. 1.3 ± 0.2; Figure 4.3.7).  
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Figure 4.3.7 Microparticles modulate primary adult human articular chondrocyte ERK1/2 
phosphorylation temporally. Primary adult human articular chondrocytes in monolayer were 
either pre-treated with 100,000 TMP for 16 hours or treated with IL-1β (30ng/ml) and 100,000 
TMP for (A) 10 minutes or (B) 40 minutes, before blotting for phospho-Akt protein. Data are 
shown as mean ± SEM of 4 separate microparticle donors and blots and expressed as relative 
intensity after normalisation to total ERK, not significant with Two-way ANOVA and Bonferroni 
post-test. TMP, TNF-α-treatment generated microparticles. With thanks to Dr Sadani Cooray for 
performing this western. 
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Collectively, these results suggest microparticles influence several signalling pathways 
in a diverse and temporally orchestrated manner. Given the number of proteins (and 
other components such as lipids) present within microparticle populations, it is difficult 
to identify one single pathway responsible for all the chondroprotective effects seen in 
microparticle and IL-1β co-culture. However, the strong indication that Hsp27 
phosphorylation is inhibited rapidly upon microparticle treatment deserves further 
investigation to determine whether it is this event that leads to the down-regulation of 
inflammatory cytokine production by chondrocytes. 
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4.3.2 FPR2 Downstream Transcriptional Target Modulation 
by Microparticles 
 
Next, the modulation of FPR2 mRNA by microparticle-associated FPR2 agonists and 
Annexin A1 was investigated, as the feed-forward regulation of FPR2 by its agonists is 
largely unknown (Figure 4.3.8). FPR2 mRNA levels were not significantly altered by IL-
1β stimulation at either 3ng/ml (1.3 ± 0.1 vs. 1 ± 0.1) or 30ng/ml (1.1 ± 0.2 vs. 1 ± 0.1) 
compared to control or by concomitant CMP treatment (CMP + IL-1β 3ng/ml 1.4 ± 0.4 
or 30ng/ml 0.7 ± 0.1 vs. 1 ± 0.1) or TMP treatment (TMP + IL-1β 3ng/ml 1.4 ± 0.4 or 
30ng/ml 0.9 ± 0.1 vs. 1 ± 0.1). Annexin A1 treatment (30nM) induced a trend of up-
regulation of FPR2 mRNA in micromasses stimulated with IL-1β (3ng/ml) compared to 
IL-1β stimulation alone (2.4 ± 0.7 vs. 1.3 ± 0.1) but this did not reach statistical 
significance.  
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Figure 4.3.8 Transcriptional regulation 
of FPR2 by agonists. Chondrocyte 
micromasses were treated with IL-1β 
(3ng/ml or 30ng/ml) and (A) 100,000 
CMP or TMP or (B) increasing 
concentrations of Annexin A1 for 6 
hours before mRNA extraction and RT-
PCR for relative expression of FPR2. 
Data shown are 2-ΔΔCT with untreated 
as calibrator and RPL32 as 
housekeeping gene. Data expressed as 
mean ± SEM of 4 microparticle donors 
or 3 separate micromass preparations, 
not significant with Two-way ANOVA 
and Bonferroni post-test of logged 
data. CMP, control microparticles, TMP, 
TMP, TNF-α-treatment generated 
microparticles. With Special Thanks to 
Dr Trinidad Montero-Melendez for 
performing this assay. 
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Downstream transcriptional targets up-regulated by FPR2 ligation (Renshaw et al., 
2010) were investigated in C28/I2 chondrocyte micromasses stimulated with IL-1β, 
microparticles and Annexin A1. Firstly, SGPP2 mRNA, which encodes sphingosine 1-
phosphate phosphatase expression was analysed (Figure 4.3.9). In chondrocytes, 
SGPP2 expression induced by IL-1β stimulation was significantly down-regulated by 
concurrent microparticle treatment (TMP 1.4 ± 0.6 vs. 2.9 ± 0.1 P<0.05 with Kruskal-
Wallis test and Dunn’s multiple comparison post-test), especially by CMP (0.9 ± 0.1 vs. 
2.9 ± 0.1 P<0.01 with Kruskal-Wallis test and Dunn’s multiple comparison post-test; 
Figure 4.3.9A). In contrast, Annexin A1 treatment did not alter SGPP2 expression in 
either resting (1.5 ± 0.6 vs. 1.2 ± 0.5) or IL-1β-stimulated chondrocytes (2.3 ± 0 vs. 2.9 
± 0.1; Figure 4.3.9B). Accumulating evidence suggests Sphingosine 1-phosphate is 
plays a role in inflammation, and its downstream phosphatase, sphingosine 1-
phosphate phosphatase, or SPP2 (encoded by SGPP2) is highly up-regulated in 
inflammatory settings. Mechtcheriakova et al. (2007) found a predicted NFκB binding 
site in the promoter of the SGPP2 gene, suggesting that its transcription is NFκB-
dependent. Furthermore, the production of several pro-inflammatory cytokines requires 
SPP2 and silencing with siRNA reduced IL-8 production induced by TNF-α stimulation 
in endothelial cells.  
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Figure 4.3.9 SGPP2, a downstream 
transcriptional target of FPR2 signalling, 
is modulated by microparticle treatment. 
Chondrocyte micromasses were treated 
with IL-1β (30ng/ml) and (A) 100,000 
CMP or TMP or (B) Annexin A1 (10nM) for 
6 hours before mRNA extraction and RT-
PCR for relative expression of SGPP2. 
Data shown are 2-ΔΔCT with untreated as 
calibrator and RPL32 as housekeeping 
gene. Data expressed as mean ± SEM of 
3 microparticle donors or 3 separate 
micromass preparations, *P<0.05 and 
**P<0.01 using Two-way ANOVA and 
Bonferroni post-test of logged data. CMP, 
control microparticles, TMP, TNF-α-
treatment generated microparticles. With 
Special Thanks to Dr Trinidad Montero-
Melendez for performing this assay. 
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Other targets, such as JAG1, JAM3, IKBK and SP1 were not significantly altered in 
these settings and require further investigation (Figure 4.3.10). 
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Figure 4.3.10 JAG1, JAM3, IKBK and SP1, downstream transcriptional targets of FPR2 
signalling, are not modulated by microparticle or Annexin A1 treatment. Chondrocyte 
micromasses were treated with IL-1β (30ng/ml) and (A, C, E, G) 100,000 CMP or TMP or (B, D, 
F, H) Annexin A1 (10nM) for 6 hours before mRNA extraction and RT-PCR for relative expression 
of JAG1, JAM3, IKBK or SP1. Data shown are 2-ΔΔCT with untreated as calibrator and RPL32 as 
housekeeping gene. Data expressed as mean ± SEM of 4 microparticle donors or 3 separate 
micromass preparations, not significant with Two-way ANOVA and Bonferroni post-test of logged 
data. CMP, control microparticles, TMP, TNF-α-treatment generated microparticles. With Special 
Thanks to Dr Trinidad Montero-Melendez for performing this assay. 
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Thus, these data are interesting, as they confirm that the effects mediated by 
microparticle interaction with chondrocytes is not wholly dependent on Annexin A1, and 
that other anti-inflammatory pathways are being induced in this setting. Collectively, 
these data suggest that the chondroprotection induced by microparticle co-culture is 
the sum of several anti-inflammatory pathways and events. Hsp27 phosphorylation 
functions to stabilise the mRNA of pro-inflammatory cytokines and this was inhibited by 
microparticle treatment. SGPP2 transcription is also associated with the further up-
regulation of pro-inflammatory cytokines such as IL-8, and this too was inhibited by 
microparticle treatment.  
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4.3.3 Microparticle Treatment Induces Chondrocyte TGF-β  
Production 
 
Previous reports have demonstrated the role of TGF-β in microparticle-induced anti-
inflammatory effects (Gasser and Schifferli, 2004). Therefore it was pertinent to 
investigate the production of TGF-β1 by C28/I2 chondrocytes cultured in micromass 
constructs. Co-culture of IL-1β stimulated micromasses with TMP significantly elevated 
TGFβ1 mRNA expression compared to IL-1β treatment alone (Figure 4.3.11A, 2.3 ± 
0.2 vs. 0.48 ± 0.2 P=0.023 with Kruskal-Wallis test and Dunn’s multiple comparison 
post-test). Treatment with CMP trended towards this effect but did not reach statistical 
significance (2.3 ± 1 vs. 0.48 ± 0.2). This suggests that microparticle treatment induces 
de novo production of TGF-β1. 
 
In addition, TGF-β1 protein levels were measured in micromass supernatants using a 
cytokine bead array kit, a highly sensitive sandwich immunoassay analysed using flow 
cytometry to detect fluorescence intensity that is proportional to the concentration of 
the analyte (Figure 4.3.11). TGF-β1 possesses potent anti-inflammatory and anabolic 
effects on chondrocytes. Microparticle culture with resting chondrocytes induced 
significant TGF-β1 production (31.4 ± 3.7 vs. 0 ± 8.9% P<0.05 with Two-way ANOVA 
and Bonferroni post-test; Figure 4.3.11A). Furthermore, microparticle co-culture with 
chondrocyte micromasses stimulated with IL-1β reversed the down-regulation of TGF-
β1 production (44.6 ± 6.2 vs. -8.7 ± 11.8% P<0.001 with Two-way ANOVA and 
Bonferroni post-test). 
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The contribution of TGFβ1 to matrix accumulation was next assessed using TGFβ 
neutralising antibodies (Figure 4.3.12). As expected, TMP reversed the reduction in 
matrix accumulation induced by IL-1β (30ng/ml) treatment (41.7 ± 1.9 vs. -19 ± 4.6%, 
P<0.001 with Two-way ANOVA and Bonferroni post-test). Treatment of micromasses 
with TGFβ neutralising antibodies had no effect in either resting (-4.6 ± 5.8 vs. 3.1 ± 
1.4%, not significant) or IL-1β stimulated micromasses (-24 ± 3 vs. -19 ± 4.6%, not 
significant). In contrast, the combination of microparticle treatment with TGFβ 
neutralising antibodies significantly down-regulated chondroprotection in IL-1β 
stimulated chondrocytes (6.5 ± 6.5 vs. 41.7 ± 1.9%, P<0.01 with Two-way ANOVA and 
Bonferroni post test) without modulating matrix production in resting chondrocytes (-6.6 
± 14 vs. 3.1 ± 1.4%, not significant). This suggests that chondrocyte TGFβ production 
induced by microparticle treatment is at least partially responsible for microparticle 
protection. 
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Figure 4.3.11 Microparticles induce TGF-β mRNA and protein expression. Chondrocyte 
micromasses were treated with IL-1β (30ng/ml) and 100,000 CMP or TMP for 24 or 6 hours 
before supernatant collection and mRNA extraction for RT-PCR. (A) Relative expression of TGFβ1 
after 6 hours. Data shown are 2-ΔΔCT with untreated as calibrator and RPL32 as housekeeping 
gene. Data expressed as median, interquartile range and range of 4 separate microparticle 
donors. (B) Total TGF-β1 protein content in supernatants were quantified by cytokine bead 
array. Data are shown as mean ± SEM of 8 separate microparticle donors. *P<0.05 and 
***P<0.001 with Two-way ANOVA and Bonferroni post-test. *P<0.05 and using Kruskal-Wallis 
test and Dunn’s multiple comparison post-test. CMP, control microparticles, TMP, TNF-α-
treatment generated microparticles. With Special Thanks to Mr Hefin Rhys Jones for performing 
the CBA assay. 
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Therefore, the production of TGF-β1, a protective growth factor for chondrocytes, was 
induced by co-culture with microparticles, and neutralisation of TGF-β reversed 
chondroprotection. This suggests that the downstream programme induced by 
microparticles involves the induction of TGF-β. 
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Figure 4.3.12 TGF-β neutralising antibodies 
significantly inhibit microparticle-induced 
chondroprotection. Chondrocyte micromasses 
were treated with IL-1β (30ng/ml) and 
100,000 TMP with or without TGF-β 
neutralising antibodies (10µg/ml) for 24 
hours before extracellular matrix 
accumulation was quantified by Alcian blue 
staining. Data are shown as mean ± SEM of 3 
separate microparticle donors. *P<0.05, 
**P<0.01 and ***P<0.001 using Two-way 
ANOVA and Bonferroni post-test. TMP, TNF-α 
generated microparticles; ECM, extracellular 
matrix; αTGFβ, Transforming growth factor β 
neutralising antibodies. 
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4.4 Microparticles Protect Cartilage-Native 
Chondrocytes Ex Vivo 
 
As microparticle treatment of arthritic chondrocytes in vitro led to an unexpected 
increase in cartilage matrix accumulation and supressed the generation of 
inflammatory cytokines, it was critical to understand whether microparticles could elicit 
similar protective effects in whole cartilage explants. This would provide more 
physiologically relevant details about microparticle-chondrocyte interaction when 
spatially divided by cartilage matrix.  
 
4.4.1 Microparticles Penetrate Cartilage Matrix 
 
To investigate any potential protective effects of microparticles on cartilage explants, a 
culture system using whole rat femoral cartilage explants was devised. Removal of the 
entire cartilage femoral head cap ensured that auto-degradation of the matrix was 
minimised, as mechanically damaging the cartilage by cutting induces a defective 
repair programme, inducing the expression of matrix metalloproteinases by 
chondrocytes. In the first instance, rat tissue rather than mouse tissue was utilised due 
to the technical challenge of removing intact murine femoral heads. 
 
Firstly, the loss of matrix integrity, measured by Safranin O staining in rat femoral head 
explants, was determined after culturing with IL-1β for a period of 14 days (Figure 
4.4.1). By day 4, IL-1β treatment (10ng/ml) had induced significant cartilage 
proteoglycan loss compared to day 0 (41.4 ± 2.9 vs. 83.5 ± 3.5% P<0.001 with Two-
way ANOVA and Bonferroni post-test), a reduction of 50%.  By day 7, control cartilage 
had lost a proportion of its integrity compared to day 0 and day 4 (53 ± 2.7 vs. day 4 
71.6 ± 3.9 and day 0 83.5 ± 3.5%), but this was significantly increased in IL-1β treated 
femoral heads (22.8 ± 2.9 vs. 53 ± 2.7% P<0.001 with Two-way ANOVA and 
Bonferroni post-test). Proteoglycan loss after this time-point plateaued, and further loss 
was not seen in either control (52.3 ± 3.1 vs. 53 ± 2.7%) or IL-1β-treated femoral heads 
(18.9 ± 2 vs. 22.8 ± 29). Thus, a 7-day time point was chosen for further experiments.  
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Figure 4.4.1 IL-1β reduces rat femoral head cartilage integrity over 4 to 14 days. Rat femoral 
head cartilage explants were treated with IL-1β (10ng/ml) every two days for 14 days and 
stained with Safranin O on days 0, 4, 7 and 14. Data are expressed as percentage area 
Safranin O positive and shown as mean ± SEM of 4 separate rats. ***P<0.001 using Two-way 
ANOVA with Bonferroni post-test.  
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As predicted, IL-1β treated femoral heads had reduced matrix integrity compared to 
control (22.8 ± 2.9 vs. 53 ± 2.7% P<0.001 with Two-way ANOVA and Bonferroni post-
test, Figure 4.4.2). Concurrent microparticle treatment with IL-1β (10ng/ml) stimulation 
every two days protected from IL-1β-induced loss in cartilage integrity (CMP 46.2 ± 8.7 
and IMP 46.9 ± 9.8 vs. 22.8 ± 2.9% P<0.01 and TMP 51.5 ± 5 vs. 22.8 ± 2.9% P<0.001 
with Two-way ANOVA and Bonferroni post-test), indicating that microparticles can 
exert effects in whole tissue explants as well a during micromass co-culture.  
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Figure 4.4.2 Microparticles protect 
from IL-1β-induced cartilage 
integrity loss at 7 days. Rat 
femoral head cartilage explants 
were treated with IL-1β (10ng/ml) 
and 100,000 CMP, TMP or IMP 
every two days for 7 days and 
stained with Safranin O on day 7. 
Data are expressed as percentage 
area Safranin O positive and 
shown as mean ± SEM of 4 
separate microparticle donors and 
4 separate cartilage donors. 
**P<0.01 and ***P<0.001 using 
Two-way ANOVA with Bonferroni 
post-test. CMP, control 
microparticles; TMP, TNF-α-
treatment generated 
microparticles; IMP, IL-8-treatment 
generated microparticles. 
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To determine whether protection of the cartilage matrix was accompanied by 
alterations in proinflammatory mediator production, Prostaglandin E2 and nitric oxide 
were measured in the culture supernatants. By day 7 significant proteoglycan loss was 
observed in the IL-1β-treated cartilage explants, and the production of prostaglandin E2 
into the supernatant was significantly higher than that of control femoral heads (0.08 ± 
0.1 vs. 4.1 ± 1.6ng/ml P<0.05 with Two-way ANOVA and Bonferroni post-test; Figure 
4.4.3). Prostaglandin E2 production was not reduced by concurrent treatment with 
CMP, TMP or IMP compared to IL-1β alone (1.5 ± 0.6, 2.8 ± 1.2 and 3.2 ± 1.5 vs. 4.1 ± 
1.6ng/ml) even though protection from proteoglycan loss was observed. 
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Figure 4.4.3 Microparticles do not affect prostaglandin E2 production induced by IL-1β on day 
7. Rat femoral head cartilage explants were treated with or without IL-1β (10ng/ml) and 
100,000 CMP, TMP or IMP every two days for 7 days. Supernatants were assayed for 
prostaglandin E2 by EIA. Data are shown as mean ± SEM of 4 separate microparticle donors and 
4 separate cartilage donors. *P<0.05 using Two-way ANOVA with Bonferroni post-test. CMP, 
control microparticles; TMP, TNF-α-treatment generated microparticles; IMP, IL-8-treatment 
generated microparticles; PGE2, prostaglandin E2. 
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In contrast, nitric oxide metabolism was increased by TMP and IMP treatment of 
resting femoral head explants on day 7 (TMP 18.1 ± 4.4 and IMP 17.8 ± 3.6 vs. 5.6 ± 
1.2µM P<0.05 with Two-way ANOVA and Bonferroni post-test; Figure 4.4.4). This was 
not the case for femoral heads stimulated with IL-1β and then treated with 
microparticles (19.7 ± 1.2 vs. CMP 29.3 ± 2.2, TMP 23.8 ± 2.8 or IMP 25 ± 1.2µM). 
This suggests that, at least in vitro, microparticles are not as effective at reducing 
proinflammatory mediator production, but can still protect from cartilage degradation in 
this chimeric rat tissue/human microparticle model. 
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Figure 4.4.4 Microparticles increase nitric oxide production in resting cartilage explants. Rat 
femoral head cartilage explants were treated with IL-1β (10ng/ml) and 100,000 CMP, TMP or 
IMP every two days for 7 days. Supernatants were assayed for Nitric oxide metabolism by Griess 
Assay. Data are shown as mean ± SEM of 4 separate microparticle donors and 4 separate 
cartilage donors. *P<0.05 and ***P<0.001 using Two-way ANOVA with Bonferroni post-test. 
CMP, control microparticles; TMP, TNF-α-treatment generated microparticles; IMP, IL-8-
treatment generated microparticles. 
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Next it was determined whether Annexin A1 treatment had any effect on cartilage 
matrix integrity as observed during in vitro experiments. Annexin A1 treatment of 
control rat femoral head explants did not induce any significant changes in 
proteoglycan retention at day 7 (50.9 ± 4.7 vs. 52.1 ± 8.8%; Figure 4.4.5). However, 
concomitant treatment with IL-1β protected cartilage matrix integrity at day 7 compared 
to IL-1β alone (55 ± 3.8 vs. 20.2 ± 1.6% P<0.01 with Two-way ANOVA and Bonferroni 
post-test), with levels of Safranin O staining similar to those observed in untreated 
femoral heads (55 ± 3.8 vs. 52.1 ± 8.8%). These data suggest that ex vivo treatment of 
cartilage explants with microparticles induces protection of the cartilage matrix integrity 
with Annexin A1 being a likely molecule responsible for this protection.  
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Figure 4.4.5 Annexin A1 protects 
from IL-1β-induced cartilage 
integrity loss. Rat femoral head 
cartilage explants were treated 
with IL-1β (10ng/ml) and 
recombinant human Annexin A1 
(10nM) every two days for 7 days 
before Safranin O staining. Data 
are expressed as percentage 
area Safranin O positive and 
shown as mean ± SEM of 4 
separate rats. *P<0.05 and 
**P<0.01 using Two-way ANOVA 
with Bonferroni post-test. AnxA1, 
Annexin A1. 
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To determine whether the Annexin A1 G-protein coupled receptors (GPCRs) were 
involved in the retention of proteoglycans, cartilage explants were obtained from mice 
with genetic knockout of Fpr1 and Fpr2/3. Wild type mouse femoral head cultures 
treated with IL-1β for 7 days  with concurrent microparticle treatment led to a greater 
retention of proteoglycans compared to IL-1β treatment alone in both wild-type (64.4 ± 
1.3 vs. 40.8 ± 5.5% P<0.05 woth Two-way ANOVA and Bonferroni post-test) and Fpr1-
/- (75.6 ± 1.7 vs. 52.5 ± 3.3% P<0.001 with Two-way ANOVA and Bonferroni post-test) 
femoral heads at day 7, at levels similar to those of untreated femoral heads (wild type 
64.4 ± 1.3 vs. 67.3 ± 4.1% and Fpr1-/- 75.6 ± 1.7 vs. 84.1 ± 1.1%; Figure 4.4.6). In 
contrast, microparticle treatment of Fpr2/3-/- femoral head explants (the murine 
orthologue of human FPR2) did not induce any retention of proteoglycans compared to 
IL-1β alone (60.7 ± 2.4 vs. 64.3 ± 3% not significant with Two-way ANOVA and 
Bonferroni post-test).   
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Figure 4.4.6 Microparticles protect from IL-1β-induced cartilage integrity loss in wild type and 
Fpr1-/- but not Fpr2/3-/- mouse femoral head cartilage. (A) Wild type, (B) Fpr1 null and (C) 
Fpr2/3 null femoral head cartilage explants were treated with IL-1β (10ng/ml) and 100,000 
TMP every two days for 7 days before Safranin O staining. Data are expressed as percentage 
area Safranin O positive and shown as mean ± SEM of 3 separate mice from each genotype. 
*P<0.05 and ***P<0.001 using Two-way ANOVA with Bonferroni post-test. TMP, TNF-α-
treatment generated microparticles. 
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These data indicate that microparticles are able to protect the cartilage matrix from 
integrity loss induced by IL-1β, but also indicate that ligation of Fpr2/3 is required for 
this protection. Thus, it was next investigated whether neutrophil microparticles can 
enter the cartilage matrix to interact with Fpr2/3 bearing chondrocytes.  
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4.4.2 Microparticles Penetrate Cartilage Matrix in Ex Vivo 
Femoral Head Explants  
 
Were microparticles delivering protective components to the chondrocytes through the 
cartilage? To identify whether the protective effects were achieved by migration of 
microparticles through the matrix to the chondrocytes, an experiment was designed to 
visualise the microparticle location.  
 
IL-1β treatment of femoral heads was carried out for 3 days (50ng/ml every day) before 
100,000 Bodipy-maleimide-labelled TMP were added to the culture. Femoral heads 
were collected 18 hours later, sectioned, and stained with anti-human MRP-8, a protein 
highly abundant in neutrophil microparticles, to determine the presence of human 
protein. Control femoral heads and those treated with only IL-1β showed no staining for 
MRP-8, or any Bodipy-maleimide (green) fluorescence above background as expected 
(Figure 4.4.7 panels a and b). In contrast, femoral heads treated with TMP showed 
abundant chondrocytes positive for both Bodipy-maleimide fluorescence and MRP-8 
(red) staining (Figure 4.4.7 panels c and d). In contrast, femoral heads treated with 
100,000 synthetic microcapsules, which have FITC integrated into their membranes 
and carry a similar content of Annexin A1, with or without IL-1β stimulation, indicated 
presence of microcapsules on the surface of cartilage explants but showed no FITC 
fluorescence within the matrix or cells (Figure 4.4.7 panels e and f). Higher 
magnification images of TMP-treated, IL-1β-stimulated femoral heads stained with 
monoclonal anti-human Annexin A1 revealed double-positive staining puncta located 
primarily within the border of chondrocytes (detectable by wheat-germ agglutinin; 
Figure 4.4.7 panel g). Occasionally, these areas of double staining co-localised with 
chondrocyte nuclei, furthermore, Annexin A1 could also be detected within cells 
suggesting uptake of proteins from the microparticles followed by redistribution 
throughout the cytoplasm.  
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Figure 4.4.7 Microparticles penetrate intact cartilage matrix whereas synthetic microcapsules 
of the same size, loaded with Annexin A1, cannot. Rat femoral head cartilage was treated with 
IL-1β (50ng/ml) for 3 days or left untreated before 100,000 Bodipy-maleimide-loaded TMP or 
synthetic microcapsules were added for 18 hours. Fixed femoral heads were sectioned and 
stained with monoclonal human MRP-8 antibodies (which does not cross-react with rat tissue), 
wheat germ agglutinin (WGA) and DAPI before confocal microscopy. (a) Untreated, (b) IL-1β 
(50ng/ml), (c) TMP only, (d) IL-1β (50ng/ml) and TMP treatment. Grey arrowheads denote 
deepest green (Bodipy-maleimide) and red (MRP8) co-localisation. (e) Microcapsules only, (f) 
microcapsules and IL-1β (50ng/ml) treatment. White arrows denote microcapsules that 
fluoresce green inherently. Scale bar denotes 50µm. (g) High magnification fluorescent confocal 
micrograph of Bodipy-maleimide (green) and AnxA1 (red) double positive microparticles within 
cartilage-resident chondrocytes. Scale bar denotes 20µm. TMP, TNF-α-treatment generated 
microparticles; AnxA1, Annexin 1; MRP8, myeloid-related protein 8. 
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Penetration of microparticles into IL-1β treated explants occurred with a higher 
distribution frequency compared to unstimulated explants, with microparticles reaching 
significantly further into IL-1β-degraded cartilage (61.8 ± 3.4 vs. 30 ± 1.9µm P<0.001 
with two-tailed Mann-Whitney t-test; Figure 4.4.8).  
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Figure 4.4.8 Microparticles penetrate further into IL-1β-treated cartilage explants. (A) Rat 
femoral head cartilage was either left untreated or (B) treated with IL-1β (50ng/ml) for 3 days 
before 100,000 Bodipy-maleimide-loaded TMP were added for 24 hours. Fixed femoral heads 
were sectioned and stained with monoclonal human MRP-8 antibodies (which does not cross-
react with rat tissue), wheat germ agglutinin and DAPI before confocal microscopy. Each 
individual microparticle or double-staining cell (representing previous microparticle uptake) 
depth was measured using image J after calibration for pixel vs. distance ratio. Each graph 
represents 140 or 166 microparticles measured over at least 10 individual micrographs. (C) 
Box and whisker summary of binned data, data are shown as Bonferroni whiskers to 
demonstrate outliers. ***P<0.001 with Mann-Whitney t-test. (D) Representative micrographs 
demonstrating microparticle measurements. Grey arrowheads denote green (Bodipy-maleimide) 
and red (MRP8) co-localisation, with their distance (µm) from the cartilage edge denoted to the 
right. Scale bar denotes 50µm. TMP, TNF-α-treatment generated microparticles, MRP8, 
myeloid-related protein 8. 
  
249 
Furthermore, using high magnification confocal microscopy and acquiring a series of z-
stack slices through the 10µm cartilage section it was possible to image three 
chondrocytes in situ with multiple microparticles within the plasma membrane of the 
chondrocytes (Figure 4.4.9). It was also possible to see that the human Annexin A1 
was present within the cells localised to the plasma membrane. In the bottom row of 
photographs, a third chondrocyte appears to the right of the first two, and it is possible 
to see at least 7 intact microparticles within this cell.   
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When the data are combined into a max projection, it is possible to see around 40 
individual double-staining circular events within the three main grouped chondrocytes  
(Figure 4.4.10). This represents a very large transfer of protein (and other microparticle 
components) from one cell type to another, suggesting that the uptake of microparticles 
by chondrocytes is likely to have a profound effect on cell phenotype, protein repertoire 
and transcriptional and translational machinery. 
 
Together, these data show that microparticles penetrate more readily into damaged 
cartilage to deliver their content to the resident chondrocytes likely to initiate a program 
that prevents the loss of proteoglycans from the matrix induced by IL-1β treatment. 
These data are extremely interesting, as the current view is that the cartilage is 
penetrable only to small molecules present within the synovial fluid. Perhaps this is not 
the case, and proteins previously detected in arthritic cartilage (for example MRP8, 
(van Lent et al., 2008)) may be present in abundance due to the penetration of 
neutrophil microparticles. 
 
Figure 4.4.9 Multiple microparticles enter each chondrocyte. Rat femoral head cartilage was 
treated with IL-1β (50ng/ml) for 3 days before 100,000 Bodipy-maleimide -loaded TMP were 
added for 16 hours. Fixed femoral heads were sectioned and stained with monoclonal human 
Annexin A1 antibodies (red; which does not cross-react with rat tissue), wheat germ agglutinin 
(purple; WGA) and DAPI (blue) before confocal microscopy. Figure shows a serial montage 
produced from a 3D confocal z-stack project. Image processing was performed using ImageJ. 
Scale bar denotes 10µm, grey arrowheads denote microparticles. TMP, TNF-α-treatment 
generated microparticles; AnxA1, Annexin A1. 
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Figure 4.4.10 Microparticles enter cartilage native chondrocytes whole before being 
dismantled. Rat femoral head cartilage was treated with IL-1β (50ng/ml) for 3 days before 
100,000 Bodipy-maleimide -loaded TMP were added for 16 hours. Fixed femoral heads were 
sectioned and stained with monoclonal human Annexin A1 antibodies (red; which does not 
cross-react with rat tissue), wheat germ agglutinin (purple; WGA) and DAPI (blue) before 
confocal microscopy. Figure shows a max projection image from the 3D confocal z-stack project. 
Images 4-20 were used to reduce WGA background. Image processing was performed using 
ImageJ. Scale bar denotes 10µm, grey arrowheads denote double-positive microparticles, open 
arrowheads denote diffuse Annexin A1 staining. TMP, TNF-α-treatment generated 
microparticles. 
 
  
253 
 
 
 
 
 
 
 
 
CHAPTER 5: EXAMINING THE ROLE 
OF NEUTROPHIL MICROPARTICLES 
IN AN IN VIVO MODEL OF ARTHRITIS  
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5.1 Microparticles Protect Cartilage In Vivo 
 
As microparticles were found to penetrate cartilage matrix in ex vivo explants, and 
protected chondrocytes from IL-1β-induced proteoglycan loss, it was next assessed 
whether microparticle treatment could protect cartilage in mouse models of arthritis. 
Again, the cross-reactivity of human microparticles on rodent tissue was relied upon. 
 
5.1.1 Intravenous Microparticle Treatment During K/BxN 
Arthritis  
 
The K/BxN serum-transfer model of arthritis, which recapitulates the flare phase of 
human rheumatoid arthritis, is driven by the innate immune cells and displays early 
onset and high disease penetrance. In-house generated serum was employed, and 
arthritis experiments carried out using a previously established protocol (Patel, 2010). 
Mice were injected with 100µl serum on day 0 and day 2 and monitored for signs of 
arthritis over an 8-day period. All mice developed clinical signs of arthritis (swollen and 
red digits, pads, wrists or ankles; Figure 5.1.1A and B) with 100% incidence by day 3 
(Figure 5.1.1C). Hind paw volume was measured for each individual using water 
displacement plethysmometry, to determine the extent of swelling (Figure 5.1.1D). 
 
At the peak of arthritis (day 5) mice were treated with 100,000 human TMP 
intravenously. The clinical scores were similar between groups across the experiment 
(maximum score was 11 out of 12; Figure 5.1.1A) yet paw oedema was slightly higher 
in the TMP-treatment group, prior to microparticle treatment, but this difference was not 
statistically significant at the peak of disease on day 5 (110 ± 31.8 vs. 42.5 ± 18µl; 
Figure 5.1.1C). These subtle differences between groups before treatment reflects the 
variability of in vivo arthritis studies, even in mice received from the same suppliers and 
housed in the same room, under the same conditions.  
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Figure 5.1.1 Disease course of K/BxN serum-transfer arthritis with intravenous microparticle 
treatment. Eight-week old male C57BL6 mice were administered 100µl K/BxN serum 
intraperitoneally day 0 and day 2. Eight mice received intravenous saline (200µl) and 5 mice 
received 100,000 TMP (in 200µl saline) intravenously on day 5 (red arrows). Six naïve mice 
were used as control. (A) Clinical arthritis score. A swollen wrist, ankle, or any swollen digits on a 
limb receives a score of 1; a swollen wrist and ankle and any digit on a limb receives a score of 
3. All limb scores are combined to generate a score out of a possible 12. (B) Representative 
photographs of naïve and arthritic fore- and hind-paws, which would receive a score of 3. (C) 
Incidence of arthritis (a score >1). (D) Hind paw oedema volume as measured by water-
displacement plethysmometry. Data shown are mean ± SEM. TMP, TNF-α generated human 
microparticles. 
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Following intravenous administration of microparticles there was no significant 
improvement in the clinical score of the arthritic mice compared to vehicle. Intravenous 
microparticle treatment did not significantly reduce histological signs of inflammation in 
the knees compared to vehicle (1 ± 0.5 vs. 4.1 ± 1.4; Figure 5.1.2). This could be due 
to the number of microparticles, or that they were only administered once during the 
experiment, leading to sub-optimal numbers of microparticles reaching inflammatory 
sites.
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Figure 5.1.2 Intravenous administration of human microparticles had no effect in K/BxN 
arthritis. Eight-week old male C57BL6 mice were administered 100µl K/BxN serum 
intraperitoneally day 0 and day 2. Eight K/BxN mice received intravenous saline (200µl) and 5 
K/BxN mice received 100,000 TMP (in 200µl saline) intravenously on day 5. Six naïve mice 
were used as control. Knee joints were collected for histology on day 8. H&E sections were 
analysed and scored by two blinded scorers. Arthritis severity was scored over three parameters 
with a possible total score of 3 for each: immune cell infiltration, pannus formation and 
disruption of cartilage structure (0=none, 1=slight, 2=moderate, 3=severe). Data shown are 
mean ± SEM from at least 3 separate micrographs from each knee, not significant with One-way 
ANOVA and Bonferroni post-test. Below are representative micrographs at 4X magnification. 
TMP, TNF-α generated microparticles; BM, bone marrow; S, synovium; L, ligament; FP, fat pad; 
C, cartilage; GP, growth plate; PF, pannus formation.  
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5.1.2 Intra-Articular Administration of Microparticles 
Protects From In Vivo Arthritis Cartilage Damage 
 
Although intravenous administration of microparticles did not reduce histological signs 
of inflammation in the knees of K/BxN mice, the effect may have been diluted by 
systemic treatment. Instead, administration of microparticle treatment directly into the 
knee joint could reveal local effects, and may recapitulate the physiological 
environment in human rheumatoid arthritis, where neutrophils recruited locally to the 
joint would generate microparticles that act locally. Furthermore, this system was 
advantageous in that the contralateral knee joint could serve as an internal control for 
each individual mouse.  
 
Microparticles were administered intra-articularly on day 3 of a 5-day K/BxN arthritis, 
before the peak of disease. The anti-inflammatory effect of intra-articular microparticle 
injection (30,000 human TMP into K/BxN mice) could be observed in vivo in live mice 
by IVIS bioluminescence imaging (Figure 5.1.3). Luminol sodium salt injected intra-
peritoneally into mice 10 minutes before imaging is catalysed into a bioluminescent 
compound by extracellular neutrophil myeloperoxidase released by activated 
neutrophils upon degranulation. The representative images showed that naïve knees 
did not give any bioluminescent signal, whether injected intra-articularly with saline (0.8 
± 0.2 x104 photons/sec) or 30,000 TMP (0.2 ± 0 x104 photons/sec). Conversely, in 
arthritic mice discrete bioluminescent signals could be observed within the inflamed 
joints. In this case, bioluminescence was observed within both forepaws of each 
mouse, and in individual hind limb digits and/or ankles. In contrast, bioluminescence in 
the knees of K/BxN mice receiving 30,000 TMP (red arrowheads) were reduced 
compared to contralateral vehicle injected knees and release fewer photons per 
second (12.8 ± 5 vs. 31.8 ± 5.8 photons/sec P<0.01 with paired two-tailed t-test; black 
arrowheads). These data suggest local administration of TMP to arthritic joints protects 
cartilage from degradation and has potent anti-inflammatory affects by reducing 
neutrophil activation within the joint. 
  
258 
0
20
40
60 Vehicle
MP
Naive K/BxN
***
*
Ph
ot
on
s 
pe
r s
ec
on
d 
(x
10
4 )
Naïve  
K/BxN  
TMP 
Vehicle 
A B 
Figure 5.1.3 Live imaging indicates intra-articular administration of human microparticles 
locally protects from K/BxN serum-induced joint inflammation. Twelve-week old male C57BL6 
mice were administered 100µl K/BxN serum intraperitoneally day 0 and day 2. Five K/BxN mice 
and 3 naïve mice received intra-articular TMP (30,000 in 5µl, right knee) and vehicle (5µl 
saline, left knee) on day 3. On day 5 mice received luminol (200mg/kg, intraperitoneally) for 10 
minutes prior to bioluminescence imaging to visualize activated neutrophil myeloperoxidase 
activity. *P<0.05 and ***P<0.01 with Mixed Model Two-way ANOVA and Bonferroni post-test. 
Data shown are paired between each mouse. Right shows bioluminescence quantification 
images. Heat map denotes emission of photons per second. Burgundy arrowheads denote 
knees that received TMP injection, black arrowheads, vehicle injection. TMP, TNF-α generated 
human microparticles. 
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Two doses of microparticles were tested in the following experiment, 10,000 and 
30,000 TMP during the onset of arthritis (day 3 of 5 of arthritis). To ensure intra-
articular injections did not cause local inflammation, the knees of each mouse were 
measured using callipers throughout the experiment (Figure 5.1.4). Following intra-
articular injection on day 3, a transient but non-significant increase in width was 
observed across all groups the following day (day 4), which then returned back to knee 
widths similar to those observed on day 3 by the end-point of the experiment (day 5). 
Importantly, the knee widths of naïve mice injected with microparticles did not vary 
significantly from the contralateral knee receiving a sham injection of saline across the 
time-course (5.6 ± 0.1 vs. 5.7 ± 0.2mm at day 5; Figure 5.1.4A). Similarly, arthritic mice 
receiving either 10,000 (5.2 ± 0.2 vs. 5.3 ± 0.2mm) or 30,000 microparticles intra-
articularly (6.4 ± 0.2 vs. 6.5 ± 0.2mm) did not show any increase of knee width 
compared to the contralateral knees (Figure 5.1.4B and C). However the accuracy of 
calliper measurements was questionable, when visible differences in the knee widths 
could be observed between microparticle and sham-treated knees following post-
mortem skin resection (Figure 5.1.4D). Injection of 30,000 TMP into the right knee of 
naïve mice showed no alteration in post-mortem knee appearance compared to 
vehicle, but interestingly, it was evident that knees receiving 30,000 TMP in K/BxN 
arthritic mice were not as grossly swollen as those receiving vehicle injections; and had 
a more pronounced effect than 10,000 TMP.  
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Joint inflammation was also assessed histologically by staining with haematoxylin and 
eosin to measure cellular infiltrate pannus formation and cartilage integrity (Figure 
5.1.5). No significant alteration in the histological appearance of knees of naïve mice 
injected with TMP was observed compared to contralateral vehicle injected knees (1.5 
± 0.6 vs. 1.5 ± 0.6). In contrast, K/BxN mice receiving 30,000 TMP had significantly 
lower histological scores compared to contralateral vehicle injected knees (2.4 ± 0.9 vs. 
6.6 ± 0.7 P<0.01 with paired two-tailed t-test). 
 
Figure 5.1.4 Calliper measurements of K/BxN serum-transfer arthritis with intra-articular 
microparticle administration. Twelve-week old male C57BL6 mice were administered 100µl 
K/BxN serum intraperitoneally day 0 and day 2. Seventeen K/BxN mice and 9 naïve mice 
received intra-articular TMP (30,000 in 5µl, right knee) and vehicle (5µl saline, left knee); 5 
K/BxN mice received intra-articular TMP (10,000 in 5µl, right knee) and vehicle (5µl saline, left 
knee) on day 3 (coloured arrows). (A) Caliper measurements of naïve mice receiving TMP 
(30,000) and vehicle. (B) Calliper measurements of K/BxN mice receiving TMP (10,000) and 
vehicle. (C) Calliper measurements of K/BxN mice receiving TMP (30,000) and vehicle. (D) 
Representative photographs of knees following post-mortem skin resection, allowing 
visualisation of the extent of arthritic inflammation. Black bars highlight inflamed tissue 
margins. Data shown are mean ± SEM, not significant with matched Two-way ANOVA with 
Bonferroni post-test.  TMP, TNF-α generated human microparticles. 
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Figure 5.1.5 Intra-articular administration of human microparticles protects from K/BxN 
serum-induced joint inflammation. Twelve-week old male C57BL6 mice were administered 
100µl K/BxN serum intraperitoneally day 0 and day 2. Eleven K/BxN mice and 5 naïve mice 
received intra-articular TMP (30,000 in 5µl, right knee) and vehicle (5µl saline, left knee) on day 
3. Knee joints were collected for histology on day 5. H&E sections were analysed and scored by 
two blinded scorers. Arthritis severity was scored over three parameters with a possible total 
score of 3 for each: immune cell infiltration, pannus formation and disruption of cartilage 
structure (0=none, 1=slight, 2=moderate, 3=severe). Data shown are mean from at least 3 
separate micrographs from each knee, paired to contralateral joint in each mouse. Below are 
representative micrographs at 4X magnification. **P<0.01 using Mixed Model Two-way ANOVA 
with Bonferroni post-test. TMP, TNF-α generated human microparticles, BM, bone marrow; S, 
synovium; L, ligament; C, cartilage; GP, growth plate; PF, pannus formation. 
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Cartilage integrity was also assessed using toluidine blue. In naïve mice no change in 
proteoglycan content was noted with intra-articular injections of either TMP or vehicle 
(82.4 ± 4 vs. 81.1 ± 3.2%). In K/BxN mice receiving 30,000 TMP had significantly 
higher cartilage integrity as shown by percentage area Toluidine blue positive, 
compared to contralateral vehicle-injected controls (78.5 ± 3.1 vs. 55.1 ± 3.2% P<0.001 
with paired two-tailed t-test; Figure 5.1.6). This suggests that neutrophil microparticles, 
when injected locally into arthritic joints have both anti-inflammatory (i.e. reduce the 
recruitment of inflammatory cells and associated swelling and damage) and cartilage-
protective effects.  
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Figure 5.1.6 Intra-articular administration of human microparticles protects from K/BxN 
serum-induced cartilage extracellular matrix integrity loss. Twelve-week old male C57BL6 mice 
were administered 100µl K/BxN serum intraperitoneally day 0 and day 2. Eleven K/BxN mice 
and 5 naïve mice received intra-articular TMP (30,000 in 5µl, right knee) and vehicle (5µl 
saline, left knee) on day 3. Knee joints were collected for histology on day 5. Toluidine blue 
stained sections were analysed using ImageJ to determine extracellular matrix integrity. Data 
shown are percentage area of articular cartilage staining positively for Toluidine blue, quantified 
from at least six 20X magnification micrographs per section of 3 sections from each knee, 
paired to contralateral joint in each mouse. Below are representative micrographs at 4X and 
20X magnification. **<P<0.01 and ***P<0.001 using Mixed Model Two-way ANOVA with 
Bonferroni post-test. TMP, TNF-α generated human microparticles; ECM, extracellular matrix; 
BM, bone marrow; S, synovium; L, ligament; C, cartilage; GP, growth plate; PF, pannus 
formation. 
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To investigate the potential mechanism behind the chondroprotective effects observed 
with intra-articular injection of microparticles into arthritic mice, RNA was extracted 
from paraffin embedded sections and reverse transcribed for RT-PCR (Figure 5.1.7). 
Although no significant P values were obtained, 4 out of 5 K/BxN knee samples 
displayed an increase in Col2a1 expression compared to their contralateral vehicle-
injected knee. On the other hand, inflammation-associated genes often appeared 
somewhat elevated in TMP-treated knees at this time-point. 
 
Figure 5.1.7 Intra-articular administration of human microparticles modulates mRNA 
expression associated with K/BxN serum-induced arthritis. Twelve-week old male C57BL6 mice 
were administered 100µl K/BxN serum intraperitoneally day 0 and day 2. Five K/BxN mice and 
5 naïve mice received intra-articular TMP (30,000 in 5µl, right knee) and vehicle (5µl saline, left 
knee) on day 3. Knee joints were collected for histology on day 5. RNA was extracted from 
paraffin embedded sections using a commercially available kit before RT-PCR. Relative 
expression of pro-arthritic (A) Adamts5, (B) Il1b and (C) Mmp13 mRNA. Relative expression of 
pro-anabolic (D) Acan, (E) Col2a1 and (F) Sox9 mRNA. Data shown are 2-ΔΔCT with vehicle-
injected knee as calibrator and Rpl32 as housekeeping gene, and shown as median, 
interquartile range and range, not significant with Two-way ANOVA and Bonferroni post-test of 
logged data. TMP, TNF-α generated human microparticles. 
0.015625
0.03125
0.0625
0.125
0.25
0.5
1
2
4
8
16
Naive K/BxN
Vehicle
TMP
A
da
m
ts
5 
Ex
pr
es
si
on
 (2
-!
!
C
T )
0.03125
0.0625
0.125
0.25
0.5
1
2
4
8
16
32
Naive K/BxN
Vehicle
TMP
A
ca
n 
Ex
pr
es
si
on
 (2
-!
!
C
T )
0.25
0.5
1
2
4
8
16
Naive K/BxN
Vehicle
TMP
C
ol
2a
1 
Ex
pr
es
si
on
 (2
-!
!
C
T )
0.0625
0.125
0.25
0.5
1
2
4
8
Naive K/BxN
Vehicle
TMP
Il1
b 
Ex
pr
es
si
on
 (2
-!
!
C
T )
0.125
0.25
0.5
1
2
4
8
16
Naive K/BxN
Vehicle
TMP
M
m
p1
3 
Ex
pr
es
si
on
 (2
-!
!
C
T )
0.03125
0.0625
0.125
0.25
0.5
1
2
4
8
16
32
64
Naive K/BxN
So
x9
 E
xp
re
ss
io
n 
(2
-!
!
C
T )
A B 
D E 
C 
F 
0.015625
0.03125
0.0625
0.125
0.25
0.5
1
2
4
8
16
Naive K/BxN
Vehicle
TMP
A
da
m
ts
5 
Ex
pr
es
si
on
 (2
-!
!
C
T )
  
264 
In summary, administration of microparticles intra-articularly, but not systemically, can 
protect the cartilage during a model of inflammatory arthritis. This protection could be 
monitored in live mice using bioluminescence imaging, which detects inflammatory 
neutrophil activity and was reduced in the knees treated with microparticles. 
Furthermore, these microparticles exerted both anti-inflammatory and cartilage 
protective effects, as observed during histological analysis. Alterations in gene 
expression profiles were inconclusive and require further investigation. 
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5.1.3 Pharmacological Antagonism of Fpr2/3 Reduces the 
Chondroprotective and Anti-Inflammatory Efficacy of 
Neutrophil Microparticles in K/BxN Arthritis 
 
Next I sought to determine whether the in vivo protection delivered by neutrophil 
microparticles was mediated via Fpr2/3, as observed in both in vitro and ex vivo 
investigations. In order to achieve this, K/BxN mice received WRW4 (an Fpr2/3 specific 
inhibitor) intra-articularly together with TMP. A control group of mice received WRW4 
alone with contralateral injection of PBS to determine whether Fpr2/3 antagonism itself 
induced changes in inflammation and/or cartilage integrity.  
 
From examination of skin-resected knees it was possible to tell macroscopically that 
knees injected with TMP plus WRW4 had increased swelling compared to the 
contralateral knees injected with TMP alone. This loss in protection could also be 
observed microscopically using H&E staining (Figure 5.1.8).
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vehicle TMP vehicle 
 
TMP 
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Figure 5.1.8 Description of K/BxN serum-transfer arthritis with intra-articular microparticle 
administration with Fpr2/3 antagonism. Twelve-week old male C57BL6 mice were 
administered 100µl K/BxN serum intraperitoneally day 0 and day 2. Naïve mice received intra-
articular TMP (30,000 in 5µl, right knee) and vehicle (5µl saline, left knee); K/BxN mice 
received intra-articular TMP (30,000, left knee) and WRW4 (10µM) plus TMP (30,000 in 5µl, 
right knee); or TMP (30,000 in 5µl, right knee) and vehicle (5µl saline, left knee). 
Representative photographs of knees following post-mortem skin resection, allowing 
visualisation of the extent of arthritic inflammation. Black bars highlight inflamed tissue 
margins.  
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Paired analysis of histological sections indicated that administration of WRW4 to naïve 
mice did not induce changes in histological score compared to vehicle injection (5.5 ± 
2.5 vs. 4.5 ± 1.5). Administration of TMP significantly decreased clinical score 
compared with vehicle injection as observed previously, yet the microparticle anti-
inflammatory protection was lost upon co-administration of WRW4 (scores of 5.5 ± 1.3 
vs. 1.3 ± 0.4; Figure 5.1.9). 
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Figure 5.1.9 Pharmacological antagonism of Fpr2/3 with WRW4 blocks microparticle 
protection in K/BxN serum-induced joint inflammation. Twelve-week old male C57BL6 mice 
were administered 100µl K/BxN serum intraperitoneally day 0 and day 2. Six K/BxN mice 
received intra-articular WRW4 (10µM in 5µl) plus TMP (30,000, right knee) and TMP alone 
(30,000 in 5µl, left knee); 2 K/BxN mice received intra-articular WRW4 (10µM in 5 µl, right 
knee) and vehicle (5µl saline, left knee). These were compared to naïve and K/BxN mice that 
received TMP (30,000 in 5µl, right knee) and vehicle (5µl saline, left knee) on day 3 in a parallel 
experiment. Knee joints were collected for histology on day 5. H&E sections were analysed and 
scored by two blinded scorers. Arthritis severity was scored over three parameters with a 
possible total score of 3 for each: immune cell infiltration, pannus formation and disruption of 
cartilage structure (0=none, 1=slight, 2=moderate, 3=severe). Data shown are mean from at 
least 3 separate micrographs from each knee, paired to contralateral joint in each mouse. 
Below are representative micrographs at 4X magnification ***P<0.001 using Mixed Model 
ANOVA with Bonferroni post-tests. TMP, TNF-α generated human microparticles; BM, bone 
marrow; S, synovium; L, ligament; C, cartilage; GP, growth plate; PF, pannus formation. 
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Furthermore, antagonism of Fpr2/3 using co-administration of WRW4 with 
microparticles led to a significant decrease in proteoglycan staining by Toluidine blue 
compared to microparticle treatment alone (64.7 ± 3.8 vs. 82.6 ± 4.3 P<0.05 with 
paired two-tailed t-test; Figure 5.1.10).  
 
Together, these data suggest that both the anti-inflammatory effects of microparticles 
and the chondroprotective action of this treatment requires Fpr2/3.  
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Figure 5.1.10 Pharmacological antagonism of Fpr2/3 with WRW4 inhibits microparticle 
protection from K/BxN serum-induced cartilage extracellular matrix integrity loss. Twelve-week 
old male C57BL6 mice were administered 100µl K/BxN serum intraperitoneally day 0 and day 
2. Six K/BxN mice received intra-articular WRW4 (10µM in 5µl) plus TMP (30,000, right knee) 
and TMP alone (30,000 in 5µl, left knee); 2 K/BxN mice received intra-articular WRW4 (10µM in 
5 µl, right knee) and vehicle (5µl saline, left knee). These were compared to naïve and K/BxN 
mice that received TMP (30,000 in 5µl, right knee) and vehicle (5µl saline, left knee) on day 3 in 
a parallel experiment. Knee joints were collected for histology on day 5. Toluidine blue stained 
sections were analysed using ImageJ to determine extracellular matrix integrity. Data shown are 
percentage area of articular cartilage staining positively for Toluidine blue, quantified from at 
least six 20X magnification micrographs per section of 3 sections from each knee, paired to 
contralateral joint in each mouse. Below are representative micrographs at 4X and 20X 
magnification ***P<0.001 using Mixed Model ANOVA with Bonferroni post-tests. TMP, TNF-α 
generated human microparticles; ECM, extracellular matrix; BM, bone marrow; S, synovium; L, 
ligament; C, cartilage; GP, growth plate; PF, pannus formation. 
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5.1.4 Microparticles Do Not Protect Fpr2/3 Null Mice from 
K/BxN Arthritis 
 
For further characterisation of the requirement of the Fpr2/3 receptor in the 
microparticle-induced chondroprotection, K/BxN arthritogenic serum was administered 
to Fpr2/3 mice, that were then monitored for alterations in disease activity, cellular 
infiltration and cartilage integrity. Arthritis in Fpr2/3 mice reached 100% incidence by 
day 2 (Figure 5.1.11A). Weight loss was significantly greater than naïve Fpr2/3 null 
mice only by day 5 (-8.9 ± 1 vs. -0.5 ± 0.4% P<0.05 with Two-way ANOVA and 
Bonferroni post-test; Figure 5.1.11B) and clinical score was not different from wild type 
mice on day 5 (9.2 ± 0.7 vs. 10 ± 0.4; Figure 5.1.11C). Paw oedema was also not 
significantly different from naïve Fpr2/3 null mice (32 ± 9 vs. -6.7 ± 9.3µl) or wild type 
K/BxN arthritic mice on day 5 (32 ± 9 vs. 68.2 ± 13.5µl; Figure 5.1.11D). 
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Figure 5.1.11 Description of K/BxN serum-transfer arthritis in wild type and Fpr2/3 null mice 
with intra-articular microparticle administration. Twelve-week old male C57BL6 wild type and 
Fpr2/3-/- mice were administered 100µl K/BxN serum intraperitoneally day 0 and day 2 of 
arthritis. Five K/BxN Fpr2/3-/- mice and 3 naïve Fpr2/3-/- mice received intra-articular TMP 
(30,000 in 5µl, right knee) and vehicle (5µl saline, left knee) on day 3 (lilac arrows) and were 
compared to wild type mice receiving the same treatment in a parallel experiment. (A) Clinical 
arthritis score. A swollen wrist, ankle, or any swollen digits on a limb receives a score of 1; a 
swollen wrist and ankle and any digit on a limb receives a score of 3. All limb scores are 
combined to generate a score out of a possible 12. (B) Incidence of arthritis (a score >1). (C) 
Paw oedema as measured by water-displacement plethysmometry. (D) Weight change as 
percentage change from baseline over the course of the experiment.  Data shown are mean ± 
SEM. *P<0.05, **P<0.01 and ***P<0.001 vs. control of the same genotype using matched 
Two-way ANOVA with Bonferroni post-test. TMP, TNF-α generated human microparticles. 
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Caliper measurements were taken daily in naïve and arthritic Fpr2/3 null mice from day 
0 to day 5. Measurements were not significantly different between TMP-injected or 
sham-injected knees in either naïve (5.1 ± 0.1 vs. 5.8 ± 0mm) or K/BxN Fpr2/3 mice 
(6.9 ± 0.3 vs. 6.4 ± 0.2mm; Figure 5.1.12). Inspection of skin resected knees post-
mortem revealed no observable swelling in naïve mice. Following administration of 
K/BxN serum, significant swelling was observed as indicated by increased joint 
margins (black lines) yet no gross morphological differences were seen between 
vehicle and TMP treated knees. This suggests that microparticles do not provide any 
protection from macroscopic signs of inflammation in Fpr2/3 null mice. 
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Figure 5.1.12 Caliper measurements of K/BxN serum-transfer arthritis in Fpr2/3 null mice 
with intra-articular microparticle administration. Twelve-week old male C57BL6 wild type and 
Fpr2/3-/- mice were administered 100µl K/BxN serum intraperitoneally day 0 and day 2. Five 
K/BxN Fpr2/3-/- mice and 3 naïve Fpr2/3-/- mice received intra-articular TMP (30,000 in 5µl, 
right knee) and vehicle (5µl saline, left knee) on day 3 (red arrows). (A) Calliper measurements 
of naïve mice receiving TMP (30,000) and vehicle intra articular injections. (B) Calliper 
measurements of K/BxN mice receiving TMP (30,000) and vehicle. (C) Representative 
photographs of knees following post-mortem skin resection, allowing visualisation of the extent 
of arthritic inflammation. Black bars highlight inflamed tissue margins. Data shown are mean ± 
SEM, not significant with matched Two-way ANOVA and Bonferroni post-test.  TMP, TNF-α 
generated human microparticles. 
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Similarly, naïve mice showed no histological differences between vehicle and TMP 
injected knees (1.4 ± 0.6 vs. 1.1 ± 0.2). Microparticle treatment in Fpr2/3 null mice did 
not protect from serum-induced histological signs of inflammation (4.8 ± 1 vs. 4 ± 1.4, 
not significant with paired two-tailed t-test) compared to contralateral vehicle-injected 
knees (Figure 5.1.13). Therefore, the protection from inflammation afforded by 
microparticle treatment is lost in Fpr2/3 knockout mice. 
 
Figure 5.1.13 Intra-articular administration of human microparticles does not protect from 
K/BxN serum-induced joint inflammation in Fpr2/3 null mice. Twelve-week old male C57BL6 
wild type and Fpr2/3-/- mice were administered 100µl K/BxN serum intraperitoneally day 0 and 
day 2. Five K/BxN Fpr2/3-/- mice and 3 naïve Fpr2/3-/- mice received intra-articular TMP 
(30,000 in 5µl, right knee) and vehicle (5µl saline, left knee) on day 3 and were compared to 
wild type mice receiving the same treatment in a parallel experiment. Knee joints were collected 
for histology on day 5. H&E sections were analysed and scored by two blinded scorers. Arthritis 
severity was scored over three parameters with a possible total score of 3 for each: immune cell 
infiltration, pannus formation and disruption of cartilage structure (0=none, 1=slight, 
2=moderate, 3=severe). Data shown are mean from at least 3 separate micrographs from each 
knee, paired to contralateral joint in each mouse. Below are representative micrographs at 4X 
magnification. Not significant using Mixed Model ANOVA with Bonferroni post-tests. TMP, TNF-α 
generated human microparticles; BM, bone marrow; S, synovium; L, ligament; C, cartilage; GP, 
growth plate; PF, pannus formation; FP, fat pad. 
0
2
4
6
8
10
12
Vehicle
TMP
Naive K/BxN K/BxN
Wild Type
Naive
Vehicle
TMP
Fpr2/3 -/-
n.s.
Hi
st
ol
og
ic
al
 S
co
re
 /9
K/BxN (TMP) 
K/BxN (Vehicle) 
Naïve (TMP) 
Naïve (Vehicle) 
Fpr2/3 -/- 
S 
FP 
C 
L 
BM 
S C 
L 
BM 
S FP 
C 
L 
BM 
S 
PF 
C 
L 
BM 
  
272 
Similarly to wild type naïve mice, no measureable differences between TMP and 
vehicle injection were observed in naïve Fpr2/3 null mice (83.8 ± 3.7 vs. 82.6 ± 3.3%). 
Compared with wild type mice, which exhibit marked loss in proteoglycans following 
administration of K/BxN serum, arthritic Fpr2/3 null mice retained the majority of their 
proteoglycans as assessed by Toluidine blue staining (76.6 ± 3.5 vs. wild type vehicle 
injected knee 55 ± 3.2%), even with overt signs of inflammation both clinically, 
macroscopically and microscopically (Figure 5.1.14). Regardless, TMP treatment in 
Fpr2/3 null arthritic mice did not rescue this small loss in proteoglycans, no matter how 
small (70.1 ± 4.6 vs. 76.6 ± 3.5%).  
 
Figure 5.1.14 Intra-articular 
administration of human microparticles 
has no effect on extracellular matrix 
integrity in Fpr2/3 null mice. Twelve-week 
old male C57BL6 wild type and Fpr2/3-/- 
mice were administered 100µl K/BxN 
serum intraperitoneally day 0 and day 2. 
Five K/BxN Fpr2/3-/- mice and 3 naïve 
Fpr2/3-/- mice received intra-articular TMP 
(30,000 in 5µl, right knee) and vehicle 
(5µl saline, left knee) on day 3 and were 
compared to wild type mice receiving the 
same treatment in a parallel experiment. 
Knee joints were collected for histology on 
day 5. Toluidine blue stained sections 
were analysed using ImageJ to determine 
extracellular matrix integrity. Data shown 
are percentage area of articular cartilage 
staining positively for Toluidine blue, 
quantified from at least 6 20X 
magnification micrographs per section of 
3 sections from each knee, paired to 
contralateral joint in each mouse. Below 
are representative micrographs at 4X and 
20X magnification ***P<0.001 using 
Mixed Model ANOVA with Bonferroni post-
tests. TMP, TNF-α generated human 
microparticles; ECM, extracellular matrix; 
BM, bone marrow; S, synovium; L, 
ligament; C, cartilage; GP, growth plate; 
PF, pannus formation; FP, fat pad. 
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Taken together, these pharmacological and gene knockout data demonstrate that 
protection from cartilage loss induced by microparticles requires the expression of 
Fpr2/3. Paradoxically, Fpr2/3 null mice retained much of their proteoglycans compared 
to wild type mice. This discrepancy between genotypes cannot be accounted for at this 
time, and requires further assessment. 
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5.1.5 Labelled Neutrophils Infiltrate K/BxN Arthritic Joints 
and Release Microparticles that are Observed to be 
Abundant Within the Cartilage Matrix and 
Chondrocytes 
 
I needed to investigate whether microparticle penetration into the cartilage matrix is a 
phenomenon that occurs physiologically, as this could have important implications for 
the pathogenesis of rheumatoid arthritis and other cartilage-associated diseases such 
as osteoarthritis or injury. BODIPY-maleimide labelled mouse neutrophils were 
adoptively transferred into mice undergoing K/BxN arthritis on day 4, when disease 
was nearing its peak.  Neutrophils were isolated from donor mice via zymosan 
peritonitis recruitment and labelled with Bodipy-maleimide (2.5µM), prior to intravenous 
administration into the tail vein into recipient arthritic mice. On day 5, sections from 
joints were obtained by freezing in OCT medium and cutting using a cryostat with no 
prior decalcification to preserve tissue-resident fluorescence. 
 
Sections of wrists from naïve and arthritic mice were stained with anti-mouse 
monoclonal MRP-14 antibodies (red) and visualised with a confocal microscope. 
Surprisingly, the cartilage of wrists affected by K/BxN serum arthritis displayed 
abundant double-positive MRP14/Bodipy-maleimide puncta both on the surface of the 
cartilage, within the matrix, and contained within the chondrocytes (Figure 5.1.15). 
Microparticle double-fluorescence appeared to reach a certain depth before they 
accumulated but could not penetrate further; morphological inspection of this border 
appeared to be the tidemark where articular cartilage meets calcified cartilage; beyond 
which microparticles were unable to penetrate. Several chondrocytes contained more 
than one microparticle; others had diffuse staining of one fluorochrome or both, 
presumably where microparticle up-take had completed and the microparticle 
dismantled. In contrast, the wrist joint of naïve mice (the same joint visualised as in 
K/BxN mice) showed no positivity for MRP-14 or Bodipy-maleimide fluorescence 
indicating that the fluorescent neutrophils did not infiltrate the joint nor produce 
microparticles that entered the cartilage.  
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Figure 5.1.15 Adoptively transferred Bodipy-labelled neutrophils infiltrate arthritic joints and 
release microparticles that penetrate articular cartilage. Twelve-week old male C57BL6 mice 
were administered 100µl K/BxN serum intra peritoneally day 0 and day 2. Three K/BxN mice 
and 3 naïve mice received 1x106 Bodipy-maleimide-labelled mouse neutrophils intravenously 
on day 3 which had been isolated from peritoneal lavages of wild type donor mice administered 
1mg/mouse intraperitoneal zymosan from Saccharomyces for four hours. Wrist joints were 
collected into OCT cryo-embedding medium on day 5 and sections cut on a cryostat with no 
prior decalcification. Sections were stained with anti-mouse monoclonal MRP14 and DAPI prior 
to confocal microscopy. Grey dotted lines indicate opposing cartilage surface within the wrist, 
white arrows denote whole double-staining microparticles. Open arrows denote chondrocytes 
within lacunae containing microparticles. Scale bar denotes 20µm. Left-hand images are from a 
K/BxN mouse; right-hand images are from a naïve mouse receiving intravenous labelled 
neutrophils. C, cartilage, TM, tidemark. 
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In summation, the data generated during these in vivo experiments suggest that 
neutrophils generate microparticles following infiltration to the arthritic joint. The 
microparticles, rich in Annexin A1, penetrate the cartilage matrix and interact with 
Fpr2/3 to induce a cartilage-protective programme, which is especially effective in 
neutrophilic arthritis such as the K/BxN model.   
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CHAPTER 6: DISCUSSION OF 
RESULTS  
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The aim of this project was to determine the contribution of neutrophil microparticles to 
the pathogenesis of inflammatory arthritis, as they are abundant in RA synovial fluid. 
Previous reports have uncovered pro-inflammatory roles for microparticles of platelet 
(Boilard et al., 2010) and immune-cell origin (Distler et al., 2005a) in the context of 
animal models of RA. In contrast, microparticles of specifically neutrophil origin exert 
anti-inflammatory effects (Gasser and Schifferli, 2004, Dalli et al., 2008, Pliyev et al., 
2014, Eken et al., 2010). We found that microparticles of neutrophil origin induced a 
pro-anabolic phenotype in chondrocytes that were stimulated in vitro with 
proinflammatory cytokines relevant to RA (Figure 6.1). Microparticles increased ECM 
accumulation in chondrocyte micromasses in a dose-dependent manner and inhibited 
ECM release into the medium. Microparticle treatment up-regulated SOX9 transcription 
factor required for the expression of cartilage-associated genes; prevented 
chondrocyte apoptosis and abrogated the release of pro-inflammatory mediators such 
as IL-8, prostaglandin E2 and IL-6. The net effect of these events resulted in a pro-
anabolic, chondroprotective phenotype. We envisage a mechanism whereby 
neutrophils infiltrate the arthritic joint and become activated, whereupon they release 
microparticles, which can efficiently migrate into the cartilage and deliver a cargo of 
protein and lipids, which reprogram the chondrocyte into an apoptosis-resistant 
phenotype that produces ECM. For these effects we have shown that microparticle-
derived Annexin A1 and its receptor FPR2/ALX play a role in chondroprotection (Figure 
6.2).  
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Figure 6.1 Schematic: Microparticles generated from neutrophils protect from cartilage 
erosion. Neutrophils migrate to the inflamed joint and are activated by inflammatory cytokines. 
This leads to the release of microparticles, which can migrate into the cartilage, and interact 
with chondrocytes. Microparticle-associated Annexin A1 ligates FPR2/ALX on the chondrocytes 
eliciting a chondroprotective program. 
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The current dogma is that cartilage is an impenetrable, dense, avascular matrix 
through which metabolites from the synovial fluid must diffuse (La Rocca et al., 2013). 
These experiments provide the first evidence that microparticles are able to cross this 
barrier to deliver proteins that have functional effects on the chondrocytes. The 
communication of chondrocytes with other cell types has not been demonstrated within 
the cartilage before. Previous reports have detected myeloid related protein 8 (MRP8) 
in arthritic cartilage (van Lent et al., 2008), and it has been linked to cartilage 
degradation, but the source of this myeloid protein was not confirmed to be 
chondrocytes themselves. We propose that MRP8, which is highly expressed by 
neutrophil microparticles (Dalli et al., 2013) is transferred from neutrophils to 
chondrocytes via microparticles as demonstrated for Annexin A1. Indeed, application of 
TMP to mouse femoral head cultures yielded penetration into mid to deep-zone of the 
cartilage layers. In our confocal analyses both human Annexin A1 and MRP8 were 
identified within the chondrocyte, together with co-localised immunostaining in an 
apparent vesicular form, indicating that the microparticles may enter the chondrocyte in 
their entirety, and then release their content perhaps by fusion with cytosolic elements.  
Studies with endothelial cells have shown that platelet microparticles are avidly 
engulfed and remain intact for ≥15 minutes (Dasgupta et al., 2012).  
 
Previous reports have described the presence of several cytoskeletal proteins in 
neutrophil microparticles, a finding that can underlie their ability to locomote in 
response to stimulation (Dalli et al., 2013). Chondrocytes produce IL-8 in response to 
injurious stimuli and supernatants from stimulated chondrocytes are capable of 
inducing neutrophil chemoattraction, which can be blocked, at least in part, by anti-IL-8 
antibodies (Vaamonde-Garcia et al., 2012). Neutrophils are the primary target for IL-8, 
and they respond with chemotaxis, degranulation and up-regulation of adhesion 
molecules – classical markers of neutrophil activation (Scapini et al., 2010). Data here 
provide speculation that IL-8 or formylated proteins released from dying chondrocytes, 
perhaps in analogy with that reported for damaged liver (McDonald et al., 2010), may 
provide the chemotactic stimulus required for these microparticles to migrate into the 
damaged cartilage. The details of this mechanism remain of interest, and will need to 
be elucidated in future studies. In pathological settings, microparticles may be effective 
in transporting Annexin A1 to the chondrocytes in view of their ability to migrate (Dalli 
et al., 2013) and selective tissue-direction may be achieved via specific adhesion 
molecules. Indeed, neutrophil microparticles express β2 integrins, which are required 
for their anti-bacterial properties, along with αM and β3 integrins (Timar et al., 2013). 
Microparticles from other cell types have been shown to express integrins (Kapustin et 
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al., 2011), which could represent a common microparticle “homing” capability, allowing 
adhesion to specific cell types.  
 
The stimulant that induces the production of microparticles plays a significant role in 
shaping the proteome of the offspring microparticles, such that they may serve 
separate functions. Timar et al. (2013) demonstrated that neutrophils generate 
elevated levels of microparticles when stimulated with opsonised Staphylococcus 
aureus, compared to resting neutrophils, but only those generated by this specific 
opsonised-bacterial stimulus effected anti-microbial properties. Neutrophils stimulated 
with C5a or fMLP release microparticles that have differing efficacy at reducing IL-8 
production in LPS or zymosan-stimulated human macrophages (Gasser and Schifferli, 
2004). Neutrophils activated in suspension, or adherent to endothelial cell monolayers, 
produce microparticles with differential proteomes and exert different functions (Dalli et 
al., 2013). Here we demonstrate an enrichment of Annexin A1 in TNF-α- and IL-8-
derived neutrophil microparticles compared to those produced under resting conditions. 
Expression levels of ceruloplasmin, α2-macroglobulin and heat shock protein 70 were 
also altered whereas MRP8 and 14 remained unchanged. This fortifies the idea that 
microparticle phenotype is adjusted according to setting and that content loading is 
prioritized, so that net protein expression is not merely a function of microparticle size 
or number.  
 
Active content loading requires regulated actin and myosin cytoskeletal reorganisation, 
as microparticles produced under conditions of cytoskeletal destabilisation lost their 
protective qualities. Microparticles contain a 3D scaffold similar to that of their parent 
cells, the composition of which is not altered by agonist stimulation (Latham et al., 
2013, Bernimoulin et al., 2009). Data reported here show that neutrophil microparticles 
stain positively with phalloidin, demonstrating the presence of filamental actin. It is 
therefore not surprising that microparticle generation was heavily affected by drugs that 
interfere with F-actin polymerisation. The process of microparticle production and 
release (vesiculation) requires the dynamic coordination of cellular components for 
effective destabilisation of the plasma membrane. It has been observed that during 
microparticle formation in cerebral microvascular endothelial cells, there is dissolution 
of the cortical F-actin network, followed by prominent actin stress fibre formation, and 
redistribution of vinculin to the newly formed fibres (Latham et al., 2013). Consistent 
with these findings, data presented here show that treatment of neutrophils with 
jasplakinolide, which promotes actin polymerisation and stabilises actin filaments into 
an amorphous mass, inhibits microparticle release. In contrast, treatment with 
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cytochalasin D, a potent inhibitor of actin polymerisation, increasing the cellular 
membrane fluidity, which increases microparticle release. This increase in microparticle 
shedding was not accompanied by an increase in chondroprotective effects in co-
culture however. This suggests that regulated microparticle formation is reliant on the 
ability of actin to polymerise and depolymerise in a coordinated fashion. 
 
Disrupting the interaction of actin and myosin did not lead to alterations in the number 
of microparticles shed. Instead, this cytoskeletal machinery may play a role in the 
orchestrated packing of these microparticles with protective components, as 
microparticles produced under these conditions also lost their chondroprotective 
effects. In addition, microparticle release, along with many cellular processes, is 
calcium-dependent. Intracellular calcium chelation led to blockade of microparticle 
shedding. Similarly, neutrophils treated with the calcium chelator BAPTA-AM and 
cultured in transwells over micromasses did not protect chondrocytes from IL-1β-
induced damage. Together these data suggest that blockade of microparticle 
formation, or disrupting the cytoskeleton during vesiculation abrogates the protective 
ability of these structures, and that the neutrophils themselves are not innately 
chondroprotective.  
 
Annexin A1 was partially responsible for the chondroprotective effects seen in vitro. 
Although Annexin A1 did not reduce pro-inflammatory mediator release induced by IL-
1β or effectively enhance gene expression at a 6-hour time point, abundant 
extracellular matrix accumulation was observed in micromass culture. Annexin A1 
orchestrates the resolution of inflammation by terminating leukocyte recruitment to the 
site of inflammation, promoting neutrophil apoptosis and efferocytosis by resident 
macrophages, which favours cell phenotype switching, and activates tissue repair 
programmes as seen in the context of gut and eye epithelia (Ortega-Gomez et al., 
2013, Leoni et al., 2013). The effects of Annexin A1 treatment in chondrocytes have 
not been previously reported. 
 
Annexin A1 externalisation is mediated primarily by the ATP-binding cassette ABCA1, 
part of a large group of transporters with varied roles that include the externalization of 
proteins (Omer et al., 2006). Genetic deletion of ABCA1 reduces microparticle release 
(Combes et al., 2005). Therefore the Annexin A1 secretion process may occur 
predominantly within microparticles that are copiously released from activated 
neutrophils via the ABCA1 transporter. To exert its biological functions Annexin A1 
must bind to acid phospholipids in the presence of calcium cations to acquire the active 
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conformation with extrusion of the N-terminal region (Gerke et al., 2005). Thus 
microparticles, with their uneven segregation of phosphatidylserine on the outer leaflet 
(Freyssinet and Toti, 2010) and their dependence on calcium for shedding, may afford 
both of these fundamental requirements. Exposure of the pharmacophore N-terminal 
region of Annexin A1 would then allow interaction with its receptor FPR2/ALX (Bena et 
al., 2012a). In addition, the bivalent activity of annexins may support membrane fusion 
in the final stages of microparticle formation as they are released from the cell plasma 
membrane (Gerke et al., 2005, McNeil et al., 2006).  
 
Annexin A1 expression is up-regulated upon neutrophil transmigration (Damazo et al., 
2006), thus, neutrophil microparticles are enriched in Annexin A1 following stimulation 
and in the rheumatoid joint compared to paired plasma samples (manuscript in 
preparation). Annexin A1 lacks a signal peptide (Gerke et al., 2005) yet it is abundantly 
found in inflammatory exudates, including RA synovial fluids (Goulding et al., 1995). 
During models of inflammatory arthritis, such as K/BxN serum transfer, Annexin A1 
alone is not sufficient for protection from chondrolysis (Patel et al., 2012). Proteinase 3, 
released by neutrophils, limits the functionality of Annexin A1 by cleaving it at its N-
terminus, rendering it inactive (Vong et al., 2007). The packaging of Annexin A1 inside 
microparticles may preserve its functionality, making it cleavage resistant and 
increasing its potency, in analogy to alpha2-macroglobulin loaded microparticles. These 
microparticles exerted greater increases of survival during a caecal-ligation and 
puncture model of bacterial sepsis compared to the administration of soluble alpha2-
macroglobulin (Dalli et al., 2014). Furthermore, cleavage-resistant Super-Annexin 
inhibited joint inflammation and preserved the proteoglycan content of the cartilage in 
this experimental arthritis setting whereas soluble un-modified Annexin A1 treatment 
was similar to that of vehicle (Patel et al., 2012).       
 
The loading of microparticles with Annexins is calcium-dependent, and increasing 
concentrations of intracellular calcium recruits increasingly calcium-insensitive 
Annexins to the plasma membrane in order to protect cells from plasmalemmal injury 
by creating blebs and pinching off sections of damaged membrane (Potez et al., 2011). 
Annexin A6, possibly in analogy to Annexin A1 observed in neutrophil-derived 
microparticles, was expressed on both the outer and inner membrane of the 
microvesicles (Kapustin et al., 2011). This may account for the higher expression of 
Annexin A1 in IL-8 derived microparticles by flow cytometric analysis, which only 
detects surface-associated protein targets, but relatively lower concentrations of 
Annexin A1 by western blotting compared to TMP. Proportions of the vesicle-
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associated annexins however are not removed by treatment with EGTA suggesting a 
tight calcium-independent incorporation into the plasma membrane (Kapustin et al., 
2011), an interesting observation that requires further investigation.  
 
Microparticles bear antigens from their parent cells, allowing phenotypic measurements 
to be made about their parent cell origin (Ettelaie et al., 2013). The experiments herein 
have relied heavily upon this as a strategy for corroborating microparticle identity in 
microscopy analyses. The exposure of phosphatidylserine, a key process in 
microparticle formation, was also demonstrated (Gasser and Schifferli, 2004). 
Microparticles contained MRP8, which is unsurprising, as this protein makes up around 
40% of the total neutrophil cytosolic protein fraction (Edgeworth et al., 1991, Kerkhoff 
et al., 1999). Also demonstrated here was the expression of MRP8’s non-covalent 
binding partner, MRP14. Both of these proteins are present within the cytosol of 
neutrophils (and also circulating monocytes, but not tissue macrophages or 
lymphocytes), and associate with the cytoskeleton and plasma membrane upon 
increases in intracellular calcium (Roth et al., 1993), for example during microparticle 
shedding. Although several reports have demonstrated inflammatory roles of this 
heterodimeric protein pair, implicating it in the increased expression of complement 
component C3 (Schonthaler et al., 2013), vascular inflammation and atherosclerotic 
plaque formation (Croce et al., 2009) and exclusively bind arachidonic acid in human 
neutrophils (Kerkhoff et al., 1999), MRP8/MRP14 is nevertheless required for efficient 
chemoattractant-induced calcium signaling (McNeill et al., 2007) and the abundance of 
the heterodimer in the serum of healthy patients suggests that they do not necessarily 
play a constitutively active pathological role in health and disease (Vogl et al., 2004). 
The role of these proteins in RA requires further investigation, especially in terms of 
expression via microparticles. It is plausible that certain controls will be exerted at the 
level of the receptor, i.e. receptor expression can set in motion MRP8/14 activities, of 
which RAGE is one example (Nacken et al., 2004); along with TLR4 (Schelbergen et 
al., 2012). 
 
Other microparticle proteins may be contributing to the chondroprotective effects seen. 
Putative immunomodulatory proteins were found within the microparticles. Alpha2-
macroglobulin has in particular been harnessed by enriching in microparticles to 
improve the outcome in a mouse model of sepsis (Dalli et al., 2014). Alpha2-
macroglobulin is a tetrameric glycoprotein, which functions as a major anti-proteinase 
in the circulation. Alpha2-macroglobulin readily traps proteinases of all classes (serine, 
carboxyl, thiol, metallo-) including the proteinases released by granulocytes during 
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inflammation. In addition, alpha2-macroglobulin has major cytokine quenching abilities 
and changes its conformation upon protease exposure initiating high-affinity binding to 
several cytokines including TNF-α and IL-6, which are then cleared by endocytosis into 
hepatocytes, and IL-1β, whereby alpha2-macroglobulin directly inhibits its functions. In 
contrast, TGF-β may bind to either the native form, which stabilises TGF-β and 
increases its half-life in the exudate, or the fast (proteinase-cleaved) form of alpha2-
macroglobulin which is cleared by bystander cells. Furthermore, it functions as a 
scavenger of peptide mediators and defensins in inflamed tissues, contributing to 
inflammation containment. Relevant specifically to experiments performed herein, 
alpha2-macroglobulin has anti-apoptotic behaviour, regulated by the expression of the 
low-density lipoprotein receptor protein (LRP) (Rehman et al., 2013).   
 
Chondrocytes express LRP-1, and the major ligand for this receptor, lactoferrin, has 
reportedly pro-proliferative effect in chondrocytes comparable to TGFβ (Brandl et al., 
2010). Lactoferrin is abundant in neutrophil microparticles (Timar et al., 2013, Dalli et 
al., 2013). Although the expression of microparticle lactoferrin was not explored here, 
its effects on C28/I2 chondrocyte micromasses was assessed. Lactoferrin is an iron-
chelating glycoprotein stored in the secondary granules and released upon neutrophil 
stimulation. Levels are elevated in the rheumatoid synovial fluid, to around 10µg/ml, 
compared with 0.2 to 0.6µg/ml in the circulation and correlate with CRP and disease 
severity (Wong et al., 2009). Lactoferrin is thought to have anti-inflammatory properties 
due to its iron sequestering abilities: iron accumulates within the rheumatoid synovium 
and acts in the conversion of hydrogen peroxide and superoxide into damaging 
hydroxyl radicals via the Fenton/Haber Weiss reaction (the reduction of ferric to ferrous 
iron by superoxide which feeds into the Fenton reaction producing ferric iron plus 
hydroxyl radicals and hydroxide (Haber and Weiss, 1932)). Chelation of iron could 
therefore remove a source of reactive oxygen intermediates (Wong et al., 2009) and 
could be an explanation for the reduced inflammation observed following intra-articular 
injection of lactoferrin into the joints of mice undergoing experimental septic and 
collagen induced arthritis (Guillen et al., 2000). However, lactoferrin also extends the 
lifespan of neutrophils (at concentrations of 50 and 100µg/ml), and depletion of 
lactoferrin within the synovial fluid reduces synovial fluid neutrophil lifespan (Wong et 
al., 2009). Furthermore, lactoferrin has been shown to induce the expression of matrix 
metalloproteinases in a mechanism thought to be necessary for the degradation of 
damaged tissue followed by the proliferation of chondrocytes for reconstruction (Brandl 
et al., 2010). The proliferative effects of lactoferrin were not observed in chondrocytes, 
and co-culture of chondrocyte micromasses with lactoferrin did not rescue IL-1β-
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induced matrix degradation, possibly consistent with matrix metalloproteinase up-
regulation. It would be interesting to explore whether lactoferrin prevented chondrocyte 
apoptosis in this setting, however. 
 
Microparticle treatment induced chondroprotection that could be partially blocked with 
TGFβ neutralizing antibodies or by coating the microparticles with an excess of 
Annexin V to bind exposed phosphatidylserine. Both of these effects have been 
reported previously (Gasser and Schifferli, 2004), and may constitute a generic anti-
inflammatory effect of neutrophil derived microparticles. TGFβ1 is a multifunctional 
growth factor that exerts pleiotropic effects in chondrocytes, which includes the 
stimulation of type II collagen and aggrecan synthesis (Morales and Roberts, 1988, 
Redini et al., 1988, Rosier et al., 1989, Shuler et al., 2000). TGF-β1 was increased in 
micromasses treated with microparticles alone without IL-1β, even though there was no 
associated increase in matrix accumulation. Cells produce TGFβ as a homodimer, 
which binds the latency-associated protein to confer protection and modulate its 
reactivity (Rossol et al., 2011, Shi et al., 2014). This latency-associated protein (LAP) is 
removed in vivo in inflammatory settings by proteases, reactive oxygen species or in 
low pH milieu. The cytokine bead array requires the removal of the LAP by acidification 
of sample supernatants, thus, the total TGFβ1 concentration is assayed, including both 
latent and active protein. It is possible therefore that in resting chondrocytes, 
microparticle treatment induces the production of TGFβ1, but matrix accumulation is 
not altered as the proteases required for activation of the growth factor are only 
minimally produced compared to IL-1β stimulation. Testing this hypothesis was 
attempted, by performing western blotting on the supernatants (both with and without 
spin-column concentration) and probing for dimerised LAP, but unfortunately the 
protein levels were below the limit of detection.  
 
Analyses with Fpr2/3-/- mice and cartilage explant cultures, together with experiments 
conducted with selective antagonists, indicated unequivocal requirement of the 
receptor for the chondroprotection afforded by microparticles. The data produced with 
Annexin A1 null neutrophil microparticles provide further support to this mechanism. 
Although Annexin A1 was the major determinant in the microparticle 
chondroprotection, residual anti-catabolic effects were observed. Contributing effects of 
other vesicle components, from precursors of bioactive lipids (Norling et al., 2011, Dalli 
and Serhan, 2012) to microRNA (Bolukbasi et al., 2012), therefore cannot be excluded. 
In addition, neutrophil microparticles were protective during K/BxN serum transfer 
arthritis but this protection was not apparent in Fpr2/3 null mice. Interestingly, Fpr2/3 
  
288 
knockout mice were observed to retain more of their sulphated glycosaminoglycan 
content compared to wild type arthritic mice. How Fpr2/3 is involved in the regulation of 
matrix depletion in vivo is not known, however, as it is a receptor known to bind a 
variety of protein and non-protein ligands, including SAA, lipoxin A4 and Resolvin D1 
(Ye et al., 2009), and has opposing inflammatory and anti-inflammatory functions, it is 
possible that as-of-yet-unappreciated GPCR associated pathways may contribute to 
the anabolic phenotype encountered. Furthermore, the pro-anabolic effects seen 
during treatment of resting human chondrocyte micromasses with Annexin A1 appears 
to be FPR1 mediated. This could indicate that Annexin A1 is cleaved by proteinases 
within the chondrocyte supernatant allowing binding to the FPR1 receptor (Hayhoe et 
al., 2006). The biological effects of the N-terminal cleavage peptide, Ac2-26, warrants 
investigation. This may also account for some of the differential effects between 
microparticle and Annexin A1 treatment, where packaging inside microparticles may 
prevent Annexin A1 cleavage. This could be tested by treatment of microparticles or 
Annexin A1 in parallel, with different proteases and assessing the product size by 
western blotting.  
 
Downstream of FPR2/ALX receptor ligation is the activation of ERK1/2 phosphorylation 
and conformational changes of the receptor allowing association with G0, G2 and Gαi6 
proteins leading to receptor desensitization and recycling; interaction with Gαii, Gαi2 
and Gαi3 leads to intracellular calcium flux, activation of phospholipase A2 and the PI3K 
and MAPK pathways (Bena et al., 2012a). In myeloid cells, this receptor is responsible 
for chemokinesis, yet in non-myeloid cells its effects are not fully understood. The 
transcriptional targets of FPR2/ALX include SGPP2, JAG1, JAM3, IKBK and SP1 
(Renshaw et al., 2010), of which only SGPP2 was modulated by microparticle 
treatment in chondrocytes. GPCR signaling is also made more complex by the 
propensity for receptors to hetero and homodimerise. Recently, the signaling pathway 
downstream of FPR2/ALX homodimerisation was characterized. Cooray et al. (2013) 
showed that upon FPR2/ALX homodimerisation, and following ligation of lipoxin A4, 
Annexin A1 or its N-terminal derived anti-inflammatory peptide Ac2-26, p38 is 
phosphorylated leading to the phosphorylation of MAPKAPK2. This in turn 
phosphorylates Hsp27 leading to IL-10 production, to drive the resolution of 
inflammation. Chondrocytes do not produce IL-10, and is likely to have other 
intracellular signalling machinery, thus a panel of signaling molecules were probed for 
activation.  
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Microparticle treatment directly inhibited Hsp27 phosphorylation, which acts to reduce 
large Hsp27 oligomers (which can be as large as 700kDa, forming 24mers) into dimers 
and monomers, where they function to stabilize the mRNA of unstable inflammatory 
cytokines, such as IL-8, IL-6 and TNF-α (Lambrecht et al., 2010, Jones et al., 2009, 
Alford et al., 2007). Concurrently, reduced production of prostaglandin E2, IL-8 and IL-6 
was observed in microparticle co-culture with IL-1β-stimulated chondrocytes. 
Regulation of mRNA stability by phosphorylated Hsp27 is mediated by the 3’ 
untranslated region of the target mRNA. Hsp27 target mRNAs (for genes such COX-2, 
TNF-α, GM-CSF, IL-8 and IL-6) contain a repeating pentamer sequence AUUUA 
(known as AU-rich elements, or AREs) that dictates stability or instability and 
characterizes this class of unstable cytokine mRNA species. The stability of mRNAs in 
microparticle/chondrocyte co-culture could be assessed by stimulating the 
chondrocytes with IL-1β plus microparticles whilst inhibiting protein synthesis using 
actinomycin D, then sampling over a time course to determine if microparticle 
treatment increases mRNA degradation. Investigations into how the microparticles 
inhibit Hsp-27 phosphorylation would be important, as the destabilisation of 
inflammation associated gene mRNA could prove a valuable target in the treatment of 
human disease. 
 
Microparticle detection and measurement analyses were optimised extensively to 
ensure robust data collection. Classical flow cytometric analysis was modified to help 
discriminate microparticle populations from electronic noise generated within the 
machines by analysing the side-scatter information rather than forward scatter 
information traditionally used for relative cell size. This method allowed for the more 
accurate detection of 500nm beads, and could be used to determine the positivity of 
microparticles for the expression of proteins and externalisation of phosphatidylserine. 
However, multiple detection analyses were used to corroborate microparticle size, 
including nanoparticle tracking analysis and analyses with the ImagestreamX mk. II 
imaging cytometer. Using these techniques it was found that microparticles at a range 
of sizes could be detected, but only ImagestreamX analysis allowed the simultaneous 
detection of larger (≥1µm) and smaller (approximately 100nm) microparticle 
populations and parent cells. With this technology, microparticle kinetics could be 
measured for the first time. 
 
The real-time temporal kinetics of microparticle production has not been reported for 
neutrophils. Static measurements of microparticle number have been made, for 
example using aliquots of cerebral vascular endothelial cell line supernatant taken and 
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tested by flow cytometry (Latham et al., 2013) or by spectrophotometric analysis of the 
supernatants of adherent glial cells stimulated with an ATP mimetic (Bianco et al., 
2009). During glial cell culture, stimulation with ATP induced a plateau of microparticle 
production after 20 minutes, and with time-lapse microscopy, microparticle shedding 
could be observed (but not quantified) 1-2 minutes after stimulation (Bianco et al., 
2009). Reported here, time-lapse fluorescent microscopy over a period of 10 minutes 
was corroborated with ImageStreamX analysis whereby freshly isolated neutrophils in 
suspension were stimulated with TNF-α and microparticle generation was analysed 
real-time over 45 minutes. Although a plateau in microparticle production was not 
reached over this time-point, the limiting factor of data collection was the file sizes 
generated during such an experiment. However, this assay could be translated to 
explore the real-time kinetics of microparticle generation in combination with 
cytoskeletal inhibitors, such as those used in single time-point experiments.  
 
Using these techniques, in combination, allowed several new observations to be made 
about microparticles. Firstly, the number of microparticles generated from 98% pure 
neutrophil populations following stimulation increased compared to resting cells from 
the same donor. TNF-α stimulation induced double the amount of microparticle 
shedding, but counts were approximately another two-fold greater using flow cytometry 
compared to ImageStreamX analysis. This could be for two main reasons: firstly, the 
ImageStreamX analyser uses high-accuracy syringe-driven fluidics rather than vacuum 
driven fluidics that are prone to bubble formation, affecting analysis. Second, each of 
the gates used for microparticle detection can be interrogated by eye to ensure they 
contain only microparticles, whereas the event signals generated using flow cytometry 
cannot be corroborated visually. Together, even though approximately 95% of events 
are measured using the ImageStreamX, it is likely that these counts are more robust 
than the noise-prone flow cytometry data. Nanoparticle tracking analysis also revealed 
double the number of microparticles were present in TMP samples compared to CMP, 
and interpolating these data showed that for every 1 million resting neutrophils, around 
2.5 million microparticles were generated basally and this rose to 4.195 million 
microparticles per million neutrophils upon stimulation with TNF-α. Although this 
analysis completely excludes microparticles 1µm in size and larger, it accurately 
enumerates microparticles lower than this size. Overall, a putative lower biological limit 
for microparticle size can only be measured using this technology, and appears to be 
50nm in the TMP sample analysed by NTA, where only 3.5% of the TMP population fell 
below 50nm. These smaller microparticles fall below the resolution of light 
microscopes, and it is therefore only possible to measure the entire population of 
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microparticles with transmission electron microscopy, which is low through-put and in 
itself prone to artefacts in the sample processing. 
 
This is the first report of the presence of the receptor FPR2/ALX, together with the 
cognate receptor FPR1, in chondrocytes. FPR1 expression was augmented by 
catabolic stimulation.  Annexin A1 was also expressed in human chondrocytes but not 
modulated in our experimental settings. Previous reports showed FPR2 mRNA and 
protein expression is increased in the joints of K/BxN arthritic mice compared to naïve 
mice, and could be visualised within the articular cartilage (Patel et al., 2012). We 
observed no alterations in the levels of FPR2 or FPR1 gene transcripts during 
stimulation of human chondrocytes in vitro with IL-1β for 6 hours; yet at 24 hours, 
FPR1 was up-regulated. The expression of GPCRs, such as those recognising formyl-
methionine terminated peptides are known to be regulated at a number of levels, 
including modulation of receptor function, subcellular localisation and gene expression. 
FPR1 mRNA exhibits constitutive instability and has a half-life in resting conditions of 
60 to 90 minutes. This allows the cells to rapidly modulate receptor expression by 
controlling transcript abundance via stabilisation (Mandal et al., 2005). Regulation of 
FPR2/ALX expression in non-immune cells, on the other hand, is not well understood. 
Synovial fibroblasts, when stimulated with TNF-α or IL-1β, up-regulate their FPR2 
mRNA expression, whereas only a modest increase was observed in IL-1β-stimulated 
enterocytes (Waechter et al., 2012). Hence, the lack of alteration of mRNA levels 
reported here might be due to a non-optimal time-point being investigated. 
 
The murine FPR gene family is made up of at least 8 members, whereas humans 
express only 3 (termed FPR1, FPR2/ALX and FPR3). Both murine Fpr2 and Fpr3 
genes share the lipoxin A4 binding capacity of human FPR2/ALX (Ye et al., 2009, He et 
al., 2013) and knockout of both of these genes was achieved by inserting the gene 
cassette (and GFP reporter) in reverse orientation into intron 1 of Fpr2 thus preventing 
transcriptional read-through of both Fpr2 and Fpr3 genes (Dufton et al., 2010). These 
mice have been reported to display some degree of exacerbation of K/BxN arthritis 
(Dufton et al., 2010), which was not replicated fully here. This is probably due to the 
small number of mice used, and variation between the batches of K/BxN serum used. 
The scoring system employed used both in vivo and employed during histology 
analyses does not encapsulate the extent of inflammation once pannus formation or 
oedema is present; the pannus formation in the Fpr2/3 null mice far exceeded the 
severity of wild type mice for example, but as infiltration was present in both, the score 
ceiling was reached. Digestion of the paws and flow cytometric analysis between the 
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two groups could yield much more detailed analysis of the activation status and identity 
of the infiltrating cells. Fpr2/3 null mice did not reveal any improvement of cartilage 
integrity upon microparticle treatment compared to vehicle-injected knees. This 
supports experiments performed in vitro and ex vivo with either pharmacological 
inhibition or genetic deletion. Curiously, Fpr2/3 mice retained more proteoglycan 
content overall compared to wild type mice. This warrants further exploration. We plan 
to see whether Fpr2/3 nullification during osteoarthritis models, such as the 
destabilization of the medial meniscus (DMM) to exclude an overtly inflammatory 
component to the protection observed in these experiments.  
 
The transcriptional targets after FPR2/ALX ligation were monitored for modulation by 
RT-PCR. Although the mRNA for the receptor itself was not drastically altered, the 
down-regulation of SGPP2 mRNA was observed in co-cultures. This gene encodes 
sphingosine-1-phosphate phosphatase type 2, and is highly up-regulated in a number 
of cell types in response to inflammatory stimuli (Mechtcheriakova et al., 2007). SGPP2 
functions to cleave sphingosine 1 phosphate, a bioactive lipid able to counteract the 
effects of IL-1β in chondrocyte co-culture (Stradner et al., 2014, Stradner et al., 2013, 
Moon et al., 2012, Stradner et al., 2008) and dose-dependently inhibits IL-1β-induced 
NF-κB p65, COX2, MMP-1, -3, -13 and -14 mRNA expression, prostaglandin E2 
synthesis and glycosaminoglycan degradation (Moon et al., 2012).  
 
Microparticles modulated the production of Prostaglandin E2 in micromass cultures. At 
lower concentrations of IL-1β stimulus, microparticles increased the level of 
Prostaglandin E2 synthesis, which may be helpful in the turnover of cartilage matrix (Li 
et al., 2009). At higher levels of IL-1β, microparticles were able to reduce the 
Prostaglandin E2 levels to similar concentrations as those seen in the low dose IL-1β 
stimulation. IL-8-derived microparticles were the least efficient at reducing 
Prostaglandin E2, and this reflects possible different functions of this subset of 
microparticles. Prostaglandin E2 is increased in osteoarthritis, but unlike other pro-
inflammatory or catabolic stimuli, it can reverse aggrecan degradation induced by IL-1β 
and stimulate gene expression of type II collagen (Sun et al., 2011). It has been 
reported that the effects exerted by Prostaglandin E2 in cartilage is very much 
concentration dependent. Low concentrations of Prostaglandin E2 induce anabolic 
gene expression such as type II collagen and aggrecan and aids in matrix deposition 
(Nedelec et al., 2001, Saklatvala, 1986). High concentrations however act as a strong 
catabolic stimulus and induce the cells of the joint to express MMPs and ADAMTSs (Li 
et al., 2009). This may be why an up-regulation of Prostaglandin E2 in micromasses 
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treated with both IL-1β (3ng/ml) and microparticles is observed in conjunction with 
increased matrix deposition. This is in contrast with observations in micromasses 
treated with high levels of IL-1β (30ng/ml) where much higher levels of Prostaglandin 
E2 are generated – and addition of microparticles to these cultures significantly 
decreases the amount of Prostaglandin E2 produced. Combined, these data suggest 
microparticles play a modulatory role on the production of Prostaglandin E2 by 
chondrocytes. The microparticles themselves may also contribute to a shift in lipid 
mediators in this model by donation of bioactive lipid precursors (Dalli and Serhan, 
2012). Indeed, the exogenous addition of Resolvin D1 protected chondrocytes in 
micromass culture from IL-1β-induced matrix degradation. 
 
The cause of Scott syndrome, a rare bleeding disorder characterised by a reduced 
number of microparticles and phosphatidylserine exposure has recently been 
elucidated. Missense mutations in the putative scramblase TMEM16F prevent 
phosphatidylserine exposure and subsequently microparticle shedding in red blood 
cells, platelets and lymphocytes. The microparticle shedding of other cell types are 
likely to be affected too (Bevers et al., 1992, Kunzelmann et al., 2014). Supporting this, 
TMEM16F deficient mice have impaired osteoblast mineralisation resulting in reduced 
skeletal development (Kunzelmann et al., 2014). Ehlen et al. (2013) described skeletal 
abnormalities associated with absent phosphatidylserine exposure in TMEM16F null 
mice: hypertrophic chondrocytes present within the deep zones of the cartilage release 
vesicular structures, which serve as an initial nucleation site for mineral formation 
during embryogenesis. These matrix vesicles are derived from the phospholipid bilayer 
in a similar manner to microparticles and once released into the extracellular matrix, 
accumulate calcium and inorganic phosphate. The transformation from the amorphous 
to crystalline phase requires the formation of a nucleation complex involving a 
phosphatidylserine-associated pool of calcium, phosphate and annexins (Balcerzak et 
al., 2008), which leads to the formation of hydroxyapatite during bone formation. It is 
therefore possible that TMEM16F null mice lack the capability of releasing 
microparticles from a variety of cell types, in addition to platelets and red blood cells. 
 
The calcifying properties of microparticles have been described and play pathological 
roles in atherosclerosis (Kapustin et al., 2011, New et al., 2013). In the atherosclerotic 
plaque, vascular smooth muscle cells acquire chondrogenic and osteoblastic 
phenotypic features and enhance mineral deposition inappropriately to enhance arterial 
stiffening via increases in extracellular calcium. These microparticles share phenotypic 
characteristics of the microvesicles released by chondrocytes during osteogenesis. 
  
294 
They carry similar cargo of Annexin A2, A5 and A6 and seem associated with collagen 
fibrils in patients with various levels of calcification in vessels. It is possible that 
microparticles have a generic set of roles as a function of their size, calcium-
dependence and exposure of phosphatidylserine, which, in settings such as 
atherosclerosis have deleterious effects, whereas in cartilage and at the interface with 
calcified bone, are required for normal physiology.   
 
The induction of SOX9 protein and mRNA during microparticle coculture was 
unexpected. ECM production is governed by the transcription factor SOX9, which 
directly drives the expression of type II collagen and aggrecan, the two most abundant 
cartilage proteins (Bi et al., 1999). SOX9 expression has also been shown to limit 
chondrocyte apoptosis through binding to the Pik3ca subunit of PI3K (Ikegami et al., 
2011). SOX9 is a close relative of the sex-determining region Y protein (SRY) and is 
up-regulated in the repair phase in adult cartilage following fracture and precedes type 
II collagen expression (Sakano et al., 1999). Huang et al. (2000) demonstrated that 
phosphorylation of SOX9 enhances its ability to transactivate type II collagen. It is 
therefore possible that the increased molecular weight SOX9 bands observed in 
microparticle-micromass co-culture represent phosphorylated SOX9, accounting for 
increased extracellular matrix accumulation.  
 
Although the chronic erosive progression of RA is recognised, acute inflammatory 
events, known as flares, also contribute to the presentation of the disease. The flare 
process within the synovial fluid encompasses local production of chemokines and 
cytokines with chemoattractive properties, as well as inflammatory mediators such as 
leukotriene B4 and products of complement activation, which work in concert to attract 
massive amounts of neutrophils to the synovial fluid. These same agents stimulate the 
post capillary endothelium to become efficient at binding circulating cells. In addition, 
vasoactive mediators such as histamine, produced by mast cells, and prostaglandin E2, 
facilitate extravasation of inflammatory cells into the synovial fluid. This phase of the 
disease adds a reiterative dimension to the chronic, underlying inflammation, with 
successive events stimulating progressive amplification of inflammation (Lipskey, 
2008). Neutrophils produce a variety of matrix metalloproteinases during this phase, as 
well as further cytokines following phagocytosis of immune complexes within the joint, 
which contribute to the pathogenesis of the disease (Cassatella et al., 1997, 
Cassatella, 1995, Quayle et al., 1995, Quayle et al., 1994).  
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The involvement of neutrophils in the pathogenesis of various autoimmune diseases is 
well delineated. Depletion of neutrophils by Ly6G (1A8) antibody treatment in a mouse 
model of multiple sclerosis (experimental autoimmune encephalomyelitis, EAE) 
attenuated preclinical central nervous system inflammation and abrogated the 
development of EAE. Administration on Ly6G antibody after the clinical onset of EAE 
had no effect on disease incidence or severity suggesting that the contribution of 
neutrophils is to the onset of EAE. Furthermore, it was observed that the CNS-derived 
neutrophils mediated APC maturation in part by the production of reactive oxygen 
species (Steinbach et al., 2013). Therapeutic adsorptive granulocyte apheresis 
(selective depletion of cells expressing Fcγ, therefore including monocytes) in patients 
refractive to traditional treatments for generalised pustular psoriasis saw an 
improvement in area of erythroderma, pustules and oedema (Ikeda et al., 2013). 
Neutrophil depletion, again using the specific Ly6G antibody, in experimental 
epidermolysis bullosa yielded significantly lower titers of autoantibodies compared with 
isotype controls (Samavedam et al., 2014).  
 
The role of neutrophils in arthritis has been historically overlooked, but more recent 
evidence is accumulating, implicating neutrophils in the initiation and progression of 
inflammatory arthritis in animal models. The molecular pathology of human rheumatoid 
arthritis shows strong neutrophil involvement: neutrophils are present within the 
synovial fluid and lining, and neutrophil-derived products can be found in joint tissues. 
Primed or activated neutrophils (as compared to circulating neutrophils) have an 
extended lifespan, synthesise inflammatory mediators and are capable of presenting 
antigen to T cells (Cross et al., 2003), and therefore have the ability to actively drive 
inflammatory processes (Wright et al., 2010). Expression of MHC II and co-stimulatory 
molecules (CD80 and CD86) on synovial neutrophils is equivalent to or greater than 
monocyte and B cell expression levels (Sandilands et al., 2005) and can be expressed 
rapidly during in vitro stimulation (Sandilands et al., 2006). Furthermore, neutrophils 
have been shown to synthesise and secrete IL-8 in response to TNF-α stimulation, 
(Fujishima et al., 1993) increasing neutrophil recruitment to the joint. Activated 
neutrophils also produce IL-1, IL-6, IL-12, TGF-β, TNF-α, oncostatin M and B-
lymphocyte stimulator (BLyS) (Cross et al., 2003, Scapini et al., 2005, Scapini et al., 
2008), thus contributing to the increased local inflammatory milieu within the 
rheumatoid joint. 
 
Depletion of neutrophils in models of experimental arthritis attenuates inflammation. 
Elevated levels of G-CSF, important for basal and inflammatory granulopoiesis, have 
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been detected in RA synovial fluid and serum, and levels correlated with disease 
activity and severity (Nakamura et al., 2000). Depletion of Gr-1 positive cells (mainly 
neutrophils but also subsets of monocytes, CD8+ T cells and plasmacytoid dendritic 
cells) reduced the clinical score of CIA mice down to 0.5, compared with isotype 
treated mice who retained a clinical score of >4. This was confirmed using the Ly6G 
(1A8) antibody, to selectively deplete neutrophils, and the score was also reduced 
compared to isotype, but not to the same extent (Eyles et al., 2008). Neutrophil 
elastase has been shown to degrade articular cartilage directly in in vitro assays 
(Moore et al., 1999). It is clear that neutrophils play important pathogenic roles in 
rheumatoid arthritis, but many of the reports on neutrophil function in RA models are of 
the overall inflammatory component of this disease. Focussing uniquely on the 
cartilage in this disease (of which the erosion is the causative feature of joint loss-of-
function) neutrophil depletion using an irradiation protocol significantly decreased 
proteoglycan synthesis in zymosan-induced arthritis (ZIA) compared to non-depleted 
mice (Gresnigt et al., 2012). This model of ZIA is highly dependent on IL-1β, therefore 
this report directly relates to the data presented here, suggesting that the role of 
neutrophils in arthritic cartilage is not necessarily degradative. We propose that the 
mechanism of cartilage protection is overwhelmed in RA, thus with depletion of 
neutrophils and/or neutrophil microparticles, cartilage destruction may be much greater 
in this setting.  
 
The concept that neutrophils play a role in limiting inflammation and contribute to the 
resolution of inflammation in certain settings is gaining ground. Neutrophil apoptotic 
bodies reprogram macrophages from M1 to M2 phenotype via efferocytosis (Hoffmann 
et al., 2005, Huynh et al., 2002, Li et al., 2003). Wound healing in neutrophil depletion 
models is delayed (Harty et al., 2010), and depletion of neutrophils in certain 
autoimmune diseases, such as ulcerative colitis, leads to an exacerbation of disease 
(Kuhl et al., 2007, Campbell et al., 2014). Although controversially reported by several 
authors (De Santo et al., 2010, Glowacka et al., 2010), it has been shown that human 
neutrophils cannot produce IL-10 as the IL-10 genomic locus is in an inactive state 
(Davey et al., 2011, Tamassia et al., 2013). Mouse neutrophils do express IL-10 mRNA 
and protein in inflammatory contexts (Kasten et al., 2010, Doz et al., 2013), but are 
dispensable in survival during polymicrobial sepsis (Ocuin et al., 2011). These studies 
demonstrate that murine versus human biology is different, and cautions against 
extrapolating observations directly from mice to man. Neutrophils are also involved in 
nerve regeneration and protection post-injury (Kurimoto et al., 2013, Stirling et al., 
2009). Neutrophil proteases, classically thought to degrade the extracellular matrices 
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and cells surrounding the inflammatory event, are conversely shown to deactivate 
inflammatory cytokines produced by mononuclear cells independently of ROS 
production or phagocytosis (Gresnigt et al., 2012).  
 
Further non-redundant immunoregulatory functions of neutrophils involve their 
interaction with other cell types. Jaeger et al. (2012) report that the Genista neutrophil 
(CD11b+Ly6Ghigh)-depleted mouse mutant had hyporesponsive, hyperproliferative 
natural killer (NK) cells with poor cellular survival and blockade at the immature stage. 
These mice have a point mutation in Gfi-1 (growth factor independence-1; induced by 
the C/EBPα lineage-determining transcription factor; critically required for the 
development of mature neutrophils) leading to a termination of granulopoiesis after the 
metamyelocyte stage, but they do have an atypical circulating population of 
CD11b+Ly6Gintermediate population which retain a small proportion of mature neutrophil 
characteristics (Ordonez-Rueda et al., 2012). When wild type NK cells were adoptively 
transferred into Genista mice, their responsiveness was suppressed, supporting the 
notion that NK defects were extrinsic to the cells. Genista NK cells adoptively 
transferred into wild type mice regained full reactivity in host wild type NK cells, 
showing that, although NK cells express the Gfi-1 gene modified in this mutant mouse, 
the point mutation was not sufficient to affect NK cell function. The maturation of NK 
cells through stages of CD27/CD11b positivity and negativity were terminated at the 
intermediate double-positive stage in Genista and also wild type neutrophil-depleted 
mice, suggesting that neutrophils are required for the final maturation of NK cells. 
These results were then recapitulated in human patients with severe congenital 
neutropenia, who displayed a higher proportion of immature, hyporeactive NK cells 
compared to healthy controls. It was observed that in wild type mice, NK cells and 
neutrophils formed conjugates in the spleen and lymph nodes far more frequently than 
T or B cells did with neutrophils (approximately 75% versus less than 10 percent for T 
and B cells). These cells can be seen with considerable plasma-membrane contact 
with one another, under resting conditions. These data extend the previously 
characterized interaction of neutrophils and NK cells under inflammatory settings 
(Costantini et al., 2011a, Costantini et al., 2011b).  
 
Furthermore, there are reports that neutrophil microparticles down-regulate 
inflammatory cytokine production in NK cells (Pliyev et al., 2014) and induce phenotype 
switching of macrophages (Eken et al., 2013, Eken et al., 2010), suggesting that 
neutrophil microparticles may be involved in limiting chronic inflammation, adding 
another anti-inflammatory or pro-resolving aspect to the neutrophil repertoire. We 
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propose that these cells produce protective microparticles to try to limit inflammation 
and joint destruction, which is overwhelmed in RA. This is in analogy to the higher 
levels of TGF-β1 also present within the synovial fluid, thought to represent an 
overwhelmed protective response to inflammation, by driving regulatory T cell 
differentiation (Lipskey, 2008). 
 
To recapitulate the flare phase of rheumatoid arthritis, which is when neutrophils, and 
therefore neutrophil microparticles are most abundant, we adopted the K/BxN serum 
transfer arthritis. The inflammation seen in this phenotype is entirely dependent on the 
innate immune cells, mainly neutrophils (Elliott et al., 2011). Serum harvested from 
KRN transgenic mice crossed into mice carrying the H-2g7 haplotype of the MHC locus, 
has high titres of autoantibodies to glucose-6-phosphate isomerase. Serum transfer 
into C57BL/6 mice initiates an aggressive, symmetrical polyarthritis, which is 
dependent upon neutrophils and mast cells (Monach et al., 2007, Monach et al., 2008) 
although the role of mast cells has recently been called into question (Elliott et al., 
2011). These autoantibodies selectively deposit on the surface of the cartilage, which 
is detected by neutrophils via the Fcγ receptor (Elliott et al., 2011), but also fixes 
complement, releasing bioactive complement fragments such as C5a, initiating local 
inflammatory events, including recruitment of phagocytic cells to the site (Laudisi et al., 
2013). The production of leukotriene B4 leads to the infiltration of neutrophils, which in 
turn produce large amounts of IL-1β when stimulated by immune complexes present 
within the joint space. IL-1β induces chemokine production, and thus more neutrophils 
are recruited to the joint in a self-perpetuating inflammatory loop (Chou et al., 2010).  
 
Systemic treatment of K/BxN mice with 100,000 TMP was unsuccessful. This is not 
surprising, as this is a relatively small amount of microparticles, and the dilution effect 
across the entire system would have been significant. Furthermore, it is not known 
whether neutrophil microparticles are capable of transmigrating through endothelial 
cells to the site of inflammation following margination, capture, rolling and adhesion to 
the endothelium, as their parent cells do. Importantly, however, it was possible to 
determine that mice receiving microparticle treatment displayed no adverse effects, 
and their arthritis was not worsened. Direct delivery of microparticles intra-articularly 
did induce chondroprotection compared to sham-injected knees. Treatment did not 
affect the clinical scores of mice, which are measured in peripheral, distal joints. This 
does not preclude microparticle treatment in human patients with rheumatoid arthritis, 
however, as synovial fluid aspiration is a common procedure for these patients. 
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Cartilage integrity was increased in the knees of arthritic mice injected with TMP 
compared to contra-lateral vehicle injected knees as determined macroscopically and 
by toluidine blue staining. Caliper measurements of arthritic knees were not sufficiently 
sensitive to distinguish arthritic from naïve knees, or treated versus vehicle knees, 
even when differences could clearly be seen post skin resection. In fact, the 
macroscopic appearance of the knee correlated to histological knee score almost 
100% of the time, and provided a good measure of treatment efficacy. Decreased knee 
inflammation in microparticle treated knees could also be seen in live mice with 
bioluminescence imaging. Using luminol sodium salt, which is cleaved to a fluorescent 
compound when exposed to extracellular neutrophil myeloperoxidase, the inflammation 
induced by K/BxN serum transfer could be monitored in both peripheral joints and the 
knees (Gross et al., 2009). Microparticle treated knees had significantly less 
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Figure 6.2 Schematic: Microparticle effects on chondrocytes. Microparticles, carrying various 
immunomodulatory components, have multiple effects on chondrocytes. Following ligation of 
FPR2/ALX, microparticles induce a program of chondroprotection and cartilage matrix 
accumulation via unknown mechanisms. Microparticles induce the up-regulation of SOX9, and 
type II collagen and aggrecan mRNA, inhibit cartilage matrix degradation and induce the 
production of TGF-β. Microparticle treatment also inhibits chondrocyte apoptosis and reduces 
levels of IL-8, IL-6 and COX-2, possibly via the inhibition of Hsp27 phosphorylation. MP, 
microparticles; α2M, α2-Macroglobulin; RvD1, Resolvin D1; CP, ceruloplasmin; AnxA1, Annexin 
A1; ECM, extracellular matrix.  
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inflammation compared to vehicle treated knees, and this method would allow for more 
long term experiments to be performed with data analysis across time points.  
 
RNA extraction and measurement of gene expression from formalin-fixed, paraffin 
embedded sections did not reveal any significant results. Probably, a combination of 
variation within the arthritis experiment, and the low number of mice used for the study 
contributed to the results seen. Plus, RT-PCR is an extremely sensitive method for 
measuring labile RNA, thus, in future, joints prepared specifically for RNA analysis 
would help reduce variance. 
 
To determine whether neutrophil microparticles were involved physiologically in the 
process of arthritis, two approaches were adopted. Firstly, Bodipy-maleimide labelled 
neutrophils transferred into mice undergoing K/BxN arthritis appeared within arthritic 
joints. Microparticles could be observed within the cartilage and double-stained for 
MRP14. This suggests that the appearance of myeloid-related proteins in human 
arthritic joints are localised there due to microparticles. Secondly, we attempted to 
block microparticle interaction in vitro to determine whether any protocols could be 
used in vivo. One way in which we tried, unsuccessfully, to block microparticle 
interaction with chondrocytes was via the addition of Annexin V in excess to coat the 
exposed phosphatidylserine. Although recent reports have demonstrated that the 
phosphatidylserine exposed by apoptotic cells down-regulates inflammation during 
efferocytosis, in this case, blocking exposed phosphatidylserine did not inhibit 
microparticle protection. This, and previous reports of similar coating experiments, 
suggests that although microparticles and apoptotic bodies may share overlapping 
anti-inflammatory qualities, their functions are separate, and that phosphatidylserine is 
only partially responsible for the chondroprotection observed. Inhibiting microparticle 
formation in a manner that is translatable in vivo has proven difficult. Neutrophils are 
terminally differentiated cells and can only be minimally manipulated before retransfer 
into live mice. Furthermore, depletion of neutrophils before K/BxN serum transfer 
arthritis interferes with disease onset, and is not feasible after the onset of clinical 
signs, as the transmigrated tissue neutrophils will remain unaffected by depletion 
protocols.  
 
Analysis of microparticle number and phenotype has the potential to become a 
powerful biomarker in a variety of human pathologies. Our laboratory recently reported 
that neutrophil microparticles can be heterogeneous, identifying subtypes more 
abundant in plasma during systemic inflammation (Dalli et al., 2013).  The results 
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presented in this study, although preclinical, indicate that autologous neutrophil 
microparticles may easily find a translational application, as has been seen with cell-
based therapies, such as autologous chondrocyte implantation or stem cell-based 
technologies (Singh, 2012). Enrichment of a patient’s neutrophil microparticle 
population within the joint represents a desirable therapy for RA due to the envisaged 
minimal side effects and low treatment cost. Autologous transplantation of patients’ 
own microparticles to improve disease outcome represents the future of personalised 
medicine as these microparticles are inherently readily generated. Furthermore, in view 
of their ability to enter the avascular cartilage, autologous microparticles could be 
manipulated or engineered to transport bioactive molecules to chondrocytes, to deliver 
therapies by a means that cannot be achieved in current medicine. In summary, these 
data shed new light on our understanding of functional and cellular association 
between immune system and cartilage biology, delineating new strategies for 
innovative drug discovery approaches. 
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The ascribed functions of microparticles from various cellular origins in physiological 
and pathophysiological settings are continuously expanding. Here, the protective roles 
of neutrophil microparticles specifically in terms of chondrocyte biology and physiology 
have been explored. To fully conclude research herein, future considerations of how to 
inhibit microparticle formation to demonstrate a definitive phenotype must be 
demonstrated experimentally. Patients with Scott syndrome have recently had the 
putative mutation causing their syndrome delineated, and missense mutations in 
TMEM16F have been shown to be pivotal in proper phosphatidylserine scrambling and 
therefore microparticle shedding.  
 
I have established a collaboration with Professor Lily Jan at University of California, 
San Francisco who has generated TMEM16F global and TMEM16Fflox/flox mice. My 
intention is to perform a K/BxN arthritis study on these recently generated TMEM16F 
null mice and to compare the severity in clinical score and histologic presentation of the 
disease with wild type littermate controls. We hypothesise that the absence of 
microparticles may exacerbate the loss of proteoglycans in experimental arthritis. 
Although neutrophil-specific TMEM16F conditional mice do not yet exist, plans are 
underway to obtain TMEM16Fflox/flox mice and breed them with neutrophil-specific GCcre 
or MRP8cre mice to observe the effects of specific neutrophil microparticle deletion in 
various biological and pathophysiological settings. As a first step, a K/BxN model in 
globally TMEM16F null mice will suffice to demonstrate the role of neutrophil 
microparticles in arthritis, as this model is so heavily dependent on neutrophil 
infiltration. We envisage an overwhelmed response of neutrophil microparticle 
protection in rheumatoid and other inflammatory arthritides. 
 
This report opens up other avenues for future investigation. The newly uncovered roles 
of Annexin A1 and the receptors FPR2 and FPR1 deserve further investigation, 
especially as the retention of glycosaminoglycans was noted in Fpr2/3-/- vehicle groups 
without microparticle treatment. To investigate the control of cartilage metabolism in a 
setting with a less overt inflammatory phenotype, a model of osteoarthritis, the 
destabilisation of the medial meniscus (DMM), will be employed. 
 
The mouse model of inflammatory arthritis used during this study was purely 
dependent on innate immune cells. Further studies using more chronic, adaptive 
immunity-driven models of arthritis, such as collagen-induced arthritis and glucose-6-
phosphate isomerase immunisation are underway. Whether neutrophil microparticles 
will ameliorate disease in these models is totally unknown, and few, if any, reports of 
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the effect of neutrophil microparticles interacting with lymphocytes exist. It is possible 
that the chondroprotective effects will still be present in chronic models, but it is not 
known whether neutrophil microparticles will have any bearing on the presentation of 
chronic inflammation. 
 
The mechanism of neutrophil microparticle migration into the cartilage matrix is an area 
of pertinent interest as drug delivery strategies to target chondrocytes are currently 
lacking. These microparticles were able to efficiently migrate across arthritic cartilage 
to native chondrocytes where evidence of microparticle uptake was observed. Packing 
drugs into these microstructures could represent a potent new way of targeting these 
otherwise almost untreatable cells, and have important implications for the future of 
drug delivery programmes. 
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